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Abstract 
The capacity to achieve elite athletic success is known to be highly heritable and 
physiologically complex. Recently, there has been a substantial rise in the number of peer 
reviewed sports genomics publications, however the majority of these have focused on the 
genetic components of either strength/sprint/power or endurance athletes, with little 
attention given to team sports. Since rugby union (RU) athletes perform under a well-defined 
set of rules and parameters, which are ubiquitous across all playing positions, they present 
an ideal cohort via which to study the importance of genetic variation in sport and as such is 
the purpose of the present thesis. The aims of the present thesis were, firstly, to recruit a 
large cohort of elite RU athletes and compare the genetic profile of these athletes to that of 
a control population. Secondly, because of the large physiological differences between elite 
RU playing position, the present thesis further aimed to compare the genetic diversity in RU 
inter-positional variation. 1164 participants, consisting of 454 elite RU athletes and 710 
controls from the general population were recruited for the present thesis. Genotyping data 
was generated for SNPs within the APOE ε4 (rs429358 and rs7412), ACTN3 (rs1815739), 
ACE I/D or ACE tag SNP (rs4341), COL5A1 (rs12722 and rs3196378) and FTO (rs9939609) 
genes. Only the COL5A1 SNPs were different when comparing the entire elite RU cohort to 
controls. However, observations of APOE ε4 frequency did reveal that ~30% of elite RU 
athletes are at higher risk of poor outcome following mTBI (concussion). Regarding playing 
position, both ACTN3 and FTO showed position specific variation, with the greatest 
associations in the backs playing position. There were no associations between elite RU 
athletes and controls for ACE I/D. When incorporating all of the above SNPs into a polygenic 
profile, the entire elite RU cohort, the backs and forwards showed significant deviation from 
controls. Interestingly by using an ROC model the present thesis identified significant 
polygenic sensitivity in discriminating between elite RU backs and forwards which trended 
towards the backs. The data generated in the present thesis are the first to show genetic 
variation in a large cohort of elite RU athletes, with particular emphasis on positional 
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specificity. These data are only the ‘tip of the iceberg’ in understanding the molecular aspect 
of elite RU physiological underpinnings and analysis of many more variants are required in 
addition to replication of the present results. Nonetheless, these data are the first step in this 
understanding and may have implications in positional selection, position specific training 
and injury management, in the future. Follow up studies should focus on further recruitment 
of elite RU athletes and combining genetic data with phenotypic data, specific to elite RU 
athletes and with particular attention to injury susceptibility. 
3 | P a g e  
 
Chapter 1  
 
 
 
 
 
Thesis introduction 
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1.1 Introduction 
The majority of scientific investigation into player performance in rugby union has focused 
on environmental factors such as training methods, dietary supplementation and recovery 
strategies (West et al., 2013; Barr et al., 2014; Bradley et al., 2015), with a great deal of 
epidemiological research also investigating injury frequency and risk including a recent 
focus on brain injury (Raftery, 2013; Gardner et al., 2014; Fuller et al., 2015a; Williams et 
al., 2015b; Fuller et al., 2016). However, considerable evidence shows that performance and 
injury traits are highly (but variably) heritable (Simoneau & Bouchard, 1995; Bouchard et 
al., 1999; Hakim et al., 2003; De Moor et al., 2007; Peeters et al., 2007), yet little scientific 
effort has been invested to elucidate this inter-individual variation within rugby union. For 
example, Simoneau and Bouchard (1995) showed the genetic heritability of muscle fibre 
type proportion was ~50%, with larger heritability for body mass index and mass at ~60%, 
height at ~80%, elbow flexion and knee extension strength at ~50% and hand grip strength 
at ~60% (Silventoinen et al., 2008). 
 
Rugby union athletes are qualitatively and quantitatively different from other athlete groups 
(both individual and team) in that there are vast differences in the physiological and 
anthropometric characteristics across a single rugby union team according to playing 
position (Smart et al., 2013). Rugby union is also distinctive as individual clusters of 
positions require different movement patterns in elite players (Quarrie et al., 2013) and thus 
differ in their metabolic demands. For example, anthropometric and physiological variables 
differ significantly across playing positions, with elite scum half players averaging ~177 cm 
and ~85 kg, in contrast to props averaging ~185 cm and ~117 kg – a difference of 8 cm and 
32 kg (Fuller et al., 2013). Furthermore, in terms of positional specific physiological 
differences that may be reflected in players’ genetic variation, backs show lower maximal 
strength compared to forwards in terms of bench press (difference ~11 kg), back squat 
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(difference ~18 kg) and power clean (difference ~9 kg; Smart et al., 2014). However, backs 
are faster, sprinting 10 m (difference = ~0.09 s) and 20 m (difference = ~0.11 s) than 
forwards (Smart et al., 2014) and these differences become larger when specific positions 
are considered (Smart et al., 2013). Positional differences are further evidenced by game 
demand data that shows the requirement for differing metabolic capacities dependent on 
playing position (Deutsch et al., 2007; Roberts et al., 2008; Cahill et al., 2013; Quarrie et 
al., 2013). For example, backs travelled 12% greater total distance (6545 m versus 5850 m), 
achieved maximum speeds 16% faster (30.4 km.h-1 versus 26.3 km.h-1) and engaged in over 
four times more (58% versus 13%) high-intensity running activities (> 5.0 m.s-1), as a 
proportion of total activity compared to forwards (Roberts et al., 2008; Cahill et al., 2013). 
 
In sports genomics, elite sprint/power athletes are often compared to elite endurance athletes 
for the purpose of elucidating genetic variation at the ends of the human physical 
performance spectrum (Eynon et al., 2009; Eynon et al., 2010; Eynon et al., 2011b; Ruiz et 
al., 2011a; Eynon et al., 2013b). However, these athletes often originate from different 
geographical regions where socioeconomic backgrounds and levels of sporting 
professionalism in their community differ and these things are likely to drive their choice to 
engauge with a particular sporting discipline, not their inate physiological ability. These 
considerations are less of a challenge in the elite rugby union community, particularly when 
considering the genetic variation within playing position, as individuals choose to play rugby 
prior to being selected into their most suitible playing position. As such, since rugby union 
athletes perform under a well-defined set of rules and parameters, they present an ideal 
cohort via which to study the importance of genetic variation in sport and thus is the purpose 
of this thesis. 
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1.1.1 Thesis overview 
Chapter 2.1 outlines the current knowledge of rugby union characteristics. Part one will 
discuss positional diversity within rugby union athletes considering anthropometric and 
physiological phenotypic data. Game monitoring technology such as time motion analysis 
and global positioning system (GPS) systems have allowed us to estimate the metabolic 
demands of match play and are widely used, in the field, by practical scientists (Twist & 
Worsfold, 2015). Thus, to assess the molecular genetic differences in playing position, 
reviewing and extrapolating the appropriate data in relation to these metabolic demands (i.e. 
different activation of molecular pathway proportions) are vital. Furthermore, given the 
collision and high speed nature of rugby union, injuries are a common and ever growing 
issue within the game. World Rugby and national governing bodies (such as the Rugby 
Football Union (RFU)) have invested substantial resources in assessing the current state of 
injuries within the elite game. Understanding the genetic underpinnings of injury 
susceptibility may aid in injury management in the future and this thesis embarks on the first 
step to this potential. Given the current interest in concussion (Raftery, 2013) and the known 
clinical impact of such injuries (Bennett et al., 2013), this particularly important aspect of 
injury is reviewed separately. 
 
Chapter 2.2 reviews and discusses the current knowledge of physical performance trait 
heritability. It is generally accepted that the physiological/psycho-physiological components 
of any human performance trait is a composite of environmental (infant nutritional status, 
socioeconomic considerations, training etc.) and heritability (genetics). As such, attempting 
to study any human performance trait without acknowledging the heritable element renders 
any discussion incomplete and these topics are therefore reviewed herein. The study of sports 
genomics has grown substantially in recent years (Ahmetov & Fedotovskaya, 2012), with 
larger athlete biobanks being generated worldwide (Pitsiladis et al., 2013) and coming 
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together in the Athlome consortium (Pitsiladis et al., 2016). Even though the field shows 
considerable promise in understanding the molecular basis of elite athlete physiology, in 
relation to team sport athletes, few investigations have embarked upon understanding the 
genetic variation. Those that have, often show considerable methodological flaws and are 
reviewed (Chapter 2.2.4), with the intention of addressing these concerns in the present 
thesis. An inherited proportion of rugby union ability was proposed in the early 20th century 
(Jack, 1922) with further small pilot investigations showing potential for genetic variation 
(Bell et al., 2009; Bell et al., 2010; Bell et al., 2012c). These primary inquiries are thoroughly 
reviewed herein. Following a broad review and introduction into the field of sports 
genomics, a specific detailed review of the candidate genes that were investigated within 
this thesis and their rationale for inclusion are discussed (Chapter 2.3). These review 
elements consist of the fundamental rationale generating the aims of the thesis. 
 
Because of the similarities in the scientific methods used for the experimental chapters (4, 
5, 6 and 7), chapter three presents a detailed description of the methodology applied and will 
be referred to as the experimental chapters unfold. The following five chapters consist of the 
main body of the thesis and the purpose of its production - the experimental chapters (4, 5, 
6, 7 and 8). Here, all experimental data are presented in journal article format, link directly 
to the present thesis aims and contribute to the further understanding elite rugby union 
molecular physiology. Chapter nine, the general discussion, amalgamates the thesis 
components, explores the findings in a deeper context and considers the limitations, future 
direction of research and possible practical implications of the molecular underpinnings 
inherent to elite rugby union physiology.
8 | P a g e  
 
Chapter 2  
 
 
 
 
 
Literature review 
 
 
 
 
A portion of part 2.2 of this chapter is published in: 
 
Heffernan S. M., Kilduff L. P., Day S. H., Pitsiladis Y. P. & Williams A. G. (2015). 
Genomics in rugby union: A review and future prospects. European Journal of Sport 
Science, 15(6), 460-468. 
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2.1 Part 1: Rugby union athlete characteristics 
 
2.1.1 Elite player physiological characteristics 
Rugby union is an intermittent team sport that requires a high level of strength, power, speed 
and aerobic/anaerobic fitness (Roberts et al., 2008; Twist & Worsfold, 2015). Compared to 
most other team sports that require these traits, rugby is unique, as it includes large 
acceleration forces often culminating in high impact collusions (Cunniffe et al., 2009; Owen 
et al., 2014; Bradley et al., 2015). Furthermore, rugby union is comprised of diverse playing 
positions - forwards (loose-head props, hookers, tight-head props, left locks, right locks, 
blind-side flankers, open-side flankers, and number eights) and backs (scrum halves, fly 
halves, left wings, inside centres, outside centres, right wings, and full backs). Each have 
different physiological and technical attributes (Deutsch et al., 2007; Roberts et al., 2008; 
Cahill et al., 2013; Quarrie et al., 2013). Briefly, along with the hooker, the loose-head and 
tight-head props make up the front row forwards, which refers to their position in the scrum 
(appendix 4). To be successful, both props and the hooker must be extremely strong in the 
neck, shoulders, upper body and legs. Locks make up the second row forwards and are 
described as the ‘power house’ of the scrum. They are required to be tall, heavy and powerful 
players. Flankers and number eights must have considerable speed, strength, and fitness 
attributes. Scrum half’s tend to be smaller players, act as the link between the forwards and 
the backs and needs good vision, speed and awareness. Fly half’s are the ‘play makers’, 
responsible for coordinating the attack and defiance, while being physically capable of 
exploiting weaknesses in the opposition. Wingers are generally the fastest players that 
require great relative power to finish planned moves and attacks. Centres tend to be strong 
and powerful athletes, dynamic runners that again exploiting weaknesses in the opposition. 
Fullbacks are similar to wingers in that they are among fastest players that require great 
relative power to finish planned moves and attacks. Additionally, fullbacks have a greater 
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responsibility in defiance and are often required to make high impact tackles (England 
Rugby, 2016). For a more detailed description of the player roles, see appendix 4. 
 
Rugby athletes are required to perform “static and dynamic exertion efforts” (scrums, mauls, 
rucks and lineouts) when competing to gain or maintain possession of the ball (Deutsch et 
al., 2007; Smart et al., 2014), which requires athletes to develop and maintain high force and 
velocity dominant physiological phenotypes (Cross et al., 2014; Table 1). However, these 
and other physiological abilities are highly positional specific and require particular inherent 
abilities to perform a given static and dynamic exertion effort. For example height, in 
combination with their lower body power output and vertical jump performance, is vital for 
a forwards to be successful in rugby union lineouts (Table 1). Evidence now supports the 
notion that since the advent of professionalism in rugby union, over 20 years ago, players 
have become progressively taller, heavier, stronger and faster (Appleby et al., 2012; Sedeaud 
et al., 2012; Barr et al., 2014). From the assessment of Rugby World Cup data (1987 to 
2007), forwards and backs have become heavier by ~6.6 kg and ~6.7 kg and taller by ~0.6 
cm and ~1.1 cm, respectively, with the most successful teams consisting of the tallest backs 
and heaviest forwards (Sedeaud et al., 2012). Furthermore, the positional-specific physical 
evolution of elite rugby athletes remains consistent in both European and Southern 
hemisphere domestic competition (Fuller et al., 2013; Sedeaud et al., 2013; Smart et al., 
2013). Rugby athletes are generally taller, heavier and leaner (Table 1) than equivalent 
athletes prior to the professional era (Sedeaud et al., 2013). This suggests that by artificial 
selection, coaches now favour more physically imposing athletes (Table 1), which will be 
partly determined by genetic inheritance
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Table 1 Rugby union (RU) players and general population anthropometric and physiological descriptive variables presented as means. Some rugby union variables presented 
as positional subgroups. Dashed cells (______) represents an absence of data within the available literature. 
Phenotype Group 
General population Forwards Backs Props Locks Hookers Backrow Half backs Centres Back 3 
Anthropometrics           
Height (m) 1.78 1.89 1.82 1.85 1.98 1.81 1.90 1.79 1.84 1.83 
Mass (kg) 75 111 91 117 113 104 106 87 96 92 
Body fat (%) 22 13 10 16 13 15 12 11 11 9 
FFM (kg) 64 *92 *81 94 95 89 90 79 84 81 
Fibre type (% of type II) 53 53 56 ______ ______ ______ ______ ______ ______ ______ 
           
Strength and Power           
Lower body power output  
 W·kg-1 
 W 
 
11 
221 
 
*51 
*5606 
 
*58 
*5370 
(Props, Locks and Hookers) 
48 
5416 
 
54 
5796 
 
56 
5000 
 
58 
5680 
 
60 
5431 
Max bench press (kg) 57 136 125 133 121 124 119 111 113 109 
Max back squat (kg) 69 186 168 184 157 185 169 155 163 157 
Max power clean (kg) ______ 104 95 102 102 101 98 91 93 91 
           
Running speed           
Max sprint times 
 10 m  
 20 m  
 30 m 
 
1.90 
3.25 
4.42 
 
1.78 
3.07 
______ 
 
1.69 
2.96 
4.04 
 
1.85 
3.21 
______ 
 
1.79 
3.13 
______ 
 
1.81 
3.14 
______ 
 
1.76 
3.06 
______ 
 
1.72 
2.96 
4.14 
 
1.70 
2.95 
4.12 
 
1.68 
2.89 
4.11 
           
Game Demands           
Total Distance  
covered (m) 
______ 4679 5957 3698 5027 4746 5244 5693 5907 6272 
Distance covered at (> 5 m·s–1) 
high speed (m) 
______ 178 511 102 158 147 306 381 586 566 
High-intensity static exertion 
activities (min:s) 
______  
7:56 
 
1:18 
(Props and Locks) 
8:03 
(Backrow and Hookers) 
7:47 
(Out halves and Centres) 
1:33 
 
1:05 
RHIE  
 Bouts 
 Recovery from bouts (s) 
 
______ 
 
 
*12 
*428 
 
*6 
*638 
(Props, Locks and Hookers) 
11 
398 
 
13 
457 
 
5 
612 
 
7 
751 
 
6 
551 
Adapted from (Jardine et al., 1988; George et al., 1999; Scott et al., 2003; Glaister et al., 2008; Roberts et al., 2008; Crewther et al., 2009; Nuzzo et al., 2010; Ahmetov et al., 2011; Menzel & Hilberg, 2011; 
Santiago et al., 2011; Chtourou et al., 2012; Crewther et al., 2012; Fuller et al., 2013; Smart et al., 2013; Smart et al., 2014; Jones et al., 2015). 
FFM, fat free mass; RHIE, repeated high intensity exercise. *Value generated by averaging the individual playing position data in the absence the data from the literature. 
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2.1.2 Anthropometrics 
Given the positional selective pressures and performance roles, backs (generally speaking) 
are shorter (~0.07 cm), have less mass (~10 kg), less FFM (~11 kg) and a higher proportion 
of type II muscle fibres (~3%) than forwards (Jardine et al., 1988; Smart et al., 2013; Smart 
et al., 2014). These anthropometric quantities are indicative of the body type required for 
backs, specifically the back three (Table 1), to perform high velocity running – the main 
performance criterion of their selection to elite status (Chapter 2.1.3). Correspondingly, the 
opposite anthropometric values (i.e. taller, heavier etc.) show the required body type for 
forward positional requirements (Chapter 2.1.3). 
 
2.1.3 Strength and Power 
Arguably, strength and power capacities better convey the positional variation within rugby 
union. Backs show lower maximal strength compared to forwards in terms of bench press 
(~11 kg), back squat (~18 kg) and power clean (~9 kg). However, backs are faster sprinters 
over 10 m (~0.09 s) and 20 m (~0.11 s) than forwards (Smart et al., 2014; Table 1 ) and show 
considerable variation across rugby union playing positions. Importantly, note the 
comparisons between absolute/relative peak power outputs and playing position (Table 1). 
Considering relative power output, as a ratio scale of mass, the back positions have greater 
values (W·kg-1) than forwards, however the relationship is reversed when considering 
absolute lower body power output (Crewther et al., 2012). This scaling variation is an 
important consideration for accurate field based physiological testing but also in assessing 
molecular genetic characteristics of muscle phenotypes because of the individuality of 
genetic variation, such as fat and muscle mass.  
 
2.1.4 Running speed 
One of the most vital physiological quantities for backs, particularly back three and centres, 
is the ability to achieve high sprinting velocities. Backs achieve faster running velocities 
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over 10 m (~0.09 s), 20 m (~0.10 s) and this positional variation exemplifies considering 
specific playing positions (Table 1). Importantly in the context of case-control genetic 
association studies, such as the present thesis, there are considerable physiological 
differences from the general public (Table 1). Props have only 0.04 s faster 20 m sprint 
capacity to the general population, whereas the back three players are 0.36 s faster (Table 
1). All rugby athletes undergo rigorous training regimes for speed (Barr et al., 2014), yet 
there is such a slight difference between props and the general population. This difference is 
likely to be an artefact of both specific training and the genetic determinant of trainability, 
where a response to a particular training modes are modulated by genotypic and allelic 
variation (Bouchard et al., 1999). It is highly likely that prior to elite selection, young athletes 
were at least partially selected to their playing position based on their affinity to a particular 
physiological capacity (strength, mass, sprint, repeated sprint recovery etc.). 
 
2.1.5 Game demands 
Recently, GPS tracking and time-motion analysis have been used to estimate the physical 
demands of rugby athletes and compare forwards to backs during high-level match play 
(Roberts et al., 2008; Cahill et al., 2013; Johnston et al., 2014; Jones et al., 2015). Backs 
travel 12% greater total distance (6545 m versus 5850 m), achieved maximum speeds 16% 
faster (30.4 km.h-1 versus 26.3 km.h-1) and engaged in over four times (58% versus 13%) 
high-intensity running activities (> 5.0 m.s-1), as a proportion of total activity compared to 
forwards (Roberts et al., 2008; Cahill et al., 2013). These data suggests a more sprint-
oriented metabolic demand in backs compared to forwards. Furthermore, due to the 
complexities of forward play, forwards performed sixfold more (9.9%) high-intensity static 
exertion activities (rucks, mauls, scrums and line-outs) than backs (1.6%) and spend 19.8% 
more time running above 80% of their maximal speed (Roberts et al., 2008; Cahill et al., 
2013, respectively). This implies that forwards, although often of higher body mass, (Fuller 
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et al., 2013) are more likely to benefit from fatigue-resistant physiological qualities than 
backs. Accordingly, Deutsch et al (2007) showed that forwards had a notably higher work-
to-rest ratio than backs (1:7 and 1:22, respectively) in UK top flight Northern hemisphere 
rugby. Furthermore, in Sothern hemisphere top flight competition, lower work-to-rest (1:4 
and 1:6) were identified but showing a similar relationship to the UK data (Figure 1; Austin 
et al., 2011a). Given that the roles of backs and forwards differ significantly in terms of 
physiological demands, these differences may be reflected in distinct genetic characteristics. 
 
More recent technological advances in game analysis have seen the inclusion of 
accelerometer data in addition to GPS allowing practitioners to more stringently assess 
repeated high-intensity exercise (RHIE) and collisions (Jones et al., 2015; Twist & 
Worsfold, 2015). A RHIE bout is defined as, > 3 high accelerations (> 2.79 m·s-1), high 
speed (>5 m·s-1) or contact efforts with less than 21 s recovery between bouts (Spencer et 
al., 2004; Austin et al., 2011b; Gabbett et al., 2012). As before, significant positional 
differences exist (Table 1) under these defined parameters (hookers and backrow = 13 bouts 
versus half backs = 5 bouts) and are further exemplified by the recovery time between bouts 
Props and
locks
Backrow and
hookers
Forwards Halves and
Centres
Back 3 Backs
7.3 7.5 7.4
20.9
22.8
21.8
4 4
5
6
UK Super 14
Figure 1 Work-to-rest data by positional group for top tier UK and Super 14 rugby 
union. Adapted from Austin et al. (2011a) and Deutsch et al. (2007). Chart numbers 
are the units of work as a ratio of one unit of rest (1:X). 
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(front five = 398 s, halves = 612 s; Jones et al., 2015). As such, these collective movement 
patterns suggests a requirement for a high proportion of fast twitch muscle fibres and highly 
developed anaerobic energy metabolism within the backs, with the forwards’ patterns 
suggesting a requirement for a high proportion of slow twitch fibres, greater capacity for 
rapid recovery between high-intensity static exertion/RHIE activities and a more developed 
aerobic endurance capacity. Given the highly heritable nature of these and other physical 
traits, and their contribution to success in a given playing position, these physiological 
differences should be reflected in distinct genetic characteristics. 
 
Furthermore, these recent technologies allow for the quantification of match play collisions 
and unsurprisingly forwards perform more game impacts than backs (Cunniffe et al., 2009; 
Bradley et al., 2015; Owen et al., 2015). In fact, when considering only the highest level 
impacts, forwards were involved in 60% more collisions (Cunniffe et al., 2009). Moreover, 
front row and scrum half athletes showed greater low-intensity impacts, with backrow 
players experiencing the greatest number of high-intensity impacts (Owen et al., 2015). 
These data present an insight into the true physiological demands of rugby union, given its 
collision nature (Twist & Worsfold, 2015). Importantly, Jones et al. (2014) recently showed 
the relationship between the change in creatine kinase levels at both +16 h (r = 0.438) and 
+40 h (r = 0.638) and the number of game impacts. Combining these data with the elite rugby 
work-to-rest data (Figure 1), the heritable notion of artificial selection in assigning playing 
position is further supported. 
 
2.1.6 Injury epidemiology 
Owing to the collision nature of rugby union, injuries are a common and a growing artefact 
of the increasing size and strength of the athletes (Cunniffe et al., 2009; Sedeaud et al., 2013; 
Owen et al., 2014; Bradley et al., 2015) and thus greater changes in momentum during player 
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collisions, as well as during voluntary accelerations and decelerations. This has, resulted in 
rugby union having one of the highest reported injury incidence in professional team sports 
(Brooks & Kemp, 2008). In recent years World Rugby and the RFU have instigated injury 
surveillance schemes in order to quantify the incidence and severity of injuries at the elite 
level of the game (Fuller et al., 2008; England Professional Rugby Injury Surveillance 
Project Steering Group, 2016). The greatest achievement here is the standardised method of 
data collection and analysis that can be applied across all rugby codes (Fuller et al., 2007) 
and allows for pooling of data from many teams and competitions to give an accurate picture 
of the injury epidemiology (Fuller et al., 2015a). Indeed, injury assessment is not only 
important for player safety, but also results in rule changes (Trewartha et al., 2015). Player 
injury results in an inability to select the best players and disruption to an athletes training 
availability. As such, recent data shows a negative correlation between days absence through 
injury (22% of mean) and team success, as defined by competitive league points tally (Figure 
2; Williams et al., 2015b). Using genetic data for injury susceptibility could enhance 
individualised player management, in that training load and game time could be adjusted to 
allow increased availability for matches and greater team success. 
 
 
 
 
 
 
 
 
 
Figure 2 Pearson correlation, 90% CI and qualitative inference for team-averaged values 
of each injury (injury burden) and team success (league points tally) outcome. Smallest 
worthwhile effect: r ± 0.3. Adapted from Williams et al. (2015b). 
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Meta-analysis data have shown that for every 1000 h of match play, a player will typically 
experience 81 injuries and three per 1000 h from training (Williams et al., 2013). However, 
no difference between backs and forwards was identified (Williams et al., 2013). 
Interestingly, figures 3 and 4 show that the majority of these injuries are ligament, tendon 
and muscle injuries of the lower limb (Williams et al., 2013). This is not surprising as the 
majority of injuries occur during the tackle (Figure 5), which tends to involve lower body 
collisions. These data are supported by more recent results from Southern hemisphere Super 
Rugby, where injury incidence per 1000 h was 83 for game play and two per 1000 h during 
training (Schwellnus et al., 2014). Williams et al. defined injury severity as minimal (2-3 
days), mild (4-7 days), moderate (8-28 days) and severe (> 28 days). Of these definitions, 
the most common (moderate) resulted in 28 incidence per 1000 h followed by mild (23 
incidence), minimal (17 incidence) and severe (15 per 1000 h; Williams et al., 2013). Adding 
genetic data to a player’s injury and performance profile might aid in athlete welfare and 
injury management.
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Figure 3. Injury incidence (95 % CI) by cause of injury incident. Adapted from Williams et al., (2013). 
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Injury incidence differs between rugby union playing positions (Figure 6). In a sample of 
899 athletes from the top tier of English rugby, hookers had the highest injury rate among 
the forwards mainly consisting of cervical disk injury but also including significant soft 
tissue (rotator cuff, meniscal/cartilage, cruciate ligament, calf muscle, hematoma, Achilles 
tendon and ankle lateral ligament) injuries. Among the backs, centres showed the greatest 
injury incidence compared to other backs and mainly consisting of hamstring muscle injuries 
(Brooks & Kemp, 2011). These positional differences in injury incidence further support 
research into the inclusion of genetic data for the management of player injury.
Figure 4. Injury incidence (95 % CI) by injury incident, injury incidence by location of 
injury. Adapted from Williams et al. (2013). 
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Figure 5 Injury incidence (95 % CI) by injury type. Adapted from Williams et al. (2013). 
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2.1.7 Concussion (mTBI) 
Omalu et al. (2005; 2006), showed for the first time that repeated head injury due to athletic 
collisions caused significant long term neurological injury which he termed “Chronic 
Traumatic Encephalopathy” (CTE) and attributed it to repeated mild-traumatic brain injury 
(mTBI; concussion). As concussion is a form of mTBI and is classified as such (Roozenbeek 
et al., 2013), concussion will be referred to as mTBI from here on. The long-term effects of 
mTBI on neurodegenerative illness are unknown (McCrory et al., 2013), however hints 
towards cognitive decline and depression have been suggested in retired (> 20 years) rugby 
union players (Decq et al., 2016). These symptoms are similar to those experienced by 
retired American Football athletes who were subsequently the subject of autopsy, resulting 
from suicide (~50 years old), in the discovery of CTE (Omalu et al., 2005; Omalu et al., 
2006; Omalu et al., 2011). Unfortunately, the only method currently available to identify 
CTE is post-mortem, leaving these analysis of rugby athletes difficult and unlikely. 
A 
B 
Figure 6 Incidence, average severity and days of absence due to injury for A, forwards and B, 
backs. Bubble size: days of absence/1000 player-hours. Adapted from (Brooks & Kemp, 2011) 
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Nonetheless, World Rugby have addressed this concern and have implemented strategies to 
minimise the risk of CTE in rugby athletes (Raftery, 2013; Fuller et al., 2015b; Raftery et 
al., 2016). Current mTBI incidence for elite 15’s rugby union range between 4.6-8.9 per 
1000 playing hours, with 40-50% resulting from a tackle situation (Gardner et al., 2014; 
Cross et al., 2015; Fuller et al., 2015a) - similar to that of most other injuries (Brooks & 
Kemp, 2011). However, the lower end of this range of mTBI incidence (< 5) is likely to be 
an underestimation because it is based upon data from several years ago (2012-2013 season), 
prior to the implementation of the recent mTBI reporting and return to play guidelines 
(Figure 7). The most recent data from Cross et al. (2015) more truly represents the current 
rugby mTBI incidence rate and is consistent with the English professional rugby union data 
from the 2013-2014 and 2014-2015 seasons (Figure 5: England Professional Rugby Injury 
Surveillance Project Steering Group, 2016). Of particular note was the finding that players 
diagnosed with mTBI who returned-to-play in the same season had a 60% greater chance of 
a subsequent time-loss injury than those that did not sustain a mTBI (Cross et al., 2015). 
 
Figure 7 Incidence per 1000 player hours of reported match concussions by season. Vertical 
blue line denotes change in data collection methods to electronic capture. Vertical dark red 
line denotes introduction of the pitch side concussion assessment. Adapted from the England 
Professional Rugby Injury Surveillance Project (2016). 
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Positional variation data in mTBI incidence are scarce and variable. Fuller et al. (2015a) 
reported no difference between backs and forwards, however the mTBI severity in centres 
was reported as 105 days absent per 1000 h (Risk ratio = 2.54) and greater than other backs 
(Brooks & Kemp, 2011). Higher mTBI metrics in centres are supported in Irish international 
players, with centres showing the second highest number of mTBI (16%) preceded by 
flankers (backrow; 22%) during the 2010-2011 season (Table 2: Fraas et al., 2014). Again, 
if there truly is a difference in mTBI rate between playing positions, given the possible 
catastrophic outcomes (Omalu et al., 2005; Omalu et al., 2006; Omalu et al., 2010; Omalu 
et al., 2011) and the re-injury rate following a mTBI event (Cross et al., 2015), knowledge 
of relevant molecular genetic variation among rugby athletes could lead to greater player 
welfare. 
 
 
 
 
 
 
 
 
Table 2. mTBI by playing position, Irish Rugby Football Union 
(IRFU) data. Adapted from Fraas et al., (2014). 
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2.2 Part 2: Sport Genomics 
 
2.2.1 Heritability 
Classical genetics is the process of estimating the heritability of a given trait and is 
investigated by studying families, identical twins (monozygotic; MZ) and fraternal twins 
(dizygotic; DZ). A number of physiological variables have been investigated in this way and 
are usually the preceding step to investigating specific target genes (Table 3). For example, 
Simoneau and Bouchard (1995) showed the heritability of muscle fibre type proportion was 
~50% when investigating 58 DZ and 35 MZ twin pairs. Following 20 weeks of endurance 
training in 98 two-generation families (n = 481), the heritable component of the ability to 
adapt, specifically an increase VO2max, was ~50% in the well-known HERITAGE Family 
Study (Bouchard et al., 1999). While these heritability estimates are substantial, other 
anthropometric phenotypes are estimated to be even greater. For example in a sample of over 
one million participants, heritability was estimated for body mass index (BMI) and mass at 
~60%, height at ~80%, elbow flexion and knee extension strength at ~50% and hand grip 
strength at ~60% (Silventoinen et al., 2008). Other phenotypes have been given even larger 
heritability estimates (Table 3; Calvo et al., 2002; Peeters et al., 2007; Missitzi et al., 2008; 
Busjahn et al., 2009; Schutte et al., 2016). 
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Table 3 Heritability estimates for selected phenotypes. 
Physiological phenotype Heritability Reference 
Muscle enzymes ~50% (Bouchard et al., 1986) 
% body fat ~30% (Bouchard & Perusse, 1988) 
% fibre type ~50% (Simoneau & Bouchard, 1995) 
Max O2 uptake ~60% (Schutte et al., 2016) 
Δ Max O2 uptake ~50% (Bouchard et al., 1988) 
Leg strength ~30% (Tiainen et al., 2004) 
Leg strength ~60% (Zhai et al., 2004) 
Mesomorphy ~80% (Peeters et al., 2007) 
Athlete status ~70% (De Moor et al., 2007) 
Left Ventricular mass ~80% (Busjahn et al., 2009) 
Height ~80% (Visscher et al., 2006) 
Frozen shoulder 
Tennis elbow 
~40% 
~40% 
(Hakim et al., 2003) 
Total joint replacement 
Joint stiffness 
~50% 
~30% 
(Williams et al., 2015a) 
Knee extension strength 
Hand grip strength 
Mass 
BMI 
~50% 
~50% 
~60% 
~60% 
(Silventoinen et al., 2008) 
Hand grip strength ~60% (Frederiksen et al., 2002) 
Explosive anaerobic power 
Max power development (5 s) 
Max O2 uptake (@2 min) 
Δ lactate deficit 
~70% 
~70% 
~90% 
~70% 
(Calvo et al., 2002) 
Max EMG activity ~80% (Missitzi et al., 2008) 
Brain plasticity  ~70% (Missitzi et al., 2011) 
Muscular degeneration (age-
related) 
~50% (Hammond et al., 2002) 
Longevity ~20% (Herskind et al., 1996) 
Skeletal muscle mass ~80% (Livshits et al., 2016) 
Max, maximum; BMI, body mass index; EMG, electromyography. 
 
Possibly the most useful future application of predictive genetics within sports genomics 
will be in the field of injury risk and severity estimation. However, little data exists on the 
heritability of injuries. Hakim et al. (2003) examined frozen shoulder (FS; characterised by 
tendon and ligament injury) and tennis elbow (TE; tendon inflammation) in 865 MZ and 963 
DZ twin pairs and reported 42% heritability for FS and 40% for TE. More recent research 
has examined joint stiffness (32%) and fibrotic conditions (connective tissues; 28%) and 
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even the likelihood of having a total joint replacement (46%; Table 3; Williams et al., 
2015a). Additionally, while the author is not aware of heritability estimates for mild-to-
moderate traumatic brain injury (TBI), the likelihood of suffering more severe future 
neurological disorders following these injuries is significant (Goldman et al., 2006). Brain 
plasticity is a significant factor in the recovery from brain injury (Pearson-Fuhrhop et al., 
2009) and has recently been shown to have a heritability of 68% in a small twin study 
(Missitzi et al., 2011). More specific to the present thesis, De Moor et al. (2007) investigated 
the genetic component of athlete status in female (1,000 DZ and 793 MZ) twins and reported 
a heritability estimate of ~70% for athlete status. These data show the considerable genetic 
component of many phenotypes related to sports performance and investigating this genetic 
variation is vital to truly understand any physiological trait (Table 3). 
 
2.2.2 Human genetic variation 
The variation that exists in the human genome has only relatively recently been documented 
via progress of the Human Genome Project. Initially, ~11 million single nucleotide 
polymorphisms (SNPs) and 3 million short insertions and deletions were identified 
(Sachidanandam et al., 2001; International HapMap Consortium, 2005; Frazer et al., 2007) 
and, at the time of writing, more than 88 million SNPs have been validated 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi). The vast majority of the ∼3 
billion nucleotides that constitute a human genome do not code for proteins, although most 
of those nucleotides nonetheless contribute to biological function in some manner via 
regulation of gene expression (ENCODE Project Consortium, 2012). There are a number of 
different types of human genomic variation that affect biological function, including rare 
mutations, structural variations and common SNPs. 
 
27 | P a g e  
 
The loss of function nucleotide change in the myostatin (MSTN) gene is an example of a rare 
mutation of relevance to human physiological function and results in an absence of the 
myostatin protein, which is a negative regulator of muscle growth. In humans, only one 
report of this mutation exists, causing extreme hyper-muscularity and a lean phenotype. At 
six days old, the affected child, presenting as homozygous for the mutation, showed twice 
the quadriceps muscularity (cross-sectional area) than that of an age-matched control (6.7 
cm2 compared to 3.1 cm2; Schuelke et al., 2004). The negative impacts (if any) of this 
mutation have not yet been reported and at 4.5 years the child showed no pathological 
symptoms. However, because myostatin affects other muscle types including cardiac 
muscle, later-onset pathological symptoms resulting from excessive myocardial growth are 
a possibility. 
 
Genetic variations where an allele occurs relatively commonly (≥ 1%) are called 
polymorphisms, as opposed to mutations. An example of one such polymorphism relevant 
to exercise physiology is the insertion/deletion (I/D) variation on intron 16 of the angiotensin 
converting enzyme (ACE) gene on chromosome 17. The ACE gene encodes the angiotensin 
converting enzyme, which is the main active product of the rennin-angiotensin system. The 
insertion of the 287 base pair (bp) DNA sequence (I allele), despite being in a non-protein 
coding region of the ACE gene, produces lower circulating and tissue concentrations of the 
ACE protein compared to the D allele (Almeida et al., 2010). One main action of the ACE 
enzyme is to degrade inactive angiotensin I and generate the vasoconstrictor angiotensin II, 
while another is to degrade vasodilator kinins and is therefore hypothesised to influence 
mitochondrial oxygen consumption and exercise economy in some circumstances 
(Puthucheary et al., 2011). 
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An example of a SNP relevant to exercise performance found in an exon (a region of DNA 
that encodes for protein) is the ACTN3 R577X gene variant. The ACTN3 gene encodes for 
the α-actinin-3 protein, which is expressed almost exclusively in fast glycolytic type II fibres 
and is a structural component that binds the actin thin filament to the sarcomere Z line. This 
SNP is located on exon 16 of the ACTN3 gene (North et al., 1999) and is characterised by 
the replacement of the normal codon (a 3 bp sequence that codes for an amino acid (Arg; 
R)) by a premature termination codon (X) at the 577 amino acid position and results in the 
complete absence of the α-actinin-3 protein. The absence of this protein (XX genotype) is 
associated with a lower proportion of type II muscle fibres - amongst other fibre 
characteristic - and, accordingly, is found at a lower frequency in elite power/sprint athletes 
compared to other athletes and non-athletes (Eynon et al., 2013a). Both the ACE I/D and 
ACTN3 R 577X variants will be discussed in greater detail in part 3 of this chapter as they 
are the subject of chapter 4. 
 
2.2.3 Genetics and athlete status 
In a review published in 2012, at least 79 genetic markers were identified that had been 
associated, in at least one prior research paper, with elite athlete status (Ahmetov & 
Fedotovskaya, 2012; Ahmetov et al., 2016). That number was reduced to 20 when the 
criterion was at least two prior research papers, and probably even some of those associations 
will not prove to be true as more data are accumulated. The first scientific investigation to 
assess the molecular genetic component of elite athlete status (Gayagay et al., 1998) showed 
a significant association of the ACE I/D variant (mentioned previously) with elite status in 
64 rowers. Subsequently, the ACE I allele has been associated with elite performance in a 
variety of sports, though not consistently, and the research is probably best summarised by 
reference to the meta-analysis of Ma et al. (2013) who found that the II genotype of ACE I/D 
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was associated with physical performance (Odds ratio (OR) = 1.23), especially endurance 
performance (OR = 1.35). 
 
For the ACTN3 R577X variant already mentioned, the R allele has been consistently 
associated with elite power and sprint athletes from a variety of backgrounds and in top elite 
sprinters, a complete absence of the XX genotype has been identified (Yang et al., 2003; 
Niemi & Majamaa, 2005), compared to an XX genotype frequency of ~18% in the general 
Caucasian population. Again, the meta-analysis by Ma et al. (2013) nicely summarises the 
association of the R allele with elite power athlete status (OR = 1.21). 
 
A number of athlete cohorts have gradually emerged, hosting steadily larger samples of elite 
and sub-elite athletes from various sports for the investigation of athlete status (Pitsiladis et 
al., 2013). A UK athlete cohort is currently being established, of which the samples within 
this thesis are part (RugbyGene project; Chapter 3.1.1). Furthermore, an advancement of 
sports genomics has seen the inclusion of team sport athlete data, however considerable 
methodological limitations have been identified and are discussed in the following. 
2.2.3.1 Genetic and team sports. 
Unlike individual or single attribute based sports (e.g. sprint speed in sprinters, max oxygen 
uptake in endurance athletes), the evidence for genetics playing a role in elite status within 
team sports is less compelling (for a full overview of each sport see appendix 5). Consistent 
with individual sporting performance, the most convincing evidence within team sport 
genomic investigations are of ACTN3 gene polymorphisms. Furthermore, evidence form 
soccer athletes shows the most compelling genetic associations between elite team sport 
athlete status and ACTN3 (Santiago et al., 2008; Egorova et al., 2014). Other genetic 
associations are certainly less convincing (see limitations below), for example low 
participant numbers and to a lesser extent the classification of “elite” is questionable in a 
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number of studies that have investigated associations of ACE I/D, TNF G308A and FGFR1 
genes with team sport athlete status (Gronek et al., 2013; Salles et al., 2015). Similar to the 
coverage of genetics of elite status in these aforementioned team sports, rugby is also poorly 
described with little convincing, yet potential, evidence for the specific role played by 
genetics and is discussed below. 
 
2.2.3.2 Genetics and rugby 
As early as 1922 scientists were hypothesising about the role of heritability in rugby union 
athletes. Jack (1922) documented the playing positions in 23 sets of elite rugby-playing 
brothers (n = 63), including a number of international representatives and concluded that 
“the ability required for playing in certain positions in rugby football is inherited” (page 
161). Five full publications in peer-reviewed journals applying molecular genetics to rugby 
union exist (appendix 5). Goh et al. (2009) reported that the ACE II genotype was associated 
with a higher ventilatory threshold in non-elite Asian rugby players but the very small cohort 
(n = 17) is a major limitation to that study. Bell et al. recently assessed ACE I/D and ACTN3 
R577X genotypes in 68 and 102 young non-elite rugby union players, respectively (Bell et 
al., 2009; Bell et al., 2010; Bell et al., 2012c). No associations were identified between either 
polymorphism and athlete status, playing position or the physiological and anthropometric 
parameters assessed, perhaps due to the rather small sample size and the sub-elite status of 
the players. However, a statistical tendency was identified within playing positions for 
ACTN3 (P = 0.066; Bell et al., 2012c), which suggests that with a greater sample size and 
higher standard of player statistical significance may be reached. With such little data 
regarding the genetic characteristics of rugby union players in the literature, this gap should 
be filled with high quality data using appropriate experimental designs (as per section 2.2.6).  
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2.2.4 Limitations in team sport genetics 
The scientific literature has recently seen a substantial rise in the number of peer reviewed 
sports genomics publications (Ahmetov & Fedotovskaya, 2012; Ahmetov et al., 2016). 
Because of this increase in publication volume, multiple reviews have been published 
concerned with updating the readers on the advancements in the field (Rankinen et al., 2001; 
Pitsiladis et al., 2013; Bouchard, 2015; Loos et al., 2015). To date, a large portion of reviews 
have focused specifically on the genetic variation of either endurance athletes (Eynon et al., 
2011c; Wilber & Pitsiladis, 2012), strength/power/speed athletes (Berman & North, 2010; 
Hughes et al., 2011; Eynon et al., 2013a) or a combination of the two (Puthucheary et al., 
2011; Ma et al., 2013; Tucker et al., 2013). However, there has been little synthesis of sports 
genomic data in relation to team sports such as soccer, rugby, field and ice hockey, – i.e. 
those that do not also exist as individual sports such as relay swimming or running, doubles 
badminton or tennis, etc. 
Additionally, recent publications have exposed inconsistencies in the reporting of important 
statistical analyses within the peer-reviewed literature of well-known academic journals such 
as Nature Genetics, American Journal of Human Genetics, American Journal of Medical 
Genetics, Cell and others (Salanti et al., 2005; Kirkham & Weaver, 2015; Namipashaki et 
al., 2015; Chavalarias et al., 2016). These inadequacies have been suggested to result in false 
findings despite appearing as statistically significant results (Ioannidis, 2005). An 
investigation of this kind has never been performed in the context of sports genomics and 
could identify important, yet rectifiable errors within the scientific literature. 
 
It is important for sport and exercise genomic research to be of the highest possible standard 
(better than its current state; Pitsiladis et al., 2013) and to learn from the mistakes of other 
fields of genetic investigation (Mattsson et al., 2016). These limitations might have 
substantial implications for ethical matters (Wackerhage et al., 2009) such as familial 
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sensitivity in relation to personal genetic data and magnified by the possibility of 
misunderstanding of particular health-associated genomic information (Webborn et al., 
2015). Improving the quality of team sport genomic research can be achieved by reviewing 
the currently available literature, identifying persistent methodological limitations that can 
be rectified and uniformly adopted/applied across the field. Therefore, the purpose of this 
section was to review team sport genomic publications (appendix 5) and to identify 
methodological concerns specific to the genomic investigation of team sport athletes and 
attempt to rectify these limitations in the experimental chapters of the present thesis. 
 
2.2.4.1 Summary of findings 
The large number of sports genomic publications that were identified can be categorised into 
those that include team sport athletes (Multi Sport Articles), normally pooled into a single 
group (mixed) for comparison with either endurance or sprint/power/strength athletes, and 
those that solely investigate individually team sport athletes (Single Sport Articles; see 
appendix 5). Of these team sport publications, a total of 67 original articles were identified 
with 27 assessing only individual team sports within the analysis, the majority of those being 
soccer athletes (55.5%) followed by rugby union (18.5%), with the rest divided between four 
other sports (Figure 8). These data show that of the limited scientific attention devoted to 
sports genomics, the majority of these involve soccer athletes - with little investigation of 
other team spots athletes. It is clear that more scientific efforts need to be devoted to the 
genomic variation of other team sport athletes and the present thesis attempts to do this 
regarding elite rugby union athletes.  
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Figure 8 (insert) further documents the yearly growth (R2 = 0.77) in team sport genomic 
publications, following 2014, with the greatest growth occurring from 2011-2014 and a 
reduction in 2015. This drop in publications following 2014 is possibly a reflection of the 
pattern change in sport genomic research driving towards research collaboration and 
generation of larger athlete cohorts (Pitsiladis et al., 2016). Furthermore, it is noteworthy 
that of the single sport articles identified, 51.9% of the publications had a sample size ≤ 100, 
33.3% had ≤ 201 and 14.8% showed > 200 (Table 4). This identifies a significant issue in 
the field of sports genomics, however attempts are being made to combat this issue with 
largescale internationally collaborative consortia (Pitsiladis et al., 2016). 
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Figure 8 Number of sports genomics publications until December 31st 2015 that include 
team sport athletes, categorised by sport. Insert: Number of sports genomic publications that 
include team sports by year. Regression coefficient describes an exponential curve 
(Microsoft Excel, 2013). 
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In relation to statistical analysis within the published team sport genomic research, 
considerable shortcomings were identified (Table 4). Hardy-Weinberg equilibrium was 
absent in ~36% of all reviewed articles and in 37% of individual team sports publications. 
Reporting some form of effect estimate was present in only 29% of all reviewed articles and 
34% of single team sport genomic original investigations. However, the most concerning 
result pertains to the extremely low consideration of multiple testing errors, with only 31% 
and 33% of articles reporting corrections (Table 4). Thus ~70% of peer-reviewed sports 
genomic investigations containing team sport athletes may be fundamentally flawed 
(assuming that ≥ 2 null-hypothesis are performed) and contain type 1 errors. Given these 
methodological limitations and that team sport specific genetic publications are generally 
growing (Figure 6 insert), future research within sports genomics needs to improve on 
quality and correct these simple inadequacies. 
 
Table 4 Summary of statistical and sample size findings for all reviewed articles and individual 
single sport analysis articles. 
 Statistical tests All articles 
n = 67 (%) 
Single sport analysis 
n = 27 (%) 
Hardy-Weinberg  Chi Square 43 (64.2) 17 (63.0) 
 
Effect size 
 
Regression analysis, likelihood ratio and 
Odds ratio (OR) 
 
OR specifically  
22 (32.8) 
 
 
19 (86.4) 
9 (29.6) 
 
 
7 (77.8) 
Multiple correction  FDR, Bonferroni, Holm–Bonferroni, 
Benjamini-Hochberg and Scheffe’s 
multiple comparison  
 
FDR specifically 
14 (21.9) 
 
 
 
3 (4.7) 
5 (19.2) 
 
 
 
2 (7.7) 
Athlete sample size n ≤ 100   21 (31.4) 14 (51.9) 
 n = 101 - 200   24 (35.8) 9 (33.3) 
 n ≥ 201   22 (32.8) 4 (14.8) 
These data are generated under the assumption that all reviewed investigations required the above statistics analysis. 
Multiple corrections data includes investigations undertaking ≥ 2 null-hypothesis test for the genetic analysis, i.e. for 
all articles n = 64 and for single sports analysis n = 26. 
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2.2.5 Considerations based on team sport review findings 
 
2.2.5.1 Sex 
Striving to identify genetic variants important for athlete populations have led researchers to 
combine male and female athletes in their genetic analysis (appendix 5). However, because 
athleticism is highly phenotypically specific, consideration of the physiological diversity 
between male and female elite athletes must be accounted for. As such, while genetic 
variation may be similar between sexes, autosomally speaking, physiological demands and 
capabilities differ considerably at the respective elite levels (Reilly & Borrie, 1992; Stølen 
et al., 2005; Gabbett, 2007; Marques et al., 2009; Ziv & Lidor, 2009; Lidor & Ziv, 2010; 
Ziv & Lidor, 2010; Lidor & Ziv, 2015; Morehen et al., 2015). Because of these physiological 
differences, combining male and female elite athletes is not appropriate and may introduce 
false negatives into study results. If, when both sexes are assessed individually in genotype-
phenotype and case-control associations involving the same variant(s), combining the sexes 
may become viable and warranted. Until then, assessing both male and female elite athletes 
separately (Holdys et al., 2013) and for a given individual team sport or athletic category 
(sprint/power or endurance) is the only way to reduce the possibility of diluting the 
experimental findings due to physiological diversity between elite athletes of different sexes. 
Nonetheless, combining males and females in the control group is appropriate, as long as the 
frequency of the genetic variants being studied does not differ between sexes, with the 
genetic similarities detailed within the scientific report. 
 
2.2.5.2 Eliteness 
Classifying athletic level is a considerable challenge regarding team sport athletes and a 
sport specific standardised method that could be easily replicated - therefore easily 
comparable between studies - would give the field greater transparency regarding the results 
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from individual investigations. Current findings regarding the genetic contribution to athletic 
status have so far been generally inconclusive (Pitsiladis et al., 2013) and might, partly, be 
a result of the variation in athletic level and the combination of athletic levels within a given 
cohort/group/category. Thus, there is a necessity to define the highest athletic level 
(eliteness) for individual sports within a given scientific investigation. For example, are 
soccer athletes competing in the top Spanish league (Pruna et al., 2013) equivalent to Polish 
top league athletes (Egorova et al., 2014)? As such, is it possible to compare their genetic 
association results? Within rugby union the author proposes a definition of ‘elite’ as athletes 
competing in the highest competitive league of a ‘Tier 1’ rugby nation (detailed in chapter 
3.1.1), originally defined by World Rugby (the governing body for rugby union; 
International Rugby Board, 2004). While it is appreciated that defining ‘elite’ in this way 
may be difficult for some sports, defining eliteness for a given sport and all following 
research adhering to that perimeter would significantly enhance the confidence in scientific 
findings and allow genuine replication. 
 
2.2.5.3 Sample size 
The nature of genetics research dictates that extremely large sample sizes are needed before 
genuine conclusions can be made about the variation within a given cohort, for a given 
phenotype (Gauderman, 2002). Due to the natural rarity of elite athletes it is difficult to 
congregate large samples of particular athlete groups (power/endurance/team sport athletes) 
and even more difficult to recruit large cohorts of single sport athletes (such as Rugby 
Union). As such, intentions to recruit large cohorts have led some authors to combine ‘a 
single athlete’ from a number of sports (all with considerable physiological differences, for 
example shooting (n = 1), cycling (n = 1), jazz dance (n = 1) etc.) within the cohort for 
genetic analysis (Boraita et al., 2010; Jin et al., 2015) and invariably, have led to misleading 
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findings. This type of athlete inclusion is analogous to taking 1000 ‘sick’ people (suffering 
from various medical conditions) and looking for the ‘sick gene’. 
 
Nevertheless, to overcome this issue of sample size, a number of athlete cohorts have 
emerged hosting large cohorts of elite, sub-elite and non-elite athletes from various sports 
(Pitsiladis et al., 2013). Some of these cohorts combine to reduce the likelihood of type 1 
error. The largest of these merged cohort studies included 2178 Caucasian athletes of 
Russian (n = 1780) and polish (n = 398) ancestry, of which 31% were classified as elite 
(Mustafina et al., 2014). While this design rightfully attempts to combat the issue of sample 
size, it may also increase the likelihood of type 1 error. In fact, estimations for adequate 
sample size have been postulated for both single SNP case control and genome wide studies 
(Hong & Park, 2012). Depending on the genetic model of interest, the minor allele frequency 
and statistical power of 80%, a sample of 248 cases (team sport athletes in this case) and the 
same in controls are the minimum requirements. Acquiring this number of elite samples is 
difficult enough, however in the case of team sports athletes where the physiological 
demands differ considerably across positional groups, this number is required for each 
individual group (playing position) in order for the results to be conclusive. Due to the 
difficulties in recruiting large cohorts of homogenous athletes (i.e. the same team sport), 
preliminary investigations should include approximately this number (n = 248) of elite cases 
and controls for initial analysis – which is often not the case (Table 4). Furthermore, the 
development of the cohort should eventually include this sample size within each positional 
group. For example, basketball comprises three positional groups (centres, guards and 
forwards) and therefore would ultimately require ~744 cases to test a single polymorphism 
among playing positions. This number of participants would give the analysis the appropriate 
statistical power for one to be confident in the research findings - that the studied 
polymorphism was truly associated (or not) with basketball athlete status. However 
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acquiring a sample of this size of elite (often professional) team sport athletes is extremely 
difficult and would require many years to accomplish. 
 
2.2.5.4 Geographical ancestry considerations 
Geographical ancestry are important considerations for case-control and genotype-
phenotype association studies (Jorde & Wooding, 2004) because individual genetic variants 
are known to differ in allele frequency between populations (1000 Genomes Consortium, 
2012). Therefore, investigations of molecular genetic markers should be performed on 
athletes from well-defined geographic ancestries. Only when one understands the genetic 
diversity of individual geographical ancestries can one compare ethnic diversities for a given 
variant. Current team sport genetic publications, for the most part (however not exclusively, 
for example Pruna et al., 2013), consider geographical ancestry in their study design, but is 
still a substantial consideration worth mentioning within the context of the present thesis. 
 
2.2.5.5 Positional analysis 
Investigating the genetic components of team sport athleticism provides the unique 
consideration of positional differences, in terms of physiological demands. These differences 
can be quantified by game demand data (for rugby union see chapter 2.1.2; Table 1) that 
shows a preference for differing metabolic pathway proportions dependent on playing 
position (Bradley et al., 2013; Jones et al., 2015). Furthermore many physiological quantities 
(maximal strength, running speed, aerobic capacity, muscle power, etc. for rugby union see 
Table 1) differ by playing position (Abdelkrim et al., 2010; Smart et al., 2013) and should 
be considered as these quantities may have considerable genetic components. Three recent 
investigations of elite athletes have considered positional specificity in their genetic analysis 
of team sport athletes (Ginevičienė et al., 2009; Egorova et al., 2014; Gineviciene et al., 
2014). When soccer athletes were arranged into positional groups (forwards, defenders, 
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midfielders and goalkeepers), Gineviciene et al. (2014) identified genetic variation across 
playing position for ACE, PPARGC1A and PPARA. Similar positional variation with ACE, 
ACTN3, PPARA, UCP2 was associated in Russian soccer athletes (Egorova et al., 2014). 
However, an earlier investigation showed no difference in terms of ACE I/D variation 
(Ginevičienė et al., 2009). These data show the importance of positional analysis when 
considering team sport athletes - where the physiological and positional demands differ 
(further evidence is presented in chapter 4 and 5). 
 
2.2.6 Statistical aspects 
Molecular genetic association studies aim to investigate specific genetic variations in a 
population, which have a phenotypic consequence. Applying the correct statistical analyses 
and interpretation of the results generated from these analyses is paramount to allow 
meaningful conclusions to be drawn from the research findings. However, lacklustre use and 
reporting of statistical analysis are a considerable concern across the biomedical literature 
(Table 4; Salanti et al., 2005; Kirkham & Weaver, 2015; Namipashaki et al., 2015; 
Chavalarias et al., 2016). Nevertheless, a number of small but important statistical 
considerations can strengthen the confidence of athlete-genomic research findings and 
enhance the progress of the field. 
 
2.2.6.1 Hardy-Weinberg principle 
The Hardy-Weinberg principle (HWP; Hardy, 1908; Weinberg, 1908) states that in a 
randomly mating population, genotypic frequencies are indicative of the sample function of 
allele frequencies and in the absence of perturbing forces, such as selection, genetic drift, 
mutation and migration will remain constant over time (Waples, 2015). Because mutations 
are extremely rare and genetic drift is a function of sample populations (occurs in small 
isolated populations; Waples, 2015) and team sport genetic samples come from the wider 
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population, these indicatives can be ignored in the context athlete genomics. Regardless, a 
sample that deviates from this principle is not indicative of the wider population and is likely 
due to population stratification (Wigginton et al., 2005) or genotyping error (Xu et al., 2002). 
It is important to assess the HWP to insure that the population of interest is representative of 
the general population, specifically within the control sample. In fact, Ziegler et al. (2011) 
recommended that in case-control study designs the HWP should be assessed in the control 
group only because a deviation from HWP in ‘cases’ may indicate a genetic association. 
Considering athlete-genome assessment, researchers are artificially selecting cases (athletes) 
aiming to identify the presence or absence of local population stratification. Testing these 
groups, to be an indicative sample of the general population, is rather meaningless in a case-
control design (Ziegler et al., 2011). However, when investigation genotype-phenotype 
associations (in the absence of a control group) or in case-control athlete group(s), testing 
for the HWP should be applied as an indication of genotyping error, as population 
stratification is unlikely because most sport genomic investigations control for geographical 
ancestry. In the present chapter of team sport genetic association studies (n = 67), 36% did 
not report adherence to or deviation from HWP which is similar to that reported in other 
fields of genetic investigation - in highly prestigious journals (Salanti et al., 2005; 
Namipashaki et al., 2015). It is important that the field of sports genomics overcomes this 
simple oversight, which does appear to be the case in the more recent publications (appendix 
5). 
 
2.2.6.2 Corrections for multiple hypothesis testing 
Following analysis of the HWP and the appropriate null-hypothesis test, the consideration 
of type 1 error (discovering false positives), through multiple testing corrections, is often 
neglected in sports genomic investigations (Table 4). Given the large number of statistical 
tests often applied in genomic investigation, controlling for false positives is of paramount 
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importance to generate valid results. Essentially, the greater the number of statistical tests 
performed, the greater the likelihood of discovering false positives leading to spurious and 
often un-reproducible results. There are two main ways of controlling for this error, the 
family-wise error rate (FWER; such as the Bonferroni method, 1936) or the false discovery 
rate (FDR; such as Benjamini & Hochberg method; Benjamini & Hochberg, 1995). Often, 
the FWER, which effectively makes the confidence coefficient 99% (rather than the 
traditional 95%) may be too strict, as the amount of null-hypothesis tests increases (Noble, 
2009). This, may lead to the occurrence of type 2 errors (failing to detect associations) and 
as such the FDR is the preferred method (Noble, 2009). The FDR takes into account the 
statistical significance of the tested null hypotheses as a ranked proportion of the number of 
tests performed (for a more comprehensive view of multiple testing procedures, see Dudoit 
& Van Der Laan, 2007) and in doing so also controls FWER (Benjamini & Yekutieli, 2001). 
There have been multiple variations of FDR tests developed (reviewed in Austin et al., 2014) 
since the original proposal (Benjamini & Hochberg, 1995). Perhaps the most interesting, and 
applicable to the present chapter, is the recently proposed hierarchical testing procedure 
which allows for the control of FDR and provides a more reliable basis for the identification 
of variant associations while maintaining statistical power (Peterson et al., 2016). The 
Peterson et al. method allows for the hypotheses tested to be subgrouped into “families” of 
hypotheses to investigate specific scientific questions which may relate to the specific 
phenotype being tested. This method is worthy of consideration for future reports, 
specifically within team sport investigations when positional considerations will require 
additional statistical tests. Presently, only 22% of team sport genetic studies reported any 
form of multiple testing corrections (Table 4). This is considerably lower than other 
biomedical fields of investigation (72%; Kirkham & Weaver, 2015). Furthermore, only three 
studies (4.7%) reviewed within the present chapter considered FDR (Table 4). Given the 
importance of identifying valid results, controlling for type 1 and 2 errors is of principal 
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importance for sports genomics investigation and the best method of doing this currently 
stands with FDR testing. 
 
2.2.6.3 Effect size 
It has long been suggested that the null-hypothesis testing approach (such as the P value) is 
an inappropriate statistical approach for drawing conclusions from scientific investigations, 
at least as an exclusively reported value. One journal ‘Basic and Applied Social Psychology’ 
have banned the reporting of P values from any future submissions and requires every 
submitted article to provide some measure of effect size (Trafimow & Marks, 2015). An 
effect size can be defined as “a quantitative reflection of the magnitude of some phenomenon 
that is used for the purpose of addressing a question of interest” (page 137; Kelley & 
Preacher, 2012). This can be interpreted as the extent (magnitude) of an association that a 
genetic variant(s) has on a given parameter (athletic status, positional specificity, phenotypic 
measures) within a team sport, and can be measured with an effect statistic. There are a 
number of ways to estimate the effect size of an association, for example relative risk, odds 
ratio (OR) etc. risk ratios for example, can only be calculated when groups intended for 
comparison are from the same population sample (as in, the effect of drug A or B in a 
disease). Whereas in a case-control design when one of the cohorts has been specifically 
selected (athletes) and is being compared to a completely separate cohort (control), the 
appropriate effect static is the OR (Clarke et al., 2011), with equivalent effect estimates 
considered when genotype-phenotype study designs are applied (Lakens, 2013). 
 
Within the current sample of team sport genomic inquiries, only 33% of the reviewed articles 
presented findings pertaining to some form of effect size with 86% of those 33% reporting 
OR (Table 4). Interpretations of OR statistics have been recently investigated, with the 
magnitude of the observed effect suggested as small (OR ≤ 1.68), medium (OR ≤ 3.47) and 
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large (OR ≤ 6.71; Chen et al., 2010). Furthermore, an OR < 2.2 has been identified as having 
low predictive efficiency in terms of binary genetic analysis and an OR > 5.4 presenting as 
high (Rubanovich & Khromov-Borisov, 2014). If a large OR is identified with appropriately 
tight confidence intervals this will be an indication that the sample size was effective and 
the effect was real. As such, within sports genomic investigations it is no longer acceptable 
to report significance values without some measure of the effect. Furthermore, the 
interpretation and discussion of OR results should be centred on greater predictive ability of 
OR statistics (i.e. OR ≥ 5.4). 
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2.3 Part 3: Rationale for thesis candidate gene variants 
 
2.3.1 ACE I/D and ACE tag SNP rs4341 
Angiotensin converting enzyme (ACE) degrades the inactive decapeptide angiotensin I and 
generates the vasoconstrictor octapeptide angiotensin II (Dzau, 1988a; Munzenmaier & 
Greene, 1996), while accelerating the degradation of vasodilating kinins (Dietze & 
Henriksen, 2008). The ACE enzyme is the main active product of the rennin-angiotensin 
system (RAS; Erdös & Skidgel, 1987), which is the system responsible for control and 
regulation of blood pressure/volume and exists in a number of tissues. Local RAS has been 
identified in adipose tissue (Jonsson et al., 1994), human myocardium (Dzau, 1988b), and 
skeletal muscle (Reneland & Lithell, 1994). Interestingly, in skeletal muscle, angiotensin II 
has been shown to modulate muscle hypertrophy in response to mechanical load (Gordon et 
al., 2001) and appears to regulate smooth (Geisterfer et al., 1988; Berk et al., 1989) and 
cardiac (Sadoshima et al., 1993; Ishigai et al., 1997) muscle growth. 
 
A common ACE gene variant has been identified and is characterized by the presence 
(insertion; I allele) or the absence (deletion; D allele) of a 287-bp sequence in intron 16 of 
chromosome 17, representing an Alu repeat element. Furthermore, an ACE tag SNP (rs4341) 
has been identified in perfect linkage disequilibrium with ACE I/D in Caucasians (Glenn et 
al., 2009) and Asian (Tanaka et al., 2003) populations and is now commonly used. The I 
allele has been associated with lower circulating (Rigat et al., 1990; Almeida et al., 2010) 
and myocardial tissue (Danser et al., 1995) ACE activity and a higher proportion of slow-
twitch type I skeletal muscle fibres (Zhang et al., 2003). In humans, ACE genotype has been 
associated with cardiac and skeletal muscle hypertrophy in response to exercise training 
(Montgomery et al., 1997; Folland et al., 2000). Specifically, the D-allele has been 
repeatedly associated with increased left ventricular mass following training in military 
45 | P a g e  
 
recruits (Montgomery et al., 1997), endurance athletes (Di Mauro et al., 2010) and elite 
footballers (Fatini et al., 2000). 
 
In the context of human physical performance, the ACE I allele has been associated with 
elite endurance performance in a variety of events (Gayagay et al., 1998; Montgomery et 
al., 1998; Myerson et al., 1999; Alvarez et al., 2000; Cieszczyk et al., 2009; Cieszczyk et 
al., 2010), with the D allele being associated with sprint and power-related sports (Woods et 
al., 2001; Kikuchi et al., 2012; Eider et al., 2013; Papadimitriou et al., 2016). However, 
several other studies have reported no association between ACE I/D and athlete status, while 
in Israeli athletes the D allele is overrepresented in endurance athletes compared to sprinters 
(Amir et al., 2007), possibly due to different geographic ancestry, accidental selection bias 
or other ACE-related molecular interactions (Raleigh, 2012). In terms of association studies 
of mixed metabolically demanding sports, the D allele appears more prevalent, but only in 
soccer athletes (Juffer et al., 2009; Egorova et al., 2014; Gineviciene et al., 2014), with no 
difference in others (Bell et al., 2009; Bell et al., 2010). Furthermore, in a recent meta-
analysis, Ma et al (2013) reported the II genotype was associated with physical performance 
(OR = 1.23), especially endurance performance (OR = 1.35; Figure 9), justifying the 
inclusion of ACE I/D in the present thesis (Table 5). Interestingly, Gineviciene et al. (2014) 
showed that ACE DD genotype frequency was lower in defenders (P = 0.033) and 
midfielders (P = 0.012) compared to controls, suggesting the existence of positional 
variation. Given that ACE D allele appears more prevalent in elite soccer athletes, it is 
plausible that this relationship may extend to rugby athletes and warrants investigation (see 
experimental chapter 4).
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2.3.2 ACTN3 R577X rs1815739 
Alpha-actinins constitute a family of actin-binding proteins necessary to anchor actin 
filaments to the sarcomeric Z-line (Blanchard et al., 1989; MacArthur & North, 2004). The 
Figure 9 Meta-analysis of the association between sport performance and ACE I/D 
polymorphism (II vs. ID+DD). Abbreviation: CI, confidence interval; OR, odds ratio. Adapted 
from (Ma et al., 2013). 
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α-actinin-3 protein is one such structural component that binds the actin thin filament to the 
Z line by its distinct N terminal actin binding domain and is expressed almost exclusively in 
fast glycolytic type II muscle fibres (Beggs et al., 1992; Mills et al., 2001). A functional 
single nucleotide polymorphism (SNP) in the ACTN3 gene, located in exon 16 of 
chromosome 11, has been identified (North et al., 1999) and is characterized by a C > T 
transition. This results in an arginine codon (R) being replaced by a premature termination 
codon (X) at the 577 amino acid position. Therefore, RR homozygotes have the fully 
functioning gene variant, whereas individuals homozygous for the X allele are unable to 
produce the α-actinin-3 protein and occurs in ~18% of Europeans (Yang et al., 2003). 
Recently, a dose-dependent effect on α-actinin-3 protein and mRNA expression levels were 
identified in rodents, where the equivalent to the human RR genotype showed the greatest 
expression levels (Hogarth et al., 2016). 
 
Furthermore, the R allele has been frequently reported to be associated with elite power and 
sprint athlete status (Yang et al., 2003; Niemi & Majamaa, 2005; Druzhevskaya et al., 2008; 
Papadimitriou et al., 2008; Roth et al., 2008; Eynon et al., 2010; Papadimitriou et al., 2016), 
while the X allele has been associated with endurance performance (Zhang et al., 2003; 
Niemi & Majamaa, 2005). However, inconsistent observations exist  (Saunders et al., 2007). 
Interestingly, both Yang et al. (2003) and Niemi and Majamaa (2005) found a complete 
absence of the XX genotype in the very best sprinters and low frequencies in good sprinters 
(~6%), which suggests the importance of the α-actinin-3 protein for high velocity muscular 
contractions. Additionally, meta-analysis have reported the ACTN3 R allele association with 
speed and power performance (OR = 1.21, Figure 10; Ma et al., 2013) and the RR genotype 
with strength and power (Alfred et al., 2011). Consequently, due to the differences in 
physical characteristics between rugby union athletes and the general population and the 
diverse physiological demands within rugby union (Table 1), this genetic marker could 
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predispose rugby athletes to success or selection at the elite level either through strength and 
power or endurance characteristics.
Figure 10 Meta-analysis of the association between sport performance and ACTN3 R577X 
Polymorphism (RR vs. RX+XX). Abbreviation: CI, confidence interval; OR, odds ratio. 
Adapted from (Ma et al., 2013). 
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Mechanistically, an α-actinin-3 deficiency might impair the performance of the type II fibres 
(MacArthur & North, 2007), that are bigger (Broos et al., 2016), are able to contract faster 
and produce more power than type I muscle fibres (Bottinelli et al., 1996; Gilliver et al., 
2009). However, of benefit to certain physiological phenotypes, a higher propensity for 
aerobic enzymatic activity (porin, COX IV, hexokinase, citrate synthase, succinate 
dehydrogenase and β-hydroxyacyl CoA dehydrogenase; Seto et al., 2011; Seto et al., 2013) 
and greater force recovery after fatigue that has been identified in α-actinin-3 deficient mice 
(Seto et al., 2011). This could indicate that humans with the XX genotype (α-actinin-3 
deficiency) might have a greater capacity for recovery from fatiguing exercise. This notion 
is further corroborated by findings from knockout (KO) mouse models that α-actinin-3 
deficiency results in lower muscle mass and strength, longer time to exhaustion and 
enhanced recovery from fatigue (MacArthur et al., 2008; Chan et al., 2011). Confirmation 
in human models are beginning to emerge, with one recent investigation showing XX 
individuals could attain the ventilatory threshold at higher speeds, suggesting that they can 
sustain higher running speeds at lower exercise intensity (Pasqua et al., 2016). With others 
showing greater sprint, power and strength abilities for RR individuals (Table 5; Garton & 
North, 2016). 
 
2.3.3 FTO rs9939609 
The fat mass and obesity associated (FTO) gene is the most investigated gene in the genetics 
of obesity and has complex molecular mechanisms which are yet to be fully elucidated. 
Recent genome-wide association studies (GWAS) have identified several common SNP in 
the human FTO gene in association with obesity, body mass index (BMI; Jacobsson et al., 
2012), cardiovascular disease and hypertension (Liu et al., 2013; He et al., 2014). These 
FTO SNPs, which are in strong linkage disequilibrium (r2  > 0.80), are located in a cluster 
on the first intron of chromosome 16 and consequently exhibit similar obesity-related traits 
(Loos & Yeo, 2014). Thus, within different FTO variants, those alleles that have been 
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positively associated with obesity-related phenotypes are referred to as risk alleles, and those 
demonstrating a protective effect are referred to as protective alleles. Homozygotes for the 
minor risk allele consistently demonstrate greater BMI and body mass (3-10 kg) in 
comparison to protective allele carriers (Table 5; Frayling et al., 2007; Rauhio et al., 2013; 
Woehning et al., 2013). This greater body mass associated with risk allele carriers is likely 
to be adipose tissue (Andreasen et al., 2008; Rampersaud et al., 2008; Tanofsky-Kraff et al., 
2009; Wing et al., 2009; Liu et al., 2010; Lear et al., 2011; Sonestedt et al., 2011; Luis et 
al., 2012; Matsuo et al., 2012; Matsuo et al., 2014), although there exist some suggestions 
of greater fat free mass (FFM) in addition to fat mass (Jess et al., 2008; Sonestedt et al., 
2011). 
 
Environmental lifestyle factors (diet and physical activity) have also been investigated for 
FTO gene-environment interactions. Risk allele carriers are more likely to choose a high fat 
diet when compared to protective allele carriers (Sonestedt et al., 2009; Tanofsky-Kraff et 
al., 2009; Corella et al., 2011; Lear et al., 2011; Lappalainen et al., 2012; McCaffery et al., 
2012; Moleres et al., 2012; Phillips et al., 2012). However, with administration of a high 
protein diet (25% energy intake) risk allele carriers demonstrated greater reduction in body 
mass, fat mass and percentage body fat (Zhang et al., 2012), due to a greater reduction in 
food cravings and appetite suppression than protective allele carriers (Huang et al., 2014). 
Furthermore, physically active risk allele carriers demonstrate a 30% reduction in the odds 
of becoming obese and have 36% less body fat compared to inactive individuals (Kilpeläinen 
et al., 2011). Similarly, data from the HERITAGE Family Study showed that following 20 
weeks of endurance training, protective homozygotes exhibited reductions in fat mass, three 
times greater than risk allele carriers (Rankinen et al., 2010). Interestingly, when comparing 
normal weight and obese individuals who participate in sport, no differences in FTO 
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variation were observed (P = 0.97), which was contrasted by those not participating (P = 
0.02; Muc et al., 2015). 
 
Eynon et al. (2013b) investigated FTO rs9939609 in three European cohorts of power (n = 
258; 58% elite) and endurance athletes (n = 266; 57% elite) from a variety of sporting 
disciplines - but identified no associations. This lack of association was likely due to the 
considerable differences in physiological demand between the varieties of athletic 
disciplines included, plus further variability in the standard of athlete. Therefore, as rugby 
includes athletes of remarkably distinct anthropometric and body composition phenotypes, 
elite rugby provides a unique opportunity to investigate FTO in individuals at the extreme 
upper end of physical fitness (Chapter 2.2). 
 
2.3.4 APOE ε4 rs429358 and rs7412 
The APOE gene is located on chromosome 19, encodes apolipoprotein E-based peptide 
(ApoE) and is a candidate marker for risk and severity of mild traumatic brain injury (mTBI). 
ApoE is a protein that plays a pivotal role in cholesterol metabolism (Weisgraber, 1994) and 
has been linked to neurobiological function (Teasdale et al., 1997; Laskowitz et al., 2010), 
specifically, susceptibility to late-onset and sporadic Alzheimer’s disease via APOE gene 
polymorphisms (Busjahn et al., 2009). In humans, ApoE is a 299 amino acid protein and has 
three common isoforms (Apo ε2, ε3, and ε4) which differ by two separate single amino acid 
changes (both cysteine/arginine). In all three isoforms, the C-terminal domain is largely 
responsible for lipid binding, whereas the N-terminus is comprised of a four α-helix motif 
that includes the receptor binding region (Laskowitz & Vitek, 2007). The APOE gene has a 
ε2/ε3/ε4 haplotype derived from two nonsynonymous SNPs (rs429358 and rs7412) within 
exon 4 and results in three distinct alleles (ε2, ε3, and ε4) with six possible genotypes (APOE 
ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4; Hixson & Vernier, 1990; Bennett et al., 2016). 
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Carriers of the APOE ε4 allele have presented with reduced motor rehabilitation outcomes, 
poorer neurocognitive outcomes, increased cognitive impairments, amnesia and memory 
defects following TBI (Lichtman et al., 2000; Crawford et al., 2002; Müller et al., 2009; 
Noé et al., 2010). Furthermore, multiple meta-analysis have shown an increased risk of poor 
outcome greater than 6 months post TBI (Zhou et al., 2008; Zeng et al., 2014; Li et al., 2015) 
with one suggesting that APOE ε4 was responsible for up to 64% of the hazardous effect of 
TBI (Lawrence et al., 2015). Of particular concern for athletic populations, where mTBI is 
generating increasing interest (McCrory et al., 2013; Raftery, 2013; Fuller et al., 2016; 
Kemp et al., 2016; Raftery et al., 2016), Lawrence et al. (2015) reported that APOE ε4 was 
accountable for 38% of the ‘hazardous influence’ towards delaying recovery from mTBI 
(this analysis included, but was not limited to, concussion data: Figure 11). As concussion 
is a form of mTBI and is classified as such (Roozenbeek et al., 2013), it will be referred to 
as mTBI from here on. 
 
 
There appears to be no association between APOE ε4 and self-reported history of sport-
related mTBI (Terrell et al., 2008; Tierney et al., 2010) or between prospective mTBI 
assessment (Kristman et al., 2008). This is not surprising, as large clinical studies show little 
Figure 11 Breakdown of the influence of APOE ε4 on TBI outcome at a study-based level 
on traumatic brain injury (TBI) severity. Adapted from (Lawrence et al., 2015). 
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APOE ε4 association with ‘immediate’ severity or morbidity, but instead shows a poorer 
trajectory towards recovery (Noé et al., 2010; Pruthi et al., 2010; Ponsford et al., 2011). 
Similar to  that of TBI, APOE ε4 athletes experience prolonged symptomatic responses to 
sport-related mTBI (Kutner et al., 2000; Merritt & Arnett, 2016), which have recently been 
categorised as physical, cognitive, affective and sleep (Merritt & Arnett, 2016). In a sample 
of 42 college athletes who suffered an mTBI event, Merritt and Arnett (2016) divided 
participants into two groups, those possessing the ε4 allele (ε4+) and those not (ε4-). 
Consistently for all post-mTBI symptoms, ε4+ suffered more severe symptoms with a 
medium effect size for cognitive (Cohen’s d = 0.60) and a large effect size for physical 
symptoms (d = 0.87), more than 3 months post-mTBI (Figure 12). Despite the limited 
information on APOE ε4 and sport related mTBI data, inferences can be made considering 
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other classifications of TBI to conclude that APOE ε4 is a substantial factor in mTBI 
recovery and as such warrants assessment in elite rugby athletes (Table 5). 
At this point it is important to consider the long-term effects of repeated mTBI, first eluded 
to by Omalu et al. (2005; 2006; 2010) in a series of publications focused on retired American 
football suicide victims. Here, Omalu et al. identified a pathological condition termed 
chronic traumatic encephalopathy (CTE). CTE can only be identified by autopsy and is 
consistent with retired boxers (Geddes et al., 1999). A recent systematic review of CTE cases 
across various sports identified 153 CTE cases (86% boxers and American football players) 
and concluded that there is ample evidence to associate mTBI and CTE (Maroon et al., 
2015). Furthermore, in 80 cases APOE genotype was assessed and the ε4 genotype was 
Figure 12 Means and standard errors of each symptom variable are presented in the figure, 
according to ε4 allele group. Total symptom score comparisons are illustrated in figure a 
and symptom cluster comparisons are illustrated in figure b. Adapted from (Merritt & 
Arnett, 2016). 
55 | P a g e  
 
present in 9.4% of CTE, which is higher than the general population (2.9%), and with 
relatively normal distribution across other APOE genotypes. However, no large studies of 
CTE and APOE ε4 exists (Maroon et al., 2015). It is also likely that older athletes with CTE 
are often misdiagnosed as having age related neurological decline, therefore no detailed 
neurological autopsy will be performed. This is possible because 51% of CTE cases are 
identified in individuals over the age of 60 yr (Maroon et al., 2015). CTE has gathered 
considerable attention in the rugby scientific community (Raftery, 2013; Calderwood et al., 
2015; Stewart et al., 2015; Raftery et al., 2016) and as the identified incidence of mTBI is 
growing (Chapter 2.1.4), understanding any genetic predisposition to mTBI could help 
improve player welfare and management so that players avoid having a post-mortem CTE 
diagnosis. 
 
Functionally, the APOE ε4 allele has also been associated with neurodegenerative cascade 
subsequent to TBI, the severity of axonal injury in mouse models (Sabo et al., 2000; Hartman 
et al., 2002; Bennett et al., 2013) and more likely to show deposition of β-amyloid in brain 
tissue following head injury (Nicoll et al., 1995; Teasdale et al., 1997). Furthermore, in the 
intensive care setting following TBI, ApoE ε4 isoform have increased systemic CNS 
inflammatory responses (Lynch et al., 2003) and the APOE ε4 polymorphism has been 
associated with increased systemic inflammatory responses (Moretti et al., 2005). The 
cellular mechanisms by which the molecular processes of APOE isoforms’ differ are not 
fully understood. However, owing to the role of ApoE peptides, inferences can be made in 
relation to neurophysiological inflammatory response. 
 
In microglial cell cultures exposed to ApoE, phosphorylation of c-Jun N-terminal kinases 
(JNK) leads to suppression of important inflammatory factors such as TNF-α, IL -6 and IL-
12 (Hidding et al., 2002; Pocivavsek et al., 2009a). ApoE induces a reduction of JNK 
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phosphorylation and suppresses nitric oxide synthase synthesis (Pocivavsek et al., 2009a) - 
a key neurotransmitter. Furthermore, this cellular interaction appears to be mediated by 
lipoprotein receptor-related protein (LRP), of which show ApoE isoforms express specific 
binding (ε3 binds with greater affinity than ε4; Pocivavsek et al., 2009b; Bell et al., 2012b). 
These data suggest that ApoE isoforms may mediate microglial immune response which 
could be triggered by cellular trauma, such as TBI. Moreover, animal models have shown 
that ApoE ε4 isoforms are associated with Mitogen-activated protein kinase (MAPK) 
signalling pathways (regulator of, proliferation, expression, differentiation and apoptosis; 
Maezawa et al., 2006). This is interesting given the recent finding that APOE ε4 increased 
trauma-induced-early-apoptosis via a reduction in potassium current in a neuronal/glial cell 
cultures, resulting in an increase of intracellular calcium (Chen et al., 2015). For a more 
comprehensive review of the proposed biological mechanisms see Gokhale & Laskowitz 
(2013). The current understanding of APOE ε4 is continuing to grow and these in vitro and 
mouse models further support the notion of impaired recovery following mTBI. Therefore, 
investigating if these ‘risk’ individuals have been filtered out before competing at the elite 
level of competitive rugby is a necessary step towards understanding the molecular bases of 
mTBI in rugby union. 
 
2.3.5 COL5A1 rs12722 and rs3196378 
Probably the most explored gene regarding tendon and ligament injuries is the COL5A1 
gene, which encodes for a minor fibrillar collagen protein (Hildebrand et al., 2004). Collagen 
is the primary structurally connective tissue protein of the extra cellular matrix (Figure 13) 
that regulates fibrogenesis through its fibril structure and diameter (Birk et al., 1990; Chanut-
Delalande et al., 2004; Wenstrup et al., 2006). Two amino acid components (collagen type 
V and type I fibrils) co-polymerise to form heterotypic fibres. The major collagen type V 
isoform comprises two α-1-(V) chains, encoded by the COL5A1 gene, one α-2-(V) chain 
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encoded by the COL5A2 gene (Wenstrup et al., 2004; Malfait et al., 2010) which forms 
between 1-3% of total collagen content (Birk et al., 1990; Chanut-Delalande et al., 2004; 
Wenstrup et al., 2004; Sun et al., 2011). Mutations in the COL5A1 gene have been identified 
in Ehlers-Danlos syndrome, a disease characterised by  
 
 
joint hypermobility, laxity and muscle hypotonia (Beighton et al., 1998), disrupt collagen 
type V organisation and can affect the assembly of other collagens in the extra cellular matrix 
(Zoppi et al., 2004). This results in irregularly large collagen fibrils located within 
connective tissue (Vogel et al., 1979) and is attributed to a reduced synthesis of collagen 
type V (Malfait & De Paepe, 2005; Sun et al., 2011). 
 
Figure 13 Major microstructural components of tendons associated with tendon 
pathologies/musculotendinous range of motion, identifying related genes. Adapted from 
Foster et al. (2012). 
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Two common COL5A1 gene SNPs (rs12722 and rs3196378), located in the 3′ untranslated 
region (3′ UTR), are the subject of the present chapter because of their association with 
tendon (September et al., 2009) and ligament (rs12722; Posthumus et al., 2009a) pathology 
and their sequence proximity (Figure 14). Both rs12722 and rs3196378 were associated with 
tendinopathy in Australian Caucasians, but only the former was associated with South 
African Caucasians (September et al., 2009). This is interesting considering both SNP were 
in linkage disequilibrium (D′ ≥ 0.67; September et al., 2009; Laguette et al., 2011). 
 
Furthermore, rs12722 has also been previously associated with flexibility (Collins et al., 
2009; Lim et al., 2015), anterior cruciate ligament injury (Posthumus et al., 2009b; Altinisik 
et al., 2015; O'Connell et al., 2015) and Achilles tendinopathy (Mokone et al., 2006), but 
not patellar tendon properties (Foster et al., 2014). In these studies, the minor CC genotype 
was shown to be overrepresented in the respective asymptomatic controls, suggesting a 
Figure 14 A schematic representation of the terminal exons (rectangles) and intron (horizontal 
lines) boundaries of the 39-end of the COL5A1 gene. The translated regions of the exons are 
solid whereas the untranslated region (UTR) of exon 66 is clear. All the information used to 
construct this figure was obtained from databases hosted by the NCBI 
(http://www.ncbi.nlm.nih.gov/) and Ensembl (http://www.ensembl.org/index.html). Adapted 
from (September et al., 2009) 
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protective role of the C allele against injury. Considering the high frequencies of tendon and 
ligament inquiries in elite rugby (Williams et al., 2013; King et al., 2014; Fuller et al., 2015a; 
Fuller et al., 2016), assessing these specific genetic variants may be of use to help improve 
management of individual player injury risk (Table 5). 
  
Some possible mechanisms have been proposed to explain the association of COL5A1 gene 
variants and soft tissue injury (Laguette et al., 2011; Abrahams et al., 2013). Laguett et al. 
(2011) have shown that the COL5A1 3′ UTR - wHere both rs12722 and rs3196378 are 
situated - affects miRNA stability. For both SNPs, the alleles associated with greater soft-
tissue injury risk were associated with greater Hsa-miR-608 stability, which in turn may alter 
the Col5α1 protein secondary structure - proposed to play a role in type V collagen 
production (Abrahams et al., 2013). This would suggest that C/T allele differences at 
rs12722 may alter the co-polymerisation of collagen type V and type I fibrils. However, to 
date, this has not been demonstrated experimentally and exactly how this may translate into 
functional properties is currently unknown. Assessment of these COL5A1 genetic markers, 
in combination with others yet to be identified, might provide a useful tool in rugby for 
individualising training load and mode to reduce incidence of injury. Given that the COL5A1 
variants are associated with injury phenotypes, it is plausible that at the elite level of rugby 
union, risk allele individuals may be selected out on the bases of repeated injuries which 
may be reflected in the quantification of genetic status. 
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Table 5 Thesis candidate gene variants and associated phenotypes. 
 
 
 
2.3.6 Thesis Aims and Hypothesis 
The overarching aim of the present thesis was to investigate whether elite rugby athletes, as 
part of the RugbyGene project, differed in terms of genetic variation from a control group 
and whether athletes in specialized playing positions similarly differed. As such, the specific 
aims of the present research project were; 
 To recruit a large biobank of elite rugby union athletes for the purpose of evaluating 
the molecular genetic components of elite rugby athlete status and to investigate the 
molecular underpinnings of the physiological and anthropometric differences that 
exists between elite rugby playing position. 
 
 To investigate ACE I/D and ACTN3 R577X genotype distribution in elite rugby 
athletes. Whereby it was hypothesized that the ACTN3 R allele and the ACE I allele 
would be more frequent in rugby athletes than controls. It was further hypothesized 
that ACTN3 XX and ACE II genotypes would be underrepresented in backs compared 
to forwards, due to differences in overall work-to-rest ratio and differing 
requirements for high maximum sprinting speed. 
 
Gene variant Phenotype Reference 
ACE I/D I allele associated with greater endurance 
capacity and physical performance. 
(Puthucheary et al., 2011; Jang & 
Kim, 2012; Ma et al., 2013) 
ACTN3 R allele associated with greater power 
performance and associated phenotypes 
(Ma et al., 2013; Orysiak et al., 2015; 
Papadimitriou et al., 2016) 
FTO  A allele associated with greater (fat) mass, T 
allele associated with obesity protection 
(Frayling et al., 2007; He et al., 2014) 
APOE ε4 Carriage of the ε4+ allele associated with 
poorer recovery following mTBI 
(Kutner et al., 2000; Ponsford et al., 
2011; Merritt & Arnett, 2016) 
COL5A1  C allele associated with soft tissue injury 
protection and resistance to muscle 
cramping 
(Posthumus et al., 2009b; September 
et al., 2009; O’Connell et al., 2013; 
Collins et al., 2015) 
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 To investigate if associations of FTO rs9939609 genotype differ between elite rugby 
athletes and a control population, and/or between playing positions. Based on prior 
data in obese populations, it was firstly hypothesised that the rs9939609 risk (A) 
allele would be overrepresented in playing positions typically requiring greater body 
and muscle mass, while the protective (T) allele would be more common in positions 
requiring a lean phenotype. 
 
 To quantify the ‘at risk’ APOE ε4 carriers in elite rugby athletes and to investigate if 
APOE genotypes differed between elite rugby athletes and a control population. 
Based on the published APOE ε4/ε4 association with poorer outcome following brain 
injury, it was hypothesised that the ε4/ε4 genotype and ε4+ would be 
underrepresented in elite rugby athletes compared to controls. 
 
 To investigate if associations of COL5A1 rs12722 and rs3196378 genotype and allele 
frequencies differed between elite rugby athletes and a control population. It was 
hypothesised that the COL5A1 rs12722 and rs3196378 protective C allele and CC 
genotype would be overrepresented in elite rugby athletes compared to controls. 
 
 Finally, a total genotype score (TGS) algorithm will be applied to assess the 
polygenic effect, of the gene variants examined in the first four experimental chapters 
of the present thesis, for all RU athletes, forwards and backs, compared to controls.  
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Chapter 3  
 
 
 
 
 
Experimental methods 
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3.1 Methods 
 
3.1.1 Participants 
For sports genomics research to be truly relevant to the preparation and management of elite 
competitors, the athletes from which the initial data are derived must themselves be 
considered elite. In the context of rugby union, the definition of ‘elite’ is proposes as athletes 
competing in the highest competitive league of a ‘Tier 1’ rugby nation (Regulation 16, 
www.worldrugby.org) - (International Rugby Board, 2004). Given the evolving nature of 
elite rugby, the era in which athletes competed at an elite level also needs to be defined. 
Rugby union has changed dramatically in the > 100 years of its existence and that change 
has certainly continued significantly since the sport turned professional ~20 years ago. 
Nevertheless, it is proposed that 1995 onwards is a playing era inclusion criterion that can 
sensibly be justified. Geographic ancestry is another important consideration for case-
control and genotype-phenotype association study designs and therefore analysis of 
molecular genetic markers should preferably be performed on athletes from a well-defined 
geographic ancestry cluster – in the present thesis, Caucasians of European descent. No 
population stratification was evident between UK and SA population within the present 
sample (P > 0.05), genotypic frequencies are presented in appendix 6) A more difficult aim 
to achieve would be to recruit large numbers of players from all geographic ancestry clusters 
commonly found in rugby union, although this would be a very powerful approach 
scientifically and a long term goal of the RugbyGene Project. 
 
Ethical approval was granted by Manchester Metropolitan University (MMU), University of 
Glasgow, University of Cape Town and Northampton University ethics committees and 
complies with the Declaration of Helsinki (2013), as part of the RugbyGene project. Sample 
size and participant details will differ for each experimental chapter due to increasing 
participant recruitment throughout the project time-frame, genetic data availability and as 
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participants become eligible for inclusion in the elite cohort. Therefore, precise sample 
numbers and anthropometric data will be specified in each experimental chapter (4, 5, 6, 7 
and 8). 
 
3.1.2 Sample collection 
The majority of the blood (~70% of all samples), saliva (~25%) and buccal swab samples 
(~5%) that were obtained by the author (as lead researcher on the RugbyGene project 
research team), via the following protocols. A 5 mL blood sample was drawn from a 
superficial forearm vein, by a trained phlebotomist, into an ethylenediamine tetra acetic acid 
(EDTA) anticoagulant treated tube (BD Vacutainer Systems, Plymouth, UK) and stored in 
2 mL sterile tubes (Eppendorf AG, Hamburg, Germany) at -20°C until processing. Given 
that ~24% of people have a phobia of needles (Taddio et al., 2012), alternative non-invasive 
sample collection methods were also used. Saliva samples were collected into Oragene DNA 
OG-500 collection tubes (DNA Genotek Inc., Ontario, Canada) according to the 5 step 
manufacturer’s protocol (Figure 15). Greater than 30 min abstinence from food and drink, 
participants drooled into the collection tube until the amount of liquid saliva (not 
bubbles/foam) reaches a fill line printed on the collection tube, the screw cap was tightened 
to secure the tube and was gently invert and evert for ~5 seconds (Figure 15). These samples 
were then stored at room temperature until processing, followed by long-term storage at -
20°C. For buccal cell collection, following a minimum 1-hour abstinence from food and 
drink, sterile buccal swabs (Omni swab, Whatman, Springfield Mill, UK) were rubbed 
against the buccal mucosa of the cheek for approximately 30 s. A second swab was collected 
from the opposite cheek. Tips were ejected by firmly pressing the plunger at the end of the 
handle into sterile 2 mL tubes and stored at -20°C until processing. All collection tubes, from 
all methods, were coded and labelled to ensure participant anonymity in accordance with the 
Human Tissue Act (2004). 
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3.1.3 DNA extraction 
DNA isolation and genotyping were performed in MMU (by the author), University of 
Glasgow, University of Cape Town (DNA isolation only) and University of Northampton 
laboratories. There are some differences between protocols summarized below. There was 
100% agreement among reference samples genotyped in the three genotyping centres, i.e. 
Glasgow, Northampton and MMU laboratories (verified by the author). The majority of 
samples were processed and genotyped in the MMU Sports Genomics laboratory by the 
author. Genotype calling was 100% successful for all polymorphisms in the athlete samples 
and for the majority of the control samples, however 10 of the 566 control samples for 
Figure 15 Oragene DNA collection kit procedure 
(http://www.dnagenotek.com/ROW/support/ciO
G500.html). 
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rs3196378 were unsuccessful despite repeated attempts and these were genotyped in the 
Glasgow lab. 
At MMU (performed by the author) and Glasgow, DNA isolation was performed using the 
QIAamp DNA Blood Mini kit and standard spin column protocol, following the 
manufacturer’s instructions (Qiagen, West Sussex, UK). 200 µL of whole blood/saliva, or 
one buccal swab, were combined with protease and incubated at 56°C for 10 min. Ethanol 
(96%) was added and the mixed fluid was centrifuged at 8000 rpm for 60 s leaving the DNA 
sample bound to the spin column silica-gel membrane (Appendix 3). Wash buffers were 
passed through the sample for the removal of proteins, nucleases and other impurities. 
Finally, a low-salt pH-balanced elution buffer was used to provide a 100 µL solution 
containing isolated DNA, which was stored at 4°C until further analysis. 
 
In Cape Town, DNA was isolated from whole blood using a different protocol (Lahiri & 
Nurnberger, 1991). Each sample was combined with lysis buffer, nuclei were pelleted by 
centrifugation and re-suspended in a high salt buffer. DNA was further precipitated 
following protein digestion, 100% ethanol was added and the sample was centrifuged, 
washed with 70% ethanol and dried. DNA hydration buffer was added and samples were 
stored at -20ºC until subsequent analysis. Genotyping of DNA isolated in Cape Town was 
performed in Glasgow. 
 
At Northampton, DNA was isolated from whole blood using Flexigene kits (Qiagen). Each 
sample was combined with lysis buffer, nuclei were pelleted by centrifugation and re-
suspended in protease-containing denaturation buffer. DNA was further precipitated 
following protein digestion, isopropanol was added and the sample was centrifuged, washed 
with 70% ethanol and then dried. DNA hydration buffer was added and samples were stored 
at -20ºC until subsequent analysis. 
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3.1.4 Genotyping 
Genotyping of selected SNP assays (Chapter 2.3) were performed slightly differently 
depending on genotyping centre and are described as follows. In the Glasgow laboratory, 
genotyping was performed by 10 µL Genotyping Master Mix (Applied Biosystems, Paisley, 
UK), 1 µL SNP-specific TaqMan assay (Applied Biosystems), 6 µL nuclease-free H2O and 
3 µL DNA solution (~9 ng DNA) were added per well. In the Northampton laboratory, the 
author performed all genotyping by combining 10 µL of Genotyping Master Mix, 8 µL H2O, 
1 µL assay mix with 1 µL of purified DNA (~10 ng). In both laboratories, PCR was 
performed using a StepOnePlusTM Real-Time detector (Applied Biosystems). Denaturation 
began at 95°C for 10 min, with 40 cycles of incubation at 95°C for 15 s then annealing and 
extension at 60°C for 1 min. Initial analysis was performed using StepOnePlusTM software 
version 2.3 (Applied Biosystems, https://www.thermofisher.com/uk/en/home/technical-
resources/software-downloads/StepOne-and-StepOnePlus-Real-Time-PCR-System.html; Figure 
16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Example allelic discrimination plot for COL5A1 rs12722 obtained using the 
StepOnePlusTM Real-Time PCR System. 
T allele 
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At MMU, the author (aided by other researchers of the MMU sports genomics team) 
genotyped all samples by combining 5 µL Genotyping Master Mix, 4.3 µL H2O, 0.5 µL 
assay mix (unless otherwise described in experimental chapters) and 0.2 µL of purified DNA 
(~9 ng), for samples derived from blood and saliva. For DNA derived from buccal swabs, 5 
µL Genotyping Master Mix was combined with 3.5 µL H2O, 0.5 µL assay mix and 1 µL 
DNA solution (~9 ng DNA). Either a Chromo4 real-time system (Bio-Rad, Hertfordshire, 
UK; Figure 17) or a StepOnePlusTM Real-Time detector was used. Denaturation began at 
95°C for 10 min, with 40 cycles of incubation at 95°C for 15 s then annealing and extension 
at 60°C for 1 min. Initial genotyping analysis was performed using Opticon Monitor 
software version 3.1 (http://www.bio-rad.com/en-uk/sku/soft-om-sw-opticon-monitor-
software) or StepOnePlusTM software version 2.3 
(https://www.thermofisher.com/uk/en/home/technical-resources/software-
downloads/StepOne-and-StepOnePlus-Real-Time-PCR-System.html). There was 100% 
agreement within duplicates of all samples, in all genotyping centres. 
Figure 17 Example allelic endpoint plot for COL5A1 rs12722 obtained using the Bio-
RadTM Chromo4 real-time system. Endpoint VIC representing the rs12722 C allele and 
Endpoint FAM representing the rs12722 T allele. 
 
69 | P a g e  
 
Each experimental chapter will have an abbreviated version of the above DNA isolation and 
genotyping information with additional content in relation to the specific method required 
for each assay in each experiment. For example, in chapter 4.1.2 the ACE gene 
insertion/deletion assay is used and requires three separate primers and probes (Koch et al., 
2005). The genotyping section of each experimental chapter will include this, and other, 
additional and differing details. 
 
3.1.5 Positional specification 
To assess genotype and allele frequencies within rugby union (RU) players, athletes were 
allocated to subgroups; forwards (props, hookers, locks, flankers, number eights) and backs 
(scrum halves, fly halves, centres, wings, full backs). Also, due to diverse game demands 
(Figure 18; Roberts et al., 2008; Cahill et al., 2013; Quarrie et al., 2013; Jones et al., 2015) 
and physiological quantities within rugby union (Table 1; Appleby et al., 2012; Sedeaud et 
al., 2012; Fuller et al., 2013; Sedeaud et al., 2013; Smart et al., 2013; Barr et al., 2014), 
athletes were further divided into positional groups according to their similar movement 
patterns (Cahill et al., 2013) and further physiological differences (Table 1), front five 
(props, hookers, locks), back row (flankers, number eights), half backs (scrum halves, fly 
halves), centres and back three (wings and full backs). 
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3.1.6 Statistics 
From the statistical limitations identified in previous team sport genomic investigations 
(Chapter 2.2.7), the present thesis will aim to adhere to the suggested statistical 
recommendations. Specifically the use of the HWP (Chapter 2.2.7.1), multiple testing 
correction procedures (Chapter 2.2.7.2) and estimating the effect size of any associations 
(Chapter 2.2.7.3). As such, SPSS for Windows version 22 (SPSS Inc., Chicago, IL) software 
was used to conduct Pearson’s Chi-square (χ2) tests to compare genotype and allelic 
frequencies between athletes and controls, and between positional subgroups. Where 
appropriate, CubeX online software (http://www.oege.org/software/cubex) was used to 
determine haplotype frequencies and linkage disequilibrium statistics (Gaunt et al., 2007). 
All P values generated from null-hypothesis testing were subjected to Benjamini-Hochberg 
corrections (BH; Benjamini & Hochberg, 1995) to control false discovery rate (Chapter 
2.2.7.2) and corrected probability values are reported throughout each experimental chapter 
(Chapter 4-8). Odds Ratios were calculated to estimate effect size using the highly 
recommended (Lukic, 2003) MedCalc online statistics calculator 
(https://www.medcalc.org/calc/odds_ratio.php). Additionally, receiver operating 
Figure 18 Game demand cluster analysis of rugby union playing positions. Adapted from 
(Quarrie et al., 2013). 
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characteristic (ROC) curves were used to estimate the sensitivity of a total genotype score 
(comprising the earlier mentioned SNPs, Chapter 2.3) to detect differences between backs 
and forwards (Zweig & Campbell, 1993), similar to that used by Ben-Zaken et al. (2015). 
Alpha was set at 0.05. 
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Chapter 4  
 
 
 
 
Association of ACTN3 R577X but 
not ACE I/D gene variants with elite 
rugby union player status and 
playing position 
 
 
 
This chapter is published as: 
Heffernan, S. M., Kilduff, L. P., Erskine, R. M., Day, S. H., McPhee, J. S., McMahon, G. 
E., ... & Cook, C. J. (2016). Association of ACTN3 R577X but not ACE I/D gene variants 
with elite rugby union player status and playing position. Physiological Genomics, 48(3), 
196-201. 
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4.1 Association of ACTN3 R577X but not ACE I/D gene variants with elite rugby 
union player status and playing position 
 
4.1.1 Introduction 
Rugby is an intermittent team sport comprised of diverse playing positions, each with 
different physiological, anthropometric and technical attributes (Deutsch et al., 2007; 
Roberts et al., 2008; Cahill et al., 2013) including two distinct subgroups: forwards and 
backs. Recently, global positioning system (GPS) tracking and time-motion analysis have 
been used to estimate the physical demands of rugby athletes and compare forwards and 
backs during high-level match play (Roberts et al., 2008; Cahill et al., 2013; Jones et al., 
2015). Backs travelled 12% greater total distance (6545 m versus 5850 m), achieved 
maximum speeds 16% faster (30.4 km.h-1 versus 26.3 km.h-1) and engaged in over four times 
(58% versus 13%) high-intensity running activities (> 5.0 m.s-1), as a proportion of total 
activity (Roberts et al., 2008; Cahill et al., 2013) compared to forwards. These data suggest 
a more sprint-oriented metabolic demand in backs compared to forwards. Furthermore, due 
to the complexities of forward play, forwards performed sixfold more (9.9%) high-intensity 
static exertion activities (rucks, mauls, scrums and line-outs) than backs (1.6%) and spent 
19.8% more time running above 80% of their maximal speed (Roberts et al., 2008; Cahill et 
al., 2013, respectively). This implies that forwards, although often of higher body mass, 
(Fuller et al., 2013) are more likely to benefit from fatigue-resistant physiological qualities 
than backs. Accordingly, Deutsch et al (2007) showed that forwards had a notably higher 
work-to-rest ratio than backs (1:7 and 1:22, respectively). Given that the roles of backs and 
forwards differ significantly in terms of physiological demands, these differences may be 
reflected in distinct genetic characteristics. 
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The two most studied gene variants in exercise genomics (ACE I/D and ACTN3 R577X 
polymorphisms) have recently been considered in meta-analyses. Ma et al (2013) reported 
that ACE II genotype was associated with physical performance (odds ratio (OR) 1.23), 
especially endurance performance (OR = 1.35). Furthermore, ACTN3 RR genotype was 
associated with speed and power performance (OR 1.21; Ma et al., 2013), supported 
elsewhere (Alfred et al., 2011). More extensive information regarding ACE I/D and ACTN3 
R577X polymorphisms is available (Puthucheary et al., 2011; Eynon et al., 2013a). Due to 
differences in physical characteristics between rugby athletes and the general population and 
the diverse physiological demands within rugby, these genetic markers could predispose 
athletes to success or specific roles at the elite level. 
 
One recent paper examined ACE I/D genotype frequency distribution in young, non-elite 
rugby athletes. ACE I/D genotype frequencies did not differ between forwards and backs, 
with no control group included (Bell et al., 2010). Despite this result, because presence of 
the ACE I allele is associated with lower circulating (Rigat et al., 1990; Almeida et al., 2010) 
and tissue (Danser et al., 1995) ACE enzyme activity, I allele carrying individuals generate 
less vasoconstrictive angiotensin II (Dzau, 1988a; Munzenmaier & Greene, 1996) and 
reduced degradation of vasodilating kinins (Dietze & Henriksen, 2008). As such, the ACE 
enzyme, the main active product of the rennin-angiotensin system (RAS; Erdös & Skidgel, 
1987) is the system responsible for control and regulation of blood pressure/volume and 
exists in adipose tissue (Jonsson et al., 1994), human myocardium (Dzau, 1988b), and 
skeletal muscle (Reneland & Lithell, 1994). Therefore, I allele carriers may have more 
advantages hemodynamic flow to working muscles and as such, might be beneficial for elite 
rugby performance. Bell et al. (2012c) also investigated ACTN3 R577X in 102 young male 
rugby union athletes and reported no association, despite some tendencies for the R allele to 
be more frequent in backs or subgroups of backs. Studying elite athletes would be better able 
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to answer the question whether these genetic variants are associated with elite status and 
playing position in rugby. 
 
Therefore, the purpose of the present study was to investigate whether elite rugby athletes 
and a control group differed in terms of ACE I/D and ACTN3 R577X genotype distribution, 
and whether athletes in specialized playing positions similarly differed. It was hypothesized 
that the ACTN3 R allele and the ACE I allele would be more frequent in rugby athletes than 
controls. It was further hypothesized that ACTN3 XX and ACE II genotypes would be 
underrepresented in backs compared to forwards, due to differences in overall work-to-rest 
ratio and differing requirements for high maximum speed. 
 
4.1.2 Method 
Participants 
Ethical approval was granted by Manchester Metropolitan University (MMU), University of 
Glasgow, University of Cape Town and Northampton University ethics committees and 
complies with the Declaration of Helsinki (2013). As part of the RugbyGene project, elite 
Caucasian male rugby athletes (n = 427; mean (standard deviation) height 1.85 (0.07) m, 
mass 101 (14) kg, age 29 (7) years) including 71.2% British, 17.2% South African, 7.1% 
Irish and 4.5% of other nationalities were recruited, having given written informed consent. 
Caucasian controls (61% male; n = 710; height 1.73 (0.10) m, mass 74 (13) kg, age 29 (16) 
years) included 89.6% British, 8.9% South African, 0.7% Irish and 0.8% of other 
nationalities. Of the athletes, 53.4% had competed at international level for a “High 
Performance Union” (Regulation 16, worldrugby.org). International status was confirmed as 
of 1 January 2015. 
 
76 | P a g e  
 
Sample collection 
Blood (n = 796 of all samples), saliva (n = 285) or buccal swab samples (n = 57) were 
obtained via the protocols detailed in Chapter 3.1.2. Blood sample was drawn from a 
superficial forearm vein, into an EDTA tube and stored in 2 mL sterile tubes at -20°C until 
processing. Saliva samples were collected into Oragene DNA OG-500 collection tubes 
according to the manufacturer’s protocol and stored at room temperature until processing. 
Omni swab Sterile buccal were rubbed against the buccal mucosa of the cheek for 
approximately 30 s. Tips were ejected into sterile tubes and stored at -20°C until processing. 
 
DNA isolation 
DNA isolation and genotyping were performed in the MMU, University of Glasgow, 
University of Cape Town (DNA isolation only) and University of Northampton laboratories. 
There are some differences between protocols summarized in Chapter 3.1.3, however there 
was 100% agreement among reference samples genotyped in the three genotyping centres, 
i.e. Glasgow, Northampton and MMU laboratories. The majority of samples were processed 
and genotyped in the MMU laboratory. Genotype calling was successful for both variants in 
all samples. 
 
Genotyping 
Genotyping in the Glasgow laboratory was performed on ACTN3 (rs1815739) and an ACE 
tag SNP (rs4341) in perfect linkage disequilibrium with ACE I/D in Caucasians (Glenn et 
al., 2009) and Asian (Tanaka et al., 2003). Briefly, 10 µL Genotyping Master Mix (Applied 
Biosystems, Paisley, UK), 1 µL SNP-specific TaqMan assay (Applied Biosystems), 6 µL 
nuclease-free H2O and 3 µL DNA solution (~9 ng DNA) were added per well. In the 
Northampton laboratory, genotyping was performed for ACTN3 R577X (rs1815739) by 
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combining 10 µL of Genotyping Master Mix, 8 µL H2O, 1 µL assay mix with 1 µL of 
purified DNA (~10 ng). In both laboratories, PCR was performed using a StepOnePlusTM 
real-time detector (Applied Biosystems). Briefly, denaturation began at 95°C for 10 min, 
with 40 cycles of incubation at 95°C for 15 s then annealing and extension at 60°C for 1 min. 
Initial analysis was performed using StepOnePlusTM software version 2.3 (Applied 
Biosystems). There was 100% agreement within duplicates of all samples. 
 
At MMU, samples were genotyped for ACTN3 R577X (rs1815739) by combining 5 µL 
Genotyping Master Mix, 4.3 µL H2O, 0.5 µL assay mix and 0.2 µL of purified DNA (~9 
ng), for samples derived from blood and saliva. For DNA derived from buccal swabs, 5 µL 
Genotyping Master Mix was combined with 3.5 µL H2O, 0.5 µL assay mix and 1 µL DNA 
solution (~9 ng DNA). Either a Chromo4 real-time system (Bio-Rad, Hertfordshire, UK) or 
a StepOnePlusTM was used. Briefly, denaturation began at 95°C for 10 min, with 40 cycles 
of incubation at 95°C for 15 s then annealing and extension at 60°C for 1 min. Initial 
genotyping analysis was performed using Opticon Monitor software version 3.1 (Bio-Rad) 
or StepOnePlusTM software version 2.3. Duplicates of all samples were in 100% agreement. 
For ACE I/D at MMU, 5 µL of Genotyping Master Mix, 1.55 µL H2O, 0.9 µL of I and D 
allele-specific probes and 0.38 µL of ACE primer 111, 112, 113 (sequences below) were 
combined with 0.5 µL DNA solution (~23 ng DNA) per well for blood and saliva. For DNA 
derived from buccal cells, primer and probe volumes were identical but 0.05 µL H2O and 2 
µL DNA solution (~18 ng DNA) were used. Similarly, in the Northampton laboratory, ACE 
I/D was genotyped by combining 11 µL of Genotyping Master Mix, 2 µL of I and D probes, 
2 µL of ACE primer 111, 112, 113 and 4 µL DNA solution (~40 ng DNA). Either a Chromo4 
real-time system or a StepOnePlusTM was used. Briefly, there were 50 cycles of denaturation 
at 95°C for 15 s then annealing and extension at 57°C for 1 min. Initial analysis was 
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performed using Opticon Monitor 3.1 software or StepOnePlusTM software version 2.3. 
Again, there was 100% agreement within duplicates of all samples. 
 
Primers and probes 
For rs1815739 and rs4341, the appropriate TaqMan assay was used (Applied Biosystems). 
For the direct ACE I/D assay, three primers (150 nM each) and probes (VIC, 150 nM and 
FAM, 75 nM; Koch et al., 2005) were used; 
Primer ACE111: 5ˈ-CCCATCCTTTCTCCCATTTCTC-3ˈ 
Primer ACE112: 5ˈ-AGCTGGAATAAAATTGGCGAAAC-3ˈ 
Primer ACE113: 5ˈ-CCTCCCAAAGTGCTGGGATTA-3ˈ 
I Allele specific probe (VIC-ACE100): VIC-5ˈAGGCGTGATACAGTCA-3ˈ-MGB 
D Allele specific probe (FAM-ACE100): FAM-5ˈTGCTGCCTATACAGTCA-3ˈ-
MGB 
 
Positional groups 
As detailed in Chapter 3.1.5, to assess genotype and allele frequencies within the players, 
athletes were allocated in front five (props, hookers, locks), back row (flankers, number 
eights), half backs (scrum halves, fly halves), centres and back three (wings and full backs). 
 
Data analysis 
SPSS for Windows version 22 (SPSS Inc., Chicago, IL) software was used to conduct 
Pearson’s Chi-square (χ2) tests to compare genotype and allelic frequencies between athletes 
and controls, and between positional subgroups. For ACTN3 and ACE, 26 and 16 tests, 
respectively, were subjected to Benjamini-Hochberg (BH; Benjamini & Hochberg, 1995) 
corrections to control false discovery rate and corrected probability values are reported. 
Where appropriate, OR was calculated to estimate effect size. Alpha was set at 0.05. 
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4.1.3 Results 
All genotype data for athletes and controls were in Hardy-Weinberg equilibrium. Athletes 
were taller and heavier (P < 0.0005) but not older (P = 0.871) than controls. 
 
There were no differences in genotype frequencies within the athlete or control groups 
according to nationality. For ACE I/D, there were no differences between all athletes and 
controls in genotype (P = 0.83), nor between playing subgroups (Table 6). Furthermore, for 
ACTN3 R577X there were no genotype differences between controls and all athletes (P = 
0.33). However, when considering playing position, the X allele was overrepresented in 
forwards (52.5%) compared to backs (37.8%; P = 0.02; OR = 1.49, 95%CI = 1.13-1.96, P = 
0.004) and controls (42%; P = 0.02; OR = 1.25, 95%CI = 1.02-1.54, P = 0.033; Table 6 & 
Figure 19A). Similarly, there was a tendency (P = 0.023 before BH correction) of the XX 
genotype to be overrepresented in forwards (24.8%) compared to backs (15.7%; P = 0.09; 
OR = 1.77, 95%CI = 1.09-2.89, P = 0.022) and controls (18.3%; P = 0.09), with no difference 
between backs and controls (P = 0.37).
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Table 6 Genotype and allele distribution of controls and athletes divided into positional subgroups for ACE and ACTN3, presented as 
genotype/allele counts followed by percentage in parentheses. 
Genotype RU athletes Controls Forwards Front 5 Back row Backs Half Backs Centres Back three 
ACE          
      II 92 (21.5) 113 (19.8) 49 (20.0) 36 (22.1) 13 (15.9) 43 (23.6) 14 (20.3) 14 (31.1) 15 (22.1) 
      ID 214 (50.1) 286 (50.0) 129 (52.7) 86 (52.8) 43 (52.4) 85 (46.7) 33 (47.8) 17 (37.8) 35 (51.5) 
      DD 121 (28.3) 172 (30.2) 67 (27.3) 41 (25.2) 26 (31.7) 54 (29.7) 22 (31.9) 14 (31.1) 18 (26.5) 
Total 427 572 245 163 82 182 69 45 68 
      I allele 398 (46.6) 512 (44.7) 227 (46.3) 158 (48.5) 69 (42.1) 171 (47.0) 61 (44.2) 45 (50.0) 65 (47.8) 
      D allele 456 (53.4) 630 (55.3) 263 (53.7) 168 (51.5) 95 (57.9) 193 (53.0) 77 (55.8) 45 (50.0) 71 (52.2) 
ACTN3          
      XX 90 (20.9) 130 (18.3) 61 (24.8) 39 (23.8) 22 (26.8) 29 (15.7) 12 (17.4) 11 (23.4) *6 (8.7) 
      RX 194 (45.0) 337 (47.5) 112 (45.5) 71 (43.3) 41 (50.0) 82 (44.3) 29 (42.0) 22 (46.8) 31 (44.9) 
      RR 147 (34.1) #243 (34.2) #73 (29.7) 54 (32.9) 19 (23.2) 74 (40.0) 28 (40.6) 14 (29.8) 32 (46.4) 
Total 431 710 246 164 82 185 69 47 69 
      X allele 374 (43.4) *597 (42.0) 234 (47.6) 149 (45.4) 85 (51.8) *140 (37.8) 53 (38.4) 44 (46.8) 43 (31.2) 
      R allele 488 (56.6) #823 (58.0) 258 (52.4) 179 (54.6) 79 (48.2) 230 (62.2) 85 (61.6) 50 (53.2) *95 (68.8) 
RU, rugby union. *Different from forwards. # Different from the Back three. 
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Interestingly, the 69 back three athletes (wings and fullbacks) included only six individuals 
(8.7%) of XX genotype which differed from the forwards (24.8%; P = 0.05; OR = 3.46, 
95%CI = 1.43-8.34, P = 0.006) and tended to differ from the combined half backs and centres 
group (19.8%; P = 0.08; OR = 2.59, 95%CI = 1.00-6.74, P = 0.049). Likewise, the R allele 
distribution was greater in the back three (68.8%) than the controls (58.0%; P = 0.02; OR = 
1.60, 95%CI = 1.09-2.33, P = 0.014), forwards (47.5%; P = 0.01; OR = 2.00, 95%CI = 1.34-
2.99, P = 0.0007) and the other backs (58.2%; P = 0.05; OR = 1.59, 95%CI = 1.02-2.48, P = 
0.042; (Figure 19B). 
 
Figure 19 ACTN3 genotype frequencies. A, Genotype frequency of athletes and controls, with 
athletes also divided into playing subgroup (forwards and backs). B, Genotype frequencies of 
RU athletes divided into positional groups with the addition of the ‘half backs and centres 
combined’ group. Statistical analysis between these positional groups was only performed to 
compare the back three with the half backs and centres combined. * Different from forwards. 
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4.1.4 Discussion 
The present chapter is the first to show a genetic association with elite athlete status in rugby 
union. Associations for the ACTN3 R577X polymorphism but not for ACE I/D were 
identified, thus rejecting the hypotheses regarding ACE I/D. Furthermore, no difference was 
observed for the ACTN3 R577X genotype or allele distribution between all athletes and 
controls, when playing position was not considered, thus rejecting the hypothesis that 
differences would exist between non-athletes and all players as a single cohort. However, as 
hypothesized, in backs compared to forwards there was a lower proportion of XX genotype 
and X allele, which probably reflects the greater need for speed generation in backs and more 
sustained activity in forwards. 
 
ACTN3 R577X 
The most remarkable finding of the present study was the low frequency of the XX genotype 
among the back three athletes (8.7%), approaching although not as low as the frequency 
observed in elite sprinters (Yang et al., 2003; Niemi & Majamaa, 2005). The XX genotype 
is present in ~18% of Caucasians (Table 6) and indicates absence of the α-actinin-3 protein 
(Beggs et al., 1992; Mills et al., 2001). Absence of α-actinin-3, a protein almost exclusively 
expressed in fast twitch skeletal muscle fibres, could hinder back three (wing and full back) 
sprint ability. R allele carriers have a greater proportion of type II and IIx fibres and larger 
relative surface area per IIx fibre than XX carriers (Vincent et al., 2007; Ahmetov et al., 
2011; Broos et al., 2012). Furthermore, Seto et al (2013) recently showed the likely 
mechanism for this genotype-phenotype association is via the calcineurin muscle fibre 
remodeling pathway. They found greater calcineurin activity (which induces slow myogenic 
programming and a shift towards oxidative phenotype) in α-actinin-3 knockout mice (KO) 
and humans (ACTN3 577XX genotype) due to preferential binding of α-actinin-2 
(upregulated in the absence of α-actinin-3) to the fast fibre-specific calsarcin-2 (an inhibitor 
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of calcineurin). This could explain the advantage of R allele carriers over α-actinin-3 
deficient XX individuals for high velocity contractions – particularly important for back 
three players. While backs and forwards previously showed similar fibre type proportions 
(Jardine et al., 1988), these older data are arguably not relevant to modern rugby athletes, 
given their changed physical characteristics in recent years (Fuller et al., 2013). Skeletal 
muscle fibre type proportions are unknown in contemporary elite rugby athletes who now 
compete in a more popular, fully professional sport and complete much higher training loads 
than previously. Recent in vivo data also shows that R allele carriers exhibit greater muscle 
volume and maximal power output (Gomez-Gallego et al., 2009; Erskine et al., 2014). While 
forwards show greater maximal power, backs are able to generate greater power relative to 
body mass (W·kg-1; Crewther et al., 2012), which corresponds with the greater R allele 
frequency in the backs and especially the back three players. In fact, Broos et al. (2016) 
showed corresponding single fibre characteristics. Fibres of RR humans showed greater 
contractile velocity than XX individuals while exhibiting similar isometric force production. 
This suggests a strong rationale for the R allele advantage in elite sprinters (Yang et al., 
2003; Niemi & Majamaa, 2005) and the back three athletes of the present chapter (Table 6 
and Figure 19). This also supports the ACTN3 R allele having a more relevant association 
with relative muscle power as opposed to absolute power (Kikuchi et al., 2014b), due to 
preservation of force at high contractile velocities - a crucial relationship for sprinting 
performance (Miller et al., 2012; Morin et al., 2012) - and less so at reduced velocities (Broos 
et al., 2016). As such, those rugby athletes where relative muscle power is an important 
quantity (Crewther et al., 2012) would have a greater selective advantage with position of 
the R allele, as evidenced in the results of the present results (Table 6 and Figure 19). These 
data, plus evidence that type II fibres are larger and more powerful per unit volume than type 
I (Gilliver et al., 2009), suggest the R allele would benefit back three rugby athletes for 
muscle power and fast fibre characteristics - which supports the present findings (Table 6 
and Figure 19). 
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Arguably, the higher propensity for aerobic enzyme activity (porin, COX IV, hexokinase, 
citrate synthase, succinate dehydrogenase and β-hydroxyacyl CoA dehydrogenase; Seto et 
al., 2011; Seto et al., 2013) and greater force recovery after fatigue observed in α-actinin-3 
deficient mice (Seto et al., 2011), could indicate that XX genotype humans might have a 
greater capacity for recovery from fatiguing exercise - a trait which would benefit forwards 
with their more sustained match play intensity and necessity for quick recovery. The shorter 
rest periods for forwards compared with backs (work to rest ratios 1:7.4 and 1:21.8, 
respectively; Deutsch et al., 2007) indicates that greater fatigue resistance would be 
particularly beneficial for forwards. Moreover, the greater calcineurin activity in XX 
homozygote humans and approximately threefold increase in calcineurin activity and 
distance run after endurance training in KO mice (Seto et al., 2013), further support the 
notion that forwards would benefit from a greater fatigue resistance, especially with 
exposure to extensive training. These data are consistent with the observation that forwards 
exhibit higher XX genotype and lower R allele frequencies than backs and controls (Table 
6). Additionally, these data could explain the present tendency for different allele 
frequencies between the forwards and backs (P = 0.09; P = 0.023 before BH correction; 
Figure 19). In that R allele carriers have a greater ability to achieve high velocity contractions 
– particularly important for back three players (Jones et al., 2015) – and α-actinin-3 deficient 
XX individuals may have a greater capacity for recovery from repeated sprints – particularly 
important for the forwards (Deutsch et al., 2007; Austin et al., 2011a). 
 
When considering many sports simultaneously, team sport athlete status showed no 
association with ACTN3 R577X genotype (Eynon et al., 2014). However, due to a relatively 
small number of athletes (205) with mixed status (56.6% elite) from a range of sports (ice 
hockey, handball, soccer, etc.), that is perhaps not surprising. While combining cohorts from 
different sports can boost sample size and theoretically increase statistical power, if an 
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association does not exist in all sports, or even in all athletes within a particular sport due to 
positional differences, one would be less likely to detect an association. The positional 
differences identified within the present study demonstrate the value of studying a large 
sample from a single sport and, in the absence of detailed physiological data (often difficult 
to obtain from large numbers of elite athletes), provides a viable alternative for future genetic 
research involving team sport athletes. 
 
ACE I/D 
The current study reports no difference between rugby athletes and controls or any positional 
subgroups for ACE I/D. This lack of association contrasts with a recent meta-analysis where 
the ACE I allele was associated with physical performance (Ma et al., 2013).  
 
However, Ma et al. also reported that specialized distance/endurance athletes showed the 
strongest association with the I allele (OR 1.35). Given the mixed metabolic nature of rugby, 
a comparable association in the present study was less likely. Furthermore, the importance 
of ACE I/D remains controversial in the literature, with no associations reported in other 
isolated team sports such as elite European soccer (Gineviciene et al., 2014) and non-elite 
rugby athletes (Bell et al., 2010). These prior data, in conjunction with the current findings 
in a larger study that also considers playing position, suggest that ACE I/D plays little role 
in performance of team sport athletes. ACE I/D genotype-athlete phenotype associations are 
more likely to exist in specialized endurance athletes (Puthucheary et al., 2011). 
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Effect size and future applications 
Odds ratios were calculated to estimate the likelihood that individuals with the advantageous 
genotype/allele become an elite rugby athlete in a specific position. The ACTN3 XX 
genotype was almost twice (OR = 1.77) as common in forwards than backs, which suggests 
α-actinin-3 deficient individuals are more suited to forward play. Furthermore, forwards 
were over three times (OR = 3.46) more likely to be XX genotype than the back three 
athletes, while the remaining backs (centres and halves) were over twice as likely to show 
the α-actinin-3 deficient genotype than the back three (OR = 2.59). These data suggest the 
ACTN3 R577X polymorphism shows potential to contribute to position-specific player 
profiling when combined with other genetic and physiological data in the future. In contrast, 
the ACE I/D polymorphism (OR ~1) does not show equivalent potential in rugby. 
 
While the present cohort size is large compared to previous single sport genetic analyses, 
when the cohort was subdivided into playing position, the numbers were reduced so 
enlargement of the present cohort and replication would be welcome. Accordingly, the 
RugbyGene project continues to recruit elite rugby union players, so will steadily become 
better able to investigate genetic aspects of specific demands within rugby. 
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Chapter 5  
 
 
 
 
Fat mass and obesity associated 
(FTO) gene influences elite rugby 
union playing position. 
 
 
 
Data from this chapter are published as: 
Heffernan, S.M, G. K. Stebbings, L. P. Kilduff, R. M. Erskine, S. H. Day, C. I. Morse, J. S. 
McPhee, C. J. Cook, B. Vance, W. J. Ribbans, S. M. Raleigh, C. Roberts, M.A. Bennett, G. 
Wang, M. Collins, Y. P. Pitsiladis & A. G. Williams. Fat mass and obesity associated (FTO) 
gene influences skeletal muscle phenotypes in non-resistance trained males and elite rugby 
playing position. BMC genetics, 18(1), 4. 
 
88 | P a g e  
 
5.1 Fat mass and obesity associated (FTO) gene influences elite rugby union playing 
position. 
 
5.1.1 Introduction 
Fat mass and obesity associated (FTO) is the most investigated gene in obesity and has 
complex molecular mechanisms that are yet to be fully elucidated. Recent genome-wide 
association studies (GWAS) have identified several common single nucleotide 
polymorphisms (SNP) in the human FTO gene associated with obesity, body mass index 
(BMI; Jacobsson et al., 2012), cardiovascular disease and hypertension (Liu et al., 2013; He 
et al., 2014). These FTO SNPs, which are in strong linkage disequilibrium (r2 > 0.80), are 
located in a cluster on the first intron of chromosome 16 and consequently exhibit similar 
obesity-related traits (Loos & Yeo, 2014). Thus, within different FTO variants, those alleles 
that have been positively associated with obesity-related phenotypes are referred to as risk 
alleles, while those negatively associated with such traits are referred to as protective alleles. 
Homozygotes for the minor risk allele consistently demonstrate greater BMI and body mass 
(3-10 kg) in comparison to protective allele carriers (Frayling et al., 2007; Rauhio et al., 
2013). This greater body mass is likely to be adipose tissue (Andreasen et al., 2008; 
Tanofsky-Kraff et al., 2009; Liu et al., 2010; Sonestedt et al., 2011; Matsuo et al., 2014), 
although there exist some suggestions of greater lean mass (LM) in addition to fat mass (Jess 
et al., 2008; Sonestedt et al., 2011). 
 
Environmental lifestyle factors (diet and physical activity) have also been investigated for 
FTO gene-environment interactions. Risk allele carriers are more likely to choose a high fat 
diet than protective allele carriers (Tanofsky-Kraff et al., 2009; Corella et al., 2011; Phillips 
et al., 2012). However, with administration of a high protein diet (25% energy intake) risk 
allele carriers demonstrated a greater reduction in body mass, fat mass and percentage body 
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fat (Zhang et al., 2012), due to greater appetite suppression than in protective allele carriers 
(Huang et al., 2014). Additionally, physically active risk allele carriers have a 30% reduction 
in likelihood of becoming obese and have 36% less body fat compared to inactive risk allele 
carrying individuals (Kilpeläinen et al., 2011). Similarly, data from the HERITAGE Family 
Study showed that following 20 weeks of endurance training, protective allele homozygotes 
exhibited reductions in fat mass three times greater than risk allele carriers (Rankinen et al., 
2010). Interestingly, when comparing normal weight and obese individuals who participate 
in sport, no differences in FTO genotype were observed (P = 0.97), which was contrasted by 
those not participating (P = 0.02; Muc et al., 2015). Considering the attenuation of FTO-
associated obesity with environmental factors and the greater FTO-associated LM reported 
in obese populations (Jess et al., 2008; Sonestedt et al., 2011), investigating habitually 
trained elite athletes, in which body mass varies considerably across playing position, would 
be worthwhile. 
 
To date, one study has considered FTO rs9939609 in athletic populations. Eynon et al. 
(2013b) investigated three European cohorts of power (n = 258; 58.3% elite) and endurance 
athletes (n = 266; 57.1% elite) from a variety of sporting disciplines - but identified no 
associations. This lack of association was likely due to the considerable differences in 
physiological demand between the various athletic disciplines included, plus further 
variability in the standard of athlete. The RugbyGene sample (Chapter 3) provides a unique 
opportunity to investigate FTO in individuals at the extreme upper end of physical fitness 
(100% elite athletes; Chapter 2). Indeed, RU athlete positional divisions provide an ideal 
cohort to compare different anthropometric and physical quantises, while having some 
control over the environment of each athlete, as their training load and nutritional guidance 
are relatively similar. In terms of positional specific physiological differences that may be 
reflected in players’ genetic variation, backs lower mass, lean mass, height and show lower 
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maximal strength and power measures compared to forwards. However, backs are faster, 
have a greater relative power output, cover more distance during games and have greater 
recovery than forwards (Table 1). Furthermore, the previous chapter has shown the ability 
of genetic research, in a single sport with player roles that differ distinctly, to reveal context-
specific competitive advantages provided by particular alleles (Chapter 4). 
 
Therefore, the main aims of the present study were to investigate whether FTO rs9939609 
genotype differed between elite rugby athletes and a control population, and/or between RU 
player positions. Based on prior data in obese populations, it was hypothesised that the 
rs9939609 risk (A) allele would be overrepresented in player positions typically requiring 
greater body and muscle mass while the protective (T) allele would be more common in 
positions requiring a lean phenotype. 
 
5.1.2 Method 
Participants 
A total of 1089 individuals were recruited and gave written informed consent to participate 
in the present study. The total sample comprised elite Caucasian male rugby athletes (n = 
450; height 1.85 (0.07) m, mass 101 (14) kg, age 29 (7) yr, BMI 29.4 (3.7) kg∙m-2; mean 
(standard deviation (SD)) including 73% British, 16% South African, 7% Irish and 4% from 
other nationalities and non-athlete Caucasian control participants (60% male; n = 559; height 
1.75 (0.10) m, mass 75 (13) kg, age 29 (16) yr, BMI 24.5 (3.6) kg∙m-2) including 86% British, 
12% South African, 1% Irish and 1% from other nationalities. Of the RU athletes, 52.7% 
had competed at an international level for a “High Performance Union” (Regulation 16, 
worldrugby.org). All data for the athlete group’s international status were confirmed as of 
1st June 2016. 
91 | P a g e  
 
Sample collection 
Blood (n = 762 of all samples), saliva (n = 272) or buccal swab samples (n = 55) were 
obtained via the protocols detailed in Chapter 3.1.2. Blood sample was drawn from a 
superficial forearm vein, into an EDTA tube and stored in 2 mL sterile tubes at -20°C until 
processing. Saliva samples were collected into Oragene DNA OG-500 collection tubes 
according to the manufacturer’s protocol and stored at room temperature until processing. 
Omni swab Sterile buccal were rubbed against the buccal mucosa of the cheek for 
approximately 30 s. Tips were ejected into sterile tubes and stored at -20°C until processing. 
 
DNA isolation 
DNA isolation and genotyping were performed in the MMU, University of Glasgow, 
University of Cape Town (DNA isolation only) and University of Northampton laboratories. 
There are some differences between protocols summarized in Chapter 3.1.3; however, there 
was 100% agreement among reference samples genotyped in the three genotyping centres, 
i.e. Glasgow, Northampton and MMU laboratories. The majority of samples were processed 
and genotyped in the MMU laboratory. Genotype calling was successful for both variants in 
all samples. 
 
Genotyping 
Genotyping in all three genotyping centres was performed on FTO (rs9939609). Briefly, in 
the Glasgow laboratory 10 µL Genotyping Master Mix (Applied Biosystems, Paisley, UK), 
1 µL SNP-specific TaqMan assay (Applied Biosystems), 6 µL nuclease-free H2O and 3 µL 
DNA solution (~9 ng DNA) were added per well. In the Northampton laboratory, genotyping 
was performed by combining 10 µL of Genotyping Master Mix, 8 µL H2O, 1 µL assay mix 
with 1 µL of purified DNA (~10 ng). In both laboratories, PCR was performed using a 
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StepOnePlusTM real-time detector (Applied Biosystems). Briefly, after an initial 10 min at 
95°C, 40 cycles of denaturation at 95°C for 15 s then annealing and extension at 60°C for 1 
min were used. Genotyping calls were performed using StepOnePlusTM software version 2.3 
(Applied Biosystems). At MMU, 5 µL Genotyping Master Mix, 4.3 µL H2O, 0.5 µL assay 
mix and 0.2 µL of purified DNA (~9 ng) were used in each reaction for samples derived 
from blood and saliva. For DNA derived from buccal swabs, 5 µL Genotyping Master Mix 
was combined with 3.5 µL H2O, 0.5 µL assay mix and 1 µL DNA solution (~9 ng DNA). 
Either a Chromo4 (Bio-Rad, Hertfordshire, UK) or StepOnePlusTM real-time PCR system 
was used. Briefly, after an initial 10 min at 95°C, 40 cycles of denaturation at 95°C for 15 s 
then annealing and extension at 60°C for 1 min were used. Genotyping calls were performed 
using Opticon Monitor software version 3.1 (Bio-Rad) or StepOnePlusTM software version 
2.3. The Taqman assay included VIC and FAM dyes that indicated A and T alleles on the 
forward DNA strand, respectively. Thus, VIC/FAM were interpreted as: 5′-
GTGAATTT[A/T] GTGATGCA-3′. 
 
Positional groups 
As detailed in Chapter 3.1.5, to assess genotype and allele frequencies within the players, 
athletes were allocated in front five (props, hookers, locks), back row (flankers, number 
eights), half backs (scrum halves, fly halves), centres and back three (wings and full backs). 
 
Data analysis 
SPSS for Windows version 22 (SPSS Inc., Chicago, IL) software was used to conduct 
Pearson’s Chi-square (χ2) tests to compare genotype and allelic frequencies between athletes 
and controls, and between positional subgroups. Thirty tests were subjected to Benjamini-
Hochberg (BH; Benjamini & Hochberg, 1995) corrections to control false discovery rate and 
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corrected probability values are reported. Where appropriate, OR was calculated to estimate 
effect size. Alpha was set at 0.05. 
 
5.1.3 Results 
Athletes were taller and heavier (P < 0.05) but not older (P > 0.05) than controls. There were 
no genotype frequency differences between RU athletes (P = 0.16) and controls (only 
additive models presented). 
 
In terms of player position, backs had a greater frequency of T allele carriers than forwards 
(P = 0.03, Table 7, Figure 20) and showed greater odds of being T allele carriers than AA 
genotype (OR = 1.84, Table 8). When combined, the back three and centres group contained 
less AA homozygotes and more T allele carriers than controls (P = 0.03, P = 0.02, 
respectively; Figure 20A and Table 7). Additionally, controls had more than twice the odds 
of being AA than the back three and centres group, with greater odds of T allele carriers in 
the back three and centres than controls (Table 8). 
 
Compared to forwards and all other RU athletes, TT genotype (P = 0.03; P = 0.03, 
respectively) and T allele carriers (P = 0.02; P = 0.02, respectively) were more common in 
the back three and centres group (Figure 20A and Table 7). Likewise, forwards and all other 
RU athletes had greater than three times the odds of being AA genotype than the back three 
and centres group, with greater odds of T allele carriers in the back three and centres group 
than forwards and all other RU athletes (Table 8). Furthermore, the back three and centres 
group showed a greater T allele frequency than both forwards and all other RU athletes 
(Figure 20B) and almost one and a half times greater odds of possessing the T allele (Table 
8). 
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Figure 20 FTO genotype data of athletes and controls. A Recessive model. Grey bars are T 
allele carriers, black bars are AA genotypes. B Allele frequency for selected subgroups. Grey 
bars represent the T allele, black bars represent the A allele. 
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Table 7 Genotype and allele distribution of controls, RU athletes and divided into positional subgroups for FTO, presented 
as genotype/allele counts followed by percentage in parentheses. 
Genotype/Allele 
RU 
athletes 
Controls Forwards Backs Front 5 Back row 
Half 
backs 
Back three 
& centres 
FTO         
      AA 69 (15.3) 90 (16.1) 48 (18.5) 21 (11.0) 30 (17.0) 18 (21.7) 13 (17.8) 8 (6.8)* 
      AT 235 (52.3) 266 (47.6) 133 (51.4) 102 (54.7) 94 (53.4) 39 (47.0) 34 (46.6) 68 (57.6) 
      TT 146 (32.4) 203 (36.3) 78 (30.1) 68 (34.3) 52 (29.6) 26 (31.3) 26 (35.6) 42 (35.6)‡ 
Total 450 559 259 191 176 83 73 118 
      A allele 375 (41.4) 446 (39.9) 229 (44.2) 144 (37.7) 154 (43.7) 75 (45.2) 60 (41.1) 84 (35.6)‡ 
      T allele 527 (58.6) 672 (60.1) 289 (55.8) 238 (62.3) 198 (56.3) 91 (54.8) 86 (58.9) 152 (64.4) 
RU, rugby union. *Different from controls (P < 0.04). ‡Different from forwards (P = 0.03). 
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Table 8 Odds ratio statistics for RU athlete status by playing position for 
FTO genotype (TT/AA), allele (T/A) and recessive (T/AA) genetic 
models. 
Positional 
Comparison 
Genetic 
Model 
Odds 
Ratio 
95% 
Confidence 
Interval 
P 
Value 
Backs v Forwards T/AA 1.84 1.06-3.19 0.029 
     
Back three and 
centres v Controls 
TT/AA 
T/AA 
2.33 
2.64 
1.05-5.16 
1.05-5.16 
0.038 
0.012 
     
Back three and 
centres v Forwards 
TT/AA 
T/AA 
T/A 
3.23 
3.12 
1.44 
1.39-7.46 
1.43-6.84 
1.04-1.97 
0.006 
0.004 
0.026 
     
Back three and 
centres v all other 
RU athletes 
TT/AA 
T/AA 
T/A 
3.08 
3.09 
1.37 
1.36-6.98 
1.43-6.68 
1.01-1.86 
0.007 
0.004 
0.045 
     
Back three and 
centres v other 
backs 
TT/AA 
T/AA 
2.98 
2.63 
1.17-7.59 
0.96-7.19 
0.022 
0.060 
       RU, rugby union. 
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5.1.4 Discussion 
In agreement with the chapter hypothesis, the present data have shown that elite RU athlete 
playing positions more reliant on a lean phenotype for success (Smart et al., 2013) possess 
a greater FTO rs9939609 T allele and TT genotype frequency than controls, while the A 
allele is more common in those positions where total body mass is more important (Sedeaud 
et al., 2012; Figure 20, Table 7 and 8). The present findings disagree with Eynon et al. 
(2013b) who did not identify an association between FTO rs9939609, power (n = 258; 58.3% 
elite) and endurance (n = 266; 57.1% elite) athlete status. This lack of association was likely 
due to the considerable differences in physiological demand between the various athletic 
disciplines included together, plus further variability in the standard of athlete. It is likely 
that because of these methodological decisions, any possible association between FTO and 
athlete status might be filtered out and have produced false negative results. The present 
chapter differs in that the investigated cohort was a ubiquitous sample of 100% elite RU 
athletes from a single sport and importantly considered positional variation within RU. The 
present finding that the centre and back three group show a greater proportion of the T alleles 
suggest an advantage for these athletes in achieving elite RU status (Figure 20) and further 
show the importance positional variation within team sports. One possible biological 
mechanism underlying the present results may be the action of the iroquois homeobox 3 
(IRX3) protein through its FTO genomic loci interaction. 
 
Until recently, little was known about the molecular basis for FTO SNP associations with 
any reported phenotype measure, because there was no association between FTO SNPs and 
expression of the FTO protein (Wåhlén et al., 2008; Grunnet et al., 2009). However, FTO 
has recently been found to influence IRX3 protein expression, through evolutionarily 
conserved long-range chromatin looping. Individuals possessing the protective FTO 
genotype/allele (TT/T) display lower IRX3 expression than AA homozygotes (Smemo et 
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al., 2014). Furthermore, in contrast to IRX3 knockout (KO) mice, wild type mice exhibited 
similar FTO SNP risk (A) allele-associated phenotypes, such as greater BMI, body mass and 
body fat percentage (Smemo et al., 2014), which reflects the present results of greater A 
allele frequency in the forwards playing position (Figure 20, Table 7 and 8) and suggests an 
advantage for the A allele and elite status in forwards - typically the those with the greatest 
mass (Table 1). Interestingly, IRX3 KO mice expended more energy, particularly at night, 
due to a greater browning of white fatty tissue (Smemo et al., 2014) and recent findings 
show a link between brown fat and muscle developmental precursor Myf5 (Schulz et al., 
2011) which may provide a possible mechanism for the observation of greater FTO T allele 
carriers in the centre and back three cohort. Moreover, using a transgenic mouse model 
(Rosa26Enr-Irx3) that disrupts IRX3 function whilst maintaining the genomic interaction 
between IRX3 and FTO (mimicking more accurately the human in vivo state than the 
aforementioned KO model), the authors showed retention of the KO model phenotype traits 
(Smemo et al., 2014). These FTO-IRX3 protein interactions suggest a possible explanation 
for the results of the present chapter (Figure 20), in that T allele carriers (centres and back 
three players in the present chapter) may have a greater life-long predisposition to muscular 
development, however this has not yet been experimentally shown. 
 
The precise mechanisms of action of IRX3 in mammalian physiology are not fully 
understood, however the primary role of IRX3 in embryonic development and future actions 
in motor neuron restriction is relevant to this discussion. During neuronal development, 
IRX3 expression plays a key role in N-tubulin development and initiation of neuronal 
programming. High levels of IRX3 protein promote early tissue development but not cell 
differentiation (Bellefroid et al., 1998). It is possible that because the FTO T allele is 
associated with lower IRX3 expression, greater early differentiation might subsequently lead 
to greater muscular development. As such, for predeterminant neuronal cells to differentiate 
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into a progenitor motor neuron domain and subsequently motor neurons, it appears IRX3 
expression must be repressed by the microRNA mir-17-3p in order for OLIG2 to regulate 
the development of ventral spinal motor neurons (Chen et al., 2011). Thus, as the expression 
of OLIG2 increases, the yield of motor neurons increases in tandem (Lamas et al., 2014). 
Considering FTO T allele carriers have a lower embryonic expression of IRX3, T allele 
carriers may have a predisposition for greater LM through enhanced life-long motor neuron 
availability via OLIG2 expression (diagrammatically shown in appendix 7) and therefore, 
may be at an advantage for certain forms of athletic ability and associated performance 
phenotypes (Table 7 and 8 ; Figure 20). This rationale and the present results are consistent 
with the 85% heritability of adult muscle neuronal function (Missitzi et al., 2008). 
 
Recent associations between FTO variants and IGF-1, specifically that serum IGF-1 levels 
were greater in T allele carriers (Rosskopf et al., 2011), may provide a second mechanism 
to explain the observations of the present results. It is well known that IGF-1 is upregulated 
as a consequence of mechanical load/exercise and plays an important role in the cellular 
development of muscle hypertrophy (Sharples et al., 2015). Hence, T allele carriers may 
experience upregulation of IGF-1 compared to AA genotype counterparts. These data 
provide a further potential basis for the observation that RU athletes who require a greater 
lean phenotype (Smart et al., 2013; Smart et al., 2014) and greater muscle power relative to 
body mass (Crewther et al., 2012; center and back three group in the present chapter) show 
a greater frequency of the T allele than other playing positions (Table 7 and 8; Figure 20). 
 
The present results observed a lower frequency of the AA genotype in back three and centre 
playing positions (OR = 2.53; Table 8), however there was no difference between the entire 
rugby cohort and controls. This demonstrates the importance of defining athletes very 
carefully when conducting such comparisons, as demonstrated previously regarding another 
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genetic variant ACTN3 rs1815739 (Chapter 4). Global positioning system (GPS) data 
provide evidence for the relevance of the present finding regarding FTO genotype in elite 
athletes. Jones et al. (2015) showed that - at an elite competitive level - the back three and 
centre players express the greatest ‘instantaneous and accumulative demands for exercise’ 
(exertion index; EI) than all other athletes and spent more time at sprinting intensities. 
 
These data suggest the relevance of the FTO rs9939609 T allele to athletic success for the 
backs playing positions and the A allele for the more massive forwards. Particularly, 
considering the T allele for athletic success in the backs, the possible molecular mechanism 
from FTO via IRX3 to OLIG2 resulting in greater lifelong motor neuron availability. 
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Chapter 6  
 
 
 
 
Apolipoprotein E ε4 allele is not 
associated with elite rugby status but 
is present in 30% of athletes 
 
 
 
This chapter is under review in Plos One as: 
Heffernan, S. M., L. P. Kilduff, R. M. Erskine, S. H. Day, J, G. K. Stebbings, C. J. Cook, 
S. M. Raleigh, M. A. Bennett, G. Wang, M. Collins, Y. P. Pitsiladis & A. G. Williams. 
Apolipoprotein E ε4 allele is not associated with elite rugby status but is present in 30% of 
athletes. Submitted on 26/08/16. 
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6.1 Apolipoprotein E ε4 allele is not associated with elite rugby status but is present 
in 30% of athletes 
 
6.1.1 Introduction 
The APOE (apolipoprotein E) gene is located on chromosome 19, encodes apolipoprotein 
E-based peptide (ApoE) and is a candidate marker for risk and severity of mild-traumatic 
brain injury (mTBI) including sport-related concussion. ApoE is a 299 amino acid protein 
and has three common isoforms (Apo ε2, ε3, and ε4) which differ by two separate single 
amino acid changes (both cysteine/arginine). In humans, all three isoforms have a C-terminal 
domain that is largely responsible for lipid binding, whereas the N-terminus is comprised of 
a four α-helix motif that includes the receptor binding region (Laskowitz & Vitek, 2007). 
ApoE plays a pivotal role in cholesterol metabolism (Weisgraber, 1994; Huang & Mahley, 
2014) and has been linked to neurobiological function (Teasdale et al., 1997; Laskowitz et 
al., 2010) with a particular susceptibility to late-onset and sporadic Alzheimer’s disease via 
APOE gene polymorphisms (Busjahn et al., 2009). 
 
Carriers of the APOE ε4 allele have presented with reduced motor rehabilitation outcomes, 
poorer neurocognitive outcomes, increased cognitive impairments, amnesia and memory 
defects following traumatic brain injury (Lichtman et al., 2000; Crawford et al., 2002; 
Müller et al., 2009; Noé et al., 2010). Multiple meta-analyses have shown an increased risk 
of poor outcome greater than 6 months after mTBI (Zhou et al., 2008; Zeng et al., 2014; Li 
et al., 2015) with one study suggesting that APOE ε4 was responsible for up to 64% of the 
‘hazardous influence’ of TBI (Lawrence et al., 2015). Of particular concern for athletic 
populations, where mTBI is generating increasing interest, Lawrence et al. (2015) reported 
that APOE ε4 was accountable for 38% of the ‘hazardous influence’ towards delaying 
recovery of mTBI (this analysis included, but was not limited to, concussion data). As 
103 | P a g e  
 
concussion is a form of mTBI and is classified as such (Roozenbeek et al., 2013), the present 
chapter will refer to concussion as mTBI from here on. 
 
There appears to be no association between APOE ε4 and self-reported history of sport-
related mTBI (Terrell et al., 2008; Tierney et al., 2010) or mTBI diagnosed by a medical 
professional in a prospective study (Kristman et al., 2008). This is not surprising, as large 
clinical studies show little APOE ε4 association with ‘immediate’ severity or morbidity but 
a more likely association with trajectory of recovery in subjects with severe TBI during 
rehabilitation (Noé et al., 2010; Pruthi et al., 2010; Ponsford et al., 2011). Similarly, athletes 
carrying the APOE ε4 allele experience prolonged symptomatic responses to sport-related 
mTBI (Kutner et al., 2000; Merritt & Arnett, 2016), which have recently been categorised 
as physical, cognitive, affective and sleep (Merritt & Arnett, 2016). In a recent study, Merritt 
and Arnett (2016) divided 42 college athletes who suffered an mTBI event into two groups: 
those possessing the ε4 allele (ε4+) and those not (ε4-). Consistently for all post-mTBI 
symptoms, ε4+ suffered more severely with a medium effect size for cognitive (Cohen’s d 
= 0.60) and a large effect size for physical symptoms (d = 0.87) within 3 months post-mTBI. 
 
Current mTBI incidence for elite rugby union (RU) players ranges between 4.6-8.9 per 1000 
playing hours and has grown over time (Gardner et al., 2014; Cross et al., 2015; Fuller et 
al., 2015a), with considerably higher rates in elite rugby league (RL), ranging between 14.8 
- 28.3 per 1000 playing hours (Savage et al., 2013; Gardner et al., 2014; Gardner et al., 
2015b; Gardner et al., 2016). Furthermore, in RU, data from the most recent Rugby World 
Cup (2015) indicates mTBI was the most common injury (14%; n = 24) and accounted for a 
total of 184 days absence (mean ~8 days each) from training and competition during and 
after that tournament (Fuller et al., 2016). It is notable that players who returned to play in 
the same season following diagnosed mTBI have 60% greater chance of a subsequent time-
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loss injury (not limited to head injury) than those that did not sustain mTBI (Cross et al., 
2015). As APOE ε4/ε4 genotype and ε4+ individuals are at greater risk of experiencing more 
severe symptoms after mTBI, it is probably more difficult for them to withstand repeated 
head impacts during many years of training and playing rugby without increasing incidence 
and severity of mTBI and other injuries. Consequently, those individuals would be forced to 
miss training, selection and competitive events important for their career progression, and 
thus might be at a disadvantage compared to ε4- individuals in terms of their ability to 
achieve success in elite competitive rugby. 
 
Therefore, the aims of the present chapter were to establish the proportion of elite rugby 
athletes expected to be at higher risk of mTBI, due to carriage of the APOE ε4 allele and to 
investigate if APOE genotype differed between elite rugby athletes and a control population. 
Based on the published association of the APOE ε4 allele with poorer outcome following 
brain injury, it was hypothesised that the ε4/ε4 genotype and ε4+ allele would be 
underrepresented in elite rugby athletes compared to controls. 
 
6.1.2 Method 
Participants 
A total of 926 individuals were recruited and gave written informed consent to participate in 
the present study. The sample comprised elite Caucasian male rugby athletes (n = 443; mean 
(standard deviation) height 1.85 (0.07) m, mass 101 (14) kg, age 29 (7) years) including 72% 
British, 16% South African, 7% Irish and 5% of other nationalities. Caucasian controls (61% 
male; n = 483; height 1.74 (0.10) m, mass 73 (13) kg, age 25 (11) years) included 98% 
British, 1% Irish and 1% of other nationalities. 51.9% of RU athletes had competed at 
international level for a “High Performance Union” (Regulation 16, worldrugby.org). All 
data for the athlete group’s international status were confirmed as of 1st June 2016. 
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Sample collection 
Blood (n = 704 of all samples), saliva (n = 252) or buccal swab samples (n = 50) were 
obtained via the protocols detailed in Chapter 3.1.2. Blood sample was drawn from a 
superficial forearm vein, into an EDTA tube and stored in 2 mL sterile tubes at -20°C until 
processing. Saliva samples were collected into Oragene DNA OG-500 collection tubes 
according to the manufacturer’s protocol and stored at room temperature until processing. 
Omni swab Sterile buccal were rubbed against the buccal mucosa of the cheek for 
approximately 30 s. Tips were ejected into sterile tubes and stored at -20°C until processing. 
 
DNA isolation 
DNA isolation and genotyping were performed in the MMU, University of Glasgow, 
University of Cape Town (DNA isolation only) and University of Northampton laboratories. 
There are some differences between protocols summarized in Chapter 3.1.3; however, there 
was 100% agreement among reference samples genotyped in the three genotyping centres, 
i.e. Glasgow, Northampton and MMU laboratories. The majority of samples were processed 
and genotyped in the MMU laboratory. Genotype calling was successful for both variants in 
all samples. 
 
Genotyping 
Genotyping in all three genotyping centres was performed on APOE (rs429358 and rs7412). 
Briefly, in the Glasgow laboratory 10 µL Genotyping Master Mix (Applied Biosystems, 
Paisley, UK), 1 µL SNP-specific TaqMan assay (Applied Biosystems), 6 µL nuclease-free 
H2O and 3 µL DNA solution (~9 ng DNA) were added per well. In the Northampton 
laboratory, genotyping was performed by combining 10 µL of Genotyping Master Mix, 8 
µL H2O, 1 µL assay mix with 1 µL of purified DNA (~10 ng). In both laboratories, PCR was 
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performed using a StepOnePlusTM real-time detector (Applied Biosystems). Briefly, after an 
initial 10 min at 95°C, 40 cycles of denaturation at 95°C for 15 s then annealing and 
extension at 60°C for 1 min were used. Genotyping calls were performed using 
StepOnePlusTM software version 2.3 (Applied Biosystems). At MMU, 5 µL Genotyping 
Master Mix, 4.3 µL H2O, 0.5 µL assay mix and 0.2 µL of purified DNA (~9 ng) were used 
in each reaction for samples derived from blood and saliva. For DNA derived from buccal 
swabs, 5 µL Genotyping Master Mix was combined with 3.5 µL H2O, 0.5 µL assay mix and 
1 µL DNA solution (~9 ng DNA). Either a Chromo4 (Bio-Rad, Hertfordshire, UK) or 
StepOnePlusTM real-time PCR system was used. Briefly, after an initial 10 min at 95°C, 40 
cycles of denaturation at 95°C for 15 s then annealing and extension at 60°C for 1 min were 
used. Genotyping calls were performed using Opticon Monitor software version 3.1 (Bio-
Rad) or StepOnePlusTM software version 2.3. The TaqMan assay included VIC and FAM 
dyes that for rs429358 and rs7412 indicated C and T alleles on the forward DNA strand, 
respectively. Thus, for rs429358, VIC/FAM were interpreted as: 5′-
AGGACGTG[C/T]GCGGCCGC-3′ and for rs7412 as: 5′-TGCAGAAG[C/T]GCCTGGCA-
3′. The APOE gene ε2/ε3/ε4 haplotype was derived from rs429358 and rs7412 producing six 
possible genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4; Hixson & Vernier, 1990). 
 
Data analysis 
SPSS for Windows version 22 (SPSS Inc., Chicago, IL) software was used to conduct 
Pearson’s Chi-square (χ2) tests to compare genotype and allelic frequencies between athletes 
and controls, and between positional subgroups. Sixteen tests were subjected to Benjamini-
Hochberg (BH; Benjamini & Hochberg, 1995) corrections to control false discovery rate and 
corrected probability values are reported. Where appropriate, OR was calculated to estimate 
effect size. Alpha was set at 0.05. 
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6.1.3 Results 
Genotype calling was successful in all samples. There was 100% agreement among reference 
samples genotyped in the three genotyping centres, i.e. Glasgow, Northampton and MMU 
laboratories. Genotype frequencies for both rs429358 and rs7412 were in Hardy-Weinberg 
equilibrium for the athletes (P > 0.27) and control group (P > 0.24). Athletes were taller and 
heavier (P < 0.05) but not older (P > 0.05) than controls. 
 
There were no differences in APOE genotype or ε4+ frequency when comparing all athletes 
(P = 0.48) with controls (additive values presented). Furthermore, no genotype frequency or 
ε4+ differences were observed between RU backs and forwards (P = 0.89, P = 0.52, 
respectively, Figure 21). However, despite RU athletes with international competitive 
experience having similar ε4/ε4 genotype frequency to controls (2.6% vs 2.3%), ε4/ε4 
genotype frequency in those international athletes was lower (P = 0.01) than in athletes 
without international experience (4.7%, Table 9; OR = 2.02, 95%CI = 0.71-5.73, P = 0.19), 
with no association between ε4+ and international competitive experience. 
 
Table 9 Genotype distribution of controls and RU athletes sub-divided by position and 
international status for APOE, presented as genotype counts followed by percentage in 
parentheses. 
Genotype Controls 
RU 
Athletes 
RU 
Internatio
nals 
RU Non-
Internatio
nals 
RU 
Forwards 
RU Backs 
APOE       
      ε2/ε2 1 (0.2) 1 (0.2) 0 1 (0.5) 1 (0.4) 0 
      ε2/ε3 59 (12.2) 53 (11.9) 18 (7.8) 35 (16.4) 29 (11.5) 24 (12.6) 
      ε2/ε4 13 (2.7) 7 (1.6) 1 (0.4) 6 (2.8) 5 (2.0) 2 (1.0) 
      ε3/ε3 288 (59.6) 259 (58.5) 142 (61.7) 117 (54.9) 145 (57.5) 114 (59.7) 
      ε3/ε4 111 (23.0) 107 (24.2) 63 (27.4) 44 (20.7) 63 (25.0) 44 (23.0) 
      ε4/ε4 11 (2.3) 16 (3.6) 6 (2.6)† 10 (4.7) 9 (3.6) 7 (3.7) 
Total 483 443 230 213 252 191 
RU, rugby union. †Different from RU non-international (P = 0.01). 
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6.1.4 Discussion 
Here are the first data of APOE genotype and elite rugby athlete status. In contrast to the 
hypothesis, there were no differences in ε4/ε4 genotype or ε4 allele frequency between elite 
RU athletes and non-athlete controls (Figure 21). Furthermore, there were no differences in 
ε4/ε4 genotype or ε4 allele frequency between RU playing positions (Table 9). 
 
In vivo, APOE ε4 has been associated with neurodegenerative cascade subsequent to TBI, 
the severity of axonal injury in mouse models (Sabo et al., 2000; Hartman et al., 2002; 
Bennett et al., 2013) and more likely to show deposition of β-amyloid in brain tissue 
following head injury (Nicoll et al., 1995; Teasdale et al., 1997). In the intensive care setting, 
mice expressing the ApoE ε4 isoform have an increased systemic central nervous system 
inflammatory responses (Lynch et al., 2003), while in humans the APOE ε4 polymorphism 
has been associated with increased systemic inflammatory responses (Moretti et al., 2005). 
Considering these data with the observation of Merritt & Arnett (2016) and others (Lichtman 
et al., 2000; Crawford et al., 2002; Zhou et al., 2008; Müller et al., 2009; Noé et al., 2010; 
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Figure 21 Presence or absence of ε4 allele in controls and athletes. Black bars represent 
ε4 carriers and grey bars represent those possessing no ε4 alleles. 
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Roozenbeek et al., 2013; Zeng et al., 2014; Lawrence et al., 2015; Li et al., 2015) that ε4 
allele carriers experience more severe cognitive and physical symptoms following mTBI, it 
was conceivable that the ε4 allele would be underrepresented in elite rugby athletes 
compared to controls. However, the present data do not support that hypothesis. As the 
present results show, the APOE ε4 allele appears to have no relationship with the ability of 
people to compete at the highest levels of competitive rugby (Figure 21), despite that being 
an environment of high risk of mTBI (Savage et al., 2013; Gardner et al., 2014; Cross et al., 
2015; Fuller et al., 2015a; Gardner et al., 2015a; Fuller et al., 2016; Gardner et al., 2016). 
 
Notwithstanding previous reports (Kutner et al., 2000; Merritt & Arnett, 2016) of ε4/ε4 
genotype athletes or those carrying at least one ε4 allele being at increased risk of more 
severe symptoms following mTBI, that does not appear to inhibit their professional sporting 
careers. Three possibilities might explain this observation: (1) the published associations 
between the APOE ε4 allele and increased severity of mTBI in athletes are not true 
associations and will not be replicated in larger studies; (2) the increased risk associated with 
the ε4 allele is not large enough to influence career progression in professional rugby, as 
injured players are managed carefully, given appropriate recovery time and subsequently 
allowed to resume their careers; (3) the increased risk associated with APOE genotype is 
compensated, in terms of rugby career progression, by some advantageous role of the ε4 
allele such as increased aerobic capacity or vitamin D availability (Hagberg et al., 1999; 
Thompson et al., 2004; Huebbe et al., 2011; Raichlen & Alexander, 2014). Higher ε4/ε4 
genotype frequency were observed in RU athletes without international experience 
compared to non-athletic controls (Table 9), which might indicate some advantage for 
competitive rugby performance. However, because this was not reflected in athletes with 
international experience, who showed no difference from controls, that observation should 
be treated with extra caution and emphasis most be placed on the data from the larger cohort 
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of all professional elite athletes regardless of international competitive experience (Figure 
21). Furthermore, despite a previous investigation showing genetic variation related to 
muscle function and anthropometrics according to elite RU playing position (Chapters 4 and 
5), no association was identified between APOE genotype and RU playing position in the 
present chapter (Table 9). 
 
It is noteworthy that there are considerable numbers of ε4/ε4 (3.3%) and ε4+ (29.8%) rugby 
athletes who may be at greater risk of cognitive and physical impairments following mTBI, 
compared to non-carriers (Lichtman et al., 2000; Crawford et al., 2002; Zhou et al., 2008; 
Müller et al., 2009; Noé et al., 2010; Roozenbeek et al., 2013; Zeng et al., 2014; Lawrence 
et al., 2015; Li et al., 2015; Merritt & Arnett, 2016). World Rugby (the international 
governing body of rugby union) estimates there are 7.23 million rugby players worldwide of 
all competitive standards (http://www.worldrugby.org/development/player-numbers). 
Assuming similar allele frequencies to the Caucasians studied here amongst all players 
worldwide for the purpose of this discussion (i.e. ignoring geographic ancestry), over two 
million ε4+ rugby players may be at relatively greater risk of poorer outcome following 
mTBI than their ε4- counterparts. As Cross et al. (Cross et al., 2015) has shown a 60% greater 
chance of time-loss injury in elite players who returned to competition in the same season as 
receiving a mTBI, correctly managing athletes that are at greater risk due to any predisposing 
factor such as the 30% who are ε4+, could become a valuable strategy for researchers, 
support scientists and medical staff in due course. Possession of the APOE ε4 allele is 
associated with differential immune responses related to nitric oxide synthesis via c-Jun N-
terminal kinases (JNK) phosphorylation (Pocivavsek et al., 2009a) and modulation of 
inflammatory processes involving TNF-α, IL -6 and IL-12 (Hidding et al., 2002). 
Furthermore, the ε4 allele increases trauma-induced early apoptosis in neuronal/glial cell 
cultures (Chen et al., 2015) while the ε3 isoform protects the blood brain barrier (BBB) by 
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controlling cyclophilin A (CypA) expression levels when compared to ε4 (Bell et al., 2012b). 
These mechanisms produce a more hazardous cellular environment for ε4 carriers following 
injury. Further research to investigate if the previously identified association between APOE 
ε4 and mTBI severity (Lichtman et al., 2000; Crawford et al., 2002; Zhou et al., 2008; Müller 
et al., 2009; Noé et al., 2010; Roozenbeek et al., 2013; Zeng et al., 2014; Lawrence et al., 
2015; Li et al., 2015; Merritt & Arnett, 2016) persists in ε4 carriers amongst elite 
professional rugby players is therefore warranted. 
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Chapter 7  
 
 
 
 
COL5A1 gene variants previously 
associated with reduced soft tissue 
injury risk are associated with elite 
athlete status in rugby union 
 
 
This chapter is under review in BMC Genomics as: 
Heffernan, S. M., L. P. Kilduff, R. M. Erskine, S. H. Day, J, G. K. Stebbings, C. J. Cook, S. 
M. Raleigh, M. A. Bennett, G. Wang, M. Collins, Y. P. Pitsiladis & A. G. Williams. COL5A1 
gene variants previously associated with reduced soft tissue injury risk are associated with 
elite athlete status in rugby union. Submitted on 16/09/16. 
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7.1 COL5A1 gene variants previously associated with reduced soft tissue injury risk 
are associated with elite athlete status in rugby union 
 
7.1.1 Introduction 
Elite rugby athletes regularly experience high velocity collisions that lead to increasingly 
high injury occurrence rates that are likely to be an artefact of the increasing size and strength 
of the athletes (Cunniffe et al., 2009; Sedeaud et al., 2013; Owen et al., 2014; Bradley et al., 
2015) and thus greater changes in momentum during player collisions, as well as during 
voluntary accelerations and decelerations. This has resulted in RU having one of the highest 
reported injury incidence rates in professional team sports (Brooks & Kemp, 2008). Meta-
analyses have shown that for every 1000 hours, an elite RU athlete will experience 
approximately 81 injuries during match play and three during training, with the majority 
being ligament, tendon and muscle injuries of the lower limbs (Williams et al., 2013). 
Indeed, in the most recent Rugby World Cup (2015) this rate of incidence was more than 90 
injuries per 1000 h (Fuller et al., 2016). Furthermore, injury incidence differs across RU 
playing position, with elite back row players showing the highest rate among forwards and 
centres the highest among backs (Fuller et al., 2016). Therefore, investigating the molecular 
genetic components of these injuries, including in the context of playing positions that differ 
in terms of physiological characteristics (Smart et al., 2013; Smart et al., 2014), match play 
demands (Jones et al., 2015) as well as genetically (Chapter 4 and 5), may progress 
understanding towards greater individualisation of match play exposure and training load 
and mode, in order to reduce injury risk. 
 
The COL5A1 gene, which encodes for a minor fibrillar collagen protein (Cappa et al., 1995; 
Imamura et al., 2000), is the most explored genetic locus in relation to tendon and ligament 
injuries. Collagen is the primary structural tissue protein of the extracellular matrix that in 
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animal models is suggested to regulate fibrogenesis (Chanut-Delalande et al., 2004; 
Wenstrup et al., 2006), with other non-human evidence suggesting this may be through 
altered fibril structure and diameter (Birk et al., 1990). Furthermore, mutations in the human 
COL5A1 gene disrupt collagen type V organisation and affect the assembly of other 
collagens in the extra cellular matrix (Zoppi et al., 2004). Two amino acid components 
(collagen type V and type I fibrils) co-polymerise to form heterotypic fibres. The major 
collagen type V isoform comprises two α-1-(V) chains, encoded by the COL5A1 gene, one 
α-2-(V) chain encoded by the COL5A2 gene (Wenstrup et al., 2004; Malfait et al., 2010) 
and forms between 1-5% of total collagen content (McLaughlin et al., 1989; Chanut-
Delalande et al., 2004). Mutations in the COL5A1 gene have been identified in Ehlers-
Danlos syndrome, a disease characterised by joint hypermobility, laxity and muscle 
hypotonia (Beighton et al., 1998). This results in irregularly large collagen fibrils within 
connective tissue (Vogel et al., 1979) and may be attributed to a reduced synthesis of 
collagen type V (Malfait & De Paepe, 2005; Sun et al., 2011). 
 
Two common COL5A1 gene SNPs (rs12722 and rs3196378) located in the 3′ untranslated 
region (3′ UTR) on chromosome 9 have been associated with tendon (September et al., 2009) 
and ligament (rs12722; Posthumus et al., 2009a) pathology. Both rs12722 and rs3196378 
were associated with tendinopathy in Australian Caucasians, but only the former in South 
African Caucasians (September et al., 2009), which is interesting considering the SNPs are 
in linkage disequilibrium (D′ ≥ 0.67; September et al., 2009; Laguette et al., 2011). 
Accordingly, rs12722 has also been previously associated with flexibility (Collins et al., 
2009; Lim et al., 2015), anterior cruciate ligament injury (Posthumus et al., 2009b; Altinisik 
et al., 2015; O'Connell et al., 2015) and Achilles tendinopathy (Mokone et al., 2006) but not 
patellar tendon dimensional or functional properties (Foster et al., 2014). In these studies, 
the minor CC genotype was shown to be overrepresented in the respective asymptomatic 
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controls, suggesting a protective role of the C allele against injury. Considering the high 
frequencies of tendon and ligament inquiries in elite rugby (Williams et al., 2013; King et 
al., 2014; Fuller et al., 2015a; Fuller et al., 2016), assessing these specific genetic variants 
may be of use to help improve management of individual player injury risk. 
 
Given the association of the two COL5A1 gene variants with injury risk, it is probably more 
difficult for individuals carrying the alleles associated with greater risk to withstand 
exposure to the environment of competitive rugby without suffering from more frequent 
injuries. Consequently, those individuals would be forced to miss training, selection and 
competitive events important for their career progression. Thus, athletes carrying the C allele 
at both rs12722 and rs3196378 might be at an advantage in terms of their ability to achieve 
success in elite competitive rugby and at a disadvantage in terms of their shorter-term and 
longer-term musculoskeletal health. Therefore, the objective of the present study was to 
investigate if COL5A1 rs12722 and rs3196378 genotype and allele frequencies differed 
between elite rugby athletes and a control population, and/or between playing positions. It 
was hypothesised that the COL5A1 rs12722 and rs3196378 injury-protective C allele and 
CC genotype would be overrepresented in elite rugby athletes compared to controls. 
 
7.1.2 Method 
Participants 
A total of 1020 individuals were recruited and gave written informed consent to participate 
in the present study. The sample comprised elite Caucasian male rugby athletes (n = 454; 
mean (standard deviation) height 1.85 (0.07) m, mass 101 (14) kg, age 29 (7) years) 
including 72% British, 16% South African, 7% Irish and 5% of other nationalities. Caucasian 
controls (62% male; n = 566; height 1.75 (0.10) m, mass 75 (13) kg, age 26 (11) years) 
included 86% British, 12% South African, 1% Irish and 1% of other nationalities recruited 
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mainly during 2012-2016. Of the RU athletes, 52.4% had competed at international level for 
a “High Performance Union” (Regulation 16, worldrugby.org). All data for the athlete 
group’s international status were confirmed as of 1st June 2016. 
 
Sample collection 
Blood (n = 714 of all samples), saliva (n = 255) or buccal swab samples (n = 51) were 
obtained via the protocols detailed in Chapter 3.1.2. Blood sample was drawn from a 
superficial forearm vein, into an EDTA tube and stored in 2 mL sterile tubes at -20°C until 
processing. Saliva samples were collected into Oragene DNA OG-500 collection tubes 
according to the manufacturer’s protocol and stored at room temperature until processing. 
Omni swab Sterile buccal were rubbed against the buccal mucosa of the cheek for 
approximately 30 s. Tips were ejected into sterile tubes and stored at -20°C until processing. 
 
DNA isolation 
DNA isolation and genotyping were performed in the MMU, University of Glasgow, 
University of Cape Town (DNA isolation only) and University of Northampton laboratories. 
There are some differences between protocols summarized in Chapter 3.1.3; however, there 
was 100% agreement among reference samples genotyped in the three genotyping centres, 
i.e. Glasgow, Northampton and MMU laboratories. The majority of samples were processed 
and genotyped in the MMU laboratory. Genotype calling was successful for both variants in 
all samples. 
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Genotyping 
Genotyping in all three genotyping centres was performed on COL5A1 rs12722 and rs3196378. 
Briefly, in the Glasgow laboratory 10 µL Genotyping Master Mix (Applied Biosystems, 
Paisley, UK), 1 µL SNP-specific TaqMan assay (Applied Biosystems), 6 µL nuclease-free 
H2O and 3 µL DNA solution (~9 ng DNA) were added per well. In the Northampton 
laboratory, genotyping was performed by combining 10 µL of Genotyping Master Mix, 8 
µL H2O, 1 µL assay mix with 1 µL of purified DNA (~10 ng). In both laboratories, PCR was 
performed using a StepOnePlusTM real-time detector (Applied Biosystems). Briefly, after an 
initial 10 min at 95°C, 40 cycles of denaturation at 95°C for 15 s then annealing and 
extension at 60°C for 1 min were used. Genotyping calls were performed using 
StepOnePlusTM software version 2.3 (Applied Biosystems). At MMU, 5 µL Genotyping 
Master Mix, 4.3 µL H2O, 0.5 µL assay mix and 0.2 µL of purified DNA (~9 ng) were used 
in each reaction for samples derived from blood and saliva. For DNA derived from buccal 
swabs, 5 µL Genotyping Master Mix was combined with 3.5 µL H2O, 0.5 µL assay mix and 
1 µL DNA solution (~9 ng DNA). Either a Chromo4 (Bio-Rad, Hertfordshire, UK) or 
StepOnePlusTM real-time PCR system was used. Briefly, after an initial 10 min at 95°C, 40 
cycles of denaturation at 95°C for 15 s then annealing and extension at 60°C for 1 min were 
used. Genotyping calls were performed using Opticon Monitor software version 3.1 (Bio-
Rad) or StepOnePlusTM software version 2.3. The TaqMan assay included VIC and FAM 
dyes that for rs12722 indicated C and T alleles on the forward DNA strand, respectively. 
Thus, VIC/FAM were interpreted as: 5′-CACACCCA[C/T]GCGCCCCG-3′. For rs3196378, 
VIC and FAM dyes indicated C and A alleles on the forward DNA strand, respectively and 
were interpreted as: 5′-CCCACCCC[A/C]GCCCTGGC-3′. 
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Data analysis 
SPSS for Windows version 22 (SPSS Inc., Chicago, IL) software was used to conduct 
Pearson’s Chi-square (χ2) tests to compare genotype and allelic frequencies between athletes 
and controls, and between positional subgroups. Fifty tests were subjected to Benjamini-
Hochberg (BH; Benjamini & Hochberg, 1995) corrections to control false discovery rate and 
corrected probability values are reported. Where appropriate, OR was calculated to estimate 
effect size. CubeX online software (http://www.oege.org/software/cubex) was used to 
determine linkage disequilibrium statistics (Gaunt et al., 2007). Alpha was set at 0.05. 
 
7.1.3 Results 
Genotype calling was 100% successful for both polymorphisms in the athlete samples and 
for rs12722 in the control samples, with just 10 of the 566 control samples for rs3196378 
unsuccessful. There was 100% agreement among reference samples genotyped in the three 
genotyping centres, i.e. Glasgow, Northampton and MMU laboratories. Genotype 
frequencies were in Hardy-Weinberg equilibrium for both rs12722 and rs3196378 in the 
control (P ≥ 0.09) and athletes (P ≥ 0.78). COL5A1 rs12722 and rs3196378 were in tight 
linkage disequilibrium for both controls (D′ = 0.902; r2 = 0.785) and all athletes (D′ = 0.876; 
r2 = 0.736). Athletes were taller and heavier (P < 0.05) but not older (P > 0.05) than controls. 
 
rs12722 
The CC genotype and C allele were overrepresented in RU athletes (22.0% and 48.7%) 
compared to controls (13.6% and 41.3%, Table 10 and Figure 22, P ≤ 0.01). Furthermore, 
the CC genotype (Table 10) and C allele (Figure 22) were overrepresented in the subgroups 
of RU forwards (22.3% and 48.7%) and backs (21.6% and 48.7%) compared to controls 
(13.6% and 41.3%). Additionally, of the RU subgroups, the back three and centres differed 
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from controls, showed the greatest C allele and CC genotype frequency (51.7% versus 41.3% 
and 24.8% versus 13.6%, respectively, Table 10 and Figure 22, P = 0.01) and had almost 
two and half times the odds possessing the C allele and CC genotype than controls (Table 
11). There were no genotype or allele frequency differences any RU playing positions (Table 
10). 
 
Table 10 COL5A1 rs12722 and rs3196378 genotype and allele distribution of controls and 
athletes separated into positional subgroups, presented as genotype/allele counts followed 
by percentage in parentheses. 
RU, rugby union. *Different from controls (P ≤ 0.03) 
 
rs3196378 
The CC genotype, proportion of C allele carriers and C allele were overrepresented in RU 
athletes (24.0%, 73.3% and 47.7%) compared to controls (15.6%, 67.1% and 42.3%, Table 
10 and Figure 22, P ≤ 0.02). Furthermore, CC genotype, proportion of C allele carriers (Table 
10) and C allele (Figure 22) were overrepresented in backs (21.6%, 75.8% and 48.7%) 
compared to controls (13.6%, 67.1% and 41.3%, P ≤ 0.02). Forwards also had higher CC 
genotype and C allele frequencies (25.8% and 46.7%; Table 10 and Figure 22) and showed 
more than three and a half times the odds of being CC genotype than carrying an A allele, 
compared to controls (Table 11). For the back three and centres group, 24.8% were CC 
Genotype Controls All athletes 
RU 
athletes 
Forwards Backs 
Back three 
& centres 
rs12722       
      TT 164 (29.0) 142 (26.2) 121 (26.7) 75 (28.8) 46 (23.7) 26 (21.5) 
      CT 325 (57.4) 279 (52.2) 233 (51.3) 127 (48.8) 106 (54.6) 65 (53.7) 
      CC 77 (13.6) 113 (21.2)* 100 (22.0)* 58 (22.3)* 42 (21.6)* 30 (24.8)* 
Total 566 534 454 260 194 121 
T allele carriers 489 (86.4) 421 (79.9)* 354 (78.0)* 202 (77.7)* 152 (78.4)* 91 (75.2)* 
C allele carriers 402 (71.0) 392 (73.4) 327 (73.3) 185 (71.2) 148 (76.3) 95 (78.5) 
rs3196378       
      AA 183 (32.9) 142 (26.6) 121 (26.7) 74 (28.5) 47 (24.2) 26 (21.5) 
      CA 286 (51.4) 268 (50.2) 224 (49.3) 119 (45.8) 105 (54.1) 65 (53.7) 
      CC 87 (15.6) 124 (23.2)* 109 (24.0)* 67 (25.8)* 42 (21.6)† 30 (24.8)* 
Total 556 534 454 260 194 121 
A allele carriers 469 (84.4) 410 (76.8)* 345 (76.0)* 193 (74.2)* 152 (78.4)* 91 (75.3)* 
C allele carriers 373 (67.1) 392 (73.2)* 333 (73.3)* 186 (71.5) 147 (78.4)* 95 (78.5)* 
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genotype, 78.5% were C allele carriers and C allele frequency was 51.7% - all of which were 
greater than controls (P ≤ 0.02; Table 10 and Figure 22, OR = 2.43, Table 11). However, 
there were no differences in rs3196378 allele or genotype frequencies between RU forwards 
and backs (Table 10). 
 
Table 11 Odds ratio statistics for RU player status of COL5A1 gene variants 
(rs12722 and rs3196378). Odds of the first genotype/allele in the first sample 
group. 
Positional comparison  Genetic 
Model 
Odds 
Ratio 
95% Confidence 
Interval 
P value 
rs12722     
RU athletes v Controls CC/TT 
C/T 
1.76 
1.24 
1.21-2.57 
1.04-1.48 
0.003 
0.015 
Forwards v Controls CC/TT 
CC/T 
1.65 
1.82 
1.06-2.55 
1.25-2.66 
0.025 
0.002 
Backs v Controls CC/TT 
CC/T 
C/T 
1.94 
1.75 
1.31 
1.18-3.20 
1.16-2.66 
1.04-1.65 
0.009 
0.008 
0.023 
Back three and centres 
v Controls 
CC/TT 
CC/T 
C/T 
2.46 
2.09 
1.46 
1.36-4.44 
1.31-3.38 
1.10-1.92 
0.003 
0.002 
0.008 
rs3196378     
RU athletes v Controls CC/AA 
CC/A 
C/A 
1.89 
1.70 
1.35 
1.32-2.73 
1.24-2.33 
1.13-1.61 
0.0006 
0.0009 
0.0009 
Forwards v Controls CC/AA 
CC/A 
C/A 
1.90 
3.45 
1.35 
1.25-2.89 
2.21-5.40 
1.09-1.66 
0.003 
<0.0001 
0.005 
Backs v Controls CC/AA 
C/A 
1.88 
1.35 
1.15-3.06 
1.07-1.70 
0.011 
0.011 
Back three and centres 
v Controls 
CC/AA 
CC/A 
C/A 
2.43 
1.78 
1.52 
1.35-4.35 
1.11-2.85 
1.15-2.01 
0.003 
0.017 
0.003 
RU, rugby union. 
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7.1.4 Discussion 
The present observations are the first to identify associations between COL5A1 rs12722 and 
rs3196378 polymorphisms and athlete status in a large cohort of elite RU athletes. As 
hypothesised, the injury-protective C allele and CC genotype, of both SNPs (September et 
al., 2009), were over-represented in elite RU athletes, compared to controls (Table 10 and 
Figure 22). This association persisted across playing position, with the C allele being 
overrepresented in RU forwards and backs including the back three and centres group, 
compared to controls (Table 11 and Figure 22). 
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The results provide an insight into the potential injury susceptibility of some elite rugby 
athletes. September et al. (2009) identified a higher frequency of the CC genotype in 
asymptomatic controls for both rs12722 and rs3196378 compared to tendinopathy patients 
(September et al., 2009; Laguette et al., 2011). Moreover, the rs12722 T allele has been 
associated with anterior cruciate ligament injury (Posthumus et al., 2009b; Bell et al., 2012a; 
Altinisik et al., 2015; O'Connell et al., 2015) and Achilles tendinopathy (Mokone et al., 
2006; September et al., 2009) with the C allele again identified as protective in these studies. 
Greater joint laxity has almost a 3-fold increase in risk of knee ligament rupture (Uhorchak 
et al., 2003) and greater joint laxity has recently been associated with the rs12722 T allele 
in non-white females (Bell et al., 2012a). These data suggest that the C allele of both rs12722 
and rs3196378 may be beneficial in protecting against tendon and ligament injuries. This is 
reflected in the present chapter showing greater C allele frequency in elite RU athletes 
compared to controls (Table 10 and 11, Figure 22). Based on these data, it is proposed that 
when exposed to the high-risk environment of RU during training and especially during 
competitive matches, ceteris paribus, carriage of the C alleles at those two SNPs provides 
both a shorter-term and longer-term advantage to rugby athletes in the form of reduced injury 
risk. Athletes with fewer and/or less severe injuries, all else being equal, will miss fewer 
matches, training and selection events and thus be more likely to progress towards elite status 
in their athletic careers compared to their peers.  
 
The rs12722 CC genotype has also been related to have a lower incidence of exercise-
associated muscle cramping (EAMC) in Caucasian ironman and ultra-marathon athletes 
(O’Connell et al., 2013). The authors hypothesised that this was due to similar mechanisms 
of reduced tendon and injury susceptibility, in that rs12722 alters soft tissue structural and 
mechanical properties (tissue thickening). However, current evidence does not support an 
association of rs12722 with structural and mechanical properties (Foster et al., 
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2014).Regardless, this suggests that in addition to protection from tendon and ligament 
injury, the greater frequencies of the C allele in elite RU athletes (Table 10 and Figure 22) 
may be protective against muscle cramping. Indeed, recent evidence from elite rugby league 
athletes shows that over 70% of athletes experience EAMC per season and that history of 
cramping is the strongest predictor of future EAMC (Summers et al., 2014). Which may be 
supported, to a lesser extent, in elite RU (23%; categorised in a subgroup with muscle 
rupture, tear and strain; Fuller et al., 2016). In contrast, the TT genotype has been associated 
with greater endurance running ability of Caucasian ironman triathletes (TT = 294.2 min, 
CC = 307.4 min; Posthumus et al., 2011). However, recent data shows no association of 
rs12722 with either running economy or VȮ2max (Bertuzzi et al., 2014). While endurance 
capacity is of value in elite rugby, the predominant focus of player selection and training 
programs is towards power, speed and strength - i.e. short-term, anaerobic performance (with 
notable differences between playing positions; Smart et al., 2013; Smart et al., 2014). 
 
Limited data exist regarding COL5A1 genetic variation and team sport athletes. In a study 
of 73 soccer athletes, including some elite players, no rs12722 TT genotype individuals were 
identified (a potentially interesting observation but difficult to interpret because of the varied 
geographic ancestry of the athletes), but there was a tendency for more severe muscle injuries 
in the TC genotype group (P = 0.08), compared to CC (Pruna et al., 2013). Here, consistent 
with those observations, the data show an overrepresentation of the protective C allele and 
CC genotype of both rs12722 and rs3196378 in elite rugby athletes (with no differences 
between playing positions). 
 
Some possible mechanisms have been proposed to explain the association of COL5A1 gene 
variants and soft tissue injury (Laguette et al., 2011; Abrahams et al., 2013). Laguett et al. 
(2011) have shown that the COL5A1 3′ UTR – where both rs12722 and rs3196378 are 
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situated - affects miRNA stability. For both SNPs, the alleles associated with greater soft-
tissue injury risk were associated with greater Hsa-miR-608 stability, which in turn may alter 
the Col5α1 protein secondary structure - proposed to play a role in type V collagen 
production (Abrahams et al., 2013). This would suggest that C/T allele differences at 
rs12722 may alter the co-polymerisation of collagen type V and type I fibrils. However, to 
date, this has not been demonstrated experimentally and exactly how this may translate into 
functional properties is currently unknown. Nevertheless, it appears that the C allele and CC 
genotype of rs12722 and rs3196378 may be beneficial for rugby athletes to achieve elite 
status, probably through greater resistance to soft tissue injury. Interestingly, while most 
relevant investigations have focussed on rs12722, the present data show, in a large cohort 
(total n = 1090), that strong linkage disequilibrium exists in both controls (D′ = 0.902; r2 = 
0.785) and athletes (D′ = 0.876; r2 = 0.736) between rs12722 and rs3196378. As such, it is 
likely that the molecular associations of rs12722 with tendon and ligament injuries would be 
similar for rs3196378. It is possible that combining genetic data from multiple gene variants 
associated with injury susceptibility, such as those presented here, with other indicators of 
injury risk and recovery during rehabilitation could be used to better manage the prevention 
of and recovery from elite player injury in the future. 
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8.1 Polygenic profile of elite rugby union athletes 
 
8.1.1 Introduction 
Elite athletic performance is highly heritable (66%; De Moor et al., 2007) and consists of 
complex physiological traits. The molecular genetic components of these traits have been 
receiving increasing interest from the scientific community in recent years (Ahmetov & 
Fedotovskaya, 2012; Ahmetov et al., 2016; Pitsiladis et al., 2016; Tanaka et al., 2016) - 
Chapter 2.2. In fact, more than 155 genetic markers have been identified in association with 
athletic performance and confirmation of these results has been building with 31 publications 
showing positive associations in at least 2 studies (Ahmetov et al., 2016). Because each 
individual genetic variant carries only a small contribution to the overall heritability of elite 
athletic status, using statistical models to combine these individual influences are required 
(Pitsiladis et al., 2013), have been developed (Williams & Folland, 2008) and have recently 
been expanded upon (Bouchard et al., 2011; Thomaes et al., 2011; Thomaes et al., 2013; 
Massidda et al., 2014b). 
 
Williams and Folland (2008) developed the total genotype score (TGS) as a way to represent 
the simultaneous influence of multiple genetic markers as a simple value, that is intuitively 
understandable. One of the main aims of the model is to combine the small accumulative 
effects of many SNPs, that may have been statistical insignificant due to statistical power 
via low sample size (a current limitation identified in chapter 2.2.4; appendix 5), to give a 
better understanding of the polygenic nature of elite athletic traits. According to the TGS, all 
scores lie between 0-100 and a higher score indicates a greater genetic suitability for a given 
phenotype such as muscle mass, sprinting speed, reduced injury risk, greater cognitive 
ability, elite athlete status – depending on the genetic variants that are used to calculate the 
specific TGS in each case. Thus, multiple TGS, each directed towards a given phenotype, 
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can be calculated for each individual. Subsequently, both hypothetical (Williams & Folland, 
2008; Hughes et al., 2011) and experimental (Gómez-Gallego et al., 2010; Ruiz et al., 2010; 
Santiago et al., 2010; Eynon et al., 2011b; Chiu et al., 2012; Drozdovska et al., 2013; 
Massidda et al., 2014a; Ahmetov et al., 2015; Ben‐Zaken et al., 2015; Grealy et al., 2015; 
Miyamoto-Mikami et al., 2016) studies have used this method in attempts to elucidate the 
‘optimal polygenetic profile’ for a given cohort with some limited success. 
 
To date, TGS has been considered in only two team sport investigations of elite soccer 
athletes, one concerned with phenotypic measures of lower body power (Massidda et al., 
2014a) and the other with positional variation and athlete status (Egorova et al., 2014). 
Massidda et al. showed no difference between TGS in the whole athlete cohort (n = 90) and 
controls, however did identify a relationship between TGS (of six SNPs) and vertical jump 
performance, using the Williams and Folland method (Williams & Folland, 2008; Massidda 
et al., 2014b). In addition to the TGS, Massidda et al. developed a genotype score (GS) that 
weighted (W) each SNP based on their phenotypic impact resulting in three SNPs being 
excluded from the WGS and showed a greater explanation of the variance in vertical jump 
performance than non-weighted TGS. Weighting each SNP based on the relevance to a given 
phenotype is an important development, however does not currently apply to investigations 
of athlete status due to the categorical nature of the data. More applicable to the present 
thesis, Egorova et al. firstly performed a case-control study of eight SNPs in 246 mixed level 
athletes (n = 51 elite), where four SNPs were identified as significant in the whole group. 
These four SNPs were then included into the Williams and Folland TGS algorithm to 
compare athletic level and positional difference to controls in a pseudo-data drive approach. 
Strictly speaking, the Williams and Folland method was developed to include both 
significant and non-significant results to ensure identification of any possible association. 
Nevertheless, they found that at all competitive levels (elite, sub-elite and non-elite) athletes 
had greater TGS than controls and of the four positional groups (comprising of elite (n = 51) 
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and sub-elite (n = 83), goalkeepers, attackers, defenders and midfielders), goalkeepers and 
midfielders were independently different from controls (Egorova et al., 2014), suggesting 
that TGS models may differ between team sport playing position and need to be considered 
within the present chapter. As shown in chapters 4 and 5, considerable genetic differences 
exist within elite rugby playing position and an exploratory polygenic investigation of the 
genetic variants studied in the present thesis is the logical next step. Indeed, because of the 
uniquely identified genetic differences between RU backs and forwards (chapters 4 and 5) 
assigning the optimal genotype score using evidence from the existing literature would 
introduce considerable errors to the model because the ‘actual’ (i.e. results from chapters 4 
and 5) data would not be represented in the model. However, assigning the genotype score 
based on these uniquely identified genetic differences (data driven approach) and following 
the inclusion of all studied variants, as originally intended by the Williams and Folland 
method (Williams & Folland, 2008), would significantly improve the accuracy of the model. 
 
Therefore, utilising the data driven approach to the Williams and Folland TGS algorithm, 
the aims of the present chapter were firstly to assess the polygenic profile, of the gene 
variants examined in the first four experimental chapters (chapters 4-7), for all RU athletes, 
forwards and backs, compared to controls. Secondly, because of the inter-positional genetic 
variation that has been identified (chapters 4 and 5), the present chapter will explore and 
compare the polygenic difference between backs and forwards. 
 
8.1.2 Method 
Participants 
A total of 881 individuals were recruited and gave written informed consent to participate in 
the present thesis. The sample comprised elite Caucasian male rugby athletes (n = 422; mean 
(standard deviation) height 1.85 (0.07) m, mass 101 (14) kg, age 29 (7) years) including 72% 
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British, 16% South African, 7% Irish and 5% of other nationalities. Caucasian controls (60% 
male; n = 459; height 1.74 (0.10) m, mass 73 (13) kg, age 25 (11) years) included 98% 
British, 1% Irish and 1% of other nationalities. Of the RU athletes, 51.9% had competed at 
international level for a “High Performance Union” (Regulation 16, worldrugby.org). All 
data for the athlete group’s international status were confirmed as of 1st June 2016. 
 
Sample collection 
Blood (n = 617 of all samples), saliva (n = 220) or buccal swab samples (n = 44) were 
obtained via the protocols detailed in Chapter 3.1.2. Blood sample was drawn from a 
superficial forearm vein, into an EDTA tube and stored in 2 mL sterile tubes at -20°C until 
processing. Saliva samples were collected into Oragene DNA OG-500 collection tubes 
according to the manufacturer’s protocol and stored at room temperature until processing. 
Omni swab Sterile buccal were rubbed against the buccal mucosa of the cheek for 
approximately 30 s. Tips were ejected into sterile tubes and stored at -20°C until processing. 
 
DNA isolation 
DNA isolation and genotyping were performed in the MMU, University of Glasgow, 
University of Cape Town (DNA isolation only) and University of Northampton laboratories. 
There are some differences between protocols summarized in Chapter 3; however, there was 
100% agreement among reference samples genotyped in the three genotyping centres, i.e. 
Glasgow, Northampton and MMU laboratories. The majority of samples were processed and 
genotyped in the MMU laboratory. 
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Genotyping 
Genotyping in all three genotyping centres was performed on APOE (rs429358 and rs7412), 
ACTN3 (rs1815739) and an ACE I/D or ACE tag SNP (rs4341), COL5A1 (rs12722 and 
rs3196378) and FTO (rs9939609). Briefly, in the Glasgow laboratory 10 µL Genotyping 
Master Mix (Applied Biosystems, Paisley, UK), 1 µL SNP-specific TaqMan assay (Applied 
Biosystems), 6 µL nuclease-free H2O and 3 µL DNA solution (~9 ng DNA) were added per 
well. In the Northampton laboratory, genotyping was performed by combining 10 µL of 
Genotyping Master Mix, 8 µL H2O, 1 µL assay mix with 1 µL of purified DNA (~10 ng). In 
both laboratories, PCR was performed using a StepOnePlusTM real-time detector (Applied 
Biosystems). Briefly, after an initial 10 min at 95°C, 40 cycles of denaturation at 95°C for 
15 s then annealing and extension at 60°C for 1 min were used. Genotyping calls were 
performed using StepOnePlusTM software version 2.3 (Applied Biosystems). At MMU, 5 µL 
Genotyping Master Mix, 4.3 µL H2O, 0.5 µL assay mix and 0.2 µL of purified DNA (~9 ng) 
were used in each reaction for samples derived from blood and saliva. For DNA derived 
from buccal swabs, 5 µL Genotyping Master Mix was combined with 3.5 µL H2O, 0.5 µL 
assay mix and 1 µL DNA solution (~9 ng DNA). Either a Chromo4 (Bio-Rad, Hertfordshire, 
UK) or StepOnePlusTM real-time PCR system was used. Briefly, after an initial 10 min at 
95°C, 40 cycles of denaturation at 95°C for 15 s then annealing and extension at 60°C for 1 
min were used. Genotyping calls were performed using Opticon Monitor software version 
3.1 (Bio-Rad) or StepOnePlusTM software version 2.3. The Taqman assay included VIC and 
FAM dyes, interpretation of the specific sequence for each SNP are presented in chapters 4, 
5, 6 and 7. 
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Positional groups 
As detailed in Chapter 3.1.5, to assess genotype and allele frequencies within the players, 
athletes were allocated to subgroups; forwards (props, hookers, locks, flankers, number 
eights) and backs (scrum halves, fly halves, centres, wings, full backs). 
 
TGS calculations 
To determine TGS’, each genotype was allocated a ‘genotype score’ (GS) of 0, 1 or 2. The 
allocation was based on the assumption that allele effects were co-dominant, and 
homozygotes deemed to have the favourable genotype for the phenotypes of interest 
(athlete/positional status) were allocated a GS of 2, heterozygotes scored 1 and the non-
favourable homozygotes scored 0. For APOE, the combination of rs429358 and rs7412 
generates the ε4 genotype, in the context of an athletic population, the presence (ε4+) or 
absence (ε4-) of the ε4 allele have been identified as the best genetic model (for details see 
chapter 6). As such, ε4+ were given the value 0 and ε4- were allocated 2. There was no 
APOE group allocated 1. Combination of each GS and transformation of the total score 
allowed the combined influence of all 6 gene variants on athlete and positional status to be 
quantified (Williams & Folland, 2008) using the following equation (equation one). 
 
Equation one: TGS = (100/12) * (GSAPOE-ε4 + GSACE + GSACTN3 + GSCOL5A1-rs12722 + GSCOL5A1-
rs3196378 +GSFTO). 
 
By following the experimental data (data driven approach), to ensure accuracy and 
specificity of the TGS model to RU athletes, presented in the previous chapters (chapter 4, 
5, 6 and 7) and including all investigated genotypes, regardless of a non-significant 
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association (Williams & Folland, 2008), decisions of the optimal GS for each genotype 
generated three TGS models. (1) Based on the observed data for all RU athletes (GSRU; Table 
12), (2) based on the observed data for the backs playing position (GSB; Table 14) and (3) 
based on the observed data for the forwards playing position (GSF; Table 13). Each model 
was calculated for both the athlete group and the control group and as such, comparisons 
between athletes (including backs and forwards) and controls were made from the same 
model. Additionally, in an attempt to normalise the TGS for positional specificity, a 
TGSB/TGSF ratio was calculated and compared between backs and forwards using receiver 
operating characteristic (ROC) curves, similar to that described in an alternative athletic 
context (Ben‐Zaken et al., 2015).
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Table 12 Genotype score details for optimal RU athlete (GSRU) status based on evidence from the thesis observations (genotype score chosen 
from the data contained within the experimental chapters, 4-7). 
Gene variant Genotype score Rationale Evidence 
ACE (I/D) 0 = DD, 1 = ID & 2 = II I allele associated with athletic performance, particularly endurance performance 
and slightly greater proportion in all elite rugby athletes. 
Chapter 2.3.1 
Chapter 4 
ACTN3 rs1815739 0 = XX, 1 = RX & 2 = RR R allele associated with sprint/power performance. X allele associated with 
endurance capacity with a greater proportion in all elite rugby athletes. 
Chapter 2.3.2 
Chapter 4 
FTO rs9939609 0 = TT, 1 = AT & 2 = AA A allele associated with greater mass and slightly greater in all elite rugby athletes. Chapter 2.3.3 
Chapter 5 
COL5A1 *rs12722 and 
#rs3196378 
*0 = TT, 1 = CT & 2 = CC 
#0 = AA, 1 = CA & 2 = CC 
C allele of both SNPs associated with protection form soft tissue injury and in all 
elite rugby athletes. 
Chapter 2.3.5 
Chapter 7 
APOE ε4 rs429358 
and rs7412 
0 = ε4+ & 2 = ε4- ε4- associated with protection from poorer outcome following mTBI and is 
identified in 70% of elite rugby athletes. 
Chapter 2.3.4 
Chapter 6 
Both APOE SNPs combine to generate the ε4 genotype (See chapter 2.3.4). 
 
Table 13 Genotype score details for optimal RU forwards (GSF) based on evidence from thesis observations (genotype score chosen from 
the data contained within the experimental chapters, 4-7). 
Gene variant Genotype score Rationale Evidence 
ACE (I/D) 0 = DD, 1 = ID & 2 = II I allele associated with athletic performance, particularly endurance performance 
and slightly greater proportion in all elite rugby athletes. 
Chapter 2.3.1 
Chapter 4 
ACTN3 rs1815739 0 = RR, 1 = RX & 2 = XX R allele associated with sprint/power performance. X allele associated with 
endurance capacity and with playing position elite rugby forwards. 
Chapter 2.3.2 
Chapter 4 
FTO rs9939609 0 = TT, 1 = AT & 2 = AA A allele associated with greater mass and elite rugby forwards. Chapter 2.3.3 
Chapter 5 
COL5A1 *rs12722 and 
# rs3196378 
*0 = TT, 1 = CT & 2 = CC 
#0 = AA, 1 = CA & 2 = CC 
C allele of both SNPs associated with protection form soft tissue injury and in all 
elite rugby athletes. 
Chapter 2.3.5 
Chapter 7 
APOE ε4 rs429358 
and rs7412 
0 = ε4+ & 2 = ε4- ε4- associated with protection from poorer outcome following mTBI and is 
identified in 70% of elite rugby athletes. 
Chapter 2.3.4 
Chapter 6 
Both APOE SNPs combine to generate the ε4 genotype (See chapter 2.3.4). 
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Table 14 Genotype score details for optimal RU backs (GSB) based on evidence from thesis observations (genotype score chosen from the data 
contained within the experimental chapters, 4-7). 
Both APOE SNPs combine to generate the ε4 genotype (See chapter 2.3.4). 
 
Gene variant Genotype score Rationale Evidence 
ACE (I/D) 0 = DD, 1 = ID & 2 = II I allele associated with athletic performance, particularly endurance performance 
and slightly greater proportion in all elite rugby athletes. 
Chapter 2.3.1 
Chapter 4 
ACTN3 rs1815739 0 = XX, 1 = RX & 2 = RR R allele associated with sprint/power performance and with playing position elite 
rugby backs. X allele associated with endurance capacity. 
Chapter 2.3.2 
Chapter 4 
FTO rs9939609 0 = AA, 1 = AT & 2 = TT T allele associated with elite rugby backs. Chapter 2.3.3 
Chapter 5 
COL5A1 *rs12722 and 
# rs3196378 
*0 = TT, 1 = CT & 2 = CC 
#0 = AA, 1 = CA & 2 = CC 
C allele of both SNPs associated with protection form soft tissue injury and in all 
elite rugby athletes. 
Chapter 2.3.5 
Chapter 7 
APOE ε4 rs429358 
and rs7412 
0 = ε4+ & 2 = ε4- ε4- associated with protection from poorer outcome following mTBI and is 
identified in 70% of elite rugby athletes. 
Chapter 2.3.4 
Chapter 6 
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Data analysis 
SPSS for Windows version 22 (SPSS Inc., Chicago, IL) software was used to conduct 
Pearson’s Chi-square (χ2) tests to compare genotype frequencies between athletes and 
controls, and between RU subgroups based on playing position (data presented in chapters 
4-7). Differences in TGS between athletes and controls were analysed using unpaired t tests. 
Additionally, area under the ROC curves (AUC) were used to estimate the sensitivity of TGS 
to detect differences between backs and forwards (Zweig & Campbell, 1993). Alpha was set 
at 0.05. 
 
8.1.3 Results 
There was 100% agreement among reference samples genotyped in the three genotyping 
centres, i.e. Glasgow, Northampton and MMU laboratories. All genotype frequencies were 
in Hardy-Weinberg equilibrium for both the athlete and control group (Chapters 4, 5, 6 and 
7). Athletes were taller and heavier (P < 0.05) but not older (P > 0.05) than controls. No 
athletes had a TGS of zero or 100, regardless of GS model (range 8-92), two controls had a 
TGS of zero and one had a TGS 100 for the forwards GS model (Table 13). 
 
Following the GSRU model, the control group (TGS = 47.4 ± 16.8) had a lower mean TGS 
than all RU athletes (TGS = 49.9 ± 15.9; Figure 23A). Considering playing position and the 
GSB model, TGS was greater (TGS = 57.1 ± 14.8) compared to controls (TGS = 53.4 ± 16.0; 
Figure 23B). Similarly, for the GSF model the TGS was greater than that of the control group 
(TGS = 50.5 ± 14.8; TGS = 47.4 ± 16.8; Figure 23C).
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Figure 23 Frequency distribution of total genotype score. A All RU athletes (kurtosis = -0.309, SE = 0.238) versus controls (kurtosis = -0.098, SE = 0.227) 
as calculated from table 12. B Backs (kurtosis = 0.254, SE = 0.365) versus controls (kurtosis = -0.298, SE = -0.227) as calculated from table 14. C Forwards 
(kurtosis = -0.474, SE = -0.312) versus controls (kurtosis = -0.908, SE = -0.227) as calculated from table 13. 
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Of the backs group, 60% had a TGS greater than or equal to 60, whereas only 40% of the 
forwards had a TGS greater than or equal to 60, for their respective GS models (Figure 23). 
Furthermore, utilising the TGSB/TGSF ratio, the backs showed a greater ratio than forwards 
(1.27 versus 1.12), with ROC analysis identifing significant, but low, discrimination 
accuracy for TGS (AUC = 0.587, 95% CI 0.532-0.642, P = 0.002; Figure 24). 
 
 
 
 
 
 
 
 
8.1.4 Discussion 
The present observations are the first to identify polygenic differences between elite RU 
athletes and a control group (Figure 23). By using the observed genotypic data to generate 
position specific GS, the present results show that the TGS of all athletes, backs and forwards 
were higher than their respective GS specific control groups (Figure 23). Furthermore, 
considerable polygenic differences were identified between backs and forwards, with the 
backs exhibiting a greater TGS and TGSB/TGSF ratio than forwards (Figure 24), for the six 
investigated genotypes. 
 
Figure 24 ROC curve for the TGSB/TGSF ratio (mean sensitivity = 0.571, mean specificity 
= 513). 
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The most unique aspect of the present chapter is the identification that the SNPs selected for 
inclusion in the present TGS models show greater predictability for the backs playing 
position (considering the results from chapter 4 and 5; Figure 24). Addition of many other 
variants are necessary to identify a more forwards oriented or positionally ubiquitous TGS 
models. Nonetheless, the present observations have identified significant polygenic 
sensitivity in discriminating between elite RU backs and forwards, with the backs exhibiting 
the greatest TGSB/TGSF ratio (AUC = 0.587; Figure 24). These results highlight the 
combined genetic impact of the observed performance (Chapter 4), anthropometric (Chapter 
5), neurobiological (Chapter 7) and soft tissue (Chapter 6) injury susceptibility observations, 
in relation to elite RU playing position. 
 
The present data are in agreement with other TGS investigations of elite athlete status, in 
that the TGS of athlete are higher than that of controls, regardless of the GS model (Ruiz et 
al., 2010; Eynon et al., 2011b; Drozdovska et al., 2013; Egorova et al., 2014; Ahmetov et 
al., 2015; Ben‐Zaken et al., 2015; Grealy et al., 2015). However, some have not identified 
an association with TGS and elite athlete status (Gómez-Gallego et al., 2010; Miyamoto-
Mikami et al., 2016). In relation to team sport specific analysis, Egorova et al. investigated 
polygenic profiles in a mixed athletic level soccer cohort (21% elite) and identified positional 
differences when compared to controls. However, they did not consider differences between 
playing positions (Egorova et al., 2014), using the ratio ROC model presented in the current 
chapter and in Ben-Zakin et al. (2015) would have been an interesting addition to the study. 
Similarly, the present results have demonstrated a positional specific polygenic profile for 
both the forwards (TGS = 50.5) and to a greater extent in the backs (TGS = 57.1), compared 
to their respective controls (Figure 23B and 23C) and support the use of TGS in team sport 
genetic cohort studies. 
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TGS is the best currently available tool to understand the collective importance of multiple 
genetic variants on a given phenotype within a population. The present chapter is the first to 
utilise this statistical model in the context of athlete positional variation and its use was 
successful in discriminating between elite RU backs and forwards. It does however have a 
number of limitations which are inherent in its application. For example, the present chapter 
included a small number of genes, of which in isolation only two (ACTN3 and FTO) were 
found to have an effect on playing position. The present models included all six studied gene 
variants within the TGS despite the association with playing position, as this was the original 
intention of the Williams and Folland method (Williams & Folland, 2008). However, the 
present chapter followed the data-driven approach to TGS and in a unique context of 
positional variation, where both homozygotes for both the ACTN3 and FTO were found to 
be advantageous in different positions (R and T for backs and the X and A for forwards, 
respectively; Table 13 and 14). As such, different models were generated and were 
successful in identifying these individual positional group relationships - importantly in the 
presence of all six SNPs. 
 
The inevitable addition of further SNPs to the elite rugby TGS model will improve the 
accuracy and confidence in the identified results and further development of these models is 
important for future investigations. Moreover, the present data show the importance of 
assessing positional specificity in terms of the allocation of the optimal genotype (Tables 12, 
13 and 14). As identified in chapter 4 and 5, considerable genetic variations exist within elite 
RU playing position that require multiple GS models to understand the genetic complexity 
of elite rugby athletes. The present chapter has identified TGS variation between backs and 
forwards (Figure 24), however RU consists of five distinct positional groups (Chapter 3.1.5) 
and evaluation of TGS in each of these groups is the next step towards understanding the 
molecular aspects of elite rugby positional variation. This is one of the long-term goals of 
the RugbyGene project and an exciting prospect as the elite rugby sample continues to grow. 
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Chapter 9  
 
 
 
 
Thesis general discussion 
 
 
 
 
A portion of part 9.1.7 of this chapter is published in: 
 
Heffernan S. M., Kilduff L. P., Day S. H., Pitsiladis Y. P. & Williams A. G. (2015): 
Genomics in rugby union: A review and future prospects. European Journal of Sport 
Science, 15(6), 460-468. 
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9.1 General Discussion 
 
9.1.1 Overview 
The capacity to achieve elite athletic success is known to be highly heritable (De Moor et 
al., 2007), however attempting to explain this heritability has proven to be extremely 
difficult. This is partly because of the vast number of human molecular genetic variants 
currently known to exist (Sachidanandam et al., 2001; International HapMap Consortium, 
2005; Frazer et al., 2007), but also due to the difficulty in identifying the heritable component 
of individual physiological traits that contribute to athletic success (Chapter 2.2.1; Table 3). 
Currently, more than 155 genetic markers have been identified in association with athletic 
performance (Ahmetov et al., 2016) and considerable effort has been devoted to 
understanding these molecular traits in recent years - often involving sprint/power or 
endurance athletes (Rankinen et al., 2001; Berman & North, 2010; Eynon et al., 2011c; 
Hughes et al., 2011; Puthucheary et al., 2011; Wilber & Pitsiladis, 2012; Eynon et al., 2013a; 
Ma et al., 2013; Pitsiladis et al., 2013; Tucker et al., 2013; Bouchard, 2015; Loos et al., 
2015) – chapter 2.2.4. To date, only a small proportion of these efforts have considered the 
genomic component of team sport athletes, such as elite RU athletes, and often with 
considerable methodological limitations (Chapter 2.2.4). The current thesis attempted to 
begin bridging the gap in the current understanding of team sport genomic variation, 
focusing on elite RU athletes. As such, the aims of the present research project were; 
 
 To recruit a large biobank of elite rugby athletes for the purpose of evaluating the 
molecular genetic component of elite rugby status and investigate the molecular 
underpinnings of the physiological and anthropometric variation that exists in elite 
rugby playing position (Chapter 3.1.1). 
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 To investigate ACE I/D and ACTN3 R577X genotype distribution in elite rugby 
athletes. It was hypothesized that the ACTN3 R allele and the ACE I allele would be 
more frequent in rugby athletes than controls. It was further hypothesized that 
ACTN3 XX and ACE II genotypes would be underrepresented in backs compared to 
forwards, due to differences in overall work-to-rest ratio and differing requirements 
for high maximum speed (Chapter 4.1). 
 
 To investigate if FTO rs9939609 genotype differs between elite rugby athletes and a 
control population, and/or between playing positions. Based on prior data in obese 
populations, it was firstly hypothesised that the rs9939609 risk (A) allele would be 
would be overrepresented in playing positions typically requiring greater body and 
muscle mass, while the protective (T) allele would be more common in positions 
requiring a lean phenotype (Chapter 5.1). 
 
 To quantify the ‘at risk’ APOE ε4 carriers in the elite rugby community and to 
investigate if APOE genotypes differed between elite rugby athletes and a control 
population. Based on the published APOE ε4/ε4 association with poorer outcome 
following brain injury, it was hypothesised that the ε4/ε4 genotype and ε4 allele 
would be underrepresented in elite rugby athletes compared to controls (Chapter 6.1). 
 
 To investigate if associations of COL5A1 rs12722 and rs3196378 genotype and allele 
frequencies differed between elite rugby athletes and a control population. It was 
hypothesised that the COL5A1 rs12722 and rs3196378 protective C alleles and CC 
genotypes would be overrepresented in elite rugby athletes compared to controls 
(Chapter 7.1). 
 
 Finally, a TGS algorithm was applied to assess the polygenic profile, of the gene 
variants examined in the first four experimental chapters of the present thesis, for all 
RU athletes, forwards and backs, compared to controls (Chapter 8.1). 
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9.1.2 Main experimental findings 
The main findings of the current thesis are discussed, in detail, in the subsequent sections of 
this chapter. However, briefly, the R allele of ACTN3 R577X rs1815739 was identified as 
advantageous for backs, particularly the back three players, reflecting their positional 
requirements (Chapter 4.1). However, the results do not support ACE I/D as a genetic marker 
for rugby performance, showing no differences between athletes and controls or positional 
groups. These chapters demonstrated the value of single sport cohorts, particularly in team 
sports, and the need for large sample sizes when conducting candidate gene association 
studies in sport. Similarly, the T allele of FTO rs9939609 may be beneficial to elite athletes 
who rely greatly on lean mass relative to total body mass for athletic success (RU back three 
and centre players; Table 1) as they are more likely to carry an obesity protective T allele 
and may ultimately be selected for the appropriate playing positions as a result (Chapter 5.1). 
The APOE ε4 genotype appears to shows no genotypic or allelic advantage for elite rugby 
athlete status. However, the data do show a considerable number of elite rugby athletes exist 
who possess one or two APOE ε4 alleles and these athletes may be at greater risk of poorer 
outcome following an mTBI event (Chapter 6.1). This particular result requires considerable 
future investigation as the possible implications of ε4 carriage may result in severely reduced 
neurological function following an athletes playing career. Chapter 7.1 presented the first 
association between the COL5A1 3′ UTR rs12722 and rs3196378 and elite competitive status 
in a large cohort of athletes. The C alleles of both polymorphisms were overrepresented in 
all RU athletes, forwards and backs versus controls. Finally, incorporating all six of the 
aforementioned polymorphisms into a polygenic profile revealed differences between elite 
RU athletes and controls. By using ROC analysis of TGSB/TGSF ratio the present results 
identified significant, but low, discrimination accuracy for TGS as a predictor of RU playing 
position (Chapter 8.1). 
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As previously mentioned in chapter 1, RU athletes are different from other athlete groups, 
in that there are vast differences in the physiological and anthropometric characteristics 
across a single RU team according to playing position (Smart et al., 2013; Table 1). RU is 
also distinctive as individual clusters of positions require different movement patterns 
(Quarrie et al., 2013) and thus differ in their metabolic demands. In terms of positional 
specific physiological differences that may be reflected in players’ genetic variation, backs 
show lower maximal strength compared to forwards in terms of bench press, back squat and 
power clean (Smart et al., 2014). However, backs are faster, sprinting 10 m and 20 m than 
forwards (Smart et al., 2014) and these differences become larger when specific positions 
are considered (Smart et al., 2013). Furthermore, meta-analyses have shown that for every 
1000 hours, an elite RU athlete will experience approximately 81 injuries during match play 
and three during training, with the majority being ligament, tendon and muscle injuries of 
the lower limbs (Williams et al., 2013). Indeed, in the most recent Rugby World Cup (2015) 
this rate of incidence was more than 90 injuries per 1000 h (Fuller et al., 2016). Furthermore, 
injury incidence differs across RU playing position, with elite back row players showing the 
highest rate among forwards and centres the highest among backs (Fuller et al., 2016). 
Current mTBI incidence for elite RU players ranges between 4.6-8.9 per 1000 playing hours 
and has grown over time (Gardner et al., 2014; Cross et al., 2015; Fuller et al., 2015a). In 
relation to head injury, the most recent Rugby World Cup data (2015) shows  that indicates 
of mTBI were the most common injury (14%; n = 24) and accounted for a total of 184 days 
absence (mean ~8 days each) from training and competition during and after that tournament 
(Fuller et al., 2016). These data are reflected, to some extent, in the genetic data observed in 
the present thesis and the following three sections will discuss these genetic findings, that 
may help in explaining some of these physiological quantities (Chapter 2.2.1) and existing 
injury rates (Chapter 2.2.3) that may predisposes rugby athletes to elite success. Following 
achievement of the first thesis aim (Chapter 2.3.6), the subsequent aims (Chapters) had three 
consistent themes; (1) comparing the genetic profiles of ‘all’ elite RU athletes to controls, 
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(2) identifying genetic difference between elite RU playing position and controls and (3) 
comparing the genetic profiles of elite RU backs to elite RU forwards. 
 
9.1.3 Genetic profile of elite RU athletes compared to controls 
Given the considerable anthropometric and physiological differences between elite RU 
athletes and the general population (Table 1), it was hypothesised that their respective 
genetic profiles would differ. The results of the present thesis shows that this is heavily 
dependent on the particular genetic variant being investigated. 
 
The results presented in chapter 7 show an association between COL5A1 3′ UTR rs12722 
and rs3196378 and elite RU athlete status. Specifically, the C alleles of both polymorphisms 
were overrepresented in all RU athletes versus controls. These results provide an insight into 
the potential injury susceptibility of some elite rugby athletes. As such, both rs12722 and 
rs3196378 have previously been associated with tendinopathy in Australian Caucasians, but 
only the former in South African Caucasians (September et al., 2009). Accordingly, rs12722 
has also shown association with flexibility (Collins et al., 2009; Lim et al., 2015), exercise-
associated muscle cramping (O’Connell et al., 2013), anterior cruciate ligament injury 
(Posthumus et al., 2009b; Altinisik et al., 2015; O'Connell et al., 2015) and Achilles 
tendinopathy (Mokone et al., 2006). In these studies, the minor CC genotype was 
overrepresented in the respective asymptomatic controls and suggests a protective role of 
the C allele against injury. 
 
Considering the high frequencies of tendon and ligament injuries in elite RU (Williams et 
al., 2013; Fuller et al., 2015a; Fuller et al., 2016), the present results that the injury protective 
C alleles were more representative of elite RU athletes than controls (Figure 22 and Table 
10), suggests a trend towards selection of athletes that are less likely to accrue injury, in 
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terms of their less frequent availability to coaches. Indeed, RU has one of the highest 
reported rate of injury incidence in professional team sports (Brooks & Kemp, 2008), with 
the most recent Rugby World Cup (2015) data indicating an incidence rate of more than 90 
injuries per 1000 playing hours (Fuller et al., 2016). Therefore, RU athletes possessing more 
C alleles at these two genetic loci are probably at a lower risk of injury, given their exposure 
to the high-risk environment of elite rugby.  
 
Continuing with possible injury susceptibility, no difference was identified in APOE ε4 
frequency between athletes and controls. However, importantly, ~30% of the present elite 
rugby athlete cohort were identified as risk allele carriers (ε4+). As mentioned in chapter 6, 
ε4+ rugby athletes may be at greater risk of cognitive and physical impairments following 
mTBI, compared to non-carriers (Lichtman et al., 2000; Crawford et al., 2002; Zhou et al., 
2008; Müller et al., 2009; Noé et al., 2010; Roozenbeek et al., 2013; Zeng et al., 2014; 
Lawrence et al., 2015; Li et al., 2015; Merritt & Arnett, 2016). This could have widespread 
practical implications because World Rugby (the international governing body of rugby 
union) estimates there are 7.23 million rugby players worldwide 
(http://www.worldrugby.org/development/player-numbers). Thus, over two million ε4+ 
rugby players may be at greater risk of poorer outcome following mTBI than their ε4- 
counterparts. As Cross et al. (2015) has recently shown a 60% greater chance of time-loss 
injury in elite players who returned to competition in the same season as receiving a mTBI, 
correctly managing athletes that are at greater risk due to any predisposing factor such as the 
30% who are ε4+, could become a valuable strategy for researchers, support scientists and 
medical staff in due course. In addition to these possible short-term effects of repeated injury, 
carriage of the ε4 allele could have considerable long-term neurological effects on retired 
players, later in life, and more scientific attention needs to be focused on these athletes. 
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The ACE I/D polymorphism is one of the most studied variants in the context of human 
performance, Ma et al. (2013) reported that the ACE II genotype was associated with 
physical performance (OR = 1.23), with the ACE I allele being associated with elite 
endurance performance in a variety of events (Gayagay et al., 1998; Montgomery et al., 
1998; Myerson et al., 1999; Alvarez et al., 2000; Cieszczyk et al., 2009; Cieszczyk et al., 
2010) and the D allele associated with superior performance in sprint and power-related 
sports (Woods et al., 2001; Kikuchi et al., 2012; Eider et al., 2013; Papadimitriou et al., 
2016). However, the current thesis reports no ACE I/D genotype difference between elite 
rugby athletes and controls (Chapter 4). This lack of association contrasts with the afore 
mentioned meta-analysis where the ACE I allele was associated with physical performance 
(Ma et al., 2013). Nevertheless, given the mixed metabolic nature of RU (Chapter 2.1.2), a 
comparable association in the present thesis was less likely. The importance of ACE I/D 
remains controversial in the literature, with no associations reported in other isolated team 
sports such as elite European soccer (Gineviciene et al., 2014) and non-elite rugby athletes 
(Bell et al., 2010). These prior data, in conjunction with the current findings in a larger study 
that also considers playing position, suggest that ACE I/D plays little role in performance of 
team sport athletes. ACE I/D genotype-athlete phenotype associations are more likely to exist 
in specialized endurance athletes (Puthucheary et al., 2011). 
 
Similar results were identified for ACTN3 R577X and FTO, in that no differences were 
observed for genotype or allele distribution between RU athletes and controls (Chapters 4, 
5 and 6). For ACTN3, this result was particularly interesting as the RR genotype has 
previously been associated with speed and power performance (key components in elite RU 
success) in two independent meta-analyses (Alfred et al., 2011; Ma et al., 2013). However, 
this result was in agreement with a study considering many sports simultaneously (reviewed 
in detail in chapter 2.2.5.7), where team sport athlete status showed no association with 
ACTN3 R577X genotype (Eynon et al., 2014) and in isolated team sports (Djarova et al., 
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2011b; Ruiz et al., 2011b; Bell et al., 2012c; Egorova et al., 2014; Garatachea et al., 2014). 
Only one study has investigated FTO genotype in an athletic populations (detailed review in 
chapter 2.3.3), in three European cohorts of power (n = 258; 58.3% elite) and endurance 
athletes (n = 266; 57.1% elite) from a variety of sporting disciplines, with no associations 
between FTO and athlete status identified (Eynon et al., 2013b). The results of the present 
thesis are again in agreement (Chapter 5) and again are surprising given that FTO genotype 
is associated with greater body mass (detailed review in chapter 2.2.3) and elite RU athletes 
are on average ~25kg heavier than the general population (Chapter 2.1.1, Table 1).  
 
Although, individually, ACE, ACTN3, FTO and APOE ε4 did not differ between all RU 
athletes and controls, when the data from these variants was combined with COL5A1 in a 
TGS (Chapter 8), athletes showed a greater score than controls (Figure 23). This result was 
in agreement with other TGS investigations of elite athletes, despite any subjectivity in SNP 
choice and optimal genotype allocation (Ruiz et al., 2010; Eynon et al., 2011b; Drozdovska 
et al., 2013; Egorova et al., 2014; Ahmetov et al., 2015; Ben‐Zaken et al., 2015). 
 
9.1.4 Genetic profile of elite RU playing position compared to controls 
While the lack of association between all RU athletes and controls may have been unforeseen 
in relation to ACE, ACTN3, FTO and APOE, it was not surprising considering positional 
variation that exists across all physiological (Chapter 2.1.1, Table 1) and game demand 
variables (Chapter 2.1.2, Table 1). It is possible that these considerable physical differences 
across RU playing positions are reflected in genetic characterises but those differences 
remain hidden when comparing the entire cohort to controls. Therefore, it was important to 
investigate the genetic differences between the positional subgroups (Chapter 3.1.1) and the 
general population. 
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One of the most remarkable findings of the present thesis was the low frequency of the 
ACTN3 XX genotype among the back three athletes (8.7%), approaching although not as 
low as the frequency observed in elite sprinters (Yang et al., 2003; Niemi & Majamaa, 2005). 
As eluded to in chapter 4, the XX genotype is present in ~18% of Caucasians (Table 6) and 
indicates absence of the α-actinin-3 protein (Beggs et al., 1992; Mills et al., 2001). Absence 
of α-actinin-3 could hinder back three (wing and full back) sprint ability. Interestingly, the 
X allele was overrepresented in forwards (52.5%) compared controls (42%), which is 
understandable because mouse models have shown a higher propensity for aerobic enzyme 
activity and greater force recovery after fatigue in α-actinin-3 deficient mice (Seto et al., 
2011; Seto et al., 2013). This could indicate that XX genotype humans might have a greater 
capacity for recovery from fatiguing exercise - a trait which would benefit forwards with 
their more sustained match play intensity and necessity for quick recovery (Chapter 2.1.2, 
Table 1). For FTO variation, there were fewer AA homozygotes and more T allele carriers 
(Chapter 5, Figure 20A and Table 7) in back three and centres group than controls. 
Additionally, controls had more than twice the odds of being AA than the back three and 
centres group, with greater odds of T allele carriers in the back three and centres than controls 
(Table 7). The results of chapter 5 suggests an RU position specific advantage, in that the 
greatest T allele and TT genotype frequencies were in the RU athletes more reliant in a lean 
phenotype for success (Table 1; Smart et al., 2013). Furthermore, the ability to rapidly 
produce high levels of power relative to body mass using the leg musculature is greater in 
those playing positions more reliant on a lean phenotype (Crewther et al., 2012). 
 
No distinct associations between playing position and controls were identified for ACE, 
APOE or COL5A1 genetic variation, however when their combined influence (including 
ACTN3 and FTO) were considered in chapter 8, differences were evident. As detailed in 
chapter 8.1.2, different GS models were generated to account for the divergence in optimal 
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polygenic profile between backs and forwards, as identified in chapters 4 and 5. For both 
backs (TGS = 57.1 ± 14.8) and forwards (TGS = 50.5 ± 14.8), TGS was greater compared 
to their respective controls (TGS = 53.4 ± 16.0, TGS = 47.4 ± 16.8; Figure 23B and 23C). 
This result was in agreement with other TGS investigations of elite athlete status (Ruiz et 
al., 2010; Eynon et al., 2011b; Drozdovska et al., 2013; Egorova et al., 2014; Ahmetov et 
al., 2015; Ben‐Zaken et al., 2015). In relation to team sports specifically, Egorova et al. 
investigated the polygenic profiles in a mixed athletic level soccer cohort (21% elite) and 
identified differences between controls and individual positional compared (Egorova et al., 
2014), with which the present findings are in agreement (Chapter 8.1.3, Figure 23). 
 
9.1.5 Variation in genetic profile of elite RU playing position 
Continuing from the discussions in the previous sections (9.1.2.1 and 9.1.2.2), where genetic 
variation was identified between all RU athletes, playing position subgroups and controls, 
the next logical step is to discuss the inter-positional variation. As such, two SNPs showed 
differing genetic variation between playing positions (ACTN3, chapter 4 and FTO, chapter 
5). 
 
The ACTN3 XX genotype was almost twice (OR = 1.77) as common in forwards than backs, 
which suggests α-actinin-3 deficient individuals are more suited to forward play. 
Furthermore, the X allele was overrepresented in forwards (52.5%) compared to backs 
(37.8%; OR = 1.49), with the R allele frequency greater in the back three (68.8%) compared 
to forwards (47.5%; OR = 2.00) and the other backs (58.2%; OR = 1.59; Chapter 4, Figure 
19B). As mentioned above, the 69 back three athletes (wings and fullbacks) included only 
six individuals (8.7%) of XX genotype which differed from the forwards (24.8%) who were 
over three times (OR = 3.46) more likely to be XX genotype than the back three athletes. 
Furthermore, the remaining backs (centres and halves) were over twice as likely to show the 
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α-actinin-3 deficient genotype than the back three athletes (OR = 2.59). It appears as though 
the shorter match play rest periods for forwards compared with backs - work to rest ratios 
1:7 and 1:22, respectively (Table 1; Deutsch et al., 2007) indicates that greater fatigue 
resistance and would be particularly beneficial for forwards. Moreover, the greater 
calcineurin activity in XX homozygote humans and approximately threefold increase in 
calcineurin activity and distance run after endurance training in KO mice (Seto et al., 2013), 
further support the notion that forwards would benefit from a greater fatigue resistance.  
 
Regarding the R allele advantage in the back three players, R allele carriers have a greater 
proportion of type II and IIx fibres and larger relative surface area per IIx fibre than XX 
carriers (Vincent et al., 2007; Ahmetov et al., 2011; Broos et al., 2012; Broos et al., 2016). 
In fact, Broos et al. (2016) showed corresponding single fibre characteristics. Fibres of RR 
humans showed greater contractile velocity than XX individuals while exhibiting similar 
isometric force production. This suggests a strong rationale for the R allele advantage in elite 
sprinters (Yang et al., 2003; Niemi & Majamaa, 2005) and the back three athletes of the 
present chapter (Table 6 and Figure 19). This also supports the ACTN3 R allele has a more 
relevant association with relative muscle power than absolute power (Kikuchi et al., 2014b), 
due to preservation of force at high contractile velocities and not absolute force (Broos et 
al., 2016), a crucial relationship for sprinting performance (Miller et al., 2012; Morin et al., 
2012). As such, rugby athletes where relative muscle power is an important quantity 
(Crewther et al., 2012) would have a greater advantage with position of the R allele, as 
shown in the present results (Table 6 and Figure 19). This would be of obvious benefit to the 
back three players as a fundamental requirement to selection in this position is sprint 
performance. Seto et al (2013) showed that the likely mechanism for this genotype-
phenotype association is via the calcineurin muscle fibre remodelling pathway (for details 
see chapter 4.1.4). This could explain the advantage of R allele carriers over α-actinin-3 
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deficient XX individuals for high velocity contractions – particularly important for back 
three players. These data suggest that the ACTN3 R577X polymorphism has the potential to 
contribute to position-specific player profiling when combined with other genetic and 
physiological data in the future. 
 
For FTO positional variation, the backs had a greater frequency of T allele carriers than 
forwards (Chapter 5.1.3, Table 7, Figure 20) and showed greater odds of being T allele 
carriers than AA genotype (OR = 1.84, Table 8). Compared to forwards, TT genotype and 
T allele carriers were more common in the back three and centres group (Chapter 5.1.3, 
Figure 20A and Table 7). Likewise, forwards had greater than three times the odds of being 
AA genotype than the back three and centres group with greater odds of T allele carriers in 
the back three and centres group than forwards (Table 8). This suggests an advantage for 
forwards that carry the A allele above those that do not, possibly a result of lower body mass 
associated with the T allele. As detailed in chapter 5, until recently little was known about 
the molecular basis for FTO SNP associations with any reported phenotype measure because 
there was no association between FTO SNPs and expression of the FTO protein (Wåhlén et 
al., 2008; Grunnet et al., 2009). However, FTO has recently been found to influence IRX3 
protein expression and individuals possessing the protective FTO genotype/allele (TT/T) 
display lower IRX3 expression than AA homozygotes (Smemo et al., 2014), which is 
hypothesised to lead to long term motor unit availability (Chapter 5). Furthermore, recent 
associations between FTO variants and IGF-1, specifically that serum IGF-1 levels were 
greater in T allele carriers (Rosskopf et al., 2011), may provide an additional mechanism to 
explain the greater T allele frequency in the back three and centres who rely on lean muscle 
tissue for success (detailed in chapter 5, Figure20). Similar to ACTN3, FTO variation has the 
potential to contribute to position-specific player profiling when combined with other 
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genetic and physiological data in the future and possibly lean muscle development (not yet 
experimentally tested). 
Again, no distinct associations between RU playing position were identified for ACE, APOE 
or COL5A1 genetic variation, however when their combined influence (including ACTN3 
and FTO) was considered in chapter 8, differences were evident. Nonetheless, the present 
observations have identified significant polygenic sensitivity in discriminating between elite 
rugby union backs and forwards, with the backs exhibiting the greatest TGSB/TGSF ratio 
(AUC = 0.587, Figure 24). This is an important advancement in identifying the molecular 
characteristics of RU playing position and as more SNPs are included the sensitivity of the 
discrimination will increase. These developments may lead to the accurate use of genetic 
information for positional identification, individualised training and injury management in 
the future. 
 
9.1.6 Study limitations 
The present research project began with a review of the methodological limitations present 
in studies of a similar design (Chapter 2.2.4) and considerable efforts were made to limit any 
identified concerns. However, some limitations exist within the present thesis despite the 
greatest effort to ‘control the controllables’ and are discussed below. 
 
Although genetic case-control association studies, such as the present thesis, have achieved 
great successes in identifying some of the genetic component of complex exercise and sport 
related phenotypes (Rankinen et al., 2001; Loos et al., 2015; Ahmetov et al., 2016), case-
control association studies only investigate variation at a select and often small number of 
loci, which only explains a limited proportion of heritability of athlete status (Pitsiladis et 
al., 2013; Tanaka et al., 2016). The present thesis only investigated seven SNPs, generating 
six genotypes, however each one of these genotypes was chosen based on their relevance to 
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the study sample and all rationale for inclusion in the present thesis were well evidenced in 
the scientific literature (Chapter 2.3). Nevertheless, including a small number of SNPs of the 
~155 identified in the context of athletic performance (Ahmetov et al., 2016) and in the 
shadow of the many yet to be identified variants (Chapter 2.2.2) remains a limitation to the 
present thesis. The fundamental reason for the inclusion of only seven SNPs was time and 
financial resources, caused by the difficulty in recruiting and gaining access to cohorts of 
elite professional RU players – a process that was often extremely time consuming and 
incurred considerable financial commitments. However, while these time and budgetary 
costs meant the inclusion of few SNPs, the present sample (RugbyGene Project) to the 
author’s knowledge, is currently the largest (100% elite) single sport athletic cohort in sports 
genomics to date, as part of the GENESIS cohort (for a review of other athlete cohorts see 
Pitsiladis et al., 2016). 
 
Secondly, the nature of genetics research dictates that extremely large sample sizes are 
needed before genuine conclusions can be made about the variation within a given cohort, 
for a given phenotype (Gauderman, 2002). However, due to the natural rarity of elite athletes 
it is difficult to congregate large samples of particular athlete groups and even more difficult 
to recruit large cohorts of single sport athletes (such as RU players). Consequently, large 
numbers (many hundreds) of ‘Tier 1’ rugby athletes are required – and was achieved through 
international research collaboration. While the present sample of ~450 elite Caucasian RU 
athletes is large by sports genomics standards (Chapter 2.2.4), confidence in the present 
results will be enhanced with a greater sample size and conducting larger analyses such as 
genome wide association studies (GWAS) requires additional samples. Regardless, for the 
purpose of the present thesis, the current sample was amply powered (Hong & Park, 2012). 
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9.1.7 Directions for future research 
 
9.1.7.1 Genotype-phenotype associations that should be investigated 
Future objectives of the RugbyGene project (based on the present thesis) within the broader 
Athlome project (Pitsiladis et al., 2016) includes investigating whether additional genetic 
variants associated with excellence in other sports are similarly associated in the 
multifaceted sport of rugby. The next step would be to investigate genotype associations 
with a range of phenotypes such as, physiological, anthropometric, other performance 
variables and incidence of injury, etc. 
 
Identifying genetic associations (in a cohort of elite RU athletes) with rugby-specific 
physiological and anthropometric variables, for example those aspects of strength, speed and 
body composition assessed by Smart et al. (2013), would further exemplify the importance 
of the genetic component to RU. Furthermore, rugby union has one of the highest reported 
incidents of match play injuries in all professional team sports (Brooks & Kemp, 2008), with 
an injury incidence of ~90 per 1000 match play hours resulting in ~30 days absence per 
injury (Fuller et al., 2016). Research collaborations that combine these kinds of large, 
meticulously-collected rugby injury databases with genetic analyses conducted on those very 
same players, could be extremely fruitful in explaining some of the as yet unexplained inter-
individual variability in injury susceptibility and could identify novel markers of injury risk 
in rugby. 
 
Concussion risk in rugby (Chapter 2.1.4), as well as consideration of the potential longer-
term consequences, is clearly and justifiably a topic of much attention at this time (Raftery, 
2013; Fuller et al., 2015b; Raftery et al., 2016). Accordingly, Gardner et al. (2014) recently 
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conducted a comprehensive meta-analysis showing that RU, the incidence rate of concussion 
was ~4.7 per 1000 match play hours. Data from 16 studies showed that at the 
elite/international level the incidence rate was lower (~1.2 per 1000 match play hours), 
though still considerable (Gardner et al., 2014). Furthermore, the most recent Rugby World 
Cup data (2015) identified mTBI as the most commonly occurring injury (14%) and 
accounted for 184 days absence from training and competition (Fuller et al., 2016). These 
notable injury rates make research efforts to identify molecular markers for the risk of 
specific rugby-related injuries, such as concussion, highly warranted. Indeed, the 
development of tools to identify individuals at greater risk of concussion in rugby and greater 
risk of longer-term pathological neurobiological changes following a career playing rugby 
would seem highly responsible in the context of player welfare. Following the demonstration 
that ~30% of rugby athletes may have a higher risk of poorer outcome follow brain injury, 
with only one genetic variant (Chapter 6), more risk variants need to be analysed for their 
presence in elite rugby athletes. Importantly, these data then need to be combined with 
concussive incidence, recovery and biochemical markers. 
9.1.7.2 Advanced genomics technology 
For RU as in other areas within sports genomics, the starting point for the investigation of 
genetic variation is through the candidate gene (hypothesis driven) approach, such as the 
present thesis. This approach of considering the biological mechanisms of a given trait (for 
example, incidence of tendinopathy or high VO2max) and investigating previously identified 
genetic variants within genes known or suspected to affect the relevant biological pathways 
is valuable initial analysis. While the candidate gene approach is by far the most utilised 
technique in quantifying molecular genetic markers of sport-related phenotypes and a good 
starting point, other more complex analysis techniques are required for the future of this field 
to realise its full potential (Pitsiladis et al., 2013). 
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The hypothesis-free approach of conducting GWAS has been utilised extensively to identify 
new genetic variants in various domains within human biology (Wolfarth et al., 2014) and 
is recommended for identifying novel genetic variants in RU. GWAS is the process of 
investigating large numbers of known SNPs simultaneously (~2 million, for example) for a 
given complex trait (Visscher et al., 2012). As already mentioned, complex traits of 
relevance to RU could be sprinting ability, muscle strength, incidence of injury or simply 
being an elite rugby union player (elite athlete status). Importantly, given the large number 
of hypotheses tested statistically, only the strongest associations are usually accepted to be 
true results (e.g. when P < 5 x 10-8), although a very large cohort size and/or strong genetic 
effect sizes are usually required for this approach to be effective. A strength of any 
hypothesis-free approach like GWAS is that new variants which reveal new biological 
insight can be discovered - and then further investigated experimentally. 
 
Genetic testing technologies have advanced to such an extent that investigating all 
nucleotides in a gene, all protein-coding genes, or even the whole genome is now possible 
via direct sequencing. Depending on the availability of funding, participants and other 
resources including laboratory equipment and bioinformatics expertise, multiple options are 
available to exploit these techniques for the identification of novel mutations, 
polymorphisms or structural variants. Firstly, targeting specific genes associated with a 
given phenotype, such as the MSTN gene and muscle mass (Schuelke et al., 2004), and 
sequencing every nucleotide (~7,000 bp) of that gene in a large cohort of elite RU players 
for whom strength and muscle mass are also known could be an elegant approach to 
identifying novel genetic variants associated with muscle size and strength in rugby players. 
To examine larger regions than one gene, one could utilise whole-exome sequencing, which 
uses the same rational as targeted gene sequencing but to a much greater extent, targeting all 
protein-coding DNA sequences (~230,000 exons or ~30 million bp; ~1% of the human 
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genome). Finally, providing that considerable resources including an appropriately large 
cohort were available, assessment of the whole-genome (~3 billion bp) would be the 
ultimate, most comprehensive method of identifying novel mutations or polymorphisms of 
functional importance in RU athletes. Currently, whole-genome-sequencing is not possible 
for reasons of cost, logistics, interpretation and statistics, although the eventual application 
to rugby is inevitable. 
 
9.2 Conclusion 
The results from the present thesis identify considerable genetic variation in a relatively large 
cohort of 100% elite RU athletes. With only a few SNPs, the thesis results show the existence 
of genetic variation across team sport playing position - which is often overlooked in the 
attempt to increase sample size. Furthermore, two of the genes studied in the present thesis 
related directly to the injury susceptibility of elite players (COL5A1 and APOE). This 
knowledge is the first step towards utilising genetic information to improve player 
management and welfare - following further research. In fact, the observation that ~30% of 
players may be at greater risk of poorer neurological recovery following mTBI requires 
direct attention from rugby governing bodies and the related science and medical 
communities. Nevertheless, the present thesis was the first to identify these genetic 
associations and should be seen as initial work for future research to build upon in order to 
progress the field of genetic analysis in sport. 
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Appendix 2: Participant documentation 
Athlete participation pack 
 
 
Department of Exercise and Sport Science 
 
 
Informed Consent Form 
   
(Both the investigator and  
participant should retain a copy of this form) 
 
 
 
Name of Participant:     
 
Principal Investigator: Dr Alun Williams 
 
Project Title: The Genetic Profile of Elite Athletes 
 
Ethics Committee Approval Number: 12.07.11 (i) 
 
Participant Statement 
 
I have read the participant information sheet for this study and understand what 
is involved in taking part. Any questions I have about the study, or my 
participation in it, have been answered to my satisfaction. I understand that I do 
not have to take part and that I may decide to withdraw from the study at any 
point without giving a reason. Any concerns I have raised regarding this study 
have been answered and I understand that any further concerns that arise 
during the time of the study will be addressed by the investigator. I therefore 
agree to participate in the study. 
 
It has been made clear to me that, should I feel that my rights are being 
infringed or that my interests are otherwise being ignored, neglected or 
denied, I should inform the The University Secretary and Clerk to the Board 
of Governors, Manchester Metropolitan University, Ormond Building, 
Manchester, M15 6BX. Tel: 0161 247 3400 who will undertake to investigate 
my complaint. 
 
 
Signed (Participant)    Date 
 
 
Signed (Investigator)   Date 
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The Genetic Profile of Elite Athletes: Questionnaire 
 
Thank you for your interest in our research study. Please answer the following questions about your 
ethnic origin, athlete status, and your training, diet and injury history.  
 
SECTION A: Questions concerning your ethnic background.  
 
Participant ID code: _________________________ Date of birth: ___________________ 
Gender (please tick): Male  / Female  Height (in metres): _______________ 
Nationality (as on passport, e.g. British): _____________ Body weight (in kg): _____________ 
What is your ethnic group? Please tick the appropriate box. 
A) White: English  Scottish  Welsh  N. Irish  Irish  
 French  South African  New Zealander  Australian  Other  
If other, please state here: ________________________________ 
B) Mixed: White & Black 
British  
White & Black 
Caribbean  
White & Black 
African  
White & 
Asian  
White & Latin 
American  
Other 
 
If other, please state here: ________________________________ 
C) Asian: British  Indian  Pakistani  Chinese  Japanese  Other  
If other, please state here: ________________________________ 
D) Black: British  Caribbean  African  Other  
If other, please state here: _____________________________________________________ 
E) Latin American:  Brazilian  Argentinian  Mexican  Colombian  Other  
If other, please state here: _____________________________________________________ 
F) Pacific Islands:  Samoa  Fiji  Tonga  PNG  Other  
If other, please state here: _____________________________________________________ 
G) Other ethnic background:  Please state here: _________________________________ 
I do not wish to state my ethnic origin   
Using the ethnic groups above as a guide, please tell us the ethnic origin of your:  
Mother: ______________________________________________________ Don’t know:  
Father: ______________________________________________________ Don’t know:  
Mother’s mother: _____________________________________________ Don’t know:   
Mother’s father: ______________________________________________ Don’t know:   
Father’s mother: ______________________________________________ Don’t know:   
Father’s father: _______________________________________________ Don’t know:   
 
Blood donation 
We would like to take a small (10 mL) blood sample from a vein in your arm. Before doing so, please 
answer the following safety questions.  
1. Have you ever been infected with a blood-borne disease? _______ Yes  No  
2.  Are you anaemic or receiving treatment for anaemia or iron deficiency? __ Yes  No  
 
If you have answered YES to any of these questions and/or you would prefer not to provide a blood 
sample, a saliva sample may be provided instead. 
 
PLEASE TURN OVER
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SECTION B: Questions concerning your athlete status.  
 
 
1. What is/was your main playing position (if team sport) or your main event (if individual 
sport). If multiple, please state preferred position/event. 
____________________________________________________________________ 
______________________________________________________________________ 
 
 
2. 
 
 
Please state the number of seasons you have competed as a professional: 
______________________________________________________________________  
 
 
3.  
 
 
Please state all the professional clubs you have competed for so far in your career: 
____________________________________________________________________ 
______________________________________________________________________ 
   
 
4. 
 
Please state the highest level that you have competed, including number of caps earned 
e.g. England under 16s (4 caps), 18s (10 caps), senior (21 caps):  
______________________________________________________________________
______________________________________________________________________ 
 
 
5. 
 
Have you any other athletic achievements? If so please state highest achievements and 
include relevant details: 
______________________________________________________________________
______________________________________________________________________ 
 
 
 
 
SECTION C: Questions concerning your training. 
 
 
1.  
 
Typically, how many hours do you train a week?  
 
______________________________________________________________________ 
  
 
2.  
 
Typically, what is your average running distance per week?  
 
______________________________________________________________________ 
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SECTION D: Questions concerning your injury history. 
  
10. Have you ever ruptured your tendon? Yes  If yes, which tendon? 
e.g. Achilles 
No  
  
 
 
 
  
 
11. 
 
If Yes, please give details of how this 
occurred and at what age. 
 
 
 
 
 
Activity 
e.g. sprinting 
 
 
 
 
Age 
e.g. 20 
 
12. 
 
Have you ever suffered from 
prolonged tendon pain during 
exercise that does not go away for 
weeks? 
 
 
Yes  
 
If yes, which tendon? 
e.g. Achilles 
 
No  
 
 
 
13. 
 
 
 
Have you ever been told that you 
have had tendinopathy?  
 
 
 
Yes  
 
 
 
If yes, which tendon? 
e.g. Achilles 
 
 
 
 
No  
 
 
 
14. 
 
 
 
If Yes, was it confirmed by a scan, 
e.g. MRI or ultrasound?  
 
 
 
Yes  
 
 
 
No  
 
 
15. 
 
 
Does anyone in your close family 
suffer from tendinopathy? 
 
 
Yes  
 
 
No  
 
 
Don’t know  
  If yes, which tendon? 
e.g. Achilles 
 
 
 
 
 
 
16. 
 
 
Has anyone in your close family ever 
ruptured a tendon? 
 
 
Yes  
 
 
No  
 
 
Don’t know  
  If yes, which tendon? 
e.g. Achilles 
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17. 
 
Have you ever fully ruptured a 
ligament? 
 
 
 
 
 
 
 
Yes  
If yes, which 
ligament? 
e.g. ACL 
 
No  
 
18. 
 
If Yes, please give details of how this 
occurred and at what age. 
Contact 
e.g. tackled 
from the side 
 
 
 
 
 
 
Non-contact 
e.g. landing 
from a jump 
 
Age 
e.g. 20 
 
19. 
 
Have you ever been told that you 
have had a ligament sprain/tear?  
 
Yes  
If yes, which 
ligament? 
e.g. ACL 
 
 
 
 
 
 
 
No  
 
20. 
 
If Yes, was it confirmed by a scan, 
e.g. MRI or ultrasound?  
 
 
 
Yes  
 
No  
 
21. 
 
Has anyone in your close family ever 
ruptured a ligament? 
 
Yes  
 
No  
 
Don’t know  
  If yes, which ligament? 
e.g. ACL 
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22. 
 
Have you ever been concussed or 
knocked out? 
 
 
 
Yes  
 
No  
 
23. 
 
If Yes, how many times have you 
been concussed or knocked out? 
 
 
 
___________ times 
24. What were you doing at the time of 
the injury(ies)? E.g. rugby tackle, 
boxing, road accident. 
 
 
 __________________________
__________________________ 
 
 
25.  
 
If Yes, how long was your recovery 
period, until the day when you had no 
signs and symptoms and were free to 
train and play fully? (tick, multiple 
times if necessary, any recovery 
periods that apply for the different 
occasions) 
 
 
 
 
<7 days  
 
 
7-10 days   
 
 
10-20 days   
  
 
20-40 days   
 
 
40-60 days   
 
 
>60 days   
 
26. 
 
If Yes, was/were your concussion(s) 
or knock-out(s) diagnosed by a 
medical professional? (tick, multiple 
times if necessary, any that apply) 
 
 
 
Yes  
 
No  
 
27.  
 
Does anyone in your close family 
(parents, siblings or grandparents) 
suffer from a neurological condition, 
such as:  
Dementia, Alzheimer’s disease, 
chronic traumatic encephalopathy 
(CTE), cognitive impairment, 
movement disorders, psychiatric 
disorders, motor neuron disease 
 
Yes  
 
No  
 
Don’t know  
  
 
Who and which condition(s)? 
e.g. grandfather, dementia 
 
_________________________  
 
_________________________ 
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Contact Details 
 
 
Thank you for your interest in this research study. Please provide us with your 
contact details, so that we may contact you with information at a later date. 
 
 
Name (PLEASE PRINT CLEARLY): 
__________________________________________ 
Email (PLEASE PRINT CLEARLY): 
__________________________________________ 
Telephone (ONLY REQUIRED IF NOT USING EMAIL): 
_________________________ 
Postal address (ONLY REQUIRED IF NOT USING EMAIL): 
_______________________ 
_______________________________________________________________________
__ 
_______________________________________________________________________
__ 
 
The ACTN3 R577X gene variant 
 
We all have two copies of the ACTN3 gene, one inherited from each parent. At a certain 
point along the length of the gene the structure can vary slightly, which means that a 
particular protein (alpha actinin-3) can/cannot be produced in the muscle. Each person is 
either RR, RX or XX genotype for the ACTN3 R577X gene variant. If you are XX 
genotype, you cannot produce alpha actinin-3, which is only found in fast-twitch muscle 
fibres. As these muscle fibres are important for producing force and power during high-
speed muscle contractions, not having the protein might be detrimental for power 
generation. RR genotype is generally associated with strength, power and greater muscle 
size, while XX is linked to elite endurance athlete status.  
 
 
Are you interested in receiving feedback regarding your ACTN3 R577X genotype?  
 
 Yes  No     
  
If yes, would you prefer to receive that feedback via email? 
 
 Yes  No     
 
 
 
 
 
 
 
Thank you for taking part in this project. All information will be kept strictly 
confidential. 
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Control questionnaire 
The Genetic Profile of Elite Athletes 
Questionnaire: Physical Activity & General Health  
 
Thank you for participating in this research study. We would like you to answer a few questions 
concerning your general health and physical activity level. Please answer the following questions as 
honestly as you can.  
 
Participant ID code: _________________________ Date of birth: ___________________ 
Gender (please tick): Male  / Female  Height: ________________________ 
Nationality (as on passport, e.g. British): _________ Body weight: ___________________ 
What is your ethnic group? Please tick the appropriate box. 
A) White: English  Scottish  Welsh  N. Irish  Irish  
 French  South African  New Zealander  Australian  Other  
If other, please state here: ________________________________ 
B) Mixed: White & Black 
British  
White & Black 
Caribbean  
White & Black 
African  
White & 
Asian  
White & Latin 
American  
Other 
 
If other, please state here: ________________________________ 
C) Asian: British  Indian  Pakistani  Chinese  Japanese  Other  
If other, please state here: ________________________________ 
D) Black: British  Caribbean  African  Other  
If other, please state here: _____________________________________________________ 
E) Latin American:  Brazilian  Argentinian  Mexican  Colombian  Other  
If other, please state here: _____________________________________________________ 
F) Pacific Islands:  Samoa  Fiji  Tonga  PNG  Other  
If other, please state here: _____________________________________________________ 
G) Other ethnic background:  Please state here: _________________________________ 
I do not wish to state my ethnic origin   
Using the ethnic groups above as a guide, please tell us the ethnic origin of your:  
Mother: ______________________________________________________ Do not know:  
Father: ______________________________________________________ Do not know:  
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Mother’s mother: _____________________________________________ Do not know:   
Mother’s father: ______________________________________________ Do not know:   
Father’s mother: ______________________________________________ Do not know:   
Father’s father: _______________________________________________ Do not know:   
 
Blood donation 
We would like to take a small (10 mL) blood sample from a vein in your arm. Before doing so, please 
answer the following safety questions.  
1. Have you ever been infected with a blood-borne disease? _____________ Yes  No  
2.  Are you anaemic or receiving treatment for anaemia or iron deficiency? __ Yes  No  
 
If you have answered YES to any of these questions and/or you would prefer not to provide a blood 
sample, a saliva sample may be provided instead. 
 
Your general health 
1. At present, do you have any health problem for which you are: 
a) on medication, prescribed (by a doctor) or otherwise ____________ Yes  No  
b) attending (visiting) your doctor _____________________________ Yes  No  
c) on a hospital waiting list ___________________________________ Yes  No  
 
2. Have you ever had any of the following? 
a) Your doctor advised you not to take vigorous exercise ___________ Yes  No  
b) Pain in your chest when you undertake physical activity? _________ Yes  No  
c) Central Nervous System disease, such as Parkinson, Alzheimer, 
Convulsions/epilepsy _____________________________________ 
 
Yes  
 
No  
d) Have you any history of chest problems, such as bronchitis, asthma or 
wheezy chest __________________________________________ 
 
Yes  
 
No  
e) Major illness, such as viral hepatitis, cancer ___________________ Yes  No  
f) Eczema ________________________________________________ Yes  No  
g) Diabetes _______________________________________________ Yes  No  
h) High blood pressure ______________________________________ Yes  No  
i) A limb fracture __________________________________________ Yes  No  
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j) Blood disorder, such as clotting problems, thrombosis, aneurysm, 
embolus) _______________________________________________ 
 
Yes  
 
No  
k) Head injury _____________________________________________ Yes  No  
l) Digestive problems _______________________________________ Yes  No  
m) Heart problems, such as heart attack, valve disease, palpitations, angina 
_________________________________________________ 
 
Yes  
 
No  
n) Problems with bones, such as osteoporosis or osteoarthritis _______ Yes  No  
o) Problems with joints, such as rheumatoid arthritis, any persistent pain, or 
any surgery on your joints ___________________________ 
 
Yes  
 
No  
p) Back problems __________________________________________ Yes  No  
q) Disturbance of balance/co-ordination, such as dizziness or balance-system 
dysfunction _______________________________________ 
 
Yes  
 
No  
r) Numbness in hands or feet _________________________________ Yes  No  
s) Disturbance of vision _____________________________________ Yes  No  
t) Physical limitations, such as visual, hearing, walking problems ____ Yes  No  
u) Thyroid problems, e.g. rapid loss or gain of weight ______________ Yes  No  
v) Kidney or liver problems __________________________________ Yes  No  
w) A severe allergic reaction, e.g. swelling, breathing difficulties in response 
to an external stimulus _____________________________ 
 
Yes  
 
No  
x) Emotional or psychiatric problems ___________________________ Yes  No  
y) Any other illness or condition that affects your general health or 
interferes with your daily activities __________________________ 
 
Yes  
 
No  
 
4. If you answered YES to any of the questions above, please describe the details briefly below or 
to the investigator if you wish.  
 _____________________________________________________________________________
_______________________________________________________________ 
 
5. Are you currently involved in any other research studies at the University 
or elsewhere? 
 
Yes  
 
No  
 If YES please provide details of the study: 
______________________________________________________________________ 
______________________________________________________________________ 
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Habitual physical activity 
 
1. What is your main occupation? _____________________________________________ 
2. At work I sit Never  Seldom  Sometimes  Often  Always  
3.  At work I stand Never  Seldom  Sometimes  Often  Always  
4. At work I walk Never  Seldom  Sometimes  Often  Always  
5. At work I lift heavy 
loads 
 
Never  
 
Seldom  
 
Sometimes  
 
Often  
 
Always  
6. After work I am tired  
Never  
 
Seldom  
 
Sometimes  
 
Often  
 
Always  
7. At work I sweat Never  Seldom  Sometimes  Often  Always  
8. In comparison with others my own age I think my work is: 
 Much heavier  Heavier  As heavy  Lighter  Much lighter  
      
9. Do you play sport or exercise?  Yes  No  
 If YES, which sport do you play most frequently? ______________________________ 
 How many hours 
per week? 
Less than 1  1 to 2  
 
2 to 3  
 
3 to 4  
 
More than 
4  
 Time per session 
(hours) 
 
½  
 
1 ½  
 
2 ½  
 
3 ½  
 
4 ½  
 How many months 
per year? 
Less than 1  1 to 3  
 
4 to 6  
 
7 to 9  
 
More than 
9  
 What proportion of 
the month? 
A few hours  A few days
 
2 weeks 
 
3 weeks 
 
Most of the 
month  
 If you do a second sport (or exercise class), which is it? _________________________ 
 How many hours 
per week? 
Less than 1  1 to 2  
 
2 to 3  
 
3 to 4  
 
More than 
4  
 Time per session 
(hours) 
 
½  
 
1 ½  
 
2 ½  
 
3 ½  
 
4 ½  
 How many months 
per year? 
Less than 1  1 to 3  
 
4 to 6  
 
7 to 9  
 
More than 
9  
 What proportion of 
the month? 
A few hours  A few days
 
2 weeks 3 weeks Most of the 
month  
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10. Compared with others of my own age I think my physical activity during leisure time is: 
 Much more  More  The same  Less  Much less  
11. During leisure time 
I sweat 
Very  
Often  
 
Often  
 
Sometimes  
 
Seldom  
 
Never  
12.  During leisure time 
I play sport  
 
Never  
 
Seldom  
 
Sometimes  
 
Often  
 
Always  
13. During leisure time 
I watch TV 
 
Never  
 
Seldom  
 
Sometimes  
 
Often  
 
Always  
14. During leisure time 
I walk 
 
Never  
 
Seldom  
 
Sometimes  
 
Often  
 
Always  
15. During leisure time 
I cycle  
 
Never  
 
Seldom  
 
Sometimes  
 
Often  
 
Always  
16. How many minutes do you walk per day to and from work, school and/or shopping? 
 Less than 5  5 to 15  16 to 30  31 to 45  More than 45  
 
Thank you for completing this questionnaire. All information will be kept strictly confidential.  
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Participant information sheet 
This participant sheet includes information on additional testing procedures not conducted 
in the present thesis, but are performed as part of the larger GENESIS project (of which 
this thesis is part). 
 
 
 
 
 
 
MANCHESTER METROPOLITAN UNIVERSITY 
Department of Exercise and Sport Science 
 
Information Sheet for Participants  
  
Title of Study:  
The Genetic Profile of Elite Athletes 
 
Ethics Committee Reference Number: 12.07.11 (i) 
 
1) This is an invitation to take part in a piece of research.  
You are being invited to take part in a research study. Before you decide whether 
or not to take part, it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following information 
carefully and discuss it with others if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Please take time to decide whether or 
not you wish to take part. 
 
2) What is the purpose of the research? 
The main purpose of the project is to investigate the influence of genetic differences 
on elite strength/power, mixed-demand and endurance athlete status compared to 
non-athletes.  
 
3) Why is the study being performed? 
Previous scientific studies have demonstrated that differences in genetic make-up are 
linked to elite athlete status, although relatively few gene variants have been identified 
and sometimes not enough participants have been recruited to find meaningful results. 
This study is being performed in very large groups of elite strength/power, mixed-
demand and endurance athletes, as well as non-athletes, in order to learn more about 
which genes influence elite athlete status.  
  
4) Why am I being asked to take part? 
We are trying to recruit people from different populations, i.e. top-level 
strength/power, mixed-demand and endurance athletes, as well as non-athletes. 
This way we can compare the genetics of elite athletes with the general population.  
 
5) Do I have to take part? 
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You are under no obligation to take part in this study. If, after reading this information 
sheet and asking any additional questions, you do not feel comfortable participating 
in the study you do not have to. If you do decide to take part, you are free to withdraw 
from the study at any point, without having to give a reason. If you do withdraw from 
the study you are free to take any personal data with you, on written request to the 
principal investigator, and this will not be included when the research is reported. If 
you decide not to take part or withdraw from the study it will not affect your 
relationship with any of the staff at the Manchester Metropolitan University. 
 
If you do decide to take part you will be asked to sign an informed consent form 
stating your agreement to take part and you will be given a copy together with this 
information sheet to keep.  
 
6) What will happen to me if I agree to take part?  
In order to obtain the following information, you will either i) be visited once by one 
of the investigators, ii) asked to come to the Crewe campus of the University on one 
occasion, or iii) sent a pack, then asked to complete information sheets and simple 
DNA-collection procedures (saliva sample), and send them to the investigators. In 
the case of iii), you will be guided through the correct procedures during a telephone 
call made by one of the named members of the research team (please see below).  
 
Questionnaires. We will ask you to complete a short survey that will give us an 
indication of your physical activity level, general health, ethnicity, sporting discipline 
and performance achievement, recent exercise and diet, injury history and one 
psychological trait questionnaire known as ‘mental toughness’. If you are female, 
you will also be asked about your menstruation status. The questionnaires will take 
about 30 minutes to complete. 
 
Body height, weight and somatotype. We will measure your height and weight using 
standard equipment, from which we will be able to calculate your body mass index. 
This will take 5 minutes to complete. If you are comfortable doing so and if time 
permits, we will also determine your somatotype, which will involve taking skinfold 
measurements from multiple sites on your body (you will need to wear shorts and t-
shirt/sports-bra). This will take a further 20 minutes to complete.  
 
Blood sample/saliva sample. If you are visited by one of the investigators or you are 
asked to visit the University laboratory, you will be asked to provide a small blood 
sample, from which we will be able to analyse your DNA, RNA and protein levels. 
While you are lying down, a qualified phlebotomist will take 10 mL blood from a vein 
in your arm. This is a relatively painless procedure and will take less than a minute 
to complete. Alternatively, if blood sampling is not possible, you will be asked to 
dribble 2 mL of saliva into a tube for a few minutes and send the sample to the 
investigators. These procedures are completely harmless and painless and you will 
be guided through the correct procedures by one of the research team members.  
 
Bone mineral density. You will be asked to undertake a bone ultrasound or 
peripheral quantitative computed tomography (pQCT) scan to give us information 
about your bone mineral density. The ultrasound scan involves a member of the 
research team scanning your shinbone with a small probe on your skin with the help 
of a lubricating gel for approximately 5 minutes. This procedure is completely 
harmless and painless. The pQCT scan (a bit like a medical X-ray) lasts 
approximately 10 minutes and involves your lower leg being placed in a supported, 
still position in the centre of the scanner. If you visit the university laboratory you will 
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be asked to complete a dual-energy X-ray absorptiometry (DEXA) scan which gives 
us information about your bone mineral density as well as muscle mass and fat 
mass. This procedure is also somewhat similar to that of a medical X-ray. You will 
be asked to lie on a plinth and remain as still as possible throughout the scan which 
will last approximately 8 minutes.  Each DEXA and pQCT scan exposes you to an 
extremely minimal dose of radiation, which is well below the maximum 
recommended dose regarded as safe (see question 7 for more details). 
 
Muscular strength and power. Muscular strength and power will measured using a 
cycle ergometer and a force platform. You will be asked to cycle as hard as you can 
for a short time (6 seconds) on the cycle ergometer.  Using the force platform, you 
will be asked to do (i) a maximal jump and (ii) a maximal pull on a static bar while 
you are standing almost upright (knees slightly bent). You will be assisted by a 
member of the research team through all tests which will include warm-up and cool-
down periods. To complete all strength and power tests will require up to 30 minutes. 
 
7) Are there any disadvantages or risks in taking part? 
Blood sample. This is not a painful procedure but some people are a little squeamish 
about blood and tend to faint. Therefore, you will be seated/lying down while we take 
the blood and you do not have to see anything. Sometimes there is a little bruising 
but this should disappear in a matter of a few days, even in the most extreme cases. 
To prevent further bleeding, you might be asked to place a cotton wool ball over the 
punctured site and to hold it in place for a few minutes or until bleeding has stopped. 
Blood samples will be stored in a locked freezer until analysis at a later date. Only 
appropriately qualified personnel will be used for taking the blood sample. Any 
personal information provided by you in connection with the blood donation will be 
held in strict confidence. Furthermore, all data will be anonymised and stored in 
secure locations to prevent identification of an individual.  
 
DEXA/pQCT Scan. Should you decide to take part in this research, you will be 
exposed to a very small amount of radiation, specifically 8 µSv (DEXA) or 10 μSv 
(pQCT), depending on which scan is completed.  This dose is extremely minimal 
and is equivalent to the amount of radiation you are subjected to over an average 
2-3 days of your life or simply travelling 30-40 miles in a car. 
 
Muscular strength and power. The three tests of muscle strength and power require 
short, maximal efforts, so you should not find them tiring.  Like any physical effort 
there is a risk of muscle strain, but by ensuring you are fully warmed up this risk will 
be kept to a minimum. 
 
8) What are the possible benefits of taking part? 
The broad benefits of the research are linked to the potential for the study to highlight 
new links between gene variants and elite athlete status. This information will 
improve our understanding of what contributes to making an elite athlete ‘elite’ and 
which genes are responsible for determining the strength, size, power and 
endurance capacity of human muscle. By providing the necessary information, you 
will be contributing to our further understanding of how the body works and what 
makes us different from one another. Furthermore, we can provide you with 
immediate feedback concerning your bone mineral density and muscle strength and 
power, plus feedback concerning ACTN3 genotype once the genetic analysis has 
taken place at a later date. This gene variant has been associated with elite 
strength/power and endurance athlete status. 
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9) Who are the members of the research team? 
 Dr Alun Williams (MMU): Principal Investigator; responsible for overall project 
design and management, collecting blood and saliva samples, conducting other 
measurements and administering questionnaires, data analysis and 
interpretation. 
 Dr Stephen Day (MMU), Dr Georgina Stebbings (MMU), Dr Robert Erskine 
(Liverpool John Moores University), Prof Craig Sale (Nottingham Trent 
University) Dr Philip Hennis and Prof Hugh Montgomery (both University College 
London): responsible for project design, collecting blood and saliva samples, 
conducting other measurements and administering questionnaires, data 
analysis and interpretation. 
 Sarah Lockey, Shane Heffernan, Adam Herbert, Jon Brazier, Mark Antrobus, 
Peter Callus (MMU): PhD Students; responsible for collecting blood and saliva 
samples, conducting other measurements and administering questionnaires, 
data analysis and interpretation. 
 
10) Who is funding the research? 
This project is being funded by the Health, Exercise and Active Living Research 
Centre at Manchester Metropolitan University.  
 
 
11) Who will have access to the data? 
All information collected during the course of this research project will be kept 
confidential and will only be used for the purposes of the study. The data will be 
stored anonymously; only the members of the research team named above will have 
access to it.  
 
The results from the study will be communicated at scientific conferences and 
published in peer-reviewed scientific journals some time in the future but in a 
manner that does not allow an individual’s identity to be determined. You may obtain 
a copy of any publication that result from the research by contacting the Principal 
Investigator (see below - section 13). 
 
12) Who do I contact if I feel my rights have been violated? 
If you wish to make a complaint regarding your involvement in the study, please 
contact:  
MMU Ethics Committee 
Registrar & Clerk to the Board of Governors 
Head of Governance and Secretariat Team 
Manchester Metropolitan University 
All Saints Building, All Saints 
Manchester  M15 6BH 
Tel: 0161 247 1390 
 
 
 
13)  Finally, thank you for considering to participate in our research study. If you 
require any more information, please contact:  
 
Dr Alun Williams 
Email: a.g.williams@mmu.ac.uk 
Tel:  0161 247 5523
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Appendix 3: Qiacube automated protocol diagram 
 
 
 
 
 
 
http://www.qiagen.com/us/resources/download.
aspx?id=%7B6F5553FD-3CA5-4E2E-9DE7-
43473DE3C173%7D&lang=en&ver=1  
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Appendix 4: Rugby union playing positions and roles 
 
 
Rugby union playing positions. Adapted from 
http://pinkrugby.com/wp-
content/uploads/2011/01/rugby-positions.jpg. 
 
Position descriptions (England Rugby, 2016) 
1 & 3 Prop - Along with the hooker, the loose-
head and tight-head props make up what is 
known as the front row, which refers to their 
position in the scrum. To be successful, both 
props must be extremely strong in the neck, 
shoulders, upper body and legs. While stopping 
their side of the scrum from moving backwards, 
the props also support the hooker's body weight, 
allowing him or her to see and strike the ball 
when it is put into the scrum. In the lineout, 
props should be able to support or lift the jumper 
to prevent the opposition winning the ball. Away 
from set pieces, props help to secure the ball 
when a player has been tackled, so it helps if they 
can combine their power with a degree of mobility. You’ll also often see them used as battering 
rams in attack, receiving short passes after a ruck or maul and hitting the opposition defence at 
pace in an attempt to occupy the defenders and make space for their own backs. 
2 Hooker - Lining up in the scrum between the two props, the hooker is one of the forwards’ key 
decision-makers. He or she will coordinate the timing at the scrum, and is also responsible for 
winning possession in the scrummage by hooking the ball back through the props' legs. To allow 
the hooker to do this effectively, the props support much of the hooker’s weight, leaving him or 
her free to concentrate on hooking the ball back, rather than pushing against the opposition 
forwards. For this reason the hooker is often the smallest member of a front-row trio. At the lineout 
he or she is responsible for throwing the ball in and must be able to accurately hit the lineout jumper 
who is expecting the ball. In open play the hooker plays a similar role to the props, securing 
possession at rucks and mauls, or taking short ‘crash’ passes. 
4 & 5 Lock - The second row forwards (also known as locks) are the power house of the scrum and 
the target men in the lineout, meaning that they need to be tall, powerful players with excellent 
scrummaging technique and pinpoint timing. In open play the second row’s duties have evolved 
from being support players at rucks and mauls to ball carriers.  
6 & 7 Flankers - Open-side and blind-side flankers are often considered to be the players with the 
fewest set responsibilities, but as such must be excellent all-rounders. Speed, strength, fitness, 
tackling and handling skills are all vital. Flankers are more often than not at the centre of the action 
– winning balls at the ruck and maul, collecting short passes from tackled players and making their 
own big tackles in open play. The open-side flanker plays on the far side of the scrum from the 
touchline and is often smaller in size than their blind-side partner, making them more mobile 
around the pitch. The blind-side flanker tends to have bigger, more physical role around the pitch, 
and also acts as a target jumper in the lineout. 
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8 Number Eight - Support play, tackling and ball-carrying are the No.8’s areas of expertise, making 
his or her duties similar to the two flankers. Together the trio forms a unit called the back row. 
Binding on right at the back of the scrum, the No.8 is also the only player from the forwards who is 
allowed to pick the ball up from the base of the scrum. It is a move that is often used to gain vital 
yards when a team is scrummaging close to the opposition try line, and for it to be truly effective 
the No.8 must be an explosive, dynamic runner. 
9 Scrum-Half - Acting as the link between the forwards and the backs, the scrum half is a key player 
when it comes to building attacks. Playing just behind the forwards, a good scrum half will control 
exactly when the ball is fed out to the backs from the rear of a scrum, ruck or maul. A scrum half 
needs good vision, speed and awareness, quick hands and lightning reactions. They tend to be one 
of the smaller players on the pitch and so rely on protection from their own forwards 
10 Fly-Half - Arguably the most influential player on the pitch The fly half must orchestrate the 
team's back line, deciding what rehearsed moves to put into action and reacting to gaps in defence. 
He or she is also the main target for the defending team's open-side flanker and so must be strong 
in the tackle. The fly half has to be able to relieve territorial pressure by kicking down the field into 
touch, and is often the team's designated place kicker for conversions, penalties and drop goal 
attempts. In defence he or she will marshal the backs to ensure each opposition player is covered, 
and a strong-tackling fly half can snuff out opposition attacks before they start. 
11 & 14 Wing - Playing out wide on the side of the pitch, the winger is a team’s finisher in attack. A 
winger is also often the last line of defence when they don’t have the ball and as such, pace is their 
major resource. 
12 & 13 Centre - The inside centre – who stands closest to the fly half when the backs line up – and 
the outside centre tend to be strong, dynamic runners with a good eye for exposing gaps in the 
opposition defence. In attack they tend to run very direct lines. The centres take on their opposite 
number in an attempt to either break the defensive line, or draw in enough opposition defenders 
to create space and try-scoring opportunities for their team-mates. As such they need to be strong 
and powerful, and when attack turns into defence, they must also be accomplished at tackling. The 
inside centre is often the more creative in a centre pairing and should be able to pass and kick nearly 
as well as the fly half. In either defence or attack, the inside centre tends to be all action – dishing 
out the tackles and then drawing the opposition defence. Meanwhile, the outside centre tends to 
be the faster of the two and the ability to offload the ball quickly to the wingers is also vital. 
15 Full-back - Lining up behind the entire back line, the full back is the closest thing that rugby has 
to a sweeper in defence. But they also receive deep kicks from the opposition, so they must be 
comfortable catching high balls and launching attacks from the resulting possession. As such, the 
full back must have enough tactical awareness to recognise when to counter-kick, and when to run 
with the ball, often from deep within his or her half.  
Reference 
England Rugby (2016). Positions guide, ed. Rugby Football Union. Rugby Football 
Union,, http://www.englandrugby.com/. 
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Appendix 5: Team sport genomic publications 
 
Single team sports 
 
Field hockey 
Just a single study reports the genetic characteristics of field hockey players. Gronek et al. 
(2013) investigated the association between ACE I/D and select physiological variables in 
elite Polish field hockey athletes (n = 47), however did not make comparison to a control 
group. No significant associations were identified, although, the ID genotype group (n = 20) 
tended towards greater estimated peak power (P = 0.085) and the II genotype group (n = 14) 
tended towards the greatest VO2max (P = 0.081). While the sample size was extremely low 
and was likely the cause of non-significant results, an estimate of the effect would have been 
useful to truly understand the research findings (the absence of which is common within 
sports genomics; Figure 8). Importantly, the sample consisted of ‘elite’ athletes (Polish 
national team) which is an important criterion in studying the genetic variation among 
athletes. 
Volleyball 
The first of two investigation to consider volleyball athletes examined the effect of ACTN3 
R577X variation on estimated leg power in elite players (n = 66; male and female) compared 
to a control group (n = 334; Ruiz et al., 2011b). There was no association identified between 
athletes and controls for genotypic frequency, nor a genotype-phenotype association with 
leg power for ether athletes or the larger cohort of controls. However, the athlete group did 
deviate from Hardy-Weinberg equilibrium This deviation could be for a number of reasons, 
however was most likely due to the small sample or genotyping error as they are the most 
common reasons for deviation (Sen & Burmeister, 2008). Salles et al. (2015) performed a 
fascinating investigating into the genetic variation of tendinopathy in elite volleyball 
athletes, examining 23 SNP’s in the BMP4, FGF3, FGF10 and FGFR1 genes. A significant 
association between tendinopathy and BMP4 rs2761884 (P = 0.03) was observed with a 2.4 
times greater susceptibility to tendinopathy (OR = 2.39) under presence of the T allele. 
Furthermore, haplotype analysis of chromosome 14 revealed an association between 
‘TTGGA’ in the BMP4 gene (P = 0.01, OR = 1.92) and tendinopathy, with a weaker 
haplotype association in chromosome 11 (FGF3 ‘TGGTA’ haplotype; P = 0.05, OR = 1.40). 
These results may have good future applications in the study of tendon injury and indeed 
tendon properties. While this study did not investigate genetic frequency variation with 
athlete status, high quality specific phenotype studies are important advances in team sport 
genomics, however significantly greater sample sizes are required. 
Basketball 
Two reports considering the genetic characteristics of basketball athletes exist, the first of 
which (Garatachea et al., 2014) investigated the association between ACTN3 R577X 
genotype and athlete status as well as estimated explosive leg power (jump performance) in 
a mixed sex group of elite Spanish basketball athletes (n = 102, 61 male) and a control sample 
(n = 283). Unsurprisingly, given previous data of a similar design (Ruiz et al., 2011b), their 
results indicated no relationship between genotype and phenotype (athlete status and 
explosive leg power), however the authors failed to consider positional differences. In senior 
male basketball athletes, physiological and anthropometric characteristics differ 
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considerably across playing positions. For example, 10 m sprint time can differ by ~0.26 s 
(13%; point guards versus centres), countermovement jump by ~12 cm (22%; small forwards 
versus power forwards) and squat maximum by ~32 kg (16%; point guards versus  centres; 
Abdelkrim et al., 2010; Scanlan et al., 2014). These and other physiological differences 
between playing positions could be reflected in genetic characteristics, yet might not be 
apparent when analysing athletes as a whole cohort (Egorova et al., 2014). While 
investigating genetic variation of female athletes is necessary to understand the complex 
athletic traits in female sport, combining male and female athletes as a single cohort, in team 
sports such as basketball (Garatachea et al., 2014) may increase the possibility of false 
negative results, which would likely be due to differences in certain physiological 
characteristics between male and female athletes - particularly jump performance (Ziv & 
Lidor, 2009). 
 
A more recent investigation of the GNB3 gene in elite Caucasian Turkish basketball players 
(n = 72) showed that the rs5443 CC genotype had the greatest VO2peak (CC = 60.1 versus 
TC = 56.7 ml·kg-1·min-1; P = 0.007) and isokinetic knee flexion (CC = 175 versus TT = 146 
N.m; P < 0.05), with the TT genotype showing the greatest drop in anaerobic power, as 
determined by a 30 s Wingate test (TT = 62.9 versus TC = 54.2%; P < 0.001; Gülyaşar et 
al., 2014). These results suggest that the T allele is associated with a reduction in exercise 
performance, specifically in elite basketball (Gülyaşar et al., 2014). However, those results 
were not supported by other elite athletic/ancestral groups investigating rs5443 (Eynon et 
al., 2009; Eynon et al., 2011a; Ruiz et al., 2011a). This illustrates the importance of exploring 
individual sports as isolated cohorts. It is possible that the results of Gülyasar et al. (2014) 
may be false positives possibly due to low sample sizes, but it could also be the case that the 
GNB3 rs5443 C allele may be of an advantage only in basketball or similar sports heavily 
dependent on the above phenotypes. 
Cricket 
Two peer-reviewed publications have considered molecular genetic variation of cricket 
athletes, with both studies consisting of the same cohort (non-elite athletes n = 14 and 
controls n = 17; Djarova et al., 2011a; Djarova et al., 2011b). The authors attempted to 
associate health markers (blood pressure, C-reactive protein, uric acid, lactate and selected 
physiological measures) to individual genetic variants (ACE I/D, ACTN3 R577X and TNF 
G308A). This sample is exceptionally small for genetic analysis and this was evident by the 
lack of ACTN3 XX (which is present in the Zulu/Bantu population (~1%; Yang et al., 2007)) 
and ACE II genotypes. There was no genetic association reported between athletes and 
controls, but an interesting finding was that the ACE D, ACTN3 R and TNF A alleles were 
associated with lower C-reactive protein levels for both cricketers and controls (P = 0.001). 
Contrastingly, TNF has been shown to have the opposite association, in that lower C-reactive 
protein levels were associated with the G allele in a much larger sample (n = 456) - including 
non-Caucasian participants (n = 232; Lakka et al., 2006). This suggests the possibility that 
the low sample size studied by Djarova et al induced type 1 statistical error and as such false 
results. 
Soccer (football) 
Within team sports genomics, soccer has received the most scientific interest, with 15 peer-
reviewed publications focusing exclusively on the molecular genetic characteristics of 
soccer athletes (Table 1 and Figure 8). Many polymorphisms have been investigated in 
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comparison to other athletes and controls, but also for a variety of phenotypic measures. In 
the first investigation to assess soccer athletes, 60 soccer players comprising of Spanish first 
(n = 18), second (n = 27) and third division (n = 15) competitors and a group of “world class” 
endurance athletes were investigated for their association with ACTN3 R577X genotype 
(Santiago et al., 2008). Soccer athletes had greater RR genotype frequencies than the 
endurance and control groups (Santiago et al., 2008), with a more recent publication 
supporting these findings (Pimenta et al., 2013). Furthermore, Egorova et al. (2014) observed 
a higher frequency of R allele carries in 57 elite players, but not in a mixed standard cohort 
(n = 240) of Russian athletes. This study design has been used to assess a number of other 
genetic variants (Juffer et al., 2009; Eynon et al., 2012; Pimenta et al., 2013; Egorova et al., 
2014; Gineviciene et al., 2014) and generally supports genetic differences between soccer 
athletes and controls. However, most of these studies compared soccer athletes to controls 
as two whole cohorts and did not account for positional differences. Those that did identified 
significant genetic variation across playing position (Egorova et al., 2014; Gineviciene et al., 
2014), which is logical because in soccer, like most other team sports, physiological 
demands differ considerably across playing position (Bradley et al., 2013). The 
consideration of positional specificity regarding team sport athlete genomics is vital to truly 
elucidate the genetic contribution to performance, injury risk, etc. 
 
Two variants of the COL5A1 gene, in combination with each other (haplotype), have been 
linked (P = 0.048) to anterior cruciate ligament (ACL) rupture among 91 injured players 
compared to uninjured players (n = 143), of the same standard (Ficek et al., 2013). While 
the statistical significance is not large, comparing medically diagnosed ACL ruptured 
athletes to non-injured athletes from the same athletic level, makes this study design strong. 
It is worth noting the absence of a significant result when each variant was assessed 
separately, with the authors showing that the sample was too low to detect an association 
(power = 47% at 95% CI) - the inclusion of an effect estimate would have assisted 
interpretation of the data. Interestingly, the same sample and design was used to investigate 
another collagen gene variation (COL2A1 rs970547) and in contrast to their hypothesis 
found no associations between injured and non-injured athletes (Ficek et al., 2014). More 
common/less severe, non-contact soft musculoskeletal tissue injuries (NCSMTIs) have been 
studied in 73 Spanish athletes, including some elite players, of mixed geographic ancestry. 
Four genetic variants (IGF2 rs3213221, CCL2 rs2857656, COL5A1 rs12722 and ELN 
rs2289360) were associated with degree of injury (mild, moderate or severe) and recovery 
time (days) following injury, specifically muscle and ligament tissue injuries (Pruna et al., 
2013). For example, depending on the genetic variant within the ELN rs2289360 (associated 
with ligament injury and tissue repair) the recovery time was 70% less for the beneficial 
genotype, although there were only 10 cases - but as preliminary data these findings are 
interesting (Pruna et al., 2013). Further caution must be taken when considering these results 
because individual genetic variants are known to differ in allele frequency between different 
geographical ancestry populations (1000 Genomes Consortium, 2012) which may be a factor 
given the combination of athletes from three geographical ancestries (European white, black 
African and Hispanic). 
 
Likewise, other polymorphisms in the VDR gene have been shown to account for 19% (P = 
0.041) of musculoskeletal injury severity in elite Italian soccer players (Massidda et al., 
2015b). Furthermore, utilising a total genotype score (TGS) of 5 SNPs (COL5A1 rs12722, 
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MTC1 rs1049434, VDR Apa I, VDR Bsm I, and VDR Fok I) and in combination with player 
training volume, Massidda et al. (2014a) predicted 10% of the variability in  injury incidence 
within the same sample of elite soccer athletes. Substantially larger replications of these 
types of study designs in soccer and other team sports may show future predictive value 
within sports genomics regarding injury risk. 
Multiple team sports 
Interestingly, three publications have concentrated specifically on combining groups of team 
sport athletes, in comparison to either controls (Ahmetov et al., 2013) or to other athletic 
groups and controls (Eynon et al., 2014; Massidda et al., 2015a). Ahmetov et al. examined a 
polymorphism in the peroxisome proliferator-activated receptor α (PPARA) gene (regulator 
of lipid and glucose metabolism) in a large mixed male and female non-elite athlete cohort 
(n = 655) from a variety of sports. They found that the C allele, previously associated with 
a higher proportion of type II muscle fibres and power-orientated athletes (Ahmetov et al., 
2006), was over-represented in the whole cohort compared to controls (P = 0.0009), although 
when each sport was analysed individually only football (n = 241) was different from 
controls (P < 0.0001). These results may be due to the low sample size of the other team 
sport groups (the largest being basketball, n = 85) or the mix of male and female athletes 
(specific gender proportions of each group were not presented). Importantly the authors 
analysed each sport separately, in addition to the whole cohort, which is something rarely 
seen in the field and important for interpretation of the overall results, as just described. 
 
Secondly, ACTN3 R577X was assessed in a combined cohort of Spanish, Polish and Russian 
Caucasian athletes, of which 72% were classified as elite (Eynon et al., 2014). The authors 
compared a group of team sport athletes (n = 205) with endurance athletes (n = 305), sprint 
athletes (n = 378) and a control group (n = 568). No associations were found between 
genotype and athletic status of team sport athletes, although the RR genotype was less 
common in team sport athletes then strength athletes (OR = 0.58, 95 % CI 0.34–0.39, P = 
0.045). The greatest concern regarding these results was the five separate sports considered 
in the team sport cohort (soccer, ice hockey, field hockey, handball and water polo), each 
with very different physiological demands and anthropometric characteristics. While 
combining team sport athletes together increases sample size, analysing sports with vastly 
different physiological and anthropometric characteristics - which is likely to be evident at 
the molecular level – may dissolve important data. The same result – no association between 
ACTN3 and team sport athletes status - was seen in an Italian cohort (Massidda et al., 2015a), 
but with similar methodological limitations. While Ahmetov et al. (2013), Eynon et al. 
(2014) and Massidda et al. (2015a) were the first to specifically analyse the genetic variation 
among team sports athletes in a relatively large cohort, some methodological considerations 
(discussed below) need to be addressed before similar studies involving team sport athletes 
should be reported. 
 
Table 1 Key characteristics of research articles included in the present chapter, separated into articles 
that investigated a single team sport (Single Sport Articles) or multiple sports including some team 
sport athletes (Multiple Sport Articles). 
Single Sport Articles 
Sport(s) Participants Genetic variant(s) Statistics Relevant associations Reference 
Rugby 
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Rugby union (n = 
431), rugby league 
(n = 83) 
507 athletes 
(all M; all 
elite) and 
710 
controls 
(61% M) 
 
UK 
South 
Africa 
ACE ID, ACTN3 
R577X rs1815739  
HW; Yes – 
all athletes 
and controls 
 
Sig test; χ2 
 
MC; 
Benjamini-
Hochberg 
 
EE; OR 
No associations with ACE ID. For 
ACTN3, no association was 
identified in the whole group. The 
X allele was overrepresented in 
RU forwards compared to backs 
(P = 0.02) and controls (P = 0.02). 
In the back three, the R allele was 
more common than controls (P = 
0.04) and forwards (P = 0.01).  
(Heffernan et 
al., 2016) 
Rugby union (n = 
102) 
102 athletes 
(All M; 
non-elite) 
and 110 
controls 
(non-rugby 
athletes) 
 
UK 
ACTN3 R577X 
rs1815739  
HW; NS 
 
Sig test; χ2, 
t tests, 
ANCOVA 
 
MC; NS 
 
EE; NS 
No association with genotype and 
physiological variables. There 
was a tendency for the grouped 
centres/wingers/full backs for 
greater RR genotype (P = 0.066) 
and R allele frequency (P = 
0.059). 
(Bell et al., 
2012c) 
Rugby union (n = 
109) 
109 athletes 
(All M; 
non-elite) 
and 108 
controls 
(non-rugby 
athletes) 
 
UK 
ACE I/D HW; Yes 
 
Sig test; χ2, 
t tests, 
 
MC; NS 
 
EE; NS 
No difference in genotype 
frequency. 
(Bell et al., 
2010) 
Rugby union (n = 
68) 
68 athletes 
(all M; non-
elite) 
 
UK 
ACE I/D HW; NS 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
Backs with ID had greater force 
(Wt %) and power output (W·kg-1) 
than forwards (P = 0.001; P = 
0.034). Backs with DD genotype 
had greater jump displacement 
(m) and velocity (m·s-1) than 
forwards (P = 0.049, P = 0.007). 
(Bell et al., 
2009) 
Rugby union (n = 
17) 
17 athletes 
(6 M & 11 
F; non-
elite)  
 
South East 
Asian 
ACE I/D HW; Yes 
 
Sig test; NS 
 
MC; NS 
 
EE; 
Multivariate 
logistic 
regression 
The likelihood of having a high 
aerobic capacity was 14.3 fold 
(OR = 14.27, P = 0.03) greater 
among subjects with the II 
genotype compared to ID.  
(Goh et al., 
2009) 
Field Hockey 
Field hockey (n = 
47) 
47 athletes 
(all M; all 
elite) 
 
Polish 
ACE I/D HW; NS 
 
Sig test; 
ANCOVA 
 
MC; NS 
 
EE; NS 
No differences between any 
physiological variables and 
genotype frequency. 
(Gronek et al., 
2013) 
Volleyball 
Volleyball (n = 138) 138 athletes 
(all M; all 
elite) 
 
Brazilian  
BMP4 rs2761884, 
rs17563, rs2855529, 
rs2071047, 
rs762642; FGF3 
rs7932320, 
rs1893047, 
rs12574452, 
rs4631909, 
rs4980700; FGF10 
rs1448037, rs900379, 
rs1011814, 
rs593307; FGFR1 
rs13317 
HW; NS 
 
Sig test; χ2, 
t tests, 
Mann–
Whitney test 
 
MC; 
Bonferroni  
 
EE; OR 
BMP4 rs2761884 was associated 
with tendinopathy (P = 0.03). 
Athletes with the risk genotype 
had 2.4 times more susceptibility 
to tendinopathy (OR = 2.39). 
Haplotype TTGGA in BMP4 (P = 
0.01) had greater risk.  
(Salles et al., 
2015) 
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Volleyball (n = 66) 66 athletes 
(31 M & 35 
F; all elite) 
and 334 
controls 
(243 M & 
91 F)  
 
Spanish 
ACTN3 R577X 
rs1815739 
HW; Yes for 
controls – 
No for 
athletes 
 
Sig test; χ2, 
ANCOVA, 
ANOVA 
 
MC; NS 
 
EE; OR 
No difference in leg power by 
genotype. 
(Ruiz et al., 
2011b) 
Basketball 
Basketball (n = 72) 72 athletes 
(all M; all 
elite) 
 
Turkish 
GNB3 rs5443 HW; Yes  
 
Sig test; 
ANOVA, 
ANCOVA 
 
MC; NS 
 
EE; NS 
CC genotype showed the greatest 
VO2peak (P = 0.007) and isokinetic 
knee flexion (P < 0.05), with the 
TT genotype showing the greatest 
drop in percentage anaerobic 
power (P < 0.001). 
(Gülyaşar et 
al., 2014) 
Basketball (n = 102) 102 athletes 
(61 M, 41 
F; all elite) 
and 283 
controls 
(216 M & 
67 F) 
 
Spanish  
ACTN3 R577X 
rs1815739 
HW; Yes – 
all athlete 
 
Sig test; χ2, 
ANOVA 
 
MC; NS 
 
EE; OR 
No association between ACTN3 
variants and explosive leg power. 
(Garatachea et 
al., 2014) 
Soccer 
Soccer (n = 54) 54 athletes 
(all M; all 
elite) 
 
Italian  
VDR (FokI, ApaI and 
BsmI) 
HW; Yes – 
all athlete 
 
Sig test; 
ANOVA, 
ANCOVA, 
R2 
 
MC; NS 
 
EE; NS 
ApaI allele was associated with 
severity of injury (P = 0.041). 
(Massidda et 
al., 2015b) 
Soccer (n = 246) 246 athletes 
(all M; 21% 
elite, 33% 
sub-elite) 
and 872 
controls (all 
M) 
 
Russian 
 
ACE I/D, ACTN3 
R577X rs1815739, 
PPARA rs4253778, 
PPARG P12A 
rs1801282, 
PPARGC1A, G482S 
rs8192678, PPARD, 
rs2016520, TFAM 
rs1937, UCP2 A55V 
rs660339 
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2, 
Fisher’s 
exact 
 
MC; Holm–
Bonferroni 
 
EE; NS 
ACE D, ACTN3 R, PPARA C and 
UCP2 Val alleles were associated 
with football player status and 
combined the TGS was higher in 
football athletes (P < 0.0001) than 
in controls. Positional differences 
were between midfielders, 
goalkeepers and controls, with 
TGS (P = 0.0023, P = 0.0004). 
(Egorova et 
al., 2014) 
Soccer (n = 243) 243 athletes 
(all M) 
 
Polish 
COL12A1 rs970547 HW; Yes 
 
Sig test; χ2, 
Fisher’s 
exact 
 
MC; NS 
 
EE; OR 
No difference between ACL 
ruptured athletes and non-rupture. 
G allele showed a greater 
likelihood of ACL injury and was 
0.82 times higher (P < 0.00001) 
than in the non-rupture group. 
(Ficek et al., 
2014) 
Soccer (n = 140)  140 athletes 
(all M; 59% 
elite) 
 
Brazilian 
ACTN3 R577X 
rs1815739 
HW; Yes 
 
Sig test; χ2 
 
MC; NS 
Greater RX and lower XX in the 
U-14’s (n = 43) and professionals 
(n = 83) compared to the armature 
athletes (P < 0.05). 
(Coelho et al., 
2014) 
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EE; NS 
Soccer (n = 64) 64 athletes 
(all M; all 
elite) 
 
Italian 
COL5A1 rs12722, 
MTC1 rs1049434, 
VDR (Apa I,  Bsm I, 
Fok I) 
HW; Yes 
 
Sig test; 
ANOVA 
 
MC; NS 
 
EE; NS 
The combined influence of 
training volume and TGS 
predicted injury rate, explaining 
10% of the variability in injury 
incidence (P = 0.03). 
(Massidda et 
al., 2014a) 
Soccer (n = 60) 60 athletes 
(all M; all 
sub-elite) 
and 30 
controls 
 
Italian  
PPARA rs4253778 HW; Yes 
 
Sig test; χ2, 
t test 
 
MC; NS 
 
EE; NS 
Greater G allele in soccer athletes 
compared to controls (P = 0.04). 
(Proia et al., 
2014) 
Soccer (n = 199) 199 athletes 
(all M; Sub-
elite) and 
167 
controls (all 
M) 
 
Lithuanian  
ACE rs1799752 
PPARGC1A 
rs8192678 PPARA 
rs4253778 
HW; Yes – 
athletes, No 
– controls 
for ACE  
 
Sig test; χ2, 
Fisher’s 
exact 
 
MC; NS 
 
EE; OR 
ACE DD genotype frequency was 
lower in defenders (P = 0.033) and 
midfielders (P = 0.012) compared 
to controls. PPARG C1A and 
PPARA differed between forwards 
and controls (P = 0.044, P = 
0.034). Grouped genotypes ACE 
II + PPARA GC were at greater 
odds of appearing in the players 
group (OR = 2.83, P = 0.047). 
(Gineviciene 
et al., 2014) 
Soccer (n = 68) 68 athletes 
(all M; non-
elite) and 
100 
controls (all 
M) 
 
Egyptian 
ACE I/D HW; NS 
 
Sig test; χ2, 
Fisher’s 
exact 
 
MC; NS 
 
EE; NS 
DD genotype had higher left 
ventricular ejection fraction (%; P 
= 0.03), right ventricular diameter 
in diastole (P = 0.04) and 
pulmonary artery systolic pressure 
(P = 0.02) than other genotypes for 
footballers compared to controls. 
(Saber-Ayad 
et al., 2013) 
Soccer (n = 73) 73 athletes 
(all M; all 
elite) 
 
Spanish 
ELN rs2289360, TTN 
rs2742327, SOX 15 
rs4227, IGF 2 
rs3213221, CCL 
rs2857656, TNC 
rs2104772, COL1A1 
rs1800012, COL5A1 
rs12722 
HW; NS 
 
Sig test; χ2, 
Fisher’s 
exact 
 
MC; 
Benjamini-
Hochberg 
 
EE; NS 
IGF2, CCL and ELN were 
associated with degree of injury (P 
= 0.034, P = 0.026, P = 0.009), and 
ELN associated with recovery 
time (P = 0.043). 
(Pruna et al., 
2013) 
Soccer (n = 200) 200 athletes 
(all M; all 
elite) 
 
Brazilian 
ACTN3 R577X 
rs1815739  
HW; NS 
 
Sig test; 
ANOVA 
 
MC; NS 
 
EE; NS 
RR genotype jumped higher and 
ran faster, XX had higher VO2max 
(P < 0.05). Higher RR genotype 
than the normal control population 
(no controls analysed in this 
study). 
(Pimenta et 
al., 2013) 
Soccer (n = 91) 91 athletes 
(all M; all 
elite) and 
141 
controls 
(also 
athletes) 
 
Polish 
COL1A1 rs1800012, 
rs1107946 
HW; Yes  
 
Sig test; χ2, 
Fisher’s 
exact 
 
MC; NS 
 
EE; OR 
G-T haplotype was associated 
with lower risk of ACL rupture (P 
= 0.048). 
(Ficek et al., 
2013) 
Soccer (n = 37) 37 athletes 
(all M; all 
elite) 
ACTN3 R577X 
rs1815739  
HW; NS 
 
Higher IL-6 concentrations for RR 
genotype post ECC training (P < 
0.05). RX and XX had higher CK 
(Pimenta et 
al., 2012) 
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Brazilian  
Sig test; 
ANOVA 
 
MC; NS 
 
EE; NS 
activity than RR post ECC 
exercise (P < 0.05). XX had the 
greatest hormonal changes post 
ECC training. 
Soccer (n = 60), 
endurance athletes (n 
= 100), power 
athletes (n = 53) 
213 athletes 
(all M; all 
elite) and 
100 
controls (all 
M) 
 
Spanish  
NOS2 786T/C 
rs2070744 
HW; Yes – 
controls and 
soccer, No – 
endurance 
and power. 
 
Sig test; χ2,  
 
MC; 
Bonferroni 
 
EE; logistic 
regression 
analysis 
Soccer athletes had lower TT than 
controls, power and endurance 
athletes (P = 0.02). 
(Eynon et al., 
2012) 
Soccer (n =54), 
endurance runners (n 
= 52) 
106 athletes 
(all M; all 
elite) and 
123 
controls (all 
M) 
 
Spanish  
ACE I/D, GDF-8 
K153R, AMPD1 
C34T 
HW; Yes - 
athletes and 
controls for 
AMPD1 and 
GDF-8. Yes 
– soccer 
players and 
controls. No 
–  endurance 
runners for 
ACE 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
Endurance runners had lower ID 
and higher II genotypes than 
controls (P = 0.026, P = 0.01). 
Soccer athletes had higher ID and 
lower II genotypes compared to 
endurance runners (P = 0.005, P = 
0.001). AMPD1 CT was lower in 
endurance runners compared to 
soccer and controls (P = 0.006, P 
= 0.014). 
(Juffer et al., 
2009) 
Soccer (n = 60), 
endurance athletes (n 
= 102) 
162 athlete 
(all M; all 
elite) and 
123 
controls (all 
M) 
 
Spanish 
ACTN3 R577X 
rs1815739  
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
Soccer athletes had higher RR 
genotype then other groups (P = 
0.041). 
(Santiago et 
al., 2008) 
Cricket 
Cricket (n = 14) 14 athletes 
(all M; non-
elite) and 
17 controls  
 
Zulu South 
African  
ACE I/D HW; NS 
 
Sig test; 
ANOVA, 
χ2, Fisher’s 
exact 
 
MC; NS 
 
EE; NS 
C-reactive protein and uric acid 
levels were lower in D allele 
carriers (P = 0.001). Knee flexion 
and extension torque was higher in 
D allele carriers (P < 0.03). ACE 
genotype differed between 
athletes and controls (P = 0.004), 
however there was an absence of 
the II genotype in athletes and 
controls. 
(Djarova et al., 
2011a) 
Cricket (n = 14) 14 athletes 
(all M; non-
elite) and 
17 controls  
 
Zulu South 
African  
ACTN3 R577X, TNF 
G308A 
HW; NS  
 
Sig test; 
ANOVA, 
χ2, Fisher’s 
exact 
 
MC; NS 
 
EE; NS 
R allele was associated with C-
reactive protein levels in 
cricketers (P = 0.0001) and 
controls (P = 0.014). ACTN3 R 
allele was associated with BMI 
and FM in cricket players (P = 
0.0001) and controls (P = 0.0007). 
TNF, A allele was associated with 
C-reactive protein levels (P = 
0.0001). No difference between 
athletes and controls for ACTN3 
(Djarova et al., 
2011b) 
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(XX genotype was absent) or TNF 
G308A. 
Multiple Sport Articles 
Sport(s) Participants Genetic variant(s) Statistics  Relevant association Reference 
Football (n = 218), 
cricket (n = 156), 
track and field (n = 
67, running events (n 
= 62), rowing (n = 
13), boxing (n = 2), 
tennis (n = 12), 
hockey (n = 26), 
gymnastics (n = 7) 
518 athletes 
(449 M and 
69 
F; all elite) 
 
North 
America  
UK 
RANK/RANKL/OPG 
rs3018362, 
rs4355801, 
rs1021188, 
rs9594738 
 
HW; Yes – 
rs3018362, 
rs1021188, 
rs9594738. 
No - 
rs4355801. 
 
Sig test; t 
tests 
 
MC; 
Bonferroni 
 
EE; OR 
8.1% of the stress fracture group 
and 2.8% of the non-stress 
fracture group were homozygote 
for the rare allele of rs1021188. 
Heterozygotes and homozygous 
for the rare allele of rs3018362 
were associated with stress 
fracture (P < 0.05). The rare allele 
of rs1021188 and individuals 
possessing at least one copy of the 
rare allele of rs4355801 were 
associated with stress fracture 
injury (P < 0.05). 
(Varley et al., 
2015) 
Endurance (n = 40), 
sprint/power (n = 
64), team sport 
athletes (n = 74) – 
Soccer (n = 64), 
Hockey (n = 10) 
178 athletes 
(all M; 57% 
elite) and 
190 
controls 
 
Italian  
ACTN3 R577X 
rs1815739 
HW; Yes – 
all athlete 
groups and 
controls. 
 
Sig test; NS 
 
MC; NS 
 
EE; OR 
Team sport athletes showed lower 
RR genotype compared to 
sprint/power group (P = 0.044).  
(Massidda et 
al., 2015a) 
Volleyball (n = 22), 
swimming (n =43), 
ice hockey (n = 34), 
canoeing (n = 86) 
185 athletes 
(all M; non-
elite) 
 
Polish 
ACTN3 R577X HW; Yes 
 
Sig test; 
MANOVA, 
χ2 
 
MC; NS 
 
EE; NS 
RR had greater relative power 
output in countermovement and 
spike jumps (P < 0.05). 
 
(Orysiak et al., 
2015) 
Football, 
basketball, 
athleticism, 
volleyball, 
handball, judo, 
wrestling, 
taekwondo, rugby 
150 athletes 
(18 F & 
132 M; all 
elite) and 
150 
controls (97 
F & 57 M) 
 
Turkish 
ACTN3 R577X 
rs1815739 
HW; NS 
 
Sig test; χ2 
 
MC; NS 
 
EE; OR 
Controls showed greater R allele 
individuals than the athletes group 
(P = 0.009). 
(Yamak et al., 
2015) 
Endurance (n = 84), 
sprint/power (n = 
47), mixed (n = 73) - 
wrestlers, tennis 
players, handball 
players, footballers 
204 athletes 
(160 M & 
44 F; all 
elite) and 
260 
controls 
 
Polish 
AMPD1 rs17602729 HW; Yes – 
all athlete 
groups and 
controls. 
 
Sig test; t 
test, 
ANOVA, 
χ2, Fisher’s 
exact 
 
MC; 
Bonferroni 
 
EE; NS 
Sprint/power athletes had the 
greatest CC genotype frequency 
compared to endurance-
orientated, mixed and control 
group (P < 0.05). 
(Ginevičienė 
et al., 2014) 
Endurance (n = 688), 
mixed - Badminton 
players (n = 24), 
basketball players 
(n = 109), baseball 
players (n = 38), 
boxers (n = 143) 
handball players (n 
= 92), ice hockey 
2664 (2262 
Russians 
and 402 
Polish; 
1540 M and 
1124 F) and 
917 
controls 
SOD2 Ala16Val 
rs4880 
HW; Yes – 
all athlete 
groups and 
controls  
 
Sig test; 
ANOVA χ2 
Spearman’s 
correlations 
SOD2 T allele had increased 
activity of CK (F, P = 0.0144) and 
creatinine level (F, P = 0.0276; M, 
P = 0.0135). TT genotype was 
lower in power/strength athletes 
compared to controls (P = 0.0076) 
and athletes involved in low-
intensity sports (P = 0.0001). 
(Ahmetov et 
al., 2014b) 
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players (n = 111), 
karate athletes (n = 
22), taekwondo 
athletes (n = 18), 
field hockey players 
(n = 19), 
synchronized 
swimmers (n = 27), 
fencers (n = 64), 
freestyle skiers (n = 
11), figure skaters (n 
= 76), archers (n = 
24), Nordic 
combined athletes (n 
= 10), snowboarders 
(n = 33), football 
players (n = 36), 
pentathletes (n = 23), 
softball players (n = 
31), rugby players 
(n = 48), table tennis 
players (n = 11), 
volleyball players 
(n = 115), mini-
football players (n 
= 9), water polo 
players (n = 59), 
white water 
slalomists (n = 5), 
wrestlers (n = 294), 
power (n = 321), 
strength (n = 203) 
(558 M and 
359 F)  
 
Russian  
Polish 
 
MC; 
Bonferroni 
 
EE; NS 
Volleyball (n = 61), 
baseball (n = 21), 
alpine skiing (n = 
18), speed skating (n 
= 19), figure skating 
(n = 32), kayak (n = 
25), cross-country 
skiing (n = 35) 
209 athlete 
(119 M & 
90 F; all 
elite)  
 
Russian  
ACTN3 R577X 
rs1815739 
HW; Yes 
 
Sig test; 
ANOVA, 
Spearman’s 
correlations 
 
MC; NS 
 
EE; NS 
Testosterone levels were higher in 
both M and F athletes with the 
ACTN3 R allele than XX 
homozygotes (P = 0.0071 for M; P 
= 00.0167 for F). 
(Ahmetov et 
al., 2014a) 
Endurance (n = 254), 
sprint power group 
(n = 338) – ice 
hockey (n = 27) 
592 athletes 
(485 M & 
107 F; all 
elite) 
 
Russian 
Polish 
EPAS1 rs895436, 
rs11689011, 
rs1867782, 
rs1867785, 
rs4035887 
 
HW; Yes – 
athlete 
groups and 
controls. 
 
Sig test; 
Multivariate 
Adaptive 
Regression 
Splines 
 
MC; NS 
 
EE; OR 
rs1867785 AA genotype was 
underrepresented in sprint/power 
athletic status (P = 0.00022).  TT 
genotype of rs11689011 was 
underrepresented in sprint/power 
athletes. The combinations of the 
AA genotype in rs4035887 with 
either the AG or GG genotypes in 
rs1867785, or with the CT or CC 
genotypes in rs11689011, were 
underrepresented in two cohorts 
of sprint/power athletes (P < 
0.005). 
(Voisin et al., 
2014) 
Endurance (n = 142), 
power (n = 91), 
mixed (n = 90) – 
fencing (n = 8), 
soccer (n = 53), 
table tennis (n = 4), 
volleyball (n = 7), 
tennis (n = 4), tae 
Kwando (n = 9) 
323 athletes 
(242 M & 
91 F; 76% 
elite) 
 
Russian 
MCT1 rs1049434 HW; Yes – 
controls, no 
– all athletes 
 
Sig test; t 
tests, χ2, 
Fisher’s 
exact 
 
MC; 
Bonferroni 
 
EE; OR 
A allele was higher in athletes 
than in controls (P < 0.0001). A 
allele and AA genotype were 
higher in rowers than in controls 
(P < 0.0001). Mean lactate 
concentration were higher in M 
rowers with the T allele compared 
with AA homozygotes (P = 
0.005). 
(Fedotovskaya 
et al., 2014) 
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Touch football (n = 
37), softball (n = 
28), basketball (n = 
25), badminton (n = 
9) 
99 athletes 
(all F; non-
elite) 
 
Japanese 
ACTN3, UCP1 
rs1800592, UCP2, 
UCP3 
HW; NS 
 
Sig test; χ2 
 
MC; NA 
 
EE; OR 
ACTN3 XX athletes that did not 
experience sports injuries had 
greater frequency than RR (P = 
0.0133). R allele frequency was 
higher than X frequency in 
athletes who experienced muscle 
injuries (P = 0.0015), with an odds 
ratio of 2.52. 
(Iwao-
Koizumi et al., 
2014) 
Endurance cohort (n 
= 305; Spanish, 
Polish & Russian), 
sprint/ power cohort 
(n = 378; Spanish, 
Polish & Russian). 
Team sport cohort - 
Soccer players (n = 
50; Spanish, n = 3; 
Polish), ice hockey 
players 
(n = 25; Polish, n = 
59; Russian), field 
hockey (n = 9; 
Polish), handball 
players (n = 21; 
Polish, n = 36; 
Russian), water 
polo (n = 2; 
Russian) 
205 athletes 
(all M; all 
elite) and 
568 
controls  
 
Spanish 
Polish 
Russia 
 
 
ACTN3 R577X 
rs1815739  
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; NS 
 
MC; NS 
 
EE; OR 
Higher RR genotype in 
power/sprint athletes than team 
sport athletes (P = 0.045). No 
differences between team sport 
athletes and controls (P = 0.765). 
(Eynon et al., 
2014) 
Endurance cohort (n 
= 114). Power group 
(n = 116), Mixed 
cohort - Soccer (n = 
44), wrestlers (n = 
26), boxers (n =23), 
judokas (n = 19), 
fencers (n = 18) 
360 athletes 
(273 M & 
87 F; 168 
elite, 192 
sub-elite) 
and 191 
controls. 
 
Polish  
NOS3 G894T 
rs1799983  
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2 
 
MC; false 
discovery 
rate 
 
EE; OR 
GG genotype (P = 0.0006) and G 
allele (P = 0.0002) were 
overrepresented in all athlete 
groups, compared to cintrols. 
(Eider et al., 
2014) 
Badminton, 
basketball, canoe, 
karate, wrestling, 
lacrosse 
253 athletes 
(144 M & 
109 F; non-
elite) 
 
Japanese  
ACTN3 R577X 
rs1815739 
HW; Yes 
 
Sig test; t 
tests, χ2, 
Fisher’s 
exact 
 
MC; NS 
 
EE; NS 
Relative peak power output was 
higher in the R allele group than in 
the XX group in M (P = 0.045), 
but not F athletes. 
(Kikuchi et al., 
2014a) 
Endurance (n = 126), 
strength/endurance 
(n = 161), 
sprint/strength (n = 
640) – football (n = 
82), ice hockey (n = 
70), strength (n = 
197) 
1124 
athletes 
(757 M & 
367 F;  
41% elite) 
and 1191 
controls 
(684 M & 
507 F) 
 
Polish 
Russian 
BDKRB2 -9/+9  HW; Yes – 
athlete 
groups and 
controls 
 
Sig test; χ2 
 
MC; 
Bonferroni 
 
EE; NS 
No differences between athletes 
and controls. 
(Sawczuk et 
al., 2013) 
Mixed cohort - 
badminton (n = 16), 
baseball (n = 28), 
basketball (n = 85), 
beach 
volleyball (n = 63), 
court tennis (n = 33), 
football (n = 241), 
665 athletes 
(M & F; 
sub-elite) 
and 1706 
controls  
 
Russian 
 
PPARA GC 
rs4253778  
HW; Yes – 
controls, no 
– athletes  
 
Sig test; χ2 
 
MC; 
Bonferroni 
C allele was higher in athletes 
compared to controls (P = 0.0009). 
Football (P < 0.0001) and softball 
(P = 0.047) athletes, 
independently, had higher 
frequencies of C allele compared 
to controls. 
(Ahmetov et 
al., 2013) 
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futsal (n = 9), 
handball (n = 24), 
ice hockey (n = 55), 
rugby (n = 48), 
softball (n = 31), 
table tennis (n = 14), 
water polo (n = 18) 
 
EE; NS 
Speed/strength 
group, 
endurance/speed/ 
strength group – 
field hockey, tennis, 
rugby, football, 
volleyball, 
basketball, 
handball, boxing, 
and kickboxing, 
canoeing, rowing. 
Endurance group 
156  
athletes 
(119 M & 
37 F; all 
elite) and 
83 controls 
(35 M & 48 
F) 
 
Polish  
UCP2 ID UTR, 
UCP3 CT  
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; 
ANOVA, t 
tests 
 
MC; NS 
 
EE; OR 
No significant differences for 
genetic markers and phenotype 
measures. 
(Holdys et al., 
2013) 
Ball game cohort - 
Soccer (n = 16), 
baseball (n = 8), 
basketball (n = 10), 
volleyball (n = 8), 
ice hockey (n = 8) 
50 athletes 
(non–elite) 
and 33 
controls 
 
Korean 
ACE G2350A rs4343  HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2, 
ANOVA 
 
MC; NS 
 
EE; NS 
No significant differences for 
genetic markers and 
cardiovascular function. 
(Jang & Kim, 
2012) 
Gymnastics (n = 17), 
100-400 m running 
(n = 12), soccer (n = 
30) 
59 elite 
athletes and 
31 controls 
 
Italian  
ACE I/D, ACTN3 
R577X  
HW; NS 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
ACE, no significant difference. 
The D allele was high in all cohort 
(DD; D: G = 53%; 70%, R = 50%; 
75%, S = 60%; 73%, C = 45%; 
66%). ACTN3, there was an 
absence of the XX genotype in the 
gymnastic group and excess RR (P 
= 0.03). No difference for ether 
ACE or ACTN3 in soccer group. 
(Massidda et 
al., 2012) 
Swimming (n = 44 
M: n = 25), 
volleyball (n = 16 
M), handball (n = 
29 F), long distance 
runners (n = 42 M: n 
= 19 F) 
125 athletes 
(102 M & 
73 F; all 
elite) and 
169 
controls (88 
M & 83F) 
 
Greek  
ACE I/D rs1799752, 
LEP G–2548A 
rs7799039, AGTR1 
 A1166C UTR 
rs12721276, 
 BDKRB2  
rs72348790 
HW; NS 
 
Sig test; 
Fisher's 
exact test 
 
MC; NS 
 
EE; NS 
Higher DD in F athletes than F 
controls (P = 0.034), with ID 
higher in all controls (P = 0.027). 
Higher I allele in F athletes (P = 
0.034). F athlete had greater DD 
genotype and the BDKRB2 +9/−9 
and LEP GA was more prevalent 
(P = 0.001, P = 0.021) then 
controls. BDKRB2 +9/+9 
genotype in F (P = 0.042) was 
greater than controls. Allele 
combinations of IG+9A and 
IG−9A (P = 0.017, P = 0.004) 
were significant compared to 
controls. 
(Sgourou et 
al., 2012) 
Power group, 
endurance group – 
800 m running, 400 
m swimming, 
hockey, Mixed 
group - Basketball, 
tennis, volleyball 
147 athletes 
(106 M & 
41 F; 69 
elite) and 
131 
controls 
 
Indian 
ACE I/D HW; NS 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
ACE I allele was higher in all 
athletes compared to controls (P = 
0.05). No difference between 
power and endurance athletes. 
(Kothari et al., 
2012) 
Endurance group (n 
= 77), power group 
(n = 51), mixed 
group (n = 65) – 
tennis (n = 3), 
handball (n = 14), 
boxing (n = 6), 
193 athletes 
(152 M 
&41 F; 43 
elite; 52 
sub-elite) 
and 250 
(167 M & 
ACE I/D rs1799752, 
ACTN3 rs1815739, 
PPARGC1A 
rs8192678, PPARA 
rs4253778 
HW; ACE 
I/D – yes 
athletes, no 
controls. 
ACTN3 – 
yes controls 
no athletes, 
PPARGC1A 
ACE II genotype individuals had 
greater short-term peak power 
(W) compared to DD in endurance 
and power group (P = 0.026). No 
difference in ACE frequency 
among athletes and controls. For 
ACTN3, elite athletes (Greater R 
allele) differed in genotype 
(Ginevičienė 
et al., 2011) 
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wrestling (n = 10), 
soccer (n = 32)   
63 F) 
controls 
 
Lithuanian  
& PPARA – 
yes form 
both. 
 
Sig test; χ2, 
ANOVA, 
ANCOVA 
 
MC; NS 
 
EE; NS 
frequency from sub-elite (P = 
0.04). PPARA C allele was more 
frequent in athletes than controls 
(P = 0.046). No difference 
between sporting disciplines. 
Apparatus 
gymnastics (n = 13), 
sprint (n = 9), speed 
skating (n = 8), 
weight lifting (n = 
27), throwing (n = 
20), badminton (n = 
7), table tennis(n = 
8), taekwondo (n = 
11), field hockey (n 
= 33), handball (n = 
15) 
151 elite 
athletes (88 
M & 63 F) 
and 183 
controls (95 
M & 88 F) 
 
Korean 
ACE I/D HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; 
Fisher's 
exact test, 
ANOVA 
 
MC; NS 
 
EE; OR 
No significant differences. (Kim et al., 
2011) 
Sprint and strength 
athletes (n = 35), 
endurance athletes (n 
= 50), mixed group 
(n = 71) – field 
hockey, tennis, 
rugby, soccer, 
volleyball, 
basketball, 
handball, boxing, 
kickboxing, 
canoeing 
156 non-
elite (119 
M & 37 F) 
and 83 
controls (35 
M & 48 F) 
 
Polish 
ACE I/D HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; 
ANOVA, t 
tests 
 
MC; NS 
 
EE; NS 
No significant differences for 
genetic markers or VO2max. 
(Holdys et al., 
2011) 
Long distance 
running (n = 21), 
middle distance 
running (n = 29), 
sprinting (n = 12), 
triathlon (n = 19), 
race walking (n = 7), 
badminton (n = 3), 
orienteering (n = 7), 
indoor soccer (n = 
3), field hockey (n = 
16), claiming (n = 4), 
fencing (n = 22), 
rhythmic gymnastics 
(n = 11), golf (n = 2), 
goalball (n = 3), 
riflery (n = 4), 
swimming (n = 16), 
waterpolo (n = 2), 
field events (n = 15), 
track events (n = 5), 
figure skating (n = 
1), archery (n = 4), 
athletics (n = 7), 
boxing (n = 7), 
cycling (n = 14), 
canoeing (n = 4), 
wrestling (n = 6), 
artistic gymnastics (n 
= 12), weight lifting 
(n = 2), judo (n = 
30), karate (n = 13), 
taekwondo (n = 1) 
299 elite 
athletes 
(193 M & 
106 F) 
 
 
Spanish  
ACE I/D rs4646994  HW; No 
whole group 
 
Sig test; χ2, 
ANOVA 
 
MC; 
Bonferroni 
 
EE; NS 
No differences in genetic markers 
for any sporting disciplines and 
cardiovascular function. DD was 
higher in power sports, ID was 
higher in endurance group (P = 
0.049). 
(Boraita et al., 
2010) 
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Endurance group (n 
= 681), strength/ 
power group (n = 
372), mixed group (n 
= 484) – all-round 
skating (n = 68), 
alpine skiing (n = 
13), artistic 
gymnastics (n = 54), 
basketball (n = 33), 
boxing (n = 36), 
diving (n = 9), ice 
hockey (n = 16), 
mountain biking (n = 
10), modern 
pentathlon (n = 19), 
shooting (n = 44), 
ski jumping (n = 14), 
soccer (n = 42), 
tennis (n = 29), 
wrestling (n = 97) 
1537 
athletes 
(1085 M & 
452 F) and 
1113 (526 
M & 587 F) 
 
Russian 
TFAM (Ser/Thr) HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2, 
Fisher’s 
exact 
 
MC; NS 
 
EE; NS 
TFAM 12Thr allele frequency was 
higher in all athletes than control 
(P = 0.0015). In M masters 
athletes, Wmax was higher in the 
12Thr allele carriers as compared 
to Ser/Ser (P = 0.01). No 
differences for any team sport 
athlete groups. 
(Ahmetov et 
al., 2010) 
Endurance group (n 
= 64), speed power 
(n = 47) and mixed 
(n = 33), team (n = 
49) – tennis (n = 3), 
soccer (n = 32), 
handball (n = 14) 
193 elite 
athletes 
(153 M & 
41 F) and 
250 (167 M 
& 83 F) 
controls 
 
Lithuanian 
ACE I/D rs1799752, 
ACTN3 rs1815739, 
PPARGC1A 
rs8192678, PPARA 
rs4253778 
HW; ACE 
I/D – yes 
athletes, no 
controls. 
ACTN3 – 
yes controls 
no athletes. 
PPARGC1A 
& PPARA – 
yes form 
both. 
 
Sig test; χ2, 
ANOVA 
 
MC; NS 
 
EE; OR 
ACE DD - higher frequency in 
endurance-orientated athletes 
compared to speed/power-
orientated. ACTN3 - M athletes 
showed greater R allele than M 
controls (P = 0.03). No difference 
for PPARA or PPARG C1A. M 
athletes with ACE II genotype had 
higher MM and AAMP compared 
to the DD athletes. Power 
orientated ACE DD genotype 
athletes had significantly higher 
AAMP than ACE II athletes than 
endurance and mixed groups. M 
athletes with PPARA CC, PPARG 
C1A Gly482Gly and ACTN3 RR 
were associated with increased 
SMCP. M athletes with PPARA 
CC and PPARG C1A Gly482Ser 
had the greatest MM. PPARG 
C1A Gly482Gly was more 
frequent in endurance and mixed 
Athletes than others (P = 0.049). 
(Ginevičienė 
et al., 2010) 
Fencing (n = 5), 
endurance (n = 5), 
basketball (n = 5) 
15 athletes 
– non-elite 
 
Egyptian 
ACE I/D HW; NS 
 
Sig test; 
Kruskal 
Wallis Test, 
Spearman's 
correlation 
 
MC; NS 
 
EE; NS 
Increased ACE protein level in DD 
(fencing and basketball) and 
elevated cardiac parameters 
compared to endurance athletes (P 
< 0.05). ACE II and ID were more 
frequent in endurance athletes. 
(Heshmat et 
al., 2010) 
Endurance group (n 
= 71), strength/ 
speed group (n = 59) 
and team sport 
group (n = 431) – 
tennis (n = 3), 
handball (n = 14), 
field hockey (n = 
21), football (n = 
393) 
561 athletes 
(all elite) 
and 174 
controls 
 
Lithuanian 
ACE I/D  HW; ACE 
I/D – yes 
athletes, no 
controls 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
Lower D allele in athletes 
compared to controls (P = 0.004). 
No difference between team sport 
athletes and controls (P = 0.24). 
No difference between football 
playing positions (P > 0.03). 
(Ginevičienė 
et al., 2009) 
Endurance group (n 
= 694), power group 
(n = 481), mixed 
group (n = 248) – 
basketball (n = 33), 
1423 (998 
M & 425 F; 
235 elite) 
athletes and 
1132 
PPARA rs4253778, 
PPARD rs2016520, 
PPARGC1A 
rs8192678, PPP3R1 
promoter 5I/5D, 
HW; Yes – 
all athlete 
groups and 
controls. 
 
UCP2 55Val, UCP3 T, VEGFA 
rs2010963 C, NFATC4 Gly160, 
PPARGC1B 203Pro and TFAM 
12Thr were all overrepresented in 
endurance group (P < 0.05). 
(Ahmetov et 
al., 2009a) 
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boxing (n = 30), ice 
hockey (n = 17), 
soccer (n = 42), 
tennis (n = 29), 
wrestling (n = 96) 
controls 
(537 M & 
595 F) 
 
Russian  
UCP2 rs660339, 
UCP3 rs1800849, 
VEGFA rs2010963, 
ACE Alu I/D, 
AMPD1 rs17602729, 
HIF1A rs11549465, 
NFATC4 
rs2229309, PPARG 
rs1801282, 
PPARGC1B 
rs7732671, TFAM 
rs1937 and VEGFA 
rs699947 
Sig test; χ2, 
Spearman's 
correlation, t 
tests 
 
MC; NS 
 
EE; NS 
Endurance group (n 
= 182), sprint group 
(n = 48), strength 
group (n = 69) and 
mixed group (n = 
172) – basketball (n 
= 28), boxing (n = 
15), tennis (n = 15), 
ice hockey (n = 13), 
soccer (n = 5), 
swimming 200-
400m (n = 5), 
wrestling (n = 36) 
471 (323 M 
& 148 F; 52 
elite) 
athletes and 
602 
controls 
(202  M & 
401 F) 
 
Russian 
VEGFR2 His472Gln 
rs1870377 
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2, 
t tests 
 
MC; NS 
 
EE; NS 
Athletes had a higher frequency of 
472Gln then controls (P = 0.0032) 
Endurance and sprint groups had 
higher frequency then controls (P 
= 0.0006, P = 0.007). The Gln 
allele showed a higher proportion 
of slow twitch muscle fibres in 
controls and athletes (P = 0.037,  P 
= 0.01). 
(Ahmetov et 
al., 2009b) 
Power-orientated 
athletes (n = 486) – 
alpine skiing (n = 
29), artistic 
gymnastics (n = 44), 
bodybuilding (n = 
23), figure skating (n 
= 10), ice hockey  (n 
= 34), jumping 
events (n = 8), 
powerlifting (n = 9), 
running 100-400m (n 
= 70), ski jumping (n 
= 18), soccer (n = 
4), speed skating (n 
= 19), swimming 50-
100m (n = 10), 
throwing events (n = 
15), volleyball (n = 
9), weightlifting (n = 
55), wrestling (n = 
58) 
486 athletes 
(363 M & 
123 F; 100 
elite) and 
1197 
controls 
(524 M & 
673 F) 
 
Russian 
ACTN3 R577X HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
The X allele and XX genotype 
was lower in athletes compared to 
controls (P = 0.0004, P = 0.001). 
(Druzhevskaya 
et al., 2008) 
Endurance group(s) 
(n = 609), 
sprint/power 
group(s) (n = 258), 
mixed (n = 289) – 
basketball (n = 20), 
boxing (n = 22), 
wrestling (n = 82), 
volleyball (n = 6), 
speed skating (n = 
62), mountain biking 
(n =   10), table 
tennis (n = 4), 
pentathlon (n = 17), 
shooting (n = 24), 
tennis (n = 15), 
soccer (n = 10), 
fencing (n = 5), ice 
hockey (n = 12)  
1256 
athletes 
(883 M & 
373 F; 386 
elite) and 
610 
controls 
(387 M & 
223 F) 
 
Russian 
PPARD 294 C/T 
rs4253778 
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2, 
fisher’s 
exact 
 
MC; NS 
 
EE; NS 
The C allele was higher in the 
athlete group (P = 0.0001). 
(Ahmetov et 
al., 2007) 
Basketball (n = 15), 
soccer (n = 41), 
baseball (n = 31), 
139 athletes 
(all M) – all 
elite and 
ACE I/D HW; NS  
 
No difference in any physiological 
measures. No difference between 
athletes and controls. 
(Oh, 2007) 
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gymnastics (n = 12), 
volleyball (n = 7), 
ice hockey (n = 17), 
judo (n = 8), 
marathon (n = 8) 
163 
controls (all 
M) 
 
Korean 
Sig test; χ2, 
ANOVA 
 
MC; NS 
 
EE; NS 
Endurance group (n 
= 491), power group 
(n = 180), Mixed 
group (n = 155) – 
boxing (n = 22), ice 
hockey (n = 15), 
wrestling (n = 63), 
tennis (n = 15)  
786 athletes 
(571 M & 
215 F; 61 
elite) and 
1242 
controls 
(559 M & 
683 F) 
 
Russian 
PPARA G/C 
rs4253778 
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; χ2, 
Spearman's 
correlation 
 
MC; NS 
 
EE; NS 
An increasing linear trend of C 
allele with increasing anaerobic 
component of physical 
performance (P = 0.029). Ice 
hockey athletes had greater CC 
frequency compared to controls (P 
= 0.032). 
(Ahmetov et 
al., 2006) 
Dancers (n = 85), 
endurance athletes (n 
= 32 F & 4 M), ball 
game sports 
(basketball & 
volleyball; n = 24 F 
& 15 M), sailing & 
fencing (n = 8 F & 1 
M), martial arts (n = 
5 F & 2 M)  
91 athletes 
– non-elite 
and 872 
controls 
 
Israeli 
SLC6A4: (promoter 
region HTTLPR and 
intron 2 VNTR), 
Arginine vasopressin 
receptor 1a 
(AVPR1a: promoter 
microsatellites RS1 
and RS3) 
HW; Yes – 
all athlete 
groups and 
controls 
 
Sig test; NS 
 
MC; NS 
 
EE; 
likelihood 
ratio 
AVPR1a haplotype frequencies 
(RS1 and RS3) and SLC6A4 
(HTTLPR and VNTR), were 
observed between dancers and 
athletes (P = 0.000044). 
(Bachner-
Melman et al., 
2005) 
Middle distance 
runners (n = 17), 
basketball (n = 10), 
handball (n = 18), 
soccer (n = 35) 
80 athletes 
–non-elite 
and 80 
controls (39 
M & 41 F) 
 
Turkish  
ACE I/D HW; NS 
 
Sig test; χ2 
 
MC; NS 
 
EE; NS 
Athletes show greater I allele 
frequency than controls (P = 
0.026). 
(Turgut et al., 
2004) 
Basketball (n = 15), 
soccer (n = 25), 
baseball (n = 32), 
gymnastics (n = 12), 
volleyball (n = 18), 
runner (n = 4), judo 
(n = 9), marathon (n 
= 5) 
120 athletes 
(all M)  
 
Korean 
Haptoglobin (Hp) HW; Yes  
 
Sig test; χ2, 
 
MC; 
Scheffe’s 
multiple 
comparison 
 
EE; NS 
Hp1-1 homozygotes had higher 
VO2max than Hp2-2 (P = 0.008). 
(Kang et al., 
2003) 
Swimmers (n = 48), 
weight bearing 
sports (n = 84) – 
volleyball, 
basketball, 
handball, high jump  
132 athletes 
(all M) and 
80 controls 
 
Japanese 
VDR (RFLP) HW; NS 
 
Sig test; 
ANOVA 
 
MC; NS 
 
EE; NS 
Weight bearing athletes with the 
FF genotype had greater bone 
mineral density then matched 
controls (P < 0.01).  
(Nakamura et 
al., 2002b) 
Weight bearing 
sports (n = 44) – 
volleyball, 
basketball, 
handball, high 
jump, triple jump 
44 athletes 
(all M) and 
44 controls 
 
Japanese 
VDR (RFLP) HW; NS 
 
Sig test; 
Students t 
test, 
ANOVA 
 
MC; NS 
 
EE; NS 
FF genotype had greater bone 
mineral density compared to 
controls (P < 0.01). 
(Nakamura et 
al., 2002a) 
Hockey (n = 26), 
cycling (n =  25), 
skiing (n = 21), track 
and field (n = 15), 
swimming (n = 13), 
120 athletes 
(81 M and 
39 F) and 
685 
controls 
ACE I/D HW; NS 
 
Sig test; NS 
 
MC; NS 
No difference between groups. (Taylor et al., 
1999) 
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rowing (n = 7), 
gymnastics (n = 5), 
other (n = 8) 
(347 M and 
338 F) 
 
Australian  
 
EE; OR 
If information is absent from cells within the table, this is because it was not evident from the article. 
Abbreviations; M, male; F, female; HW, Hardy-Weinberg equilibrium; Sig test, significance test; 
MC, multiple test correction; EE, effect estimate; OR, odds ratio; NS, not stated; AAMP, anaerobic 
alactic muscular power; SMCP, single muscular contraction power; MM, muscle mass; ECC, 
eccentric; CK, creatine kinase; BMI, body mass index; FM, fat mass; ACL, anterior cruciate ligament. 
.
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Appendix 6: UK and SA participant genotype frequencies 
 
Table 2UK and SA participant genotype frequencies. 
Gene variant Genotype frequency 
 UK participants SA participants 
ACE I/D – II,ID,DD 21.0,49.5, 29.5 22.1, 47.6, 30.3 
ACTN3 – RR,RX,XX 19.0, 47.5, 33.5 18.5, 50.1, 31.4 
FTO – AA,AT,TT 16.4, 49.5, 34.1 17.4, 47.8, 34.8 
APOE ε4 - +ε4, -ε4 29.2, 70.8 31.1, 68.9 
COL5A1  
rs12722 – TT,TC,CC 
rs3196378 – AA,AC,CC 
 
27.0, 54.3, 18.7 
27.3, 50.2, 22.5 
 
26.4, 55.3, 18.3 
27.1, 49.6, 23.3 
Chi2 showed no difference in genotypic frequency between UK and SA participants (P > 0.05).
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Appendix 7: FTO SNP/IRX3 plausible pathway 
 
 
 
 
 
 
Figure 1 FTO SNP/IRX3 plausible pathway 
222 | P a g e  
 
 
 
 
 
 
Thesis references 
 
 
 
 
 
223 | P a g e  
 
References 
1000 Genomes Consortium (2012). An integrated map of genetic variation from 
1,092 human genomes. Nature, 491(7422), 56-65. 
Abdelkrim NB, Chaouachi A, Chamari K, Chtara M & Castagna C (2010). Positional 
role and competitive-level differences in elite-level men's basketball players. 
The Journal of Strength & Conditioning Research 24(5), 1346-1355. 
Abrahams Y, Laguette MJ, Prince S & Collins M (2013). Polymorphisms within the 
COL5A1 3′‐UTR That Alters mRNA Structure and the MIR608 Gene are 
Associated with Achilles Tendinopathy. Annals of Human Genetics, 77(3), 
204-214. 
Ahmetov, II, Kulemin NA, Popov DV, Naumov VA, Akimov EB, Bravy YR, Egorova ES, 
Galeeva AA, Generozov EV, Kostryukova ES, Larin AK, Mustafina LJ, Ospanova 
EA, Pavlenko AV, Starnes LM, Żmijewski P, Alexeev DG, Vinogradova OL & 
Govorun VM (2015). Genome-wide association study identifies three novel 
genetic markers associated with elite endurance performance. Biology of 
Sport, 32(1), 3-9. 
Ahmetov, II, Popov DV, Missina SS, Vinogradova OL & Rogozkin VA (2010). 
Association of the mitochondrial transcription factor (TFAM) gene 
polymorphism with physical performance of athletes. Fiziologiia Cheloveka's 
36(2), 121-125. 
Ahmetov, II, Williams AG, Popov DV, Lyubaeva EV, Hakimullina AM, Fedotovskaya 
ON, Mozhayskaya IA, Vinogradova OL, Astratenkova IV, Montgomery HE & 
Rogozkin VA (2009a). The combined impact of metabolic gene 
polymorphisms on elite endurance athlete status and related phenotypes. 
Human Genetics, 126(6), 751-761. 
Ahmetov I, Astratenkova I & Rogozkin V (2007). Association of a PPARD 
polymorphism with human physical performance. Molecular Biology, 41(5), 
776-780. 
Ahmetov I, Donnikov A & Trofimov D (2014a). ACTN3 genotype is associated with 
testosterone levels of athletes. Biology of Sport, 31(2), 105-108. 
Ahmetov I, Naumov V, Donnikov A, Maciejewska-Karłowska A, Kostryukova E, Larin 
A, Maykova E, Alexeev D, Fedotovskaya O & Generozov E (2014b). SOD2 
gene polymorphism and muscle damage markers in elite athletes. Free 
Radical Research, 48(8), 948-955. 
Ahmetov II, Druzhevskaya AM, Lyubaeva EV, Popov DV, Vinogradova OL & Williams 
AG (2011). The dependence of preferred competitive racing distance on 
muscle fibre type composition and ACTN3 genotype in speed skaters. 
Experimental Physiology, 96(12), 1302-1310. 
Ahmetov II, Egorova E, Gabdrakhmanova L & Fedotovskaya O (2016). Genes and 
Athletic Performance: An Update. In Genetics and Sports, 2nd edn, ed. 
Posthumus M & Coollins M, pp. 41-54. Karger Publishers. 
Ahmetov II, Egorova ES & Mustafina LJ (2013). The PPARA gene polymorphism in 
team sports athletes. Central European Journal of Sport Sciences and 
Medicine, 1(1), 19-24. 
224 | P a g e  
 
Ahmetov II & Fedotovskaya ON (2012). Sports genomics: Current state of 
knowledge and future directions. Cellular and Molecular Exercise Physiology, 
1(1), e1. 
Ahmetov II, Hakimullina AM, Popov DV, Lyubaeva EV, Missina SS, Vinogradova OL, 
Williams AG & Rogozkin VA (2009b). Association of the VEGFR2 gene 
His472Gln polymorphism with endurance-related phenotypes. European 
Journal of Applied Physiology, 107(1), 95-103. 
Ahmetov II, Mozhayskaya IA, Flavell DM, Astratenkova IV, Komkova AI, Lyubaeva EV, 
Tarakin PP, Shenkman BS, Vdovina AB & Netreba AI (2006). PPARα gene 
variation and physical performance in Russian athletes. European Journal of 
Applied Physiology, 97(1), 103-108. 
Alfred T, Ben‐Shlomo Y, Cooper R, Hardy R, Cooper C, Deary IJ, Gunnell D, Harris SE, 
Kumari M & Martin RM (2011). ACTN3 genotype, athletic status, and life 
course physical capability: meta‐analysis of the published literature and 
findings from nine studies. Human Mutation, 32(9), 1008-1018. 
Almeida S, Barros C, Moraes M, Russo F, Haro A, Rosa T, Alves M, Pesquero J, 
Carmona A & Bacurau R (2010). Plasma Kallikrein and Angiotensin I-
converting enzyme N-and C-terminal domain activities are modulated by the 
insertion/deletion polymorphism. Neuropeptides, 44(2), 139-143. 
Altinisik J, Meric G, Erduran M, Ates O, Ulusal AE & Akseki D (2015). The BstUI and 
DpnII variants of the COL5A1 Gene are associated with Tennis Elbow. The 
American Journal of Sports Medicine, 43(7), 1784-1789. 
Alvarez R, Terrados N, Ortolano R, Iglesias-Cubero G, Reguero JR, Batalla A, Cortina 
A, Fernández-García B, Rodríguez C & Braga S (2000). Genetic variation in the 
renin-angiotensin system and athletic performance. European Journal of 
Applied Physiology, 82(1), 117-120. 
Amir O, Amir R, Yamin C, Attias E, Eynon N, Sagiv M, Sagiv M & Meckel Y (2007). The 
ACE deletion allele is associated with Israeli elite endurance athletes. 
Experimental Physiology, 92(5), 881-886. 
Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L, 
Andersen G, Nielsen AL, Albrechtsen A, Borch-Johnsen K & Rasmussen SS 
(2008). Low physical activity accentuates the effect of the FTO rs9939609 
polymorphism on body fat accumulation. Diabetes, 57(1), 95-101. 
Appleby B, Newton RU & Cormie P (2012). Changes in strength over a 2-year period 
in professional rugby union players. The Journal of Strength & Conditioning 
Research, 26(9), 2538-2546. 
Austin D, Gabbett T & Jenkins D (2011a). The physical demands of Super 14 rugby 
union. Journal of Science and Medicine in Sport, 14(3), 259-263. 
Austin D, Gabbett T & Jenkins D (2011b). Repeated high-intensity exercise in 
professional rugby union. Journal of Sports Sciences, 29(10), 1105-1112. 
Austin SR, Dialsingh I & Altman N (2014). Multiple Hypothesis Testing: A review. J 
Indian Soc Agricultural Stat, 68, 303-314. 
Bachner-Melman R, Dina C, Zohar AH, Constantini N, Lerer E, Hoch S, Sella S, 
Nemanov L, Gritsenko I & Lichtenberg P (2005). AVPR1a and SLC6A4 gene 
polymorphisms are associated with creative dance performance. PLoS 
Genetics, 1(3), e42. 
225 | P a g e  
 
Barr MJ, Sheppard JM, Gabbett TJ & Newton RU (2014). Long-term training-induced 
changes in sprinting speed and sprint momentum in elite rugby union 
players. The Journal of Strength & Conditioning Research, 28(10), 2724-2731. 
Beggs AH, Byers TJ, Knoll J, Boyce FM, Bruns G & Kunkel LM (1992). Cloning and 
characterization of two human skeletal muscle alpha-actinin genes located 
on chromosomes 1 and 11. Journal of Biological Chemistry, 267(13), 9281-
9288. 
Beighton P, Paepe AD, Steinmann B, Tsipouras P & Wenstrup RJ (1998). Ehlers-
Danlos syndromes: revised nosology, Villefranche, 1997. American Journal of 
Medical Genetics, 77(1), 31-37. 
Bell RD, Shultz SJ, Wideman L & Henrich VC (2012a). Collagen gene variants 
previously associated with anterior cruciate ligament injury risk are also 
associated with joint laxity. Sports Health: A Multidisciplinary Approach, 4(4), 
312-318. 
Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, 
Armulik A & Sallstrom J (2012b). Apolipoprotein E controls cerebrovascular 
integrity via cyclophilin A. Nature, 485(7399), 512-516. 
Bell W, Colley J, Evans W, Darlington S & Cooper S-M (2012c). ACTN3 genotypes of 
Rugby Union players: distribution, power output and body composition. 
Annals of Human Biology, 39(1), 19-27. 
Bell W, Colley J, Gwynne J, Glazier P, Evans WD & Darlington SE (2010). ACE ID 
genotype and leg power in Rugby Union players. Journal of Sports Medicine 
and Physical Fitness, 50(3), 350. 
Bell W, Colley J, Gwynne J, Llewellyn L, Darlington S & Evans W (2009). 
Polymorphisms of the angiotensin-converting enzyme (ACE/ID) and their 
distribution in developing young adult Rugby Union players. In Contemporary 
Sport, Leisure and Ergonomics, ed. Reilly T & Atkinson G, pp. 161. Routledge, 
NY. 
Bellefroid EJ, Kobbe A, Gruss P, Pieler T, Gurdon JB & Papalopulu N (1998). Xiro3 
encodes a Xenopus homolog of the Drosophila Iroquois genes and functions 
in neural specification. The EMBO Journal, 17(1), 191-203. 
Ben‐Zaken S, Meckel Y, Nemet D & Eliakim A (2015). Genetic score of power‐speed 
and endurance track and field athletes. Scandinavian Journal of Medicine & 
Science in Sports, 25(2), 166-174. 
Benjamini Y & Hochberg Y (1995). Controlling the false discovery rate: a practical 
and powerful approach to multiple testing. Journal of the Royal Statistical 
Society Series B (Methodological), 57(1), 289-300. 
Benjamini Y & Yekutieli D (2001). The control of the false discovery rate in multiple 
testing under dependency. Annals of Statistics, 1165-1188. 
Bennett ER, Reuter-Rice K & Laskowitz DT (2016). Genetic Influences in Traumatic 
Brain Injury. In Translational Research in Traumatic Brain Injury, ed. Laskovwi 
D & Grant G. Taylor and Francis, Boca Raton , FL. 
Bennett RE, Esparza TJ, Lewis HA, Kim E, Mac Donald CL, Sullivan PM & Brody DL 
(2013). Human Apolipoprotein E4 Worsens Acute Axonal Pathology but Not 
Amyloid-β Immunoreactivity After Traumatic Brain Injury in 3× TG-AD Mice. 
Journal of Neuropathology & Experimental Neurology, 72(5), 396-403. 
226 | P a g e  
 
Berk BC, Vekshtein V, Gordon HM & Tsuda T (1989). Angiotensin II-stimulated 
protein synthesis in cultured vascular smooth muscle cells. Hypertension, 
13(4), 305-314. 
Berman Y & North KN (2010). A gene for speed: the emerging role of α-actinin-3 in 
muscle metabolism. Physiology, 25(4), 250-259. 
Bertuzzi R, Pasqua LA, Bueno S, Lima-Silva AE, Matsuda M, Marquezini M & Saldiva 
PH (2014). Is the COL5A1 rs12722 gene polymorphism associated with 
running economy? PloS One, 9(9), e106581. 
Birk DE, Fitch J, Babiarz J, Doane K & Linsenmayer T (1990). Collagen fibrillogenesis 
in vitro: interaction of types I and V collagen regulates fibril diameter. Journal 
of Cell Science, 95(4), 649-657. 
Blanchard A, Ohanian V & Critchley D (1989). The structure and function of α-
actinin. Journal of Muscle Research and Cell Motility, 10(4), 280-289. 
Bonferroni CE (1936). Teoria Statistica delle Classi e Calcolo delle Probabilit. 
Pubblicazioni del R Istituto Superiore di Scienze Economiche e Commerciali di 
Firenze, 8, 3-62. 
Boraita A, de la Rosa A, Heras ME, de la Torre AI, Canda A, Rabadan M, Diaz AE, 
Gonzalez C, Lopez M & Hernandez M (2010). Cardiovascular adaptation, 
functional capacity and Angiotensin-converting enzyme I/D polymorphism in 
elite athletes. Revista Esoanola De Cardiologia, 63(7), 810-819. 
Bottinelli R, Canepari M, Pellegrino M & Reggiani C (1996). Force‐velocity properties 
of human skeletal muscle fibres: myosin heavy chain isoform and 
temperature dependence. The Journal of Physiology, 495(2), 573-586. 
Bouchard C (2015). Exercise genomics—a paradigm shift is needed: a commentary. 
British Journal of Sports Medicine, bjsports-2015-095294. 
Bouchard C, An P, Rice T, Skinner JS, Wilmore JH, Gagnon J, Pérusse L, Leon AS & 
Rao D (1999). Familial aggregation of V˙o2max response to exercise training: 
results from the HERITAGE Family Study. Journal of Applied Physiology, 87(3), 
1003-1008. 
Bouchard C, Boulay MR, Simoneau J-A, Lortie G & Pérusse L (1988). Heredity and 
Trainability of Aerobic and Anaerobic Performances an Update. Sports 
Medicine, 5(2), 69-73. 
Bouchard C & Perusse L (1988). Heredity and body fat. Annual Review of Nutrition, 
8(1), 259-277. 
Bouchard C, Sarzynski MA, Rice TK, Kraus WE, Church TS, Sung YJ, Rao D & Rankinen 
T (2011). Genomic predictors of the maximal O2 uptake response to 
standardized exercise training programs. Journal of Applied Physiology, 
110(5), 1160-1170. 
Bouchard C, Simoneau J, Lortie G, Boulay M, Marcotte M & Thibault M (1986). 
Genetic effects in human skeletal muscle fiber type distribution and enzyme 
activities. Canadian Journal of Physiology and Pharmacology, 64(9), 1245-
1251. 
Bradley PS, Carling C, Diaz AG, Hood P, Barnes C, Ade J, Boddy M, Krustrup P & 
Mohr M (2013). Match performance and physical capacity of players in the 
top three competitive standards of English professional soccer. Human 
Movement Science, 32(4), 808-821. 
227 | P a g e  
 
Bradley WJ, Cavanagh BP, Douglas W, Donovan TF, Morton JP & Close GL (2015). 
Quantification of training load, energy intake, and physiological adaptations 
during a rugby preseason: A case study from an elite eropean rugby union 
squad. The Journal of Strength & Conditioning Research, 29(2), 534-544. 
Brooks JH & Kemp S (2011). Injury-prevention priorities according to playing 
position in professional rugby union players. British Journal of Sports 
Medicine, 45(10), 765-775. 
Brooks JH & Kemp SP (2008). Recent trends in rugby union injuries. Clinics in Sports 
Medicine, 27(1), 51-73. 
Broos S, Malisoux L, Theisen D, Francaux M, Deldicque L & Thomis MA (2012). Role 
of alpha-actinin-3 in contractile properties of human single muscle fibers: a 
case series study in paraplegics. PloS One, 7(11), e49281. 
Broos S, Malisoux L, Theisen D, Van Thienen R, Ramaekers M, Jamart C, Deldicque L, 
Thomis MA & Francaux M (2016). Evidence for ACTN3 as a speed gene in 
isolated human muscle fibers. PloS One, 11(3), e0150594. 
Busjahn CA, Schulz-Menger J, Abdel-Aty H, Rudolph A, Jordan J, Luft FC & Busjahn A 
(2009). Heritability of left ventricular and papillary muscle heart size: a twin 
study with cardiac magnetic resonance imaging. European Heart Journal, 
30(13), 1643-1647. 
Cahill N, Lamb K, Worsfold P, Headey R & Murray S (2013). The movement 
characteristics of English Premiership rugby union players. Journal of Sports 
Sciences, 31(3), 229-237. 
Calderwood C, Murray AD & Stewart W (2015). Turning people into couch potatoes 
is not the cure for sports concussion. British Journal of Sports Medicine, 0, 1-
2. 
Calvo M, Rodas G, Vallejo M, Estruch A, Arcas A, Javierre C, Viscor G & Ventura J 
(2002). Heritability of explosive power and anaerobic capacity in humans. 
European Journal of Applied Physiology, 86(3), 218-225. 
Cappa F, Caridi G, Gimelli G & Ghiggeri GM (1995). A new biallelic DNA 
polymorphism of the human COL5A1 gene. Human Genetics, 95(5), 599-600. 
Chan S, Seto JT, Houweling PJ, Yang N, North KN & Head SI (2011). Properties of 
extensor digitorum longus muscle and skinned fibers from adult and aged 
male and female Actn3 knockout mice. Muscle Nerve, 43(1), 37-48. 
Chanut-Delalande H, Bonod-Bidaud C, Cogne S, Malbouyres M, Ramirez F, Fichard A 
& Ruggiero F (2004). Development of a functional skin matrix requires 
deposition of collagen V heterotrimers. Molecular and Cellular Biology, 
24(13), 6049-6057. 
Chavalarias D, Wallach JD, Li AHT & Ioannidis JP (2016). Evolution of reporting P 
values in the biomedical literature, 1990-2015. Journal of the American 
Medical Assocition, 315(11), 1141-1148. 
Chen H, Cohen P & Chen S (2010). How big is a big odds ratio? Interpreting the 
magnitudes of odds ratios in epidemiological studies. Comun Stats-Simulat 
Comp, 39(4), 860-864. 
Chen J-A, Huang Y-P, Mazzoni EO, Tan GC, Zavadil J & Wichterle H (2011). Mir-17-3p 
controls spinal neural progenitor patterning by regulating Olig2/Irx3 cross-
repressive loop. Neuron, 69(4), 721-735. 
228 | P a g e  
 
Chen L, Sun X, Jiang Y & Kuai L (2015). APOEε4 increases trauma induced early 
apoptosis via reducing delayed rectifier K+ currents in neuronal/glial co-
cultures model. Experimental Cell Research, 334(2), 294-300. 
Chiu L-L, Chen T-W, Hsieh SS & Hsieh L-L (2012). ACE I/D, ACTN3 R577X, PPARD 
T294C and PPARGC1A Gly482Ser polymorphisms and physical fitness in 
Taiwanese late adolescent girls. The Journal of Physiological Sciences, 62(2), 
115-121. 
Chtourou H, Chaouachi A, Hammouda O, Chamari K & Souissi N (2012). Listening to 
music affects diurnal variation in muscle power output. International Journal 
of Sports Medicine, 33(1), 43-47. 
Cieszczyk P, Krupecki K, Maciejewska A & Sawczuk M (2009). The angiotensin 
converting enzyme gene I/D polymorphism in Polish rowers. International 
Journal of Sports Medicine, 30(8), 624-627. 
Cieszczyk P, Maciejewska A, Sawczuk M, Ficek K, Eider J & Jascaniene N (2010). The 
angiotensin converting enzyme gene I/D polymorphism in ellite Polish and 
Lithuanian judo players. Biology of Sport, 27(2), 119. 
Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP & Zondervan KT 
(2011). Basic statistical analysis in genetic case-control studies. Nature 
Protocols, 6(2), 121-133. 
Coelho DB, Pimenta EM, Rosse IC, Carvalho MRS, Costa GG & Silami-Garcia E (2014). 
Comparison of the genotypes and allele frequencies of the ACTN3 of football 
players from different categories. R Bras Ci Mov, 22(4), 97-106. 
Collins M, Mokone G, September A, Van der Merwe L & Schwellnus M (2009). The 
COL5A1 genotype is associated with range of motion measurements. Scand J 
Med Sci Spor, 19(6), 803-810. 
Collins M, September AV & Posthumus M (2015). Biological variation in 
musculoskeletal injuries: current knowledge, future research and practical 
implications. British Journal of Sports Medicine, 49(23), 1497-1503. 
Corella D, Arnett DK, Tucker KL, Kabagambe EK, Tsai M, Parnell LD, Lai C-Q, Lee Y-C, 
Warodomwichit D & Hopkins PN (2011). A high intake of saturated fatty 
acids strengthens the association between the fat mass and obesity-
associated gene and BMI. The Journal of Nutrition, 141(12), 2219-2225. 
Crawford F, Vanderploeg R, Freeman M, Singh S, Waisman M, Michaels L, Abdullah 
L, Warden D, Lipsky R & Salazar A (2002). APOE genotype influences 
acquisition and recall following traumatic brain injury. Neurology, 58(7), 
1115-1118. 
Crewther B, Kilduff L, Cook C, Cunningham D, Bunce P, Bracken R & Gaviglio C 
(2012). Scaling strength and power for body mass differences in rugby union 
players. The Journal of Sports Medicine and Physical Fitness, 52(1), 27-32. 
Crewther BT, Lowe T, Weatherby RP, Gill N & Keogh J (2009). Neuromuscular 
performance of elite rugby union players and relationships with salivary 
hormones. The Journal of Strength & Conditioning Research, 23(7), 2046-
2053. 
Cross M, Kemp S, Smith A, Trewartha G & Stokes K (2015). Professional Rugby 
Union players have a 60% greater risk of time loss injury after concussion: a 
229 | P a g e  
 
2-season prospective study of clinical outcomes. British Journal of Sports 
Medicine, 0, 1-6. 
Cross MR, Brughelli M, Brown SR, Samozino P, Gill ND, Cronin JB & Morin J-B (2014). 
Mechanical properties of sprinting in elite rugby union and rugby league. 
International Journal of Sports Physiology & Performance, 10(6). 
Cunniffe B, Proctor W, Baker JS & Davies B (2009). An evaluation of the 
physiological demands of elite rugby union using global positioning system 
tracking software. The Journal of Strength & Conditioning Research, 23(4), 
1195-1203. 
Danser AJ, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA & 
Schunkert H (1995). Angiotensin-converting enzyme in the human heart 
effect of the deletion/insertion polymorphism. Circulation, 92(6), 1387-1388. 
De Moor MH, Spector TD, Cherkas LF, Falchi M, Hottenga JJ, Boomsma DI & De 
Geus EJ (2007). Genome-wide linkage scan for athlete status in 700 British 
female DZ twin pairs. Twin Research and Human Genetics, 10(06), 812-820. 
Decq P, Gault N, Blandeau M, Kerdraon T, Berkal M, ElHelou A, Dusfour B & Peyrin J-
C (2016). Long-term consequences of recurrent sports concussion. Acta 
Neurochirurgica, 158(2), 289-300. 
Deutsch M, Kearney G & Rehrer N (2007). Time–motion analysis of professional 
rugby union players during match-play. Journal of Sports Sciences, 25(4), 
461-472. 
Di Mauro M, Izzicupo P, Santarelli F, Falone S, Pennelli A, Amicarelli F, Calafiore AM, 
Di Baldassarre A & Gallina S (2010). ACE and AGTR1 polymorphisms and left 
ventricular hypertrophy in endurance athletes. Medicine and Science in 
Sports and Exercise, 42(5), 915-921. 
Dietze GJ & Henriksen EJ (2008). Angiotensin-converting enzyme in skeletal muscle: 
sentinel of blood pressure control and glucose homeostasis. Journal of Renin-
Angiotensin-Aldosterone System, 9(2), 75-88. 
Djarova T, Ramakoaba A, Basson A, Mugandani S, Grace J, Cloete J & Watson G 
(2011a). Angiotensin-converting enzyme genotypes relationship with blood 
pressure, C-reactive protein and selected physical tests in Zulu South African 
cricketers. African Journal of Biochemistry Research, 5(7), 197-205. 
Djarova T, Watson G, Basson A, Grace J, Cloete J & Ramakoaba A (2011b). ACTN3 
and TNF gene polymorphism association with C-reactive protein, uric acid, 
lactate and physical characteristics in young African cricket players. African 
Journal of Biochemistry Research, 5(1), 22-27. 
Drozdovska SB, Dosenko VE, Ahmetov II & Ilyin VN (2013). The association of gene 
polymorphisms with athlete status in Ukrainians. Biology of Sport, 30(3), 163-
167. 
Druzhevskaya AM, Ahmetov II, Astratenkova IV & Rogozkin VA (2008). Association 
of the ACTN3 R577X polymorphism with power athlete status in Russians. 
European Journal of Applied Physiology, 103(6), 631-634. 
Dudoit S & Van Der Laan MJ (2007). Multiple Testing Procedures with Applications 
to Genomics. Springer Science & Business Media, NY. 
Dzau VJ (1988a). Circulating versus local renin-angiotensin system in cardiovascular 
homeostasis. Circulation, 77(6), I3-14. 
230 | P a g e  
 
Dzau VJ (1988b). Tissue renin-angiotensin system: physiologic and pharmacologic 
implications. Circulation, 77(6), I1-I3. 
Egorova ES, Borisova AV, Mustafina LJ, Arkhipova AA, Gabbasov RT, Druzhevskaya 
AM, Astratenkova IV & Ahmetov II (2014). The polygenic profile of Russian 
football players. Journal of Sports Sciences, 32(13), 1286-1293. 
Eider J, Cieszczyk P, Ficek K, Leonska-Duniec A, Sawczuk M, Maciejewska-Karlowska 
A & Zarebska A (2013). The association between D allele of the ACE gene and 
power performance in Polish elite athletes. Science & Sports, 28(6), 325-330. 
Eider J, Ficek K, Kaczmarczyk M, Maciejewska-Karłowska A, Sawczuk M & Cięszczyk 
P (2014). Endothelial nitric oxide synthase g894t (rs1799983) gene 
polymorphism in polish athletes. Open Life Sciences, 9(3), 260-267. 
ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements in 
the human genome. Nature, 489(7414), 57-74. 
England Professional Rugby Injury Surveillance Project Steering Group (2016). 2014-
2015 Season report. In England Professional Rugby Injury Surveillance 
Project. Rugby Football Union, Twickenham, UK. 
England Rugby (2016). Positions guide, ed. Rugby Football Union. Rugby Football 
Union, http://www.englandrugby.com/. 
Erdös E & Skidgel R (1987). The angiotensin I converting enzyme. Nature, 56, 345-
348. 
Erskine R, Williams A, Jones D, Stewart C & Degens H (2014). The individual and 
combined influence of ACE and ACTN3 genotypes on muscle phenotypes 
before and after strength training. Scandinavian Journal of Medicine & 
Science in Sports, 24(4), 642-648. 
Eynon N, Alves AJ, Meckel Y, Yamin C, Ayalon M, Sagiv M & Sagiv M (2010). Is the 
interaction between HIF1A P582S and ACTN3 R577X determinant for 
power/sprint performance? Metabolism, 59(6), 861-865. 
Eynon N, Banting LK, Ruiz JR, Cieszczyk P, Dyatlov DA, Maciejewska-Karlowska A, 
Sawczuk M, Pushkarev VP, Kulikov LM & Pushkarev ED (2014). ACTN3 R577X 
polymorphism and team-sport performance: a study involving three 
European cohorts. Journal of Science and Medicine in Sport, 17(1), 102-106. 
Eynon N, Hanson ED, Lucia A, Houweling PJ, Garton F, North KN & Bishop DJ 
(2013a). Genes for elite power and sprint performance: ACTN3 leads the 
way. Sports Medicine, 43(9), 803-817. 
Eynon N, Meckel Y, Alves AJ, Nemet D & Eliakim A (2011a). Is there an interaction 
between BDKRB2− 9/+ 9 and GNB3 C825T polymorphisms and elite athletic 
performance? Scandinavian Journal of Medicine & Science in Sports, 21(6), 
e242-e246. 
Eynon N, Nasibulina ES, Banting LK, Cieszczyk P, Maciejewska-Karlowska A, Sawczuk 
M, Bondareva EA, Shagimardanova RR, Raz M & Sharon Y (2013b). The FTO 
A/T polymorphism and elite athletic performance: a study involving three 
groups of European athletes. PloS One, 8(4), e60570. 
Eynon N, Oliveira J, Meckel Y, Sagiv M, Yamin C, Sagiv M, Amir R & Duarte JA (2009). 
The guanine nucleotide binding protein β polypeptide 3 gene C825T 
polymorphism is associated with elite endurance athletes. Experimental 
Physiology, 94(3), 344-349. 
231 | P a g e  
 
Eynon N, Ruiz J, Yvert T, Santiago C, Gómez-Gallego F, Lucia A & Birk R (2012). The C 
allele in NOS3-786 T/C polymorphism is associated with elite soccer player's 
status. International Journal of Sports Medicine, 33(7), 521-524. 
Eynon N, Ruiz JR, Meckel Y, Morán M & Lucia A (2011b). Mitochondrial biogenesis 
related endurance genotype score and sports performance in athletes. 
Mitochondrion, 11(1), 64-69. 
Eynon N, Ruiz JR, Oliveira J, Duarte JA, Birk R & Lucia A (2011c). Genes and elite 
athletes: a roadmap for future research. The Journal of Physiology, 589(13), 
3063-3070. 
Fatini C, Guazzelli R, Manetti P, Battaglini B, Gensini F, Vono R, Toncelli L, Zilli P, 
Capalbo A & Abbate R (2000). RAS genes influence exercise-induced left 
ventricular hypertrophy: an elite athletes study. Medicine and Science in 
Sports and Exercise, 32(11), 1868-1872. 
Fedotovskaya ON, Mustafina LJ, Popov DV, Vinogradova OL & Ahmetov II (2014). A 
common polymorphism of the MCT1 gene and athletic performance. 
International Journal of Sports Physiology & Performance, 9(1), 173-180. 
Ficek K, Cieszczyk P, Kaczmarczyk M, Maciejewska-Karłowska A, Sawczuk M, 
Cholewinski J, Leonska-Duniec A, Stepien-Slodkowska M, Zarebska A & 
Stepto NK (2013). Gene variants within the COL1A1 gene are associated with 
reduced anterior cruciate ligament injury in professional soccer players. 
Journal of Science and Medicine in Sport, 16(5), 396-400. 
Ficek K, Stepien-Slodkowska M, Kaczmarczyk M, Maciejewska-Karlowska A, Sawczuk 
M, Cholewinski J, Leonska-Duniec A, Zarebska A, Cieszczyk P & Zmijewski P 
(2014). Does the A9285G Polymorphism in Collagen Type XII α1 gene 
associate with the risk of anterior cruciate ligament ruptures? Balkan Journal 
of Medical Genetics, 17(1), 41. 
Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H & Jones D (2000). 
Angiotensin-converting enzyme genotype affects the response of human 
skeletal muscle to functional overload. Experimental Physiology, 85(05), 575-
579. 
Foster B, Morse CI, Onambele-Pearson G, Ahmetov II & Williams AG (2012). Genetic 
variation, protein composition and potential influences on tendon properties 
in humans. Open Sports Med J, 6, 8-21. 
Foster BP, Morse CI, Onambele GL & Williams AG (2014). Human COL5A1 rs12722 
gene polymorphism and tendon properties in vivo in an asymptomatic 
population. European Journal of Applied Physiology, 114(7), 1393-1402. 
Fraas MR, Coughlan GF, Hart EC & McCarthy C (2014). Concussion history and 
reporting rates in elite Irish rugby union players. Physical Therapy in Sport, 
15(3), 136-142. 
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry 
JR, Elliott KS, Lango H & Rayner NW (2007). A common variant in the FTO 
gene is associated with body mass index and predisposes to childhood and 
adult obesity. Science, 316(5826), 889-894. 
Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, 
Boudreau A, Hardenbol P & Leal SM (2007). A second generation human 
haplotype map of over 3.1 million SNPs. Nature, 449(7164), 851-861. 
232 | P a g e  
 
Frederiksen H, Gaist D, Christian Petersen H, Hjelmborg J, McGue M, Vaupel JW & 
Christensen K (2002). Hand grip strength: A phenotype suitable for 
identifying genetic variants affecting mid‐and late‐life physical functioning. 
Genetic Epidemiology, 23(2), 110-122. 
Fuller C, Laborde F, Leather R & Molloy MG (2008). International rugby board rugby 
world cup 2007 injury surveillance study. British Journal of Sports Medicine, 
42(6), 452-459. 
Fuller CW, Molloy MG, Bagate C, Bahr R, Brooks JH, Donson H, Kemp SP, McCrory P, 
McIntosh AS & Meeuwisse WH (2007). Consensus statement on injury 
definitions and data collection procedures for studies of injuries in rugby 
union. British Journal of Sports Medicine, 41(5), 328-331. 
Fuller CW, Taylor A, Kemp SP & Raftery M (2016). Rugby World Cup 2015: World 
Rugby injury surveillance study. British Journal of Sports Medicine, In press. 
Fuller CW, Taylor A & Raftery M (2015a). Epidemiology of concussion in men's elite 
Rugby-7s (Sevens World Series) and Rugby-15s (Rugby World Cup, Junior 
World Championship and Rugby Trophy, Pacific Nations Cup and English 
Premiership). British Journal of Sports Medicine, 49(7), 478-483. 
Fuller CW, Taylor AE, Brooks JH & Kemp SP (2013). Changes in the stature, body 
mass and age of English professional rugby players: A 10-year review. Journal 
of Sports Sciences, 31(7), 795-802. 
Fuller GW, Kemp SP & Decq P (2015b). The International Rugby Board (IRB) Pitch 
side concussion assessment trial: a pilot test accuracy study. British Journal 
of Sports Medicine, 49(8), 529-535. 
Gabbett TJ (2007). Physiological and anthropometric characteristics of elite women 
rugby league players. The Journal of Strength & Conditioning Research, 21(3), 
875-881. 
Gabbett TJ, Jenkins DG & Abernethy B (2012). Physical demands of professional 
rugby league training and competition using microtechnology. Journal of 
Science and Medicine in Sport, 15(1), 80-86. 
Garatachea N, Verde Z, Santos-Lozano A, Yvert T, Rodriguez-Romo G, Sarasa FJ, 
Hernández-Sánchez S, Santiago C & Lucia A (2014). ACTN3 R577X 
polymorphism and explosive leg-muscle power in elite basketball players. Int 
J Sport Physiol Perform, 9(2). 
Gardner A, Iverson G, Stanwell P, Moore T, Ellis J & Levi C (2016). A Video Analysis 
of Use of the New ‘Concussion Interchange Rule’in the National Rugby 
League. International Journal of Sports Medicine. 
Gardner A, Iverson GL, Levi CR, Schofield PW, Kay-Lambkin F, Kohler RM & Stanwell 
P (2015a). A systematic review of concussion in rugby league. British Journal 
of Sports Medicine, 49(8), 495-498. 
Gardner AJ, Iverson GL, Quinn TN, Makdissi M, Levi CR, Shultz SR, Wright DK & 
Stanwell P (2015b). A preliminary video analysis of concussion in the National 
Rugby League. Brain injury, 29(10), 1182-1185. 
Gardner AJ, Iverson GL, Williams WH, Baker S & Stanwell P (2014). A systematic 
review and meta-analysis of concussion in rugby union. Sports Medicine, 
44(12), 1717-1731. 
233 | P a g e  
 
Garton FC & North KN (2016). The Effect of Heterozygosity for the ACTN3 Null Allele 
on Human Muscle Performance. Medicine and Science in Sports and Exercise, 
48(3), 509-520. 
Gauderman WJ (2002). Sample size requirements for association studies of gene-
gene interaction. American Journal of Epidemiology, 155(5), 478-484. 
Gaunt TR, Rodríguez S & Day IN (2007). Cubic exact solutions for the estimation of 
pairwise haplotype frequencies: implications for linkage disequilibrium 
analyses and a web tool'CubeX'. BMC Bioinformatics, 8(1), 428. 
Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS & Trent RJ (1998). Elite 
endurance athletes and the ACE I allele–the role of genes in athletic 
performance. Human Genetics, 103(1), 48-50. 
Geddes J, Vowles G, Nicoll J & Revesz T (1999). Neuronal cytoskeletal changes are 
an early consequence of repetitive head injury. Acta Neuropathologica, 
98(2), 171-178. 
Geisterfer A, Peach MJ & Owens GK (1988). Angiotensin II induces hypertrophy, not 
hyperplasia, of cultured rat aortic smooth muscle cells. Circulation Research, 
62(4), 749-756. 
George KP, Gates PE, Whyte G, Fenoglio RA & Lea R (1999). Echocardiographic 
examination of cardiac structure and function in elite cross trained male and 
female Alpine skiers. British Journal of Sports Medicine, 33(2), 93-98. 
Gilliver S, Degens H, Rittweger J, Sargeant A & Jones D (2009). Variation in the 
determinants of power of chemically skinned human muscle fibres. 
Experimental Physiology, 94(10), 1070-1078. 
Ginevičienė V, Jakaitienė A, Pranculis A, Milašius K, Tubelis L & Utkus A (2014). 
AMPD1 rs17602729 is associated with physical performance of sprint and 
power in elite Lithuanian athletes. BMC Genetics, 15(1), 1. 
Gineviciene V, Jakaitiene A, Tubelis L & Kucinskas V (2014). Variation in the ACE, 
PPARGC1A and PPARA genes in Lithuanian football players. European Journal 
of Sport science, 14(sup1), S289-S295. 
Ginevičienė V, Kučinskas V & Kasnauskienė J (2009). The angiotensin converting 
enzyme gene insertion/deletion polymorphism in Lithuanian professional 
athletes. Acta Medica Lituanica, 16(1), 11-16. 
Ginevičienė V, Pranckevičienė E, Milašius K & Kučinskas V (2010). Relating fitness 
phenotypes to genotypes in Lithuanian elite athletes. Acta Medica Lituanica, 
17(1-2), 1-10. 
Ginevičienė V, Pranckevičienė E, Milašius K & Kučinskas V (2011). Gene variants 
related to the power performance of the Lithuanian athletes. Open Life 
Sciences, 6(1), 48-57. 
Glaister M, Howatson G, Abraham C, Lockey R, Goodwin J, Foley P & McInnes G 
(2008). Caffeine supplementation and multiple sprint running performance. 
Medicine and Science in Sports and Exercise, 40(10), 1835. 
Glenn KL, Du Z-Q, Eisenmann JC & Rothschild MF (2009). An alternative method for 
genotyping of the ACE I/D polymorphism. Molecular Biology Reports, 36(6), 
1305-1310. 
234 | P a g e  
 
Goh K, Chew K, Koh A, Guan M, Wong Y & Sum C (2009). The relationship between 
ACE gene ID polymorphism and aerobic capacity in Asian rugby players. 
Singapore Medical Journal, 50(10), 997-1003. 
Gokhale S & Laskowitz DT (2013). ApoE and outcome after traumatic brain injury. 
Clinical Lipidology, 8(5), 561-571. 
Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A & Langston JW 
(2006). Head injury and Parkinson's disease risk in twins. Annals of 
Neurology, 60(1), 65-72. 
Gómez-Gallego F, Ruiz JR, Buxens A, Altmäe S, Artieda M, Santiago C, González-
Freire M, Verde Z, Arteta D & Martínez A (2010). Are elite endurance 
athletes genetically predisposed to lower disease risk? Physiological 
Genomics, 41(1), 82-90. 
Gomez-Gallego F, Santiago C, Gonzalez-Freire M, Muniesa C, Fernández DVM, Perez 
M, Foster C & Lucia A (2009). Endurance performance: genes or gene 
combinations? International Journal of Sports Medicine, 30(1), 66-72. 
Gordon SE, Davis BS, Carlson CJ & Booth FW (2001). ANG II is required for optimal 
overload-induced skeletal muscle hypertrophy. American Journal of 
Physiology-Endocrinology and Metabolism, 280(1), E150-E159. 
Grealy R, Herruer J, Smith CL, Hiller D, Haseler LJ & Griffiths LR (2015). Evaluation of 
a 7-Gene Genetic Profile for Athletic Endurance Phenotype in Ironman 
Championship Triathletes. PloS One, 10(12), e0145171. 
Gronek P, Holdys J, Konarski J, Kryściak J & Wolc A (2013). ACE genotype in 
professional field hockey players. Trends in Sport Science, 1(20), 36-40. 
Grunnet LG, Nilsson E, Ling C, Hansen T, Pedersen O, Groop L, Vaag A & Poulsen P 
(2009). Regulation and function of FTO mRNA expression in human skeletal 
muscle and subcutaneous adipose tissue. Diabetes, 58(10), 2402-2408. 
Gülyaşar T, Öztürk L, Sipahi T, Bayraktar B, Metin G, Yücesir İ & Süt N (2014). GNB3 
gene c. 825C>T polymorphism and performance parameters in professional 
basketball players. Acta Physiologica Hungarica, 101(2), 176-184. 
Hagberg JM, Ferrell RE, Katzel LI, Dengel DR, Sorkin JD & Goldberg AP (1999). 
Apolipoprotein E genotype and exercise training-induced increases in plasma 
high-density lipoprotein (HDL)- and HDL2-cholesterol levels in overweight 
men. Metabolism, 48(8), 943-945. 
Hakim A, Cherkas L, Spector T & MacGregor A (2003). Genetic associations between 
frozen shoulder and tennis elbow: a female twin study. Rheumatology, 42(6), 
739-742. 
Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE & Spector TD (2002). 
Genetic influence on early age-related maculopathy: a twin study. 
Ophthalmology, 109(4), 730-736. 
Hardy GH (1908). Mendelian proportions in a mixed population. Science, 28, 49-50. 
Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK & Holtzman DM 
(2002). Apolipoprotein E4 influences amyloid deposition but not cell loss 
after traumatic brain injury in a mouse model of Alzheimer's disease. The 
Journal of Neuroscience, 22(23), 10083-10087. 
235 | P a g e  
 
He D, Fu M, Miao S, Hotta K, Chandak GR & Xi B (2014). FTO gene variant and risk of 
hypertension: A meta-analysis of 57,464 hypertensive cases and 41,256 
controls. Metabolism, 63(5), 633-639. 
Heffernan SM, Kilduff LP, Erskine RM, Day SH, McPhee JS, McMahon GE, Stebbings 
GK, Neale JP, Lockey SJ & Ribbans WJ (2016). Association of ACTN3 R577X 
but not ACE I/D gene variants with elite rugby union player status and 
playing position. Physiological Genomics, 48(3), 196-201. 
Herskind AM, McGue M, Holm NV, Sörensen TI, Harvald B & Vaupel JW (1996). The 
heritability of human longevity: a population-based study of 2872 Danish 
twin pairs born 1870–1900. Human Genetics, 97(3), 319-323. 
Heshmat H, Azab A & El-Tantawy A (2010). ACE and ACE Gene Polymorphism and 
Some Cardiac Parameters of Fencing, Basketball and Endurance Players. 
World Journal of Sport Sciences, 3(2), 100-106. 
Hidding U, Mielke K, Waetzig V, Brecht S, Hanisch U, Behrens A, Wagner E & 
Herdegen T (2002). The c-Jun N-terminal kinases in cerebral microglia: 
immunological functions in the brain. Biochemical Pharmacology, 64(5), 781-
788. 
Hildebrand K, Frank C & Hart D (2004). Gene intervention in ligament and tendon: 
current status, challenges, future directions. Gene Therapy, 11(4), 368-378. 
Hixson JE & Vernier DT (1990). Restriction isotyping of human apolipoprotein E by 
gene amplification and cleavage with HhaI. Journal of Lipid Research, 31(3), 
545-548. 
Hogarth MW, Garton FC, Houweling PJ, Tukiainen T, Lek M, Macarthur DG, Seto JT, 
Quinlan KG, Yang N & Head SI (2016). Analysis of the ACTN3 heterozygous 
genotype suggests that α-actinin-3 controls sarcomeric composition and 
muscle function in a dose-dependent fashion. Human Molecular Genetics, 
25(5), 866-877. 
Holdys J, Gronek P, Krysciak J & Stanislawski D (2013). Genetic variants of 
uncoupling proteins-2 and-3 in relation to maximal oxygen uptake in 
different sports. Acta Biochimica Polonica, 60, 71-75. 
Holdys J, Kryściak J, Stanisławski D & Gronek P (2011). ACE I/D gene polymorphism 
in athletes of various sports disciplines. Human Movement, 12(3), 223-231. 
Hong EP & Park JW (2012). Sample size and statistical power calculation in genetic 
association studies. Genomics & Informatics, 10(2), 117-122. 
Huang T, Qi Q, Li Y, Hu FB, Bray GA, Sacks FM, Williamson DA & Qi L (2014). FTO 
genotype, dietary protein, and change in appetite: the Preventing 
Overweight Using Novel Dietary Strategies trial. The American Journal of 
Clinical Nutrition, 99(5), 1126-1130. 
Huang Y & Mahley RW (2014). Apolipoprotein E: structure and function in lipid 
metabolism, neurobiology, and Alzheimer's diseases. Neurobiology of 
Disease, 72, 3-12. 
Huebbe P, Nebel A, Siegert S, Moehring J, Boesch-Saadatmandi C, Most E, Pallauf J, 
Egert S, Muller MJ, Schreiber S, Nothlings U & Rimbach G (2011). APOE 
epsilon4 is associated with higher vitamin D levels in targeted replacement 
mice and humans. FASEB Journal, 25(9), 3262-3270. 
236 | P a g e  
 
Hughes DC, Day SH, Ahmetov II & Williams AG (2011). Genetics of muscle strength 
and power: polygenic profile similarity limits skeletal muscle performance. 
Journal of Sports Sciences, 29(13), 1425-1434. 
Imamura Y, Scott IC & Greenspan DS (2000). The Pro-α3 (V) Collagen Chain 
complete primary structure, expression domains in adult and developing 
tissues, and comparison to the structures and expression domains of the 
other types V and XI procollagen chains. Journal of Biological Chemistry, 
275(12), 8749-8759. 
International HapMap Consortium (2005). A haplotype map of the human genome. 
Nature, 437(7063), 1299-1320. 
International Rugby Board (2004). Strategic Plan. International Rugby Board, 
worldrugby.com. 
Ioannidis JP (2005). Why most published research findings are false. PLoS Medicine, 
2(8), e124. 
Ishigai Y, Mori T, Ikeda T, Fukuzawa A & Shibano T (1997). Role of bradykinin-NO 
pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat 
cardiomyocytes. American Journal of Physiology-Heart and Circulatory 
Physiology, 273(6), H2659-H2663. 
Iwao-Koizumi K, Ota T, Hayashida M, Yonetani Y, Nakata K, Kinoshita K, Koyanagi Y & 
Murata S (2014). The ACTN3 Gene is a Potential Biomarker for the Risk of 
Non-Contact Sports Injury in Female Athletes. Journal of Molecular 
Biomarkers & Diagnosis, S6, 1-2. 
Jack H (1922). Brothers in Rugby Foorball: More evidence That brothers are 
selected to play in the same or similar positions on football reams. Journal of 
Heredity, 13(4), 161-162. 
Jacobsson JA, Schiöth H & Fredriksson R (2012). The impact of intronic single 
nucleotide polymorphisms and ethnic diversity for studies on the obesity 
gene FTO. Obesity Reviews, 13(12), 1096-1109. 
Jang Y & Kim SM (2012). Influences of the G2350A polymorphism in the ACE gene 
on cardiac structure and function of ball game players. Journal of Negative 
Results in Biomedicine, 11, 6. 
Jardine M, Wiggins T, Myburgh K & Noakes T (1988). Physiological characteristics of 
rugby players including muscle glycogen content and muscle fibre 
composition. The South African Medical Journal, 73(9), 529-532. 
Jess T, Zimmermann E, Kring SII, Berentzen T, Holst C, Toubro S, Astrup A, Hansen T, 
Pedersen O & Sørensen TI (2008). Impact on weight dynamics and general 
growth of the common FTO rs9939609: a longitudinal Danish cohort study. 
International Journal of Obesity, 32(9), 1388-1394. 
Jin H-J, Hwang I-W, Kim K-C, Cho H-I, Park T-H, Shin Y-A, Lee H-S, Hwang J-H, Kim A-
R & Lee K-H (2015). Is there a relationship between PPARD T294C/PPARGC1A 
Gly482Ser variations and physical endurance performance in the Korean 
population? Genes & Genomics, 38(4), 389-395. 
Johnston RD, Gabbett TJ & Jenkins DG (2014). Applied sport science of rugby 
league. Sports Medicine, 44(8), 1087-1100. 
237 | P a g e  
 
Jones MR, West DJ, Crewther BT, Cook CJ & Kilduff LP (2015). Quantifying positional 
and temporal movement patterns in professional rugby union using global 
positioning system. European Journal of Sport Science, 15(6), 488-496. 
Jones MR, West DJ, Harrington BJ, Cook CJ, Bracken RM, Shearer DA & Kilduff LP 
(2014). Match play performance characteristics that predict post-match 
creatine kinase responses in professional rugby union players. BMC Sports 
Science, Medicine and Rehabilitation, 6(1), 1. 
Jonsson JR, Game PA, Head RJ & Frewin DB (1994). The expression and localisation 
of the angiotensin-converting enzyme mRNA in human adipose tissue. Blood 
Pressure, 3(1-2), 72-75. 
Jorde LB & Wooding SP (2004). Genetic variation, classification and'race'. Nature 
Genetics, 36(11), S28-S33. 
Juffer P, Furrer R, Gonzalez-Freire M, Santiago C, Verde Z, Serratosa L, Morate F, 
Rubio J, Martin M & Ruiz J (2009). Genotype distributions in top-level soccer 
players: a role for ACE? International Journal of Sports Medicine, 30(5), 387-
392. 
Kang BY, Kang CY, Oh SD, Bae JS, Kim KT & Lee KO (2003). The protein 
polymorphism of haptoglobin in Korean elite athletes. Medical Principles and 
Practice, 12(3), 151-155. 
Kelley K & Preacher KJ (2012). On effect size. Psychological Methods, 17(2), 137. 
Kemp S, Patricios J & Raftery M (2016). Is the content and duration of the graduated 
return to play protocol after concussion demanding enough? A challenge for 
Berlin 2016. British Journal of Sports Medicine, 50(11), 644-645. 
Kikuchi N, Min S-k, Ueda D, Igawa S & Nakazato K (2012). Higher frequency of the 
ACTN3 R allele and ACE DD genotype in Japanese elite wrestlers. The Journal 
of Strength & Conditioning Research, 26(12), 3275-3280. 
Kikuchi N, Nakazato K, Min S-k, Ueda D & Igawa S (2014a). The ACTN3 R577X 
polymorphism is associated with muscle power in male Japanese athletes. 
The Journal of Strength & Conditioning Research, 28(7), 1783-1789. 
Kikuchi N, Nakazato K, Min SK, Ueda D & Igawa S (2014b). The ACTN3 R577X 
polymorphism is associated with muscle power in male Japanese athletes. 
The Journal of Strength & Conditioning Research, 28(7), 1783-1789. 
Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, Ahmad T, Mora S, 
Kaakinen M & Sandholt CH (2011). Physical activity attenuates the influence 
of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 
children. PLoS Medicine, 8(11), e1001116. 
Kim W, Cho HI, Kim KC, So YH & Oh JG (2011). Relationships between digit ratio (2D: 
4D), ACE gene polymorphism, and physical performance in the Korean 
population. Genes & Genomics, 33(4), 407-412. 
King D, Gissane C, Clark T & Marshall SW (2014). The incidence of match and 
training injuries in rugby league: a pooled data analysis of published studies. 
Int J Sports Sci Coach, 9(2), 417-432. 
Kirkham EM & Weaver EM (2015). A review of multiple hypothesis testing in 
otolaryngology literature. The Laryngoscope, 125(3), 599-603. 
238 | P a g e  
 
Koch W, Latz W, Eichinger M, Ganser C, Schömig A & Kastrati A (2005). Genotyping 
of the angiotensin I-converting enzyme gene insertion/deletion 
polymorphism by the TaqMan method. Clinical Chemistry, 51(8), 1547-1549. 
Kothari ST, Chheda P, Chatterjee L & Das BR (2012). Molecular analysis of genetic 
variation in angiotensin I-converting enzyme identifies no association with 
sporting ability: First report from Indian population. Indian Journal of Human 
Genetics, 18(1), 62-65. 
Kristman VL, Tator CH, Kreiger N, Richards D, Mainwaring L, Jaglal S, Tomlinson G & 
Comper P (2008). Does the Apolipoprotein E4 Allele Predispose Varsity 
Athletes to Concussion? A Prospective Cohort Study. Clinical Journal of Sport 
Medicine, 18(4), 322-328. 
Kutner KC, Erlanger DM, Tsai J, Jordan B & Relkin NR (2000). Lower cognitive 
performance of older football players possessing apolipoprotein E ε4. 
Neurosurgery, 47(3), 651-658. 
Laguette M-J, Abrahams Y, Prince S & Collins M (2011). Sequence variants within 
the 3′-UTR of the COL5A1 gene alters mRNA stability: implications for 
musculoskeletal soft tissue injuries. Matrix Biology, 30(5), 338-345. 
Lahiri DK & Nurnberger JI (1991). A rapid non-enzymatic method for the 
preparation of HMW DNA from blood for RFLP studies. Nucleic Acids 
Research, 19(19), 5444. 
Lakens D (2013). Calculating and reporting effect sizes to facilitate cumulative 
science: a practical primer for t-tests and ANOVAs. Frontiers in Psychology, 
4(863), 1-12. 
Lakka H-M, Lakka TA, Rankinen T, Rice T, Rao D, Leon AS, Skinner JS & Bouchard C 
(2006). The TNF-α G-308A polymorphism is associated with C-reactive 
protein levels: the HERITAGE Family Study. Vascular pharmacology, 44(5), 
377-383. 
Lamas NJ, Johnson-Kerner B, Roybon L, Kim YA, Garcia-Diaz A, Wichterle H & 
Henderson CE (2014). Neurotrophic requirements of human motor neurons 
defined using amplified and purified stem cell-derived cultures. PloS One, 
9(10), e110324. 
Lappalainen T, Lindström J, Paananen J, Eriksson JG, Karhunen L, Tuomilehto J & 
Uusitupa M (2012). Association of the fat mass and obesity-associated (FTO) 
gene variant (rs9939609) with dietary intake in the Finnish Diabetes 
Prevention Study. British Journal of Nutrition, 108(10), 1859-1865. 
Laskowitz DT, Song P, Wang H, Mace B, Sullivan PM, Vitek MP & Dawson HN (2010). 
Traumatic brain injury exacerbates neurodegenerative pathology: 
improvement with an apolipoprotein E-based therapeutic. Journal of 
Neurotrauma, 27(11), 1983-1995. 
Laskowitz DT & Vitek MP (2007). Apolipoprotein E and neurological disease: 
therapeutic potential and pharmacogenomic interactions. 
Pharmacogenomics, 8(8), 959-969. 
Lawrence DW, Comper P, Hutchison MG & Sharma B (2015). The role of 
apolipoprotein E episilon (ɛ)-4 allele on outcome following traumatic brain 
injury: A systematic review. Brain Injury, 29(9), 1018-1031. 
239 | P a g e  
 
Lear SA, Deng WQ, Pare G, Sulistyoningrum DC, Loos RJ & Devlin A (2011). 
Associations of the FTO rs9939609 variant with discrete body fat depots and 
dietary intake in a multi-ethnic cohort. Genetics Research, 93(06), 419-426. 
Li L, Bao Y, He S, Wang G, Guan Y, Ma D, Wu R, Wang P, Huang X & Tao S (2015). 
The Association Between Apolipoprotein E and Functional Outcome After 
Traumatic Brain Injury: A Meta-Analysis. Medicine, 94(46). 
Lichtman S, Seliger G, Tycko B & Marder K (2000). Apolipoprotein E and functional 
recovery from brain injury following postacute rehabilitation. Neurology, 
55(10), 1536-1539. 
Lidor R & Ziv G (2010). Physical and physiological attributes of female volleyball 
players-a review. The Journal of Strength & Conditioning Research, 24(7), 
1963-1973. 
Lidor R & Ziv G (2015). On-field performances of female and male field hockey 
players–A review. International Journal of Performance Analysis in Sport, 
15(1), 20-38. 
Lim S-T, Kim C-S, Kim W-N & Min S-K (2015). The COL5A1 genotype is associated 
with range of motion. Journal of Exercise Nutrition & Biochemistry, 19(2), 49. 
Liu C, Mou S & Pan C (2013). The FTO gene rs9939609 polymorphism predicts risk 
of cardiovascular disease: a systematic review and meta-analysis. PLoS One, 
8(8), e71901. 
Liu G, Zhu H, Lagou V, Gutin B, Stallmann-Jorgensen IS, Treiber FA, Dong Y & Snieder 
H (2010). FTO variant rs9939609 is associated with body mass index and 
waist circumference, but not with energy intake or physical activity in 
European-and African-American youth. BMC Medical Genetics, 11(1), 57. 
Livshits G, Gao F, Malkin I, Needhamsen M, Xia Y, Yuan W, Bell CG, Ward K, Liu Y & 
Wang J (2016). Contribution of Heritability and Epigenetic Factors to Skeletal 
Muscle Mass Variation in United Kingdom Twins. The Journal of Clinical 
Endocrinology & Metabolism, 101(6), 2450-2459. 
Loos R, Hagberg JM, Pérusse L, Roth SM, Sarzynski MA, Wolfarth B, Rankinen T & 
Bouchard C (2015). Advances in exercise, fitness, and performance genomics 
in 2014. Medicine and Science in Sports and Exercise, 47(6), 1105-1112. 
Loos RJ & Yeo GS (2014). The bigger picture of FTO the first GWAS-identified obesity 
gene. Nature Reviews Endocrinology, 10(1), 51-61. 
Luis DA, Aller R, Izaola O, Conde R, Sagrado MG & Primo D (2012). Evaluation of 
weight loss and adipocytokines levels after two hypocaloric diets with 
different macronutrient distribution in obese subjects with rs9939609 gene 
variant. Diabetes/Metabolism Research and Reviews, 28(8), 663-668. 
Lukic I (2003). MedCalc Version 7.0.0.2. Software Review. The Croatian Medical 
Journal 44(1), 120-121. 
Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, Warner DS & 
Laskowitz DT (2003). APOE genotype and an ApoE-mimetic peptide modify 
the systemic and central nervous system inflammatory response. Journal of 
Biological Chemistry, 278(49), 48529-48533. 
Ma F, Yang Y, Li X, Zhou F, Gao C, Li M & Gao L (2013). The association of sport 
performance with ACE and ACTN3 genetic polymorphisms: a systematic 
review and meta-analysis. PloS One, 8(1), e54685. 
240 | P a g e  
 
MacArthur DG & North KN (2004). A gene for speed? The evolution and function of 
α‐actinin‐3. Bioessays, 26(7), 786-795. 
MacArthur DG & North KN (2007). ACTN3: A genetic influence on muscle function 
and athletic performance. Exercise and Sport Sciences Reviews, 35(1), 30-34. 
MacArthur DG, Seto JT, Chan S, Quinlan KG, Raftery JM, Turner N, Nicholson MD, 
Kee AJ, Hardeman EC & Gunning PW (2008). An Actn3 knockout mouse 
provides mechanistic insights into the association between α-actinin-3 
deficiency and human athletic performance. Human Molecular Genetics, 
17(8), 1076-1086. 
Maezawa I, Maeda N, Montine TJ & Montine KS (2006). Apolipoprotein E-specific 
innate immune response in astrocytes from targeted replacement mice. 
Journal of Neuroinflammation, 3(1), 10. 
Malfait F & De Paepe A (2005). Molecular genetics in classic Ehlers–Danlos 
syndrome. American Journal of Medical Genetics, 139 C(1), 17-23. 
Malfait F, Wenstrup RJ & De Paepe A (2010). Clinical and genetic aspects of Ehlers-
Danlos syndrome, classic type. Genetics in Medicine, 12(10), 597-605. 
Maroon JC, Winkelman R, Bost J, Amos A, Mathyssek C & Miele V (2015). Chronic 
traumatic encephalopathy in contact sports: a systematic review of all 
reported pathological cases. PloS One, 10(2), e0117338. 
Marques MC, Van den Tillaar R, Gabbett TJ, Reis VM & González-Badillo JJ (2009). 
Physical fitness qualities of professional volleyball players: determination of 
positional differences. The Journal of Strength & Conditioning Research, 
23(4), 1106-1111. 
Massidda M, Bachis V, Corrias L, Piras F, Scorcu M, Culigioni C, Masala D & Calò CM 
(2015a). ACTN3 R577X polymorphism is not associated with team sport 
athletic status in Italians. Sports Medicine-Open, 1(1), 1-5. 
Massidda M, Corrias L, Bachis V, Cugia P, Piras F, Scorcu M & Calò CM (2015b). 
Vitamin D receptor gene polymorphisms and musculoskeletal injuries in 
professional football players. Experimental and Therapeutic Medicine, 9(5), 
1974-1978. 
Massidda M, Corrias L, Bachis V, Culigioni C, Piras F, Scorcu M & Calò C (2014a). 
Genetic polymorphisms and muscle injuries among Italian Soccer Players. 
Annals of Sports Medicine and Research, 1(1), 1004. 
Massidda M, Corrias L, Scorcu M, Vona G & Calò MC (2012). ACTN-3 and ACE 
genotypes in elite male Italian athletes. Anthropological Review, 75(1), 51-59. 
Massidda M, Scorcu M & Calò CM (2014b). New genetic model for predicting 
phenotype traits in sports. International Journal of Sports Physiology & 
Performance, 9(3), 554-560. 
Matsuo T, Nakata Y, Hotta K & Tanaka K (2014). The FTO genotype as a useful 
predictor of body weight maintenance: Initial data from a 5-year follow-up 
study. Metabolism, 63(7), 912-917. 
Matsuo T, Nakata Y, Murotake Y, Hotta K & Tanaka K (2012). Effects of FTO 
genotype on weight loss and metabolic risk factors in response to calorie 
restriction among Japanese women. Obesity, 20(5), 1122-1126. 
241 | P a g e  
 
Mattsson CM, Wheeler M, Waggott D, Caleshu C & Ashley EA (2016). Sports 
genetics moving forward-lessons learned from medical research. 
Physiological Genomics, 48(3), 175-182. 
McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty LM, 
Cheskin LJ, Balasubramanyam A, Wagenknecht LE & Wing RR (2012). Obesity 
susceptibility loci and dietary intake in the Look AHEAD Trial. The American 
Journal of Clinical Nutrition, 95(6), 1477-1486. 
McCrory P, Meeuwisse WH, Aubry M, Cantu B, Dvořák J, Echemendia RJ, 
Engebretsen L, Johnston K, Kutcher JS & Raftery M (2013). Consensus 
statement on concussion in sport: the 4th International Conference on 
Concussion in Sport held in Zurich, November 2012. British Journal of Sports 
Medicine, 47(5), 250-258. 
McLaughlin J, Linsenmayer T & Birk D (1989). Type V collagen synthesis and 
deposition by chicken embryo corneal fibroblasts in vitro. Journal of Cell 
Science, 94(2), 371-379. 
Menzel K & Hilberg T (2011). Blood coagulation and fibrinolysis in healthy, 
untrained subjects: effects of different exercise intensities controlled by 
individual anaerobic threshold. European Journal of Applied Physiology, 
111(2), 253-260. 
Merritt VC & Arnett PA (2016). Apolipoprotein E (APOE) ϵ4 allele is associated with 
increased symptom reporting following sports concussion. Journal of the 
International Neuropsychological Society, 22(1), 89-94. 
Miller RH, Umberger BR & Caldwell GE (2012). Limitations to maximum sprinting 
speed imposed by muscle mechanical properties. Journal of Biomechanics, 
45(6), 1092-1097. 
Mills M, Yang N, Weinberger R, Vander Woude DL, Beggs AH, Easteal S & North K 
(2001). Differential expression of the actin-binding proteins, α-actinin-2 and-
3, in different species: implications for the evolution of functional 
redundancy. Human Molecular Genetics, 10(13), 1335-1346. 
Missitzi J, Geladas N & Klissouras V (2008). Genetic variation of maximal velocity 
and EMG activity. International Journal of Sports Medicine, 29(3), 177-181. 
Missitzi J, Gentner R, Geladas N, Politis P, Karandreas N, Classen J & Klissouras V 
(2011). Plasticity in human motor cortex is in part genetically determined. 
The Journal of Physiology, 589(2), 297-306. 
Miyamoto-Mikami E, Murakami H, Tsuchie H, Takahashi H, Ohiwa N, Miyachi M, 
Kawahara T & Fuku N (2016). Lack of association between genotype score 
and sprint/power performance in the Japanese population. Journal of 
Science and Medicine in Sport, In press. 
Mokone G, Schwellnus M, Noakes T & Collins M (2006). The COL5A1 gene and 
Achilles tendon pathology. Scandinavian Journal of Medicine & Science in 
Sports, 16(1), 19-26. 
Moleres A, Ochoa MC, Rendo-Urteaga T, Martínez-González MA, San Julián MCA, 
Martínez JA & Marti A (2012). Dietary fatty acid distribution modifies obesity 
risk linked to the rs9939609 polymorphism of the fat mass and obesity-
associated gene in a Spanish case–control study of children. British Journal of 
Nutrition, 107(04), 533-538. 
242 | P a g e  
 
Montgomery H, Marshall R, Hemingway H, Myerson S, Clarkson P, Dollery C, 
Hayward M, Holliman D, Jubb M & World M (1998). Human gene for physical 
performance. Nature, 393(6682), 221-222. 
Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi M-A, Hemingway H, Statters 
D, Jubb M, Girvain M & Varnava A (1997). Association of angiotensin-
converting enzyme gene I/D polymorphism with change in left ventricular 
mass in response to physical training. Circulation, 96(3), 741-747. 
Morehen JC, Routledge HE, Twist C, Morton JP & Close GL (2015). Position specific 
differences in the anthropometric characteristics of elite European Super 
League rugby players. European Journal of Sport Science, 15(6), 523-529. 
Moretti EW, Morris RW, Podgoreanu M, Schwinn DA, Newman MF, Bennett E, 
Moulin VG, Mba UU & Laskowitz D (2005). APOE polymorphism is associated 
with risk of severe sepsis in surgical patients. Critical Care in Medicine 33(11), 
2521. 
Morin JB, Bourdin M, Edouard P, Peyrot N, Samozino P & Lacour JR (2012). 
Mechanical determinants of 100-m sprint running performance. European 
Journal of Applied Physiology, 112(11), 3921-3930. 
Muc M, Padez C & Manco L (2015). Influence of physical activity on the association 
between the FTO variant rs9939609 and adiposity in young adults. American 
Journal of Human Biology, 27(5), 734-738. 
Müller K, Ingebrigtsen T, Wilsgaard T, Wikran G, Fagerheim T, Romner B & Waterloo 
K (2009). Prediction of time trends in recovery of cognitive function after 
mild head injury. Neurosurgery, 64(4), 698-704. 
Munzenmaier DH & Greene AS (1996). Opposing actions of angiotensin II on 
microvascular growth and arterial blood pressure. Hypertension, 27(3), 760-
765. 
Mustafina LJ, Naumov VA, Cieszczyk P, Popov DV, Lyubaeva EV, Kostryukova ES, 
Fedotovskaya ON, Druzhevskaya AM, Astratenkova IV & Glotov AS (2014). 
AGTR2 gene polymorphism is associated with muscle fibre composition, 
athletic status and aerobic performance. Experimental Physiology, 99(8), 
1042-1052. 
Myerson S, Hemingway H, Budget R, Martin J, Humphries S & Montgomery H 
(1999). Human angiotensin I-converting enzyme gene and endurance 
performance. Journal of Applied Physiology, 87(4), 1313-1316. 
Nakamura O, Ishii T, Ando Y, Amagai H, Oto M, Imafuji T & Tokuyama K (2002a). 
Potential role of vitamin D receptor gene polymorphism in determining bone 
phenotype in young male athletes. Journal of Applied Physiology, 93(6), 
1973-1979. 
Nakamura O, Ishii T, Mankyu H, Tsubakimoto S, Nomura T & Tokuyama K (2002b). 
Contribution of vitamin D receptor genotypes to bone mineral density in 
young male athletes with different impact loading. European Journal of Sport 
Science, 2(2), 1-8. 
Namipashaki A, Razaghi-Moghadam Z & Ansari-Pour N (2015). The Essentiality of 
Reporting Hardy-Weinberg Equilibrium Calculations in Population-Based 
Genetic Association Studies. Cell Journal (Yakhteh), 17(2), 187. 
243 | P a g e  
 
Nicoll JA, Roberts GW & Graham DI (1995). Apolipoprotein E &epsi; 4 allele is 
associated with deposition of amyloid β-protein following head injury. 
Nature Medicine, 1(2), 135-137. 
Niemi A-K & Majamaa K (2005). Mitochondrial DNA and ACTN3 genotypes in Finnish 
elite endurance and sprint athletes. European Journal of Human Genetics, 
13(8), 965-969. 
Noble WS (2009). How does multiple testing correction work? Nature 
Biotechnology, 27(12), 1135-1137. 
Noé E, Ferri J, Colomer C, Moliner B & Chirivella J (2010). APOE genotype and verbal 
memory recovery during and after emergence from post-traumatic amnesia. 
Brain injury, 24(6), 886-892. 
North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S & Beggs AH (1999). A 
common nonsense mutation results in α-actinin-3 deficiency in the general 
population. Nature Genetics, 21(4), 353-354. 
Nuzzo JL, McBride JM, Dayne AM, Israetel MA, Dumke CL & Triplett NT (2010). 
Testing of the maximal dynamic output hypothesis in trained and untrained 
subjects. The Journal of Strength & Conditioning Research, 24(5), 1269-1276. 
O'Connell K, Knight H, Ficek K, Leonska-Duniec A, Maciejewska-Karlowska A, 
Sawczuk M, Stepien-Slodkowska M, O'Cuinneagain D, van der Merwe W & 
Posthumus M (2015). Interactions between collagen gene variants and risk 
of anterior cruciate ligament rupture. European Journal of Sport Science, 
15(4), 341-350. 
O’Connell K, Posthumus M, Schwellnus MP & Collins M (2013). Collagen genes and 
exercise-associated muscle cramping. Clinical Journal of Sport Medicine, 
23(1), 64-69. 
Oh S (2007). The distribution of I/D polymorphism in the ACE gene among Korean 
male elite athletes. Journal of Sports Medicine and Physical Fitness, 47(2), 
250. 
Omalu B, Bailes J, Hamilton RL, Kamboh MI, Hammers J, Case M & Robert 
Fitzsimmons J (2011). Emerging histomorphologic phenotypes of chronic 
traumatic encephalopathy in American athletes. Neurosurgery, 69(1), 173-
183. 
Omalu BI, DeKosky ST, Hamilton RL, Minster RL, Kamboh MI, Shakir AM & Wecht CH 
(2006). Chronic traumatic encephalopathy in a national football league 
player: part II. Neurosurgery, 59(5), 1086-1093. 
Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL & Wecht CH (2005). 
Chronic traumatic encephalopathy in a national football league player. 
Neurosurgery, 57(1), 128-134. 
Omalu BI, Hamilton RL, Kamboh MI, DeKosky ST & Bailes J (2010). Chronic traumatic 
encephalopathy (CTE) in a National Football League Player: Case report and 
emerging medicolegal practice questions. Journal of Forensic Nursing, 6(1), 
40-46. 
Orysiak J, Busko K, Mazur-RóZycka J, Michalski R, Gajewski J, Malczewska-
Lenczowska J & Sitkowski D (2015). Relationship Between ACTN3 R577X 
Polymorphism and Physical Abilities in Polish Athletes. The Journal of 
Strength & Conditioning Research, 29(8), 2333-2339. 
244 | P a g e  
 
Owen NJ, Watkins J, Kilduff LP, Bevan HR & Bennett MA (2014). Development of a 
criterion method to determine peak mechanical power output in a 
countermovement jump. The Journal of Strength & Conditioning Research, 
28(6), 1552-1558. 
Owen SM, Venter RE, Du Toit S & Kraak WJ (2015). Acceleratory match-play 
demands of a Super Rugby team over a competitive season. Journal of Sports 
Sciences, 33(19), 2061-2069. 
Papadimitriou I, Papadopoulos C, Kouvatsi A & Triantaphyllidis C (2008). The ACTN3 
gene in elite Greek track and field athletes. International Journal of Sports 
Medicine, 29(4), 352-355. 
Papadimitriou ID, Lucia A, Pitsiladis YP, Pushkarev VP, Dyatlov DA, Orekhov EF, 
Artioli GG, Guilherme JPL, Lancha AH & Ginevičienė V (2016). ACTN3 R577X 
and ACE I/D gene variants influence performance in elite sprinters: a multi-
cohort study. BMC Genomics, 17(1), 1. 
Pasqua LA, Bueno S, Artioli GG, Lancha JR AH, Matsuda M, Marquezini MV, Lima-
Silva AE, Saldiva PH & Bertuzzi R (2016). Influence of ACTN3 R577X 
polymorphism on ventilatory thresholds related to endurance performance. 
Journal of Sports Sciences, 34(2), 163-170. 
Pearson-Fuhrhop KM, Kleim JA & Cramer SC (2009). Brain plasticity and genetic 
factors. Topics in Stroke Rehabilitation. 
Peeters M, Thomis M, Loos R, Derom C, Fagard R, Claessens A, Vlietinck R & Beunen 
G (2007). Heritability of somatotype components: a multivariate analysis. 
International Journal of Obesity, 31(8), 1295-1301. 
Peterson CB, Bogomolov M, Benjamini Y & Sabatti C (2016). Many Phenotypes 
Without Many False Discoveries: Error Controlling Strategies for Multitrait 
Association Studies. Genetic Epidemiology, 40(1), 45-56. 
Phillips CM, Kesse-Guyot E, McManus R, Hercberg S, Lairon D, Planells R & Roche 
HM (2012). High Dietary Saturated Fat Intake Accentuates Obesity Risk 
Associated with the Fat Mass and Obesity–Associated Gene in Adults. The 
Journal of Nutrition, 142(5), 824-831. 
Pimenta EM, Coelho DB, Cruz IR, Morandi RF, Veneroso CE, de Azambuja Pussieldi 
G, Carvalho MRS, Silami-Garcia E & Fernández JADP (2012). The ACTN3 
genotype in soccer players in response to acute eccentric training. European 
Journal of Applied Physiology, 112(4), 1495-1503. 
Pimenta EM, Coelho DB, Veneroso CE, Coelho EJB, Cruz IR, Morandi RF, Pussieldi 
GDA, Carvalho MR, Garcia ES & Fernández JADP (2013). Effect of ACTN3 gene 
on strength and endurance in soccer players. The Journal of Strength & 
Conditioning Research, 27(12), 3286-3292. 
Pitsiladis Y, Wang G, Wolfarth B, Scott R, Fuku N, Mikami E, He Z, Fiuza-Luces C, 
Eynon N & Lucia A (2013). Genomics of elite sporting performance: what 
little we know and necessary advances. British Journal of Sports Medicine, 
47(9), 550-555. 
Pitsiladis YP, Tanaka M, Eynon N, Bouchard C, North KN, Williams AG, Collins M, 
Moran CN, Britton SL & Fuku N (2016). The Athlome Project Consortium: A 
concerted effort to discover genomic and other "OMIC" markers of athletic 
performance. Physiological Genomics, 48, 183-190. 
245 | P a g e  
 
Pocivavsek A, Burns MP & Rebeck GW (2009a). Low‐density lipoprotein receptors 
regulate microglial inflammation through c‐Jun N‐terminal kinase. Glia, 57(4), 
444-453. 
Pocivavsek A, Mikhailenko I, Strickland DK & Rebeck GW (2009b). Microglial low-
density lipoprotein receptor-related protein 1 modulates c-Jun N-terminal 
kinase activation. Journal of Neuroimmunology, 214(1), 25-32. 
Ponsford J, McLaren A, Schönberger M, Burke R, Rudzki D, Olver J & Ponsford M 
(2011). The association between apolipoprotein E and traumatic brain injury 
severity and functional outcome in a rehabilitation sample. Journal of 
Neurotrauma, 28(9), 1683-1692. 
Posthumus M, Schwellnus MP & Collins M (2011). The COL5A1 gene: a novel 
marker of endurance running performance. Medicine and Science in Sports 
and Exercise, 43(4), 584-589. 
Posthumus M, September AV, Keegan M, O’Cuinneagain D, Van der Merwe W, 
Schwellnus MP & Collins M (2009a). Genetic risk factors for anterior cruciate 
ligament ruptures: COL1A1 gene variant. British Journal of Sports Medicine, 
43(5), 352-356. 
Posthumus M, September AV, O’Cuinneagain D, van der Merwe W, Schwellnus MP 
& Collins M (2009b). The COL5A1 gene is associated with increased risk of 
anterior cruciate ligament ruptures in female participants. The American 
Journal of Sports Medicine, 37(11), 2234-2240. 
Proia P, Bianco A, Schiera G, Saladino P, Contrò V, Caramazza G, Traina M, Grimaldi 
KA, Palma A & Paoli A (2014). PPARα gene variants as predicted 
performance-enhancing polymorphisms in professional Italian soccer 
players. Open Access Journal of Sports Medicine, 5, 273-278. 
Pruna R, Artells R, Ribas J, Montoro B, Cos F, Muñoz C, Rodas G & Maffulli N (2013). 
Single nucleotide polymorphisms associated with non-contact soft tissue 
injuries in elite professional soccer players: influence on degree of injury and 
recovery time. BMC Musculoskeletal Disorders, 14(1), 1. 
Pruthi N, Chandramouli B, Kuttappa TB, Rao SL, Subbakrishna D, Abraham MP, 
Mahadevan A & Shankar S (2010). Apolipoprotein E polymorphism and 
outcome after mild to moderate traumatic brain injury: a study of patient 
population in India. Neurology India, 58(2), 264. 
Puthucheary Z, Skipworth JR, Rawal J, Loosemore M, Van Someren K & Montgomery 
HE (2011). The ACE gene and human performance. Sports Medicine, 41(6), 
433-448. 
Quarrie KL, Hopkins WG, Anthony MJ & Gill ND (2013). Positional demands of 
international rugby union: Evaluation of player actions and movements. 
Journal of Science and Medicine in Sport, 16(4), 353-359. 
Raftery M (2013). Concussion and chronic traumatic encephalopathy: International 
Rugby Board’s response. British Journal of Sports Medicine, 48(2), 79-80. 
Raftery M, Kemp S, Patricios J, Makdissi M & Decq P (2016). It is time to give 
concussion an operational definition: a 3-step process to diagnose (or rule 
out) concussion within 48 h of injury: World Rugby guideline. British Journal 
of Sports Medicine, 50(11), 642-643. 
246 | P a g e  
 
Raichlen DA & Alexander GE (2014). Exercise, APOE genotype, and the evolution of 
the human lifespan. Trends in Neurosciences, 37(5), 247-255. 
Raleigh SM (2012). Epigenetic regulation of the ACE gene might be more relevant to 
endurance physiology than the I/D polymorphism. Journal of Applied 
Physiology, 112(6), 1082-1083. 
Rampersaud E, Mitchell BD, Pollin TI, Fu M, Shen H, O’Connell JR, Ducharme JL, 
Hines S, Sack P & Naglieri R (2008). Physical activity and the association of 
common FTO gene variants with body mass index and obesity. Archives of 
Internal Medicine, 168(16), 1791-1797. 
Rankinen T, Perusse L, Rauramaa R, Rivera MA, Wolfarth B & Bouchard C (2001). 
The human gene map for performance and health-related fitness 
phenotypes. Medicine and Science in Sports and Exercise, 33(6), 855-867. 
Rankinen T, Rice T, Teran‐Garcia M, Rao DC & Bouchard C (2010). FTO Genotype Is 
Associated With Exercise Training–induced Changes in Body Composition. 
Obesity, 18(2), 322-326. 
Rauhio A, Uusi-Rasi K, Nikkari ST, Kannus P, Sievänen H & Kunnas T (2013). 
Association of the FTO and ADRB2 genes with body composition and fat 
distribution in obese women. Maturitas, 76(2), 165-171. 
Reilly T & Borrie A (1992). Physiology applied to field hockey. Sports Medicine, 14(1), 
10-26. 
Reneland R & Lithell H (1994). Angiotensin-converting enzyme in human skeletal 
muscle. A simple in vitro assay of activity in needle biopsy specimens. 
Scandinavian Journal of Clinical and Laboratory Investigation, 54(2), 105-111. 
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P & Soubrier F (1990). An 
insertion/deletion polymorphism in the angiotensin I-converting enzyme 
gene accounting for half the variance of serum enzyme levels. Journal of 
Clinical Investigation, 86(4), 1343. 
Roberts SP, Trewartha G, Higgitt RJ, El-Abd J & Stokes KA (2008). The physical 
demands of elite English rugby union. Journal of Sports Sciences, 26(8), 825-
833. 
Roozenbeek B, Maas AI & Menon DK (2013). Changing patterns in the epidemiology 
of traumatic brain injury. Nature Reviews Neurology, 9(4), 231-236. 
Rosskopf D, Schwahn C, Neumann F, Bornhorst A, Rimmbach C, Mischke M, Wolf S, 
Geissler I, Kocher T & Grabe H (2011). The growth hormone—IGF-I axis as a 
mediator for the association between FTO variants and body mass index: 
results of the Study of Health in Pomerania. International Journal of Obesity, 
35(3), 364-372. 
Roth SM, Walsh S, Liu D, Metter EJ, Ferrucci L & Hurley BF (2008). The ACTN3 R577X 
nonsense allele is under-represented in elite-level strength athletes. 
European Journal of Human Genetics, 16(3), 391-394. 
Rubanovich A & Khromov-Borisov N (2014). Theoretical analysis of the predictability 
indices of the binary genetic tests. Russian Journal of Genetics: Applied 
Research, 4(2), 146-158. 
Ruiz J, Eynon N, Meckel Y, Fiuza-Luces C, Santiago C, Gómez-Gallego F, Oliveira J & 
Lucia A (2011a). GNB3 C825T Polymorphism and elite athletic status: A 
247 | P a g e  
 
replication study with two ethnic groups. International Journal of Sports 
Medicine, 32(2), 151-153. 
Ruiz JR, Arteta D, Buxens A, Artieda M, Gómez-Gallego F, Santiago C, Yvert T, Morán 
M & Lucia A (2010). Can we identify a power-oriented polygenic profile? 
Journal of Applied Physiology, 108(3), 561-566. 
Ruiz JR, Fernández del Valle M, Verde Z, Díez‐Vega I, Santiago C, Yvert T, Rodríguez‐
Romo G, Gómez‐Gallego F, Molina J & Lucia A (2011b). ACTN3 R577X 
polymorphism does not influence explosive leg muscle power in elite 
volleyball players. Scandinavian Journal of Medicine & Science in Sports, 
21(6), e34-e41. 
Saber-Ayad MM, Nassar YS & Latif IA (2013). Angiotensin-converting enzyme I/D 
gene polymorphism affects early cardiac response to professional training in 
young footballers. Journal of Renin-Angiotensin-Aldosterone System, 15(3), 
236-242. 
Sabo T, Lomnitski L, Nyska A, Beni S, Maronpot R, Shohami E, Roses A & Michaelson 
D (2000). Susceptibility of transgenic mice expressing human apolipoprotein 
E to closed head injury: the allele E3 is neuroprotective whereas E4 increases 
fatalities. Neuroscience, 101(4), 879-884. 
Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, 
Mullikin JC, Mortimore BJ & Willey DL (2001). A map of human genome 
sequence variation containing 1.42 million single nucleotide polymorphisms. 
Nature, 409(6822), 928-933. 
Sadoshima J-i, Xu Y, Slayter HS & Izumo S (1993). Autocrine release of angiotensin II 
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell, 
75(5), 977-984. 
Salanti G, Amountza G, Ntzani EE & Ioannidis JP (2005). Hardy–Weinberg 
equilibrium in genetic association studies: an empirical evaluation of 
reporting, deviations, and power. European Journal of Human Genetics, 
13(7), 840-848. 
Salles JI, Amaral MV, Aguiar DP, Lira DA, Quinelato V, Bonato LL, Duarte MEL, Vieira 
AR & Casado PL (2015). BMP4 and FGF3 haplotypes increase the risk of 
tendinopathy in volleyball athletes. Journal of Science and Medicine in Sport, 
18(2), 150-155. 
Santiago C, González-Freire M, Serratosa L, Morate FJ, Meyer T, Gómez-Gallego F & 
Lucia A (2008). ACTN3 genotype in professional soccer players. British 
Journal of Sports Medicine, 42(1), 71-73. 
Santiago C, Ruiz J, Muniesa C, González‐Freire M, Gómez‐Gallego F & Lucia A 
(2010). Does the polygenic profile determine the potential for becoming a 
world‐class athlete? Insights from the sport of rowing. Scandinavian Journal 
of Medicine & Science in Sports, 20(1), e188-e194. 
Santiago C, Ruiz JR, Rodríguez-Romo G, Fiuza-Luces C, Yvert T, Gonzalez-Freire M, 
Gómez-Gallego F, Morán M & Lucia A (2011). The K153R polymorphism in 
the myostatin gene and muscle power phenotypes in young, non-athletic 
men. PloS One, 6(1), e16323. 
Saunders C, September A, Xenophontos S, Cariolou M, Anastassiades L, Noakes T & 
Collins M (2007). No association of the ACTN3 gene R577X polymorphism 
248 | P a g e  
 
with endurance performance in Ironman Triathlons. Annals of Human 
Genetics, 71(6), 777-781. 
Savage J, Hooke C, Orchard J & Parkinson R (2013). The incidence of concussion in a 
professional Australian rugby league team, 1998–2012. Journal of Sports 
Medicine, 2013. 
Sawczuk M, Timshina YI, Astratenkova IV, Maciejewska-Karlowska A, Leonska-
Duniec A, Ficek K, Mustafina LJ, Cieszczyk P, Klocek T & Ahmetov, II (2013). 
The -9/+9 polymorphism of the bradykinin receptor Beta 2 gene and athlete 
status: a study involving two European cohorts. Human Biology, 85(5), 741-
756. 
Scanlan AT, Tucker PS & Dalbo VJ (2014). A comparison of linear speed, closed-skill 
agility, and open-skill agility qualities between backcourt and frontcourt 
adult semiprofessional male basketball players. The Journal of Strength & 
Conditioning Research, 28(5), 1319-1327. 
Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, Braun T, Tobin JF & 
Lee S-J (2004). Myostatin mutation associated with gross muscle 
hypertrophy in a child. New England Journal of Medicine, 350(26), 2682-
2688. 
Schulz TJ, Huang TL, Tran TT, Zhang H, Townsend KL, Shadrach JL, Cerletti M, 
McDougall LE, Giorgadze N & Tchkonia T (2011). Identification of inducible 
brown adipocyte progenitors residing in skeletal muscle and white fat. 
Proceedings of the National Academy of Sciences, 108(1), 143-148. 
Schutte NM, Nederend I, Hudziak JJ, Bartels M & de Geus EJ (2016). A Twin-Sibling 
Study and Meta-Analysis on the Heritability of Maximal Oxygen 
Consumption. Physiological Genomics, 48, 210-219. 
Schwellnus MP, Thomson A, Derman W, Jordaan E, Readhead C, Collins R, Morris I, 
Van der Linde E & Williams A (2014). More than 50% of players sustained a 
time-loss injury (> 1 day of lost training or playing time) during the 2012 
Super Rugby Union Tournament: a prospective cohort study of 17 340 
player-hours. British Journal of Sports Medicine, 48(17), 1306-1315. 
Scott AC, Roe N, Coats AJ & Piepoli MF (2003). Aerobic exercise physiology in a 
professional rugby union team. International Journal of Cardiology, 87(2), 
173-177. 
Sedeaud A, Marc A, Schipman J, Tafflet M, Hager J-P & Toussaint J-F (2012). How 
they won Rugby World Cup through height, mass and collective experience. 
British Journal of Sports Medicine, 46, 580-584. 
Sedeaud A, Vidalin H, Tafflet M, Marc A & Toussaint J (2013). Rugby 
morphologies:“Bigger and taller”, reflects an early directional selection. The 
Journal of Sports Medicine and Physical Fitness, 53(2), 185-191. 
Sen S & Burmeister M (2008). Hardy-Weinberg analysis of a large set of published 
association studies reveals genotyping error and a deficit of heterozygotes 
across multiple loci. Human Genomics, 3(1), 36-52. 
September AV, Cook J, Handley CJ, van der Merwe L, Schwellnus MP & Collins M 
(2009). Variants within the COL5A1 gene are associated with Achilles 
tendinopathy in two populations. British Journal of Sports Medicine, 43(5), 
357-365. 
249 | P a g e  
 
Seto JT, Chan S, Turner N, MacArthur DG, Raftery JM, Berman YD, Quinlan KG, 
Cooney GJ, Head S & Yang N (2011). The effect of α-actinin-3 deficiency on 
muscle aging. Experimental Gerontology, 46(4), 292-302. 
Seto JT, Quinlan KG, Lek M, Zheng XF, Garton F, MacArthur DG, Hogarth MW, 
Houweling PJ, Gregorevic P & Turner N (2013). ACTN3 genotype influences 
muscle performance through the regulation of calcineurin signaling. Journal 
of Cinical Iinvestigation, 123(10), 4255-4263. 
Sgourou A, Fotopoulos V, Kontos V, Patrinos GP & Papachatzopoulou A (2012). 
Association of genome variations in the renin-angiotensin system with 
physical performance. Human Genomics, 6(1), 1-7. 
Sharples AP, Hughes DC, Deane CS, Saini A, Selman C & Stewart CE (2015). 
Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, 
dietary restriction and protein intake. Aging Cell, 14(4), 511-523. 
Silventoinen K, Magnusson PK, Tynelius P, Kaprio J & Rasmussen F (2008). 
Heritability of body size and muscle strength in young adulthood: a study of 
one million Swedish men. Genetic Epidemiology, 32(4), 341-349. 
Simoneau J-A & Bouchard C (1995). Genetic determinism of fiber type proportion in 
human skeletal muscle. The FASEB Journal, 9(11), 1091-1095. 
Smart D, Hopkins WG, Quarrie KL & Gill N (2014). The relationship between physical 
fitness and game behaviours in rugby union players. European Journal of 
Sport Science, 14(supp 1), S8-S17. 
Smart DJ, Hopkins WG & Gill ND (2013). Differences and changes in the physical 
characteristics of professional and amateur rugby union players. The Journal 
of Strength & Conditioning Research, 27(11), 3033-3044. 
Smemo S, Tena JJ, Kim K-H, Gamazon ER, Sakabe NJ, Gómez-Marín C, Aneas I, 
Credidio FL, Sobreira DR & Wasserman NF (2014). Obesity-associated 
variants within FTO form long-range functional connections with IRX3. 
Nature, 507(7492), 371-375. 
Sonestedt E, Gullberg B, Ericson U, Wirfält E, Hedblad B & Orho-Melander M (2011). 
Association between fat intake, physical activity and mortality depending on 
genetic variation in FTO. International Journal of Obesity, 35(8), 1041-1049. 
Sonestedt E, Roos C, Gullberg B, Ericson U, Wirfält E & Orho-Melander M (2009). 
Fat and carbohydrate intake modify the association between genetic 
variation in the FTO genotype and obesity. The American Journal of Clinical 
Nutrition, 90(5), 1418-1425. 
Spencer M, Lawrence S, Rechichi C, Bishop D, Dawson B & Goodman C (2004). 
Time–motion analysis of elite field hockey, with special reference to 
repeated-sprint activity. Journal of Sports Sciences, 22(9), 843-850. 
Stewart W, McNamara P, Lawlor B, Hutchinson S & Farrell M (2015). Chronic 
traumatic encephalopathy: a potential late and under recognized 
consequence of rugby union? QJM: Journal of the Association of Physicians, 
109(1), 11-15. 
Stølen T, Chamari K, Castagna C & Wisløff U (2005). Physiology of soccer. Sports 
Medicine, 35(6), 501-536. 
Summers KM, Snodgrass SJ & Callister R (2014). Predictors of calf cramping in rugby 
league. The Journal of Strength & Conditioning Research, 28(3), 774-783. 
250 | P a g e  
 
Sun M, Chen S, Adams SM, Florer JB, Liu H, Kao WW-Y, Wenstrup RJ & Birk DE 
(2011). Collagen V is a dominant regulator of collagen fibrillogenesis: 
dysfunctional regulation of structure and function in a corneal-stroma-
specific Col5a1-null mouse model. Journal of Cell Science, 124(23), 4096-
4105. 
Taddio A, Ipp M, Thivakaran S, Jamal A, Parikh C, Smart S, Sovran J, Stephens D & 
Katz J (2012). Survey of the prevalence of immunization non-compliance due 
to needle fears in children and adults. Vaccine, 30(32), 4807-4812. 
Tanaka C, Kamide K, Takiuchi S, Miwa Y, Yoshii M, Kawano Y & Miyata T (2003). An 
alternative fast and convenient genotyping method for the screening of 
angiotensin converting enzyme gene polymorphisms. Hypertension Research, 
26(4), 301-306. 
Tanaka M, Wang G & Pitsiladis YP (2016). Advancing sports and exercise genomics: 
moving from hypothesis-driven single study approaches to large multi-omics 
collaborative science. Physiological Genomics, Ahead of print. 
Tanofsky-Kraff M, Han JC, Anandalingam K, Shomaker LB, Columbo KM, Wolkoff LE, 
Kozlosky M, Elliott C, Ranzenhofer LM & Roza CA (2009). The FTO gene 
rs9939609 obesity-risk allele and loss of control over eating. The American 
Journal of Clinical Nutrition, 90(6), 1483-1488. 
Taylor RR, Mamotte CD, Fallon K & van Bockxmeer FM (1999). Elite athletes and the 
gene for angiotensin-converting enzyme. Journal of Applied Physiology, 
87(3), 1035-1037. 
Teasdale GM, Nicoll JA, Murray G & Fiddes M (1997). Association of apolipoprotein 
E polymorphism with outcome after head injury. The Lancet, 350(9084), 
1069-1071. 
Terrell TR, Bostick RM, Abramson R, Xie D, Barfield W, Cantu R, Stanek M & Ewing T 
(2008). APOE, APOE promoter, and Tau genotypes and risk for concussion in 
college athletes. Clinical Journal of Sport Medicine, 18(1), 10-17. 
Thomaes T, Thomis M, Onkelinx S, Fagard R, Matthijs G, Buys R, Schepers D, 
Cornelissen V & Vanhees L (2011). A genetic predisposition score for 
muscular endophenotypes predicts the increase in aerobic power after 
training: the CAREGENE study. BMC Genetics, 12(1), 1. 
Thomaes T, Thomis M, Onkelinx S, Goetschalckx K, Fagard R, Lambrechts D & 
Vanhees L (2013). Genetic predisposition scores associate with muscular 
strength, size, and trainability. Medicine and Science in Sports and Exercise, 
45(8), 1451-1459. 
Thompson PD, Tsongalis GJ, Seip RL, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, 
Angelopoulos TJ & Pescatello L (2004). Apolipoprotein E genotype and 
changes in serum lipids and maximal oxygen uptake with exercise training. 
Metabolism, 53(2), 193-202. 
Tiainen K, Sipilä S, Alen M, Heikkinen E, Kaprio J, Koskenvuo M, Tolvanen A, Pajala S 
& Rantanen T (2004). Heritability of maximal isometric muscle strength in 
older female twins. Journal of Applied Physiology, 96(1), 173-180. 
Tierney RT, Mansell JL, Higgins M, McDevitt JK, Toone N, Gaughan JP, Mishra A & 
Krynetskiy E (2010). Apolipoprotein E genotype and concussion in college 
athletes. Clinical Journal of Sport Medicine, 20(6), 464-468. 
251 | P a g e  
 
Trafimow D & Marks M (2015). Editorial, basic and applied social psychology. Basic 
and Applied Social Psychology, 37(1), 1-2. 
Trewartha G, Preatoni E, England ME & Stokes KA (2015). Injury and biomechanical 
perspectives on the rugby scrum: a review of the literature. British Journal of 
Sports Medicine, 49(7), 425-433. 
Tucker R, Santos-Concejero J & Collins M (2013). The genetic basis for elite running 
performance. British Journal of Sports Medicine, 47(9), 545-549. 
Turgut G, Turgut S, Genc O, Atalay A & Atalay E (2004). The angiotensin converting 
enzyme I/D polymorphism in Turkish athletes and sedentary controls. Acta 
Medica, 47(2), 133-136. 
Twist C & Worsfold P (2015). The science of rugby. Routledge, Abingdon, OX. 
Uhorchak JM, Scoville CR, Williams GN, Arciero RA, Pierre PS & Taylor DC (2003). 
Risk factors associated with noncontact injury of the anterior cruciate 
ligament a prospective four-year evaluation of 859 west point cadets. The 
American Journal of Sports Medicine, 31(6), 831-842. 
Varley I, Hughes DC, Greeves JP, Stellingwerff T, Ranson C, Fraser WD & Sale C 
(2015). RANK/RANKL/OPG pathway: Genetic associations with stress fracture 
period prevalence in elite athletes. Bone, 71, 131-136. 
Vincent B, De Bock K, Ramaekers M, Van den Eede E, Van Leemputte M, Hespel P & 
Thomis MA (2007). ACTN3 (R577X) genotype is associated with fiber type 
distribution. Physiological Genomics, 32(1), 58-63. 
Visscher PM, Brown MA, McCarthy MI & Yang J (2012). Five years of GWAS 
discovery. The American Journal of Human Genetics, 90(1), 7-24. 
Visscher PM, Medland SE, Ferreira MA, Morley KI, Zhu G, Cornes BK, Montgomery 
GW & Martin NG (2006). Assumption-free estimation of heritability from 
genome-wide identity-by-descent sharing between full siblings. PLoS 
Genetics, 2(3), e41. 
Vogel A, Holbrook K, Steinmann B, Gitzelmann R & Byers P (1979). Abnormal 
collagen fibril structure in the gravis form (type I) of Ehlers-Danlos syndrome. 
Laboratory Investigation 40(2), 201-206. 
Voisin S, Cieszczyk P, Pushkarev VP, Dyatlov DA, Vashlyayev BF, Shumaylov VA, 
Maciejewska-Karlowska A, Sawczuk M, Skuza L & Jastrzebski Z (2014). EPAS1 
gene variants are associated with sprint/power athletic performance in two 
cohorts of European athletes. BMC Genomics, 15(382), 1-11. 
Wackerhage H, Miah A, Harris RC, Montgomery HE & Williams AG (2009). Genetic 
research and testing in sport and exercise science: A review of the issues. 
Journal of Sports Sciences, 27(11), 1109-1116. 
Wåhlén K, Sjölin E & Hoffstedt J (2008). The common rs9939609 gene variant of the 
fat mass-and obesity-associated gene FTO is related to fat cell lipolysis. 
Journal of Lipid Research, 49(3), 607-611. 
Waples RS (2015). Testing for Hardy–Weinberg proportions: have we lost the plot? 
Journal of Heredity, 106(1), 1-19. 
Webborn N, Williams A, McNamee M, Bouchard C, Pitsiladis Y, Ahmetov I, Ashley E, 
Byrne N, Camporesi S & Collins M (2015). Direct-to-consumer genetic testing 
for predicting sports performance and talent identification: Consensus 
statement. British Journal of Sports Medicine, 49(23), 1486-1491. 
252 | P a g e  
 
Weinberg W (1908). On the demonstration of heredity in man. Prentice Hall, 
Englewood Cliffs, NJ. 
Weisgraber KH (1994). Apolipoprotein E: structure-function relationships. Advances 
in Protein Chemistry, 45, 249-302. 
Wenstrup RJ, Florer JB, Brunskill EW, Bell SM, Chervoneva I & Birk DE (2004). Type V 
collagen controls the initiation of collagen fibril assembly. Journal of 
Biological Chemistry, 279(51), 53331-53337. 
Wenstrup RJ, Florer JB, Davidson JM, Phillips CL, Pfeiffer BJ, Menezes DW, 
Chervoneva I & Birk DE (2006). Murine model of the Ehlers-Danlos syndrome 
col5a1 haploinsufficiency disrupts collagen fibril assembly at multiple stages. 
Journal of Biological Chemistry, 281(18), 12888-12895. 
West D, Cunningham D, Bevan H, Crewther B, Cook C & Kilduff L (2013). Influence of 
active recovery on professional rugby union player's ability to harness 
postactivation potentiation. The Journal of Sports Medicine and Physical 
Fitness, 53(2), 203-208. 
Wigginton JE, Cutler DJ & Abecasis GR (2005). A note on exact tests of Hardy-
Weinberg equilibrium. The American Journal of Human Genetics, 76(5), 887-
893. 
Wilber RL & Pitsiladis YP (2012). Kenyan and Ethiopian distance runners: what 
makes them so good. International Journal of Sports Physiolpgy and 
Performance, 7(2), 92-102. 
Williams AG & Folland JP (2008). Similarity of polygenic profiles limits the potential 
for elite human physical performance. The Journal of Physiology, 586(1), 113-
121. 
Williams FM, Kalson NS, Fabiane SM, Mann DA & Deehan DJ (2015a). Joint Stiffness 
Is Heritable and Associated with Fibrotic Conditions and Joint Replacement. 
PloS One, 10(7), e0133629. 
Williams S, Trewartha G, Kemp S & Stokes K (2013). A meta-analysis of injuries in 
senior men’s professional Rugby Union. Sports Medicine, 43(10), 1043-1055. 
Williams S, Trewartha G, Kemp SP, Brooks JH, Fuller CW, Taylor AE, Cross MJ & 
Stokes KA (2015b). Time loss injuries compromise team success in Elite 
Rugby Union: a 7-year prospective study. British Journal of Sports Medicine, 
0, 1-6. 
Wing MR, Ziegler J, Langefeld CD, Ng MC, Haffner SM, Norris JM, Goodarzi MO & 
Bowden DW (2009). Analysis of FTO gene variants with measures of obesity 
and glucose homeostasis in the IRAS Family Study. Human Genetics, 125(5-
6), 615-626. 
Woehning A, Schultz J, Roeder E, Moeltner A, Isermann B, Nawroth P, Wolfrum C & 
Rudofsky G (2013). The A-allele of the common FTO gene variant rs9939609 
complicates weight maintenance in severe obese patients. International 
Journal of Obesity, 37(1), 135-139. 
Wolfarth B, Rankinen T, Hagberg JM, Loos RJ, Pérusse L, Roth SM, Sarzynski MA & 
Bouchard C (2014). Advances in exercise, fitness, and performance genomics 
in 2013. Medicine and Science in Sports snd Exercise, 46(5), 851-859. 
253 | P a g e  
 
Woods D, Hickman M, Jamshidi Y, Brull D, Vassiliou V, Jones A, Humphries S & 
Montgomery H (2001). Elite swimmers and the D allele of the ACE I/D 
polymorphism. Human Genetics, 108(3), 230-232. 
World Medical Association (2013). World Medical Association Declaration of 
Helsinki: ethical principles for medical research involving human subjects. 
Journal of the American Medical Association, 310(20), 2191. 
Xu J, Turner A, Little J, Bleecker ER & Meyers DA (2002). Positive results in 
association studies are associated with departure from Hardy-Weinberg 
equilibrium: hint for genotyping error? Human Genetics, 111(6), 573-574. 
Yamak B, Yuce M, Bagci H & Imamoglu O (2015). Association between Sport 
Performance and Alpha-Actinin-3 Gene R577X Polymorphism. International 
Journal of Human Genetics, 15(1), 13-19. 
Yang N, MacArthur DG, Gulbin JP, Hahn AG, Beggs AH, Easteal S & North K (2003). 
ACTN3 genotype is associated with human elite athletic performance. The 
American Journal of Human Genetics, 73(3), 627-631. 
Yang N, MacArthur DG, Wolde B, Onywera VO, Boit MK, Lau SYM-A, Wilson RH, 
Scott RA & Yannis P (2007). The ACTN3 R577X polymorphism in East and 
West African athletes. Medicine and Science in Sports and Exercise, 39(11), 
1985–1988. 
Zeng S, Jiang J-X, Xu M-H, Xu L-S, Shen G-J, Zhang A-Q & Wang X-H (2014). 
Prognostic value of apolipoprotein E epsilon4 allele in patients with 
traumatic brain injury: a meta-analysis and meta-regression. Genetic Testing 
and Molecular Biomarkers, 18(3), 202-210. 
Zhai G, Stankovich J, Ding C, Scott F, Cicuttini F & Jones G (2004). The genetic 
contribution to muscle strength, knee pain, cartilage volume, bone size, and 
radiographic osteoarthritis: a sibpair study. Arthritis & Rheumatism, 50(3), 
805-810. 
Zhang B, Tanaka H, Shono N, Miura S, Kiyonaga A, Shindo M & Saku K (2003). The I 
allele of the angiotensin‐converting enzyme gene is associated with an 
increased percentage of slow‐twitch type I fibers in human skeletal muscle. 
Clinical Genetics, 63(2), 139-144. 
Zhang X, Qi Q, Zhang C, Smith SR, Hu FB, Sacks FM, Bray GA & Qi L (2012). FTO 
Genotype and 2-Year Change in Body Composition and Fat Distribution in 
Response to Weight-Loss Diets The POUNDS LOST Trial. Diabetes, 61(11), 
3005-3011. 
Zhou W, Xu D, Peng X, Zhang Q, Jia J & Crutcher KA (2008). Meta-analysis of APOE 4 
allele and outcome after traumatic brain injury. Journal of Neurotrauma, 
25(4), 279-290. 
Ziegler A, Van Steen K & Wellek S (2011). Investigating Hardy–Weinberg equilibrium 
in case–control or cohort studies or meta-analysis. Breast Cancer Research 
and Treatment, 128(1), 197-201. 
Ziv G & Lidor R (2009). Physical attributes, physiological characteristics, on-court 
performances and nutritional strategies of female and male basketball 
players. Sports Medicine, 39(7), 547-568. 
254 | P a g e  
 
Ziv G & Lidor R (2010). Vertical jump in female and male basketball players—A 
review of observational and experimental studies. Journal of Science and 
Medicine in Sport, 13(3), 332-339. 
Zoppi N, Gardella R, De Paepe A, Barlati S & Colombi M (2004). Human fibroblasts 
with mutations in COL5A1 and COL3A1 genes do not organize collagens and 
fibronectin in the extracellular matrix, down-regulate α2β1 integrin, and 
recruit αvβ3 instead of α5β1 integrin. Journal of Biological Chemistry, 
279(18), 18157-18168. 
Zweig MH & Campbell G (1993). Receiver-operating characteristic (ROC) plots: a 
fundamental evaluation tool in clinical medicine. Clinical Chemistry, 39(4), 
561-577. 
 
